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Inequalities in outcome for oesophago-gastric cancer in England: Is there an 
association with gastroscopy rates for General Practice populations? 
Abstract: Mustafa Shawihdi  
Introduction: Oesophago-gastric (OG) cancers remain a worldwide challenge with little sign of 
major improvements in survival rates. Modern guidelines focus on alarm (or ‘red flag’) 
symptoms as key triggers for gastroscopy and recommend empirical symptomatic treatment 
and non-invasive H. pylori testing in those with simple dyspepsia.  However, the early 
symptoms of OG cancer are very common and non-specific, and the traditional alarm symptoms 
have poor sensitivity or specificity for malignancy. Diagnosis therefore necessitates 
investigation of symptoms though upper GI endoscopy in a relatively large group of patients, 
most of whom do not have malignant disease. This has fuelled considerable controversy 
regarding the role for gastroscopy in detecting cancer at a treatable stage. 
Objectives: Firstly, to develop data extraction and linkage methods for studying OG cancer 
outcome, and General Practice population rates of elective diagnostic gastroscopy, using 
administrative data for English hospitals (Hospital Episode Statistics). Secondly, to confirm the 
face-validity of the methodology using external sources of information and local audit data. 
Thirdly, to test the hypothesis that variations in rates of gastroscopy in English General Practice 
(GP) populations are associated with inequalities in OG cancer outcome. Fourthly, to explore 
whether practices with lower rates of gastroscopy exhibit a higher yield of serious pathology, 
consistent with more selective referral practice. Fifthly, to confirm the existence of wide 
variation in gastroscopy rate between practices in close geographical proximity,  
Design and methods: Analysis of Hospital Episode Statistics (2006-8) linked to death registry 
and practice population data. General practices with new cases of OG cancer were included, 
grouped into tertiles according to standardised elective gastroscopy rate per capita (low, 
medium or high). Outcome measures for cancer cases were: emergency admission during 
diagnostic pathway; major surgical resection and mortality at 1 year. Co-variates were age, 
gender, co-morbidity, and deprivation. Associations between the gastroscopy rate at the 
patient’s general practice and cancer outcomes were tested in binary logistic regression 
models, with extensive sensitivity testing of gastroscopy rate ‘exposure’ variable. An algorithm 
was developed to analyse coded diagnoses for all first elective gastroscopies, using both 
national and local audit data. Practices were mapped based on postal code. 
Results: 22,488 incident cases of OG cancer from 6,513 general practices. Mean OGD rate for 
Low, Middle, High practices: 4.4 vs 8.1 vs 12.9 per 1,000. Mean age of patients undergoing OGD 
was highest for low tertile practices (60.2 vs 59.5 vs 58.4 yrs; p<0.001). OG cancer cases 
registered with practices in the lowest tertile had the lowest rate of surgery (15.4% v 16.3% v 
17.4%; p=0.004) with the highest rate of emergency admission (34% v 26% v 25%; p<0.001), and 
the highest mortality (61.2% v 58.9% v 58.0%; p<0.001). After adjustment for co-variates in 
logistic regression, the gastroscopy rate at the patient’s general practice was an independent 
predictor of all three outcomes. Practices with low rates of gastroscopy tend to have a higher 
“diagnostic yield” of serious disease: (15.3% vs 13.9% vs 13.1%; p<0.001). Low tertile practices 
also showed a relatively lower referral rate for suspected cancer in general based on analysis of 
rates of ‘fast-track’ referrals under the two week wait pathway (17.3 vs 17.9 vs 19.3 per 1,000).   
Conclusions: Wide variation exists in gastroscopy rate among general practice populations in 
England. OG cancer patients belonging to practices with the lowest gastroscopy rates are at 
greater risk of poor outcome. Low referring practices achieve a higher yield of serious disease 
but may have increased risk of referral at a later stage in the disease process. This association is 
more apparent among the most socially deprived practices. These findings suggest that 
initiatives or current guidelines aimed at limiting the use of gastroscopy may adversely affect 
cancer outcomes. 
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1.1  Oesophago-gastric cancer background 
Oesophago-gastric cancers (OG cancers) are tumours which arise from the 
oesophagus or stomach, respectively. These two cancer sites exhibit a very similar 
age profile at diagnosis, present with an overlapping range of symptoms and signs, 
and share a common diagnostic pathway centred on a key primary diagnostic test 
(gastroscopy). They are often referred to, collectively, as upper gastrointestinal 
cancers.  
1.1.1 Anatomical description of the oesophagus and stomach. 
The oesophagus is a muscular tube that lies at the front of the spine and behind the 
trachea. It carries swallowed food through the neck and chest to the stomach. This 
tube in a human adult is usually about 18 to 26 cm long and around 2-3 cm in 
diameter at its smallest point.[1]  The oesophagus unites with the stomach at the 
gastroesophageal junction, located just beneath the diaphragm. The stomach is a J-
shaped (sac-like) muscular organ that mixes and digests food by secreting gastric 
juice and then emptying it into the duodenum, which is the first part of small 
intestine [1] (Figure 1.1) .  
Figure 1.1 also shows the wall of the oesophagus and stomach, with its several 
layers. These layers are important for an understanding of where cancers tend to 
start and the staging of the disease, which will subsequently inform the  
management of the disease, as will be described later. 
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1.1.2 OG Cancer pathological subtypes.  
The vast majority of oesophageal cancers that emerge from oesophageal tissue are 
epithelial tumours which originate at the mucosa and grow through the submucosa 
and the muscle layers.[1] Since two types of cells can line the oesophagus (Figure 
1.1), there are correspondingly two main types of oesophageal cancer, namely 
squamous cell carcinoma and adenocarcinoma of the oesophagus and the 
oesophago-gastric (OG) junction.[1, 2]  
 
 
 
Figure 1.1 Normal structure of oesophagus and stomach adapted from cancer research UK. 
[3] 
 
Oesophagus  Stomach   
This text box is where the unabridged thesis included the following third party 
copyrighted material: 
Cancer research UK. 18/06/13 [cited 2013; Available from: 
http://www.cancerresearchuk.org/cancerinfo/cancerstats/types/oesophagus/incide
nce/uk-oesophageal-cancer-incidence-statistics. 
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About 90% of gastric tissue malignancies are Adenocarcinoma.[4] Other less 
common epithelial and non-epithelial cancers include squamous cell carcinoma 
variants, small cell carcinoma, malignant melanoma, lymphomas, sarcomas, 
neuroendocrine tumors, and secondaries from other sites (for example, breast 
cancer as the primary site) [2, 5]. 
Squamous cell carcinoma tends to occur in the upper and middle (thoracic) part of 
the oesophagus. This used to be the most common variety of oesophageal cancer 
type, particularly in men with a long history of smoking and alcohol consumption.[1, 
6] Adenocarcinoma appear to affect mostly white men, and its pathogenesis is 
thought to be related mainly to gastro-oesophageal reflux disease (GORD) and the 
development of Barrett epithelium, as will be discussed later [6-9]. 
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1.1.3 Oesophago-gastric cancer epidemiology. 
Over the last few years, the incidence of adenocarcinoma of the lower oesophagus 
and gastro-oesophageal junction has increased dramatically [1, 6]. In some Western 
countries such as the UK and the USA, this type has now overtaken squamous cell 
carcinoma to become the dominant histology at diagnosis [4, 6], to the extent that 
in the year 2000, the world’s highest estimated incidence rate of adenocarcinoma 
was recorded in the UK, at a rate of 8.7 cases per 100,000 population. [8] In the 
USA, throughout the 1980s, adenocarcinoma of the oesophagus increased at a rate 
of 5 to 10 % per year.[10] Another study from Norway has also reported a 
substantial increase in the incidence of this malignant tumour, at a rate of 15% per 
year[10].  
A similar pattern of rising incidence, particularly around the gastro-oesophageal 
junction, has been widely reported in various other countries, including Sweden, 
Switzerland and Australia.[11] More recent UK figures show that the crude 
incidence rate of oesophageal cancer are 18.4 per 100,000 population for males 
and 9 per 100,00 0 for females. [12] 
There were 83,000 new gastric cancer cases in Europe in 2008 with a UK incident 
rate being below the European average at about 12.4 per 100,000 in males and 5.3 
per 100,000 in females.[13] In the UK, the trends of gastric cancer incidence have 
fallen dramatically by about 32% in males and 28% in females, comparing the 
period of 1999-2001 with 2008-2010.[13] 
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UK data from the mid-1990s also shows that there were around 7000 and 10000 
new diagnoses per year, and these were responsible for about 6700 and 7500 
deaths for oesophageal and gastric cancer respectively.[14] In more recent times, 
during 2005-2007, ONS data demonstrates that around 7919 and 7897 were newly 
diagnosed, with mortality figures of 7336 for oesophageal cancer and 5395 for 
gastric cancer. [15]   
Although the incidence of adenocarcinoma of the oesophagus is increasing, and the 
incidence of gastric carcinoma is decreasing [4], nevertheless gastric cancer remains 
the fourth most common cancer and the second main cause of cancer death 
throughout the world, [5] while oesophageal cancer ranks as the eighth most 
common cancer worldwide.[6] In the UK, however, it is ninth, and is grouped with 
gastric cancer (OG cancer) as the fifth most common malignancy and fourth most 
common cause of cancer death [5, 16-19].  
There are significant geographic and regional variations in the incidence of OG 
cancer around the world.[6] Gastric cancer for instance is very common in China, 
Japan, Eastern Europe and South and Central America while it is uncommon in 
Northern and Western Africa.[4] There was also a fourfold difference in the incident 
rate of gastric cancer in EU counties.[13] These differences may imply that genetic, 
environmental and lifestyle factors play an essential part in the aetiology of these 
cancers, as has been widely suggested. [2, 10, 20, 21]   
Generally, OG cancers remain a worldwide challenge with little sign of major 
improvements in patients’ outcomes. Taken as a whole, the 5-year survival rate in 
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England and Wales is about 13 per cent for gastric and 7 per cent for oesophageal 
cancer [2, 16, 22]. However, better survival rates have been found in some areas 
where patients have been diagnosed at an early stage of the localized disease [22]. 
These variations could also reflect the type and quality of the cancer management 
and services provision in these areas.  
It has been reported that survival rates of OG cancer in England are worse than the 
European average, and noticeably poorer than rates achieved in Japan and the 
USA.[17] This is most obvious for patients with gastric cancer, whose one year 
survival rate is 40 per cent across Europe as a whole, compared with 28 per cent in 
England (Table 1.1). [10] 
Table 1.1 One and five years survival rates, with 95% confidence intervals (CI), among 
patients with OG cancers in England and Europe. Adapted from Guidance on 
Commissioning Cancer Services, Improving Outcomes in Upper Gastro-intestinal Cancers. 
2001 [10] 
 Oesophageal  cancer  Gastric cancer 
1 year survival rate England 27 (26-28) 28 (27-29) 
1 year survival rate European average  33 (30-36) 40 (39-41) 
5 year survival rate England 9 (8-10) 12 (11-12) 
5 year survival rate European average 10 (7-14) 21 (20-22) 
 
Although the survival of cancer patients is considered an important index of the 
overall effectiveness of health services, it has been argued that international 
comparisons both within and between countries that have comparable health 
systems and wealth, such as Denmark and the UK and other European countries, 
may not be entirely reliable [23, 24].  
This text box is where the unabridged thesis included the following third party 
copyrighted material: 
Department of Health. Guidance on commissioning cancer services: improving 
outcomes in upper gastro-intestinal cancers the manual, DOH, Editor 2001. 
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“With regards to their point that the UK lag in survival is “frightening for NHS 
patients and demoralising for NHS staff,” we instead suggest that the data are 
encouraging for the UK. EUROCARE-4 was concerned with patients diagnosed in 
1995–99, and clear improvements in UK survival were seen compared with in 
1990–94. The National Cancer Plan for England was implemented in 2000 and the 
expected favourable effect will only be visible in patients diagnosed after that 
time.” [2] 
However, these survival statistics were drawn from data obtained from the 
Eurocare project, which now involves over 80 cancer registries across 23 
countries.[25-28] Furthermore, various high resolution studies have used these 
data to explore the influence of disease stage at diagnosis and of treatment, 
providing some possible explanations for such variation in survival rates.[28-31] 
Thomson CS et al (2009) for instance in a comparative analysis of the Eurocare 4 
data acknowledged some cancer sites, including oesophagus where the one year 
survival was a significant factor in 5-year survival, and thus where an earlier cancer 
diagnosis would create a significant difference.[30]  Across Europe, Bouvier et al 
(2010) also showed that differences in gastric cancer survival largely depend on 
differences in stage at diagnosis rather than on quality of treatment.[29] The size of 
the prize publication by Sir Mark Richard in 2009 concludes that UK diagnostic delay 
may help explain an estimated 5,000-10,000 additional cancer deaths each 
year.[32] To put this into perspective, Abdel-Rahman et al (2009) point out that OG 
cancers would have one of the highest numbers of ‘avoidable’ deaths, if cancer 
survival in Britain could reach the same levels as elsewhere in Europe.[33]  
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These figures support the argument that many cancer deaths could be avoidable 
simply by improving patients’ care pathway.[23, 24] Although these variations 
might reveal the type and provision of the cancer management in general, it might 
also reflect the inadequate availability, or the poor access to diagnostic services in 
these areas. In addition, it is still unknown whether these variations could result 
from the early/late specialist referral of patients who are found to have nonspecific 
symptoms. 
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1.1.4 Risk factors for developing oesophago-gastric cancer 
Illness related risk factors are anything that has an effect on an individual’s chance 
of contracting the disease. [34] In the case of cancer, the risk pattern is 
complicated. Different cancers have different risk factors, while some may not have 
a known risk factor at all.  It is important to note that having one or more risk factor 
does not indicate that the individual will necessarily develop the disease.[34]  
1.1.4.1 Patient demographics (Age, gender and race)   
Although oesophago-gastric cancers age distribution shows variations in some 
definite geographical distinct areas of the world [35-38]; generally, the chance of 
developing these cancers is low at younger ages and the risk is much greater in 
elderly people.[1] In the UK, 92% of new cases occur in those more than 55 years of 
age.[39] During the sixth and seventh decades of life oesophageal cancer is 
approximately 20 times more common than in those under 65 years. In the same 
way, in men above 80 years of age, gastric cancer peaks at 200 cases per 100,000 
individuals.[10, 40] 
Around two-thirds of OG cancers cases are found in men. Recent figures from the 
Office for National Statistics (ONS) show that the directly age-standardised rate of 
newly diagnosed cases of oesophageal cancer for men and women in England is 
13.9 and 5.5  per 100,000, respectively.[15]  The same source also records that the 
gastric cancer incidence for men is 13.3, while in women it is 5.3 per 100,000 
population.[15] ONS data also shows that the mortality rate from these cancers is 
considerably higher in men than in women at 12.9 to 4.7 deaths per 100,000 
population for oesophageal cancer and 8.5 to 3.6 per 100,000 population for gastric 
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cancer.[15] Although it is still unclear why men are at greater risk of both 
developing and dying from those cancers, it has been argued that more proactive 
health care approach need to be adopted in relation to men’s increased 
vulnerability to cancer in general.[41]  
Although researchers have hypothesized that environmental factors, such as 
differences in lifestyle and smoking, might account for this gender discrepancy, an 
increased body of evidence suggests that these variations might be deeply rooted in 
the biological differences between men and women.[42] For example, Sheh et al 
showed that treating male mice with estrogen significantly reduces their rates of 
stomach cancer caused by H. pylori chronic infection.[42] 
It is also likely that ethnicity might be one of these cancer risk factors. In the United 
States, for instance gastric cancer is shown to be more common in African 
Americans and Hispanic Americans than in non-Hispanic whites. It was also 
reported as prevalent among Asian/Pacific Islanders.[1] In England, differences in 
the incidence of oesophageal and gastric cancer have been reported at similar rates 
among various ethnic groups,[43] and this relative homogeneity has been 
suggested as being due to exposure to other risk factors.[43]  
1.1.4.2 Gastro-oesophageal reflux disease (GORD) and Barrett's oesophagus 
GORD related symptoms in terms of heartburn and acid regurgitation are 
considered one of the most common complaints in the General Practice setting.[44] 
The prevalence of this clinical condition varies greatly, although in Western world it 
ranges between 10 to 20%. [44, 45] In the UK, the incidence and prevalence of 
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GORD, when defined as at least weekly heartburn and/or acid regurgitation, were 
4.5 per 1000 person-year and 18% respectively.[45, 46]  
It has been shown that the frequency or severity of GORD symptoms could be 
sufficient to disturb the patients’ health-related quality of life [45, 47]. Reflux of 
gastric contents into the oesophagus could damage its squamous cell lining and 
associated serious complications, including erosive oesophagitis, oesophageal 
stricture and the risk of developing adenocarcinoma of the oesophagus and/ or 
gastroesophageal junction have been extensively reported in the literature [44, 48-
51].  
If reflux of gastric contents into the oesophagus continues over a long period, this 
causes the lower oesophageal squamous cells to be replaced with glandular 
(columnar) cells.[1]  These columnar cells are similar to gastric and/or small 
intestinal cells which are more resistant to gastric acid. This condition is known as 
Barrett's oesophagus. [52] 
Barrett’s oesophagus is found to be an uncommon (1% to 2%) finding at 
endoscopy.[1, 53] For symptomatic GORD, such a finding could however be as high 
as 12%.[53] It has been reported that patients with Barrett's are at around 11 times 
higher risk of developing adenocarcinoma of the lower oesophagus than in the 
normal population.[54] 
 
1.1.4.3 Helicobacter pylori (H. pylori) infection 
H. pylori was first reported in 1984 by Robin Warren and Barry Marshall.[55] Since 
then, a substantial number of studies and review articles have provided 
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considerable evidence that infection with H.pylori plays an important role in gastric 
cancer pathogenesis.[56-59] The fall in gastric cancer incidence in developed 
countries has been linked to the eradication treatment and a decline in the 
prevalence of H.pylori infection in these areas.[11, 60] Meta-analyses of 
prospective studies have suggested that chronic H pylori infection increases the risk 
of gastric cancer by 2-3 times.[61, 62] It has been shown that H. pylori has a strong 
link with dyspepsia and may be accountable for at least 5% of upper GI symptoms 
in the community.[63] 
A project conducted by the Helicobacter and Cancer Collaborative Group  combined 
twelve case control studies to measure the relative risk of gastric cancer in 
association with H. pylori infection. It found that that those with H. pylori infections 
are 5.9 times more at risk of developing non-cardia gastric cancer.[64] However, 
this study also reported that H pylori does not increase the risk of gastroesophageal 
junctional (cardia) tumours. [64] Brewster suggests that the fall in H. pylori 
prevalence presents a possible explanation for the growing incidence of 
adenocarcinoma of the oesophagus and gastric cardia, and the declining incidence 
of distal gastric cancers.[65]  
Furthermore, certain types of lymphoma of the stomach, known as mucosa-
associated lymphoid tissue (MALT) lymphoma, have been shown to be caused by 
H.pylori infection which is entirely treatable with antibiotic eradication therapy.[1, 
66]. 
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Figure 1.2 adapted from Burkitt et al 2009, shows how the development of gastric cancer is 
one of several potential outcomes of chronic gastric colonisation with H.pylori infection. 
[67] 
1.1.4.4 Alcohol and tobacco 
Alcohol drinking and the use of tobacco products, such as cigarettes, chewing 
tobacco and pipes, are well recognized risk factors for squamous cell carcinoma of 
the oesophagus, particularly in most low risk countries.[68] However, their relation 
to oesophago-gastric adenocarcenoma remain unclear. [11, 69] A meta-analysis of 
published studies, carried out to examine the gastric cancer risk associated with 
smoking status, demonstrated a relative risk of 1.48 (95% CI 1.28-1.71) for those 
that have ever smoked, in comparison to non-smokers.[70]  
Studies have also shown a dose-and-time relation, in which the greater and the 
longer the use of tobacco and alcohol, the higher the chance of developing gastric 
cancer.[11] Additionally, It has been shown that smoking and drinking could have 
synergistic effects on OG cancer development, which may augment the relative risk 
This text box is where the unabridged thesis included the following third party 
copyrighted material: 
Burkitt, M., Investigation of the importance of individual members of the Nuclear 
Factor-κB family during Helicobacter felis induced gastric carcinogenesis, in 
Gastroenterology2011, University of Liverpool. 
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over time, compared with the effect of either smoking or drinking on its own.[71] 
However, various limitations of these studies have been noted, particularly the fact 
that their lack of control for possible confounding factors such as H. Pylori infection, 
or by the level of fruit and vegetable intake, which are both highly correlated with 
tobacco smoking.[11] 
1.1.4.5 Diet and nutritional imbalance 
Poor and/or under-nutrition includes the low intake of micronutrients such as 
vitamins, antioxidants and an above average consumption of foodstuffs such as 
smoked foods, salted fish and processed meat are shown to have an increased risk 
of OG cancer.[11, 71, 72] By contrast, a diet high in fruits and vegetables has been 
related to a reduced risk.[11, 71]  
Another risk factor is over-nutrition, associated with high carbohydrate intake and 
obesity.[73-75]  Although the exact mechanism for this correlation is still not fully 
understood, it has been partly explained by the finding that obese individuals are 
more likely to develop GORD.[1] 
1.1.4.6 Socioeconomic status 
Generally, the relations between social deprivation status and cancer incidence and 
survival have been well documented in the literature. [76-78] The risks of OG 
cancer have also been linked strongly with socioeconomic indicators. [76, 78, 79] 
On average, low socioeconomic status has been consistently shown to be 
associated with an increased risk of both oesophageal and gastric cancers [76, 78, 
79]. However, analysis of cancer registry data from the West Midlands region of the 
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UK explores the relationship between the degree of deprivation and  these 
tumours, with its sub-sites and subtypes. [80] The report showed that a higher 
percentage of cases of adenocarcinoma of the lower oesophagus and gastric cardia 
were among higher social class.[80, 81]  Interestingly, it remains unproven whether 
smoking, alcohol, obesity, and/or the changing in the prevalence of H pylori 
infection are associated with OG cancer patients’ socioeconomic status.[79] Such 
explanations would help to give more insight about the variability in the incidence 
of this particular cancer among people living in more deprived communities.[11, 65] 
1.1.4.7 Other OG cancer risk factors  
A number of conditions appear to be associated with an increased risk of 
oesophageal and gastric cancer.[1, 11, 82] These factors are summarized below 
(Table 1.2).  
Table 1.2 Other risk factors for OG cancer  
Oesophageal  Gastric  
 Thermal and mechanical 
irritation or Injury to the 
oesophagus  
 History of certain other cancers 
 Achalasia 
 Tylosis 
 Oesophageal webs 
 Workplace exposures 
Chemical fumes 
 Previous stomach surgery 
 A family history of stomach cancer 
 Pernicious anaemia 
 Epstein-Barr virus infection 
 Menetrier disease (hypertrophic 
gastropathy) 
 Immune deficiency 
 Common variable immunodeficiency (CVID) 
 Type A blood 
 Inherited cancer syndromes 
BRCA1 and BRCA2 
Familial adenomatous polyposis (FAP) 
Hereditary non-polyposis colorectal cancer 
 Certain occupations 
Workers in the coal, metal, and rubber 
industries 
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Summary Box 1 
Oesophageal and gastric cancers have been linked to various risk factors. Although 
some risk factors could be avoidable (such as drinking alcohol or smoking), others 
are beyond the patient’s control, for example advancing age or family history.[34]  
The typical presentation of these tumours in older individuals has supported the 
use of arbitrary age cut-offs in referral guidelines to encourage the restriction of 
gastroscopy for simple dyspepsia to those over the age of 55 years.  Only around 
8% of gastric cancers, for instance, occur under the age of 55 years.  
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1.1.5 Clinical features  
Symptoms that might be an indication of the presence of OG cancers are very 
common and non-specific. One such symptom is dyspepsia: around one fourth of 
the general population is described as affected with dyspepsia, without necessarily 
suffering from cancer, and it is estimated that dyspepsia accounts for around 5% of 
general practice consultations and about 30% of gastroenterologists’ visits.[1]  
2000 years ago, the Greeks coined the word “dyspepsia” for “bad digestion”, which 
in English became simply  “indigestion”, a term which is widely understood by lay 
people as referring to any  pain and/or discomfort in the upper abdomen. Such pain 
may or may not be associated with bloating, postprandial fullness, nausea, 
anorexia, heartburn, regurgitation, early satiety, and burping or belching.[1] Health 
professionals on the other hand, often use dyspepsia as a term to illustrate 
heterogeneous upper abdominal symptoms that could originate from organic 
causes, including malignancy, or which could originate from an inorganic, as yet 
unspecified source. [2, 83]  
More recently, although there has been considerable progress in our understanding 
of the various clinical approaches to dyspepsia, nevertheless physicians continue to 
have difficulties in managing patients who present with such symptoms, partly 
because of the challenge of defining, investigating and treating dyspepsia.  Because 
it is a symptom (or a group of symptoms) rather than a disease, doctors’ 
interpretations of their patient symptom are highly affected by language, culture, 
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age, and past clinical experiences [2, 84]. Hence, an agreed standard definition of 
dyspepsia is essential in any given study relating to this universal clinical 
condition.[37] It has also been shown that variation in the prevalence of dyspepsia, 
which ranges from 15% in Asia to 40% in North America, were primarily due to 
differences in definition, rather than any significant medical differences in the 
geographical locations. [37]  
In a longitudinal 10 year UK follow-up study, Ford et al. found that the incidence of 
new-onset dyspepsia was almost 3% per year. This study also showed that the 
nature of this clinical condition involves a remission and relapse period, and that 
previously asymptomatic individuals may experience a new onset of symptoms 
compatible with dyspepsia. For these reasons, even over a prolonged period of 
time, in the same demographic and geographical area the prevalence of dyspepsia 
tends to remain almost the same [85, 86].  
More specific symptoms which if present, could be related to the presence of OG 
cancer are called “alarm or red flag symptoms” (Table 1.3). However, research has 
consistently shown that these symptoms have low predictive value in unearthing 
serious findings at endoscopy.[87-89]  Nevertheless, OG cancer is shown to seldom 
occur in young patients without alarm features. [90] Although these red flag 
symptoms are not uncommon in primary clinical practice, the number of studies 
which test the predictive value of each individual symptom, either alone or in 
combination, is small.[88, 91]  
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Table 1.3 Alarm features in dyspepsia that could suggest the presence of upper 
gastrointestinal malignancy. [83] 
Alarm features in dyspepsia suggestive of upper gastrointestinal malignancy 
Age above 50 years with new-onset dyspepsia 
Dysphagia 
Odynophagia 
Hematemesis or melena 
Persistent vomiting 
Unintentional weight loss 
Iron deficiency anaemia 
Family history of gastric cancer 
Palpable upper abdominal mass 
Fransen et al (2004) in a critical review of studies testing the diagnostic value of 
alarm symptoms in relation to OG cancer suggest that the sensitivity of ‘any alarm 
symptom’ as an indicator of malignancy is “rather disappointing” – a suggestion 
supported by the findings of  Vakil et al (2006). Additionally, these meta-analyses 
indicate a low positive predictive value (PPV) for having these warning symptoms, 
demonstrating that an insignificant proportion of these cases actually have cancer. 
Although this low PPV might be related simply to the low prevalence of this cancer 
type, these studies also reveal a high negative predictive value (NPV), which 
indicates that there is small probability of missing an OG cancer in patients without 
these symptoms.[88, 89]  
In relation to the disease staging, it appears that patients with alarm symptoms 
could have advanced disease at the time of presentation.[92] Previous studies have 
also reported that the majority (70%) of patients with early gastric cancer have 
presented with dyspepsia with no anaemia, dysphagia or weight loss. [93]  
In this regard, Kapoor et al state that  
This text box is where the unabridged thesis included the following third party 
cop righted material: 
Ford, A.C. and P. Moayyedi, Managing dyspepsia. Curr Gastroenterol Rep, 2009. 
11(4): p. 288-94. 
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“Unfortunately, the symptoms of early stage cancer may be indistinguishable 
from benign conditions, whereas the presence of established alarm symptoms (for 
example, dysphagia or weight loss) may signify advanced inoperable disease.” 
Kapoor 2005 [94].  
Summary box 2 
Although some upper gastrointestinal symptoms or clinical features are considered 
more important than others as indicating risk for underlying OG cancer, the 
traditional ‘red flag’ or ‘alarm’ symptoms are an unreliable means of identifying 
patients with serious causes of dyspepsia. It is doubtful that a focus on alarm 
features alone promotes early-stage diagnosis for the minority of symptomatic 
dyspeptic patients with underlying cancer. 
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1.1.6 OG cancer Diagnosis and Staging   
The World Health Organization (WHO) recommends that the diagnosis of OG cancer 
should be made by endoscopic biopsy with histological examination.[95-98] Neither 
signs, symptoms nor serologic markers may be 100 % indicative of the presence of 
OG cancer.  
Gastroscopy allows for the direct characterization of the tumour’s location, size and 
configuration.[1] It has also been recommended that at least six biopsies are 
typically required to yield a diagnosis. However, some centres may use the brush 
cytology to enhance the diagnostic yields. [1]   
Although upper GI endoscopy with biopsy is the gold standard diagnostic 
investigation, irrespective of radiological image finding in patients who are 
suspected of having this malignancy, nevertheless contrast radiographic techniques 
(e.g. Barium) may also be required in selected cases, particularly in patients with 
suspected fistula and/or complete obstruction. In addition, computed tomography 
(CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and 
endoscopic ultrasonography (EUS) are mandatory in evaluation of the surrounding 
tissues and to show the presence or absence of distant metastasis.[1, 96, 97]  
The TNM classification system is used to measure how far a cancer has spread.[1] 
Various radiological and endoscopic investigations are involved to determine the 
most consistent information about each stage of this system. The main methods 
are multi-detector CT (MDCT), EUS and PET integrated with CT (PET-CT).[99] 
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Essentially, TNM gives details in relation to the depth of tumour invasion into the 
oesophageal or gastric wall (T). Studies show that, in small “early” T1 stage cancer, 
endoscopic mucosal resection (EMR) is the favoured approach for examining 
mucosal and submucosal invasion. In more advanced lesions; however, EUS is more 
precise, because of the defined visualisation of each layer of the oesophageal and 
gastric tissue.[1, 99]  
With regard to the association of lymph nodes (N) and the existence of distant 
metastases (M); although, they are highly dependent on the anatomical location of 
the primary tumour, the highest possible accuracy has been achieved using a 
combination of EUS (alone or with CT) and/or PET-CT.[1, 99]   
Since around half of patients present with advanced disease; according to the BSG’s 
2011 recommendation, any assessment ought to establish the existence or 
nonexistence of distant metastasis. Even though MDCT is the standard technique to 
rule out metastatic disease, all three modalities need to be applied in combination 
to offer complete staging detail. [99]  
1.1.7 OG cancer treatment options 
OG cancer therapeutic options are extremely stage dependent. Only those 
infrequent patients with early stage localized disease are suitable for primary 
treatment with curative intent, predominantly in the form of radical surgical 
resection.  Such a minor group has a better opportunity for survival. 
Primary treatment options include surgery alone, which is considered the mainstay 
curative modalities particularly for adenocarcinoma; chemotherapy with radiation 
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therapy, which  has been shown to be an effective primary curative treatment for 
squamous cell carcinoma of the oesophagus; or combined modality therapy [10, 
100].  Endoscopic mucosal resection (EMR) and photodynamic therapy (PDT) also 
offer an alternative to surgery, especially in the management of high grade 
dysplasia with an early cancer of the oesophagus or stomach. Additionally, 
EMR/PDT provides the advantage of low morbidity and mortality, combined with 
the preservation of normal digestion and quality of life, with a survival rate 
comparable to that of major surgical resection [100].  
More recently, endoscopic sub-mucosal dissection is also judged to be a relatively 
safe and effective treatment, particularly for early and superficial gastric and 
oesophageal neoplasms. [101, 102] 
Definitive chemotherapy in combination with radiotherapy, as another alternative 
to surgery, has also been considered by some especially for patients unfit for 
surgery; however they are associated with high morbidity [2, 103].  
Combined modality therapy (chemotherapy with surgery, or chemotherapy and 
radiation therapy with surgery) is still under clinical assessment. Recent randomised 
control trials have shown that combining surgery with pre-operative chemotherapy 
can improve rates of 5-year survival in patients with locally resectable 
adenocarcinoma of the oesophagus, gastroesophageal Junction and stomach [104, 
105] 
At the time of diagnosis, around 30% to 50% of gastric cancers and 50% to 80% of 
oesophageal cancers patients have advanced disease and do not survive more than 
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a few months.[100] Hence, well developed palliative therapy is crucial, not only to 
offer symptom control, particularly for dysphagia, but also to provide a better 
quality of life for patients and their families by providing psychological and social 
support [10, 100].  
Palliative treatment methods include endoscopic dilatation, stenting, contacts 
thermal therapy, laser therapy, argon plasma coagulation, Cytotoxic injection 
therapy, and Photodynamic therapy.[99, 100] Other standard non-endoscopic 
palliative options may include radiotherapy as well as chemotherapy.[100] 
Additionally, pain control, proper nutritional and psychological supports are equally 
as effective as the other palliative intervention mentioned [2, 10, 100, 106]. 
All these palliative options are complementary and may be used individually or 
collectively, as required. However, no evidence has been identified to confirm the 
relative effectiveness or appropriateness of these methods [10, 106, 107]. 
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1.2 Upper GI cancer control strategies and service organization in England 
Differences in survival rates in the UK compared with other European counties, as 
noted above, have prompted and guided recent cancer control strategies in 
England [24]. While the NHS Cancer Plan was published by the Department of 
Health in 2000 [108], its roots are in the  integrated structure of cancer services in 
England and Wales, introduced by the Calman Hine report in the 1990s.[109]  This 
reflects the government’s ongoing strategy to combat cancer as one of its key 
health priorities:  
“The government responded in the 1999 White Paper Saving Lives: Our healthier 
nation (Department of Health 1999), which focused on the four big killers, one of 
which was cancer. It pledged to reduce the death rate from cancer in people under 
75 by at least a fifth (compared with 1996) by 2010, saving 100,000 lives.”  
Rebecca Rosen, Alex Smith and Anthony Harrison (2006)[110] 
The NHS Cancer Plan was designed to enable early recognition of the signs and 
symptoms of cancer, with a strong emphasis on screening and on improved 
treatment options.[108] In addition, key targets including reducing the waiting 
times both for referral to diagnosis (most importantly the introduction of the Two 
Week Wait system “TWW”), and from diagnosis to treatment.[108] There is a 
further intention to invest more heavily in staff, facilities and in the strengthening 
and extension of high quality clinical research in this area.  [10, 108] 
In 2001, the UK National Cancer Guidance Steering Group created the ‘Improving 
Outcomes Guidance’ for upper GI cancer management services.[10] 
Recommendations include the implementation of various routes of diagnosis for 
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patients presenting to general practitioners (GPs) with symptoms suggestive of OG 
cancer (Alarm symptoms).[10] 
In addition, this national guidance service recommends the establishment of a well-
linked clinical team from different specialties, hospitals and professional 
backgrounds, collaborating at the secondary care level as a coordinated multi-
disciplinary team (MDT). Similar teams operating within  the same region form a 
Cancer Network.[10] There are currently 30 networks in England (Figure 1.3).  
These networks have been established to provide proper levels of expertise at 
various stages of care, such as curative surgical treatment and specialist radiology, 
oncology and palliative services to all patients living within each distinct 
geographical area [10, 111]. 
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Figure 1.3 The 30 cancer network which has been published by the National Oesophago-
Gastric Cancer Audit 2009.[16] 
The National Guidance Steering Group also recommends appointing a lead clinician 
for each team within a Network, and that this clinician should oversee the 
production of approved assessment and referral strategies, specifying  the type and 
sequence of diagnostic and staging facilities to be used across the Network, based 
on up-to-date evidence and clinical guidelines. This is aimed at preventing 
unnecessary repetition of testing, as well as reducing delays in diagnosis.  
Furthermore, every MDT needs to avoid unbeneficial intervention, partly through 
the careful selection of patients with an early stage disease suitable for radical 
treatment (which could perhaps offer the possibility of long term survival).  
This text box is where the unabridged thesis included the following third party 
copyrighted material: 
Clinical Effectiveness Unit, The Royal College of Surgeons of England, The Association 
of Upper GI Surgeons (AUGIS), The British Society of Gastroenterology (BSG), The NHS 
Information Centre for health and social care. National Oesophago-Gastric Cancer 
Audit: An audit of the care received by people with Oesophago-Gastric Cancer in 
England and Wales 2009, BSG. 
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Although there is no clear evidence to support which palliative treatment options 
should be applied, nevertheless it is highly recommended that  a local arrangement 
within the each network should ensure the availability and efficient use of such 
palliative procedures as are necessary to improve the patients’ quality of life. [10] 
 The quality of care given to these cancer patients have recently been examined by 
the national OG cancer audit programme.[112-114] This audit mainly describes the 
organization and process of care, as well as the outcomes of both curative and 
palliative treatment, thereby helping secondary services to improve.[112-114] 
Since the introduction of urgent referral pathways for suspected cancer by the NHS 
Cancer Plan (2000) which was further supported by NICE clinical guidelines for 
urgent referral (2005),[115] the Cancer Reform Strategy (2007)  has identified early 
cancer diagnosis as the key to improving cancer outcomes in England.[116] The 
National Awareness and Early Diagnosis Initiative (NAEDI).[116-118] was also 
launched in 2008, and it currently represents the partnership between the National 
Cancer Action Team, the Department of Health, and Cancer Research UK.[116-118]  
NAEDI promotes four major work stream activities which constitute the framework 
for the ‘NAEDI pathway’ (Figure 1.4). [117, 118] The first work stream involves 
improving public awareness of common signs and symptoms of cancer. For 
example, the Doncaster Cough Campaign run by the North Trent Cancer Network 
has led to an 8% increase in the percentage of patients diagnosed at an earlier 
stage of lung cancer as a result of the following simple but informative statement: 
“Cough not better after three weeks? Better go to your doctors now” which causes 
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an improvement in the number of individuals consulting their general practitioner 
at an early stage, thus leading to a greater likelihood of earlier diagnosis.[119-121] 
The second work stream is aimed at overcoming the clinical and system interface 
between primary and secondary care, and better determining the commissioning 
and gatekeeper role of primary care.[117, 118] With around £250 million 
announced by the Department of Health, the third work stream focuses on 
improving GPs access to key diagnostic investigations such as chest x-rays, non-
obstetric ultrasound scan, MRI, and Flexi sigmoidoscopy/colonoscopy aiming to 
improve the chances of earlier diagnosis of lung, ovarian, brain and colorectal 
cancers respectively.[117, 118] The fourth work stream is intended to evaluate, 
inform and support effective NAEDI activity though high quality research 
investigation.[117, 118]  
 
Figure 1.4 The National Awareness and Early Diagnosis Initiative (NAEDI) pathway.[118]  
This text box is where the unabridged thesis included the following third party 
copyrighted material: 
Richards, M.A., The National Awareness and Early Diagnosis Initiative in England: 
assembling the evidence. British journal of cancer, 2009. 101: p. S1 - S4. 
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Guidance relating to the centralization of surgical resection is another important 
aspect of this implemented strategy,[122] since it has been demonstrated that 
there is a strong relation between the mortality rates of oesophageal and gastric 
cancer surgery and the volume of these operations performed by a specialist 
surgical centre [100, 123-126]. Recent evidence of lower short-term and longer-
term mortality for patients resected in high-volume centres has been published by 
the National Cancer Intelligent Network (NCIN) group, further supporting the call 
for greater centralisation of oesophageal and gastric cancer surgical services in 
England.[127]  
In 2011, the government strategy Improving Outcomes: A Strategy for Cancer (IOSC) 
was developed to tackle the possible inequalities, both in terms of experience of 
care and in outcomes of cancer among the UK population.[120, 121] IOSC further 
supports the above initiatives and sets out the ambitious target that by 2014- 2015 
around 5000 lives per annum could be saved, which would bring survival in England 
up to the average for Europe.[120, 121]  
Recently, the Operating Framework for the NHS 2012/13 has added further 
strength to IOSC by affirming that patients should have appropriate access to 
diagnosis and treatment.[128] It also provides patients with a right to be examined 
by specialist within two weeks from urgent GP referral where cancer is suspected. 
There is an expectation by this Operating Framework that less than 1% of patients 
should not wait longer than six weeks for a diagnostic investigation.[128]However, 
the likelihood that this waiting target can be achieved within primary care has not 
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been evaluated specially for patients with a suspected OG cancers where there is a 
predictable variation in the  interpretation of dyspepsia guidelines.   
 
Summary box 3 
The rationale, main components and ambition of the national cancer plan, cancer 
reform strategy, NAEDI and the IOSC have been described. –  At the time of 
commencing this research, there is a lack of evidence to suggest significant 
improvements in outcomes have been achieved for OG cancers in England. A 
national audit programme has described variation and trends in aspects of 
organisation, process and outcome for OG Cancer [112, 113], but its emphasis has 
been mainly on auditing specialist hospital care and pathways after cancer 
diagnosis.  Less attention has focused on the earliest stages of the diagnostic 
pathway, in particular the likelihood that legitimate variation exists within primary 
care in relation to interpretation of existing dyspepsia guidelines, thresholds for 
referral and hence rates of diagnostic gastroscopy activity within practice 
populations.  
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1.3 Gastroscopy procedure  
A gastroscopy is a procedure that uses a thin, flexible tube called an endoscope to 
visualize the oesophagus, stomach, and duodenum; hence it is called Upper GI 
endoscopy. This procedure is also commonly described as a Camera test because it 
has a light and a camera which are used to send images of the upper GI tract to a 
television monitor.  
Gastroscopy is a very common outpatient procedure, generally performed to 
investigate dyspepsia. It has been estimated that around 1% of the population of 
England annually undertook an upper GI endoscopy.[129] This type of procedure 
not only provides direct visualization that can detect Ulcers, abnormal growths, 
precancerous conditions, inflammation and hiatal hernia; it can also be used to 
biopsy tissue, to remove stuck bits and pieces such as food, and to treat conditions 
such as bleeding ulcers or varices.[1] 
Although upper GI endoscopy is widely considered to be a very safe medical 
procedure, there are some who argue that the procedure still carries a small risk of 
serious complications.[130] Potential risks of diagnostic gastroscopy include 
abnormal response to sedations (e.g stroke), infection, bleeding, and accidental 
tearing or perforation of the upper GI passages.[130-132] In England, the chance of 
such adverse effects has been estimated at 1 in 1,000 cases. [131] Data also suggest 
that 1 out of 25,000 cases may suffer a stroke related to the sedative effects of the 
procedure.[131] less serious complications such as sore throat happen in up to 10% 
of the patients.[133] 
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In the UK, it is only since the 1960s that a small number of gastroenterologists have 
been able to make use of the first commercial flexible fibrescopes.[134] However, 
the modern era of this procedure began in 1970s with the submission of Klaus 
Schiller’s  “Memorandum on Future National Needs for Fibre-Optic Endoscopy of 
the Gastrointestinal Tract” to the Department of Health [135]. The document laid 
out the case for much more serious investment in resources in this area (Schiller, 
1973):  
“It is no longer acceptable to do what is possible with available resources, but 
necessary to press for the facilities, equipment and staff to do what should be 
done... What started as a part-time hobby in the early days became a serious 
service commitment.  The toys became tools, and then taskmasters.” British 
Society for Digestive Endoscopy [135] 
One of the most important health service measures linked to this procedure in 
1970s was the initiative of providing general practitioners with free access to 
gastroscopy services.[136] Although at that time many endoscopy units were 
reserved for specialist use, various studies provided evidence that the introduction 
of open access gastroscopy (OAG) would not increase the number of “unnecessary” 
examinations, particularly for patients over the age of 50 years, and confirmed on 
the contrary its potential for reducing the burden on hospital outpatient 
departments. Such findings and recommendations led to its much wider availability. 
[136-142]  
In 1991 the British Society of Gastroenterology (BSG) stated that OAG to general 
practitioners should be offered by all endoscopy units.[143] This publication also 
described the endoscopic workload in various part of the country and dealt with the 
developmental needs and likely expansion required in terms of the professional 
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training, equipment and staffing necessary for purposely built endoscopy units. 
[143] By1994, the second BSG survey of endoscopy practice confirmed that the 
above provision of OAG in the UK had increased to 74%, and that most endoscopy 
units were offering true OAG within agreed guidelines and protocols.[142]  
Also in 1994, under the support of the Academy of Medical Royal Colleges, the Joint 
Advisory Group on Gastrointestinal Endoscopy (JAG) was established [144], with the 
objectives of setting standards for endoscopists, as well as providing UK wide 
support for endoscopic services, to make sure that practitioners would have the 
appropriate training and skills to carry out effective endoscopy.[144] JAG also aims 
to offer consultancy assistance to endoscopy units relating to their structure, 
resources, management, motivation, operations and the improvements necessary 
for providing high quality, patient-centred endoscopy services.[144] 
Within the same year, the role of nurse endoscopists was widely established, as it 
was shown that independent practitioners throughout the UK were making a  major 
contribution to endoscopic services. [79, 145] 
Nearly ten years later (2001), the Endoscopy Committee within the BSG reported its 
updated “Provision of Endoscopy Related Services in District General Hospitals”. 
This document highlighted the national increases within the requirements for 
gastroscopy which was estimated at a rate of as high as 15 gastroscopies per 1000 
population per year.[146] As a result of such high demand for this procedure, the 
society further recommended the wider spread of Open Access Services, Primary 
Care Based Endoscopy units and an increased role for Nurse Endoscopists.[146] 
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More recently, the National Institute for Health and Care Excellence (NICE) set up 
the referral criteria for upper GI endoscopy, classifying any referral as being in need 
of Immediate referral; of Urgent referral; and Non-urgent referral. Although these 
criteria were based mainly on recommendations and guidelines for managing 
dyspepsia in primary care [147], when take in conjunction with the guidance on 
referral for suspected upper GI cancer [148], it was regarded by NICE as a crucial 
first step in managing the flow of patients for endoscopy.[149] 
Summary box 4 
Gastroscopy is the gold standard test for evaluating the upper GI tract. Although 
generally safe, like any invasive medical intervention it is associated with patient 
inconvenience, discomfort and a finite risk of adverse complications. In the UK the 
idea of wide spread availability of diagnostic gastroscopy procedures has been 
developed over the last four decades. Direct access gastroscopy services have been 
implemented, evaluated and quality assured across the NHS and made available to 
primary care clinicians. The high prevalence of dyspeptic symptoms means that 
potential demand for such services is very high with major cost implications. The 
next section describes how guidelines have sought to rationalise the use of 
gastroscopy based on the low yield of serious disease, the availability of effective 
empirical treatments and the option of less invasive investigational strategies. 
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1.4 Suspected OG cancer management and referral pathways in England: a 
primary care perspective   
The cancer diagnostic process for general practice represents a complex area of 
clinical activity.  For example, some cancers such as those of the oesophagus or 
stomach are relatively uncommon conditions, rarely encountered by a typical 
general practitioner, whereas the core symptoms of this cancer as described earlier 
(dyspepsia) are very common. Hence, diagnosis of malignancies with the high 
degree of overlap in symptoms for serious and common benign conditions 
represents a real challenge.  
1.4.1 Dyspepsia clinical guidelines managements in primary care:  when to refer 
for gastroscopy?  
Dyspepsia is a common gastrointestinal complaints in general population.  It has 
been shown that 25 to 40% of the population who experience this condition will 
consult their GP doctor. [37, 150-152] Even though the main causes for primary 
consultation remain unclear, some factors have been addressed, including the 
severity of the symptoms, low socio-economic class, older age and the fear that 
cancer may prove to be the serious underlining cause.[1] Nonetheless, less than 2% 
of dyspepsia patients referred for endoscopy are subsequently found to have OG 
cancer [2, 83].  It has been estimated that in the UK, dyspepsia has per year cost of 
approximately £1 billion. [153]  
Given that dyspepsia has a major impact upon the patients’ quality of life, and 
creates enormous costs for the community [154], guidelines for effective dyspepsia 
management have been drawn up and regularly revised  (Table 1.4). [37]  Although, 
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clinical diagnosis remains relatively ineffective at distinguishing between organic 
and non-organic disease, with the detection rate of OG cancer remaining at only 1-
3%, nevertheless patients with dyspepsia are still considered to be ‘at risk’. [99, 
155]  
All recent guidelines strategies (Table 1.4, Figure 1.4) have centred around four 
main aspects; the definition of dyspepsia; when to refer patient for gastroscopy 
(the upper age limit for gastroscopy referral); the local prevalence of H.pylori (and 
the application of “Test and Treat” approach); and the use of empirical PPI.[37] 
However, none of the cost-benefit considerations supporting established guidance 
for dyspepsia have considered the case of non-referred patients – individuals who 
were considered to be at low risk but who were subsequently found to have cancer. 
In spite of the differences in the methodology used, as well as in the backgrounds of 
the development groups and the target audiences, the guidelines present a 
remarkably consistent management approach for dyspepsia.[37] However, there is 
no clear evidence for the use of an upper age limit for gastroscopy referral, a notion 
which is associated with delayed diagnosis,[37] and any concern that cases of 
malignancy may be missed still does not justify automatic endoscopy in patients 
aged less than 55 with an uncomplicated dyspepsia.[156]  
Initial diagnostic endoscopy in patient with dyspepsia who is under the age of 55 is 
still not recommended as it is considered as being not cost-effective and still there 
is not enough evidence that it does lead to improved outcome.[1]  
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In relation to cancer diagnosis per se, a more intensive strategy might seek to 
detect disease at an early stage either (a) by looking for cancer in all symptomatic 
dyspeptic subjects (without limiting prompt investigation to those with alarm 
features or non-response to initial empirical treatment); or (b) by “screening” 
symptomless individuals for early tumours.  Such an approach is still not 
recommended in “low risk” western populations, since there is no clear evidence 
that mortality rates from OG cancer would be diminished.[1]  However, “at risk” 
populations, such as those diagnosed with Barrett's oesophagus are often followed 
up through regular “surveillance” to identify pre-cancers (dysplasia) and/or early 
stage cancer (neoplasia), which it is hoped will provide significantly improved 
outcomes [1, 157, 158].  
On the other hand, in parts of Asia, such as in Japan, where gastric cancer is known 
to be a major killer, it has been proven that mass X-ray, and more recently mass 
endoscopic screening methods, are useful in the detection of early stages of gastric 
cancer, and that such strategies subsequently reduce mortality rates. Tashiro et al. 
report that the latter method can be particularly effective if a sufficient number of 
skilled endoscopists are widely available. [2, 159] 
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Table 1.4 adapted from Ford and Moayyedi’s 2008 summary of the guidelines for dyspepsia 
management according to their place of origin. [37] 
Guidelines  Dyspepsia definition Place of H. pylori test and 
treat 
Use of PPI therapy 
ACG 2005 
(US) 
Rome criteria, where 
those with 
suspected GORD are 
excluded from 
patients with 
dyspepsia. 
H. pylori test and treat if 
prevalence >10%, empirical 
PPI in lower prevalence 
areas 
Empiric PPI therapy first line in 
low H. pylori prevalence areas 
After H. pylori test if negative or 
positive and failing treatment in 
high prevalence areas Standard 
doses of PPI therapy should be 
used with double doses 
considered if symptoms persist 
ACG 2005 
(US) 
Rome criteria H. pylori test and treat if 
prevalence >10%, empirical 
PPI if prevalence <5%, if 5 -
10% strategy uncertain 
Empiric PPI therapy first line in 
low H. pylori prevalence areas 
After H. pylori test if negative or 
positive and failing treatment in 
high prevalence areas 
NICE 2004 
(England 
and 
Wales) 
All upper GI 
symptoms 
Evidence of H. pylori test 
and treat or empiric PPI 
therapy uncertain so first 
line choice left to individual 
preference. If one fails, try 
the other. 
Initial therapy should be 
standard dose for one month 
Then patient should be managed 
with on demand PPI therapy at 
the lowest dose that manage the 
patient’s symptoms 
SIGN 2003 
(Scotland) 
Rome criteria First line for those with 
dyspepsia and no alarm 
symptom at any age 
Empiric PPI therapy if H. Pylori 
eradication fails. Dose not 
explicitly stated. 
CanDys 
2005 
(Canada) 
All upper GI 
symptoms, except 
isolated heartburn 
H. pylori test and treat if 
epigastric pain is the 
dominant problem 
Empiric acid suppression if 
heartburn is the predominant 
problem. Standard dose PPI for 
4–8 weeks then consider on 
demand PPI or stepping down to 
H2RA 
Asia-
Pacific 
working 
party 
1998 
Rome criteria Consider H. pylori test and 
treat if patient fails empiric 
acid suppression and/or 
prokinetic therapy In areas 
with high prevalence of H. 
pylori, this strategy is 
unlikely to be beneficial 
First-line therapy for young 
patients with no alarm features. 
Either PPI or H2RA at standard 
dose 
 
 
This text box is where the unabridged thesis included the following third party copyrighted 
material: 
Ford, A.C. and P. Moayyedi, Current gu d lines for dyspepsia anagement. Dig Dis, 2008. 
26(3): p. 225-30. 
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Figure 1.5 Dyspepsia guidelines summary for the differences in the upper age limit for 
gastroscopy referral according to their place of origin adapted from Ford and Moayyedi’s 
2008 summary of the guidelines for dyspepsia management.[37] 
 
Summary box 5 
The potential demand for gastroscopy is large and European and North American 
guidelines have favoured initial empirical treatment and H. pylori-based ‘test and 
treat’ strategies over automatic investigation of dyspepsia unless there are obvious 
alarm features. 
 
 
Alarm features (any age) Consider 
referral to secondary care if ≥55 
years and symptoms persist. SIGN 
2003 
(Scotland).  
Age 35–55 (depending on risk of 
gastric cancer in the region) or 
alarm features (any age). Asia-
Pacific 
Working party 1998 
Age >55 or alarm features (any age) 
If H. pylori eradication and/or PPI 
fails in those ≤55 consider. AGA 
2005 (US) 
Age >50 or alarm features (any 
age) If H. pylori eradication 
and/or PPI fails in those ≤50 
consider.  CanDys 2005 (Canada) 
Age >55 or alarm features (any age) 
If H. pylori eradication and/or PPI 
fails in those ≤55 consider. NICE 
2004 (England and Wales) 
This text box is where the unabridged thesis included the following third party 
copyrighted material: 
Ford, A.C. and P. Moayyedi, Current guidelines for dyspepsia management. Dig Dis, 
2008. 26(3): p. 225-30. 
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1.5 Delays in cancer diagnosis and the role of the “gatekeeper” approach 
Distinguishing patients who can be managed within the GP practice setting from 
patients who need referral to specialist care is generally described as the 
gatekeeper role of primary care. [160] This role is considered a central aspect in the 
cancer diagnostic process, and yet it can also be a potential source of avoidable 
delay in cancer diagnosis within the NHS and in other countries with similar 
systems.[33] 
It has also been cited that patients with lower-than-average outcomes may be a 
sign of inappropriate care pathways and/or may indicate that these patients have 
deteriorated more than should have been allowed by the inadequate provision of 
healthcare in primary care, or as  outpatients in hospital. [161] 
The biological nature of the disease means that it is unavoidable that some cases of 
cancer in general will not be diagnosed until the patient is admitted to hospital as 
an emergency case. There are also some cases which may be diagnosed through 
screening programmes. However, the vast majority of  cancer cases are first 
presented, with signs and symptoms, to primary care. [162, 163] 
Researchers have noted that late cancer diagnosis and its consequences cannot be 
attributed exclusively to the primary care initiation of an investigation of potentially 
cancer-related symptoms (so-called “doctor delay”), since this might also be 
assigned to other factors include the patient’s late presentation (“patient delay”), 
or  the referral process and variations in access to diagnostics (“system delay”). 
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[164, 165] Nevertheless, primary care delay and system delay have been shown to 
account for the majority of delays within the UK system. [166]  
 
Figure 1.6 shows the various level of delay within cancer patients diagnosis and care 
pathways, adapted from Hansen et al 2011. [167] 
An ecological study investigating cancer survival rates in 19 European countries, in a 
comparison of their gate keeper systems found that the countries with a more 
restricted “strong” gatekeeping approach are associated with poorer cancer 
survival rates than those with a weak gatekeeping system.[168]  
In Denmark, which has a comparable cancer-related poor outcome, with a similar 
health-care and gatekeeper system to that of the UK, shows patient and system 
delay accounting for the majority of the delay in cancer diagnosis.[169] On the 
other hand, the Netherlands and Australia, both of which operate a similar 
gatekeeper system, report much better cancer-associated outcomes. Hence, it has 
been proposed that these differences may be explained by the different levels of 
access to diagnostics available in otherwise similar healthcare systems.[170]  
This text box is where the unabridged thesis included the following third party copyrighted 
material: 
Hansen, R.P., et al., General practitioner characteristics and delay in cancer diagnosis. a 
population-based cohort study. BMC family practice, 2011. 12: p. 100. 
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However, there is as yet no clear evidence available in the literature supporting the 
idea that the availability of open access endoscopy can be associated with 
improved survival. A study by Sunder et al. (2006) also suggests that simply by 
limiting open access gastroscopy to patients with alarm symptoms, a small number 
of patients with potentially curable disease might be missed.[171] Nevertheless, it 
was suggested that direct access endoscopy may not only reduce the time to cancer 
diagnosis, but may also provide potential psychological benefits to patients, as well 
as reducing the proportion of patients diagnosed in an emergency situation. [172, 
173] 
In the UK, despite the extensive investment that has been put into securing early 
diagnosis (in particular the establishment of the TWW for fast-track referral so that 
a specialist can see a suspected patient as quickly as possible, together with the 
supporting guidance from NICE), there has been little improvement in the detection 
of curable cancer. [164]  
Even though the logical concept that fast-track assessment of suspected cancer 
cases by specialist within 2 weeks of GP referral is worthwhile, there was no robust 
supporting evidence before its application would suggest improve outcomes.[174, 
175]        
Overall, it has been shown that the TWW did not improve the processes of 
identifying patients at their earlier staging of the disease [176], and approximately 
three quarters of cases of oesophago-gastric cancer are still diagnosed at a late and 
inoperable stage.[33, 177]  
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Studies have also demonstrated that a quite significant amount of cancer diagnosis 
occurs outside the TWW system [173, 176, 178-180]. In addition, it has been argued 
that the TWW produces a two-tier service, with a considerable number of patients 
in the second tier who have not only missed the rapid diagnostic facility, but who 
also experience longer waiting times in the routine way. [181] This group of worse-
off patients could perhaps be diagnosed though the emergency route. 
 
Figure 1.7  Cancer patients’ pathway with various stages of care and route of diagnosis and 
managements. 
Hanna et al (2005) conclude from a review of the relevant literature that the TWW 
is unsatisfactory on its own, and would not have a major effect on survival, since 
the delays caused by GPs represent simply a small portion of the ‘cancer pathway’ 
[173].  
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In 2011, the RCGP published the first English national audit of cancer diagnosis in 
primary care, in which 1170 GP practices participated, collecting a year’s worth of 
data on 915 OG cancer patients ( 596 oesophageal and 319 gastric) from 20 cancer 
networks.[182] This audit examined the number of times patients present with 
possible symptoms of cancer before being referred for specialist opinion. The 
results show that 19.3% of oesophageal and 25.8% of gastric cancer patients had 
three or more consultations before referral, and that only around 58.2% of 
oesophageal and 40.4% of gastric cancer were referred through the two week 
urgent referral pathway.[182]  
 
Summary box 6 
Delayed cancer diagnosis is a real challenge. In the UK, GPs have access to the" Two 
Week Wait" system for urgent referrals and well established access to diagnostic 
gastroscopy. But, GPs serve a ‘gate-keeper’ role which is based on guidelines and 
referral criteria for dyspepsia that focus on ‘alarm symptoms’ as triggers for 
investigation.  Current guidelines tend to encourage low rates of gastroscopy and 
endorse a ‘watch and wait’ approach. 
Does adherence to the guidance contribute to most cancer cases being diagnosed 
at a late/incurable stage?   If primary care were to adopt a lower threshold for 
gastroscopy, might that translate into better cancer outcomes? 
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1.6 Meaning and Explanation of variations in health care: differences in GP 
referral rates and health inequality.  
Variation in health care and clinical activity is a widely distributed phenomenon 
within and between countries.  There are sizable differences in terms of patients’ 
access to health care and their disease related outcomes between patients when 
aggregated at the level of GP practices, primary care trusts, hospitals and 
regions.[183-186] Wennberg (2010) sees “unwarranted variation” as “variation in 
the utilization of health care services that cannot be explained by variation in 
patient illness or patient preferences.” [186] 
Clinical practice variation has been recognized in England and Wales since 1938, 
when a tenfold difference in the rate of tonsillectomy operation was reported.[187]  
Decades later, an increasing body of data has documented large differences in the 
utilization of health care services between different geographic areas, a finding 
which holds true in many countries, regardless of the diversity of the organisation, 
operation and funding of their health care system.[188-196]  
Although healthcare managers, clinical researchers and physicians interpret 
variation differently, as they are pursuing different objectives,[197, 198] 
nevertheless variation remains of vital importance to individual patients, because at 
the personal level, the balance between good and bad depends not only on the 
evidence of the outcome of the intervention but also on the rate at which the 
intervention is accessible.[185]  
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It should be remembered that  not all variation is necessarily bad or unwarranted, 
and that some is even desirable, because new and improved ways of patients’ 
management could result from positive variation.[197]  As Mulley (2010) points 
out:  
“If all variation were bad, solutions would be easy. The difficulty is in reducing the 
bad variation, which reflects the limits of professional knowledge and failures in 
its application, while preserving the good variation that makes care patient 
centred. When we fail, we provide services to patients who don’t need or wouldn’t 
choose them while we withhold the same services from people who do or would, 
generally making far more costly errors of overuse than of underuse.”[199] 
However, the King’s Fund Group  (2011) notes that identifying what proportions of 
variation could be considered as ‘good’, or “warranted” remains highly problematic: 
[200]  
“If variations represent evidence of inappropriate care, which care is 
inappropriate? Are the regions, or institutions, or practitioners with high rates 
over-providing, or are the low ones under-providing, or does the ‘best’ rate lie 
somewhere in the middle (or beyond either end)?” [200] 
Although some commentators argue that population dissimilarity, as well as data 
issue, might provide some explanation of this phenomenon, [186] a quite significant 
body of the literature concludes that variation is generally unexplainable and is 
often unavoidable because of the complexity and the unfeasibility of controlling of 
all the variables that may generate it.[200, 201]  
Another explanation involves the notion that uncertainty about the effectiveness of 
health services and/or the level of intolerance of diagnostic uncertainty leads 
physicians to differing conclusions about when to perform various investigations or 
managements. [188] This hypothesis implies that while physicians may agree on 
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indications for procedures that are clearly appropriate, and on those that are 
clearly inappropriate, there nevertheless remains a large "grey area" in the middle, 
over which much disagreement exists.[188, 202] 
Additionally, Chassin (1993) points out that geographical differences in health care 
could arise when large numbers of physicians in one area become more 
enthusiastic about a particular procedure or health related condition. [188] In this 
regard, Cummins (1981) notes that doctors tend to have unique 'referral 
thresholds' or referral habits which are not only affected by their level of training 
and experience, but also through their tolerance of uncertainty, personal 
enthusiasms and sense of independence.[203] However, this enthusiasm may also 
lead some to employ these services for inappropriate reasons.[188]  
 In 1948, the UK developed the National Health Service (NHS)  on the basis of the 
clinical need for obtaining health care, regardless of whether a patient is able to pay 
for it. The NHS was described as a universal service, aiming at being “available to 
all irrespective of gender, race, disability, age, sexual orientation, religion or 
belief”. [204] However, variations in referral rates from generalists at the primary 
care level to their more specialised colleagues within the secondary care system 
remain a long-standing clinical and economic concern.[185, 186, 205, 206]  
It has been demonstrated that this variation cannot be explained by dissimilarities 
in patient morbidity or by data error.[207] Moreover, only small percentages of 
variation can be accounted for in terms of differences between individual GPs. [205, 
208] Even though the appropriateness of these referrals (particularly at the higher 
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level) has been questioned by many, this does not fully explain such variation.[208-
211] On the contrary, there remains serious questions concerning inequity in access 
to specialist services, the effectiveness of primary care and the ineffective 
utilization of healthcare resources.[207, 208, 212]  
In the UK, national clinical guidelines based on a mixture of evidence and expert 
agreement help GPs to decide which patients need to be referred to more specialist 
services for further investigation.[147, 148, 213] Although some studies have 
shown that these referral guidelines could be used to control the number of 
patients referred to hospitals, and might save costs and reduce unnecessary 
investigations [214, 215], nevertheless the recent NHS atlas of variation indicates 
widespread variation in GP referral rates, particularly for suspected cancer 
cases.[185]  Additionally, Baughan et al (2011) have shown  that many patients who 
fall outside the national guidelines were later diagnosed with malignancy, 
suggesting that there might be reasons other than those in the guidelines which 
might make GPs suspect the necessity for referral.[216]  
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Summary box 7 
Uncertainty remains over the role of referral guidelines per se in achieving 
reductions in the wide variations observed in referral rates from primary to 
secondary care.[217]  Current guidelines for investigating upper GI symptoms are 
controversial and lack a strong evidence base in terms of promoting optimal cancer 
outcomes. There is no current evidence to suggest that OG cancer patients 
belonging to practices at the lower end of the referral rate spectrum for 
gastroscopy experience any increased risk of poor outcome. The research described 
in this thesis seeks to apply epidemiological methods to study variations in 
gastroscopy rates within general practice populations and to test whether this 
variation is associated with OG cancer outcome.  Generating robust evidence to link 
activity levels to outcome has potential to inform guidelines and policy.[218] At the 
level of primary care, a diagnostic pathway might be associated with a wide 
spectrum of rates of investigation between practices serving similar populations. 
However, without evidence for a link to differential patient outcomes there can be 
no understanding of whether low, average or high rates of referral are optimal for 
the condition of interest. 
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1.7 Evaluation of health care  
In general, medical management aims to diagnose and treat diseases, to ease 
symptoms, to improve health-related quality of life and to save or prolong life. 
While wide variations in practice are perhaps inevitable, there is growing evidence 
that high rates of inappropriate healthcare, in terms both of the type and also the 
time of various medical interventions, can and should be avoided.[211, 219-223]  
Anecdotally, health care providers or regulators (e.g. PCT, GP practices and 
hospitals) have shown concern about continued variations in the quality of care 
provided.[224-227] Providers’ attention has also been directed toward a more 
evidence-based and cost effective approach to care provision.[228, 229] This in turn 
has led to an appreciation of the importance of using various performance and 
outcome indicators to measure  the quality of care and service.[230]  
Mainz (2003) provides a review of the definitions, characteristics, and categories of 
clinical indicators for quality improvement in health care internationally, noting that 
quality indicators are a necessary measure for helping identify the most appropriate 
course of action for  a specific group of patients, or a health-related condition, 
ensuring that this is based on the most recent clinical guidance and/or evidence-
based standards of care.[231]  
One of the most comprehensive definitions within this review was developed by 
the Canadian Council on Health Services Accreditation (1996). This describes quality 
indicators as “measurement tools, screens, or flags that are used as guides to 
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monitor, evaluate, and improve the quality of patient care, clinical support 
services, and organizational function that affect patient outcomes”.[232]   
Quality indicators can be rate-based sentinels that relate  to structures, processes 
and/or outcomes.[219] They can also be either generic or disease specific. The 
structural element is the organisational framework, including the staff (e.g doctors 
and nurses), beds, equipment, and the other resources required to meet a defined 
standard of health care on a particular health issue; process refers to how such 
activities are delivered and used; and outcome refers to the effectiveness of these 
activities of interest (e.g. diagnostic procedures or interventions) in relation to 
patients’ health. [219] 
Table 1.5 Summarizing the most widely used characteristic for an ideal indicator. Adapted 
from Mainz 2003.[231] 
Indicator is based on agreed definitions 
described exhaustively and exclusively 
Highly or optimally specific and sensitive 
Valid and reliable 
Discriminates well 
Relates to clearly identifiable events for the user 
Relevant to clinical practice 
Permits useful comparisons 
Evidence-based 
 
 
 
 
 
 
 
This text box is wh re the unabridged thesis included the following third party 
copyrighted material: 
Mainz, J., Defining and classifying clinical indicators for quality improvement. 
International Journal for Quality in Health Care, 2003. 15(6): p. 523-530. 
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Table 1.6 Examples of (A) indicators related to the structure, process and outcome of 
health care quality; (B) generic and disease specific indicators. Adapted from Mainz 2003. 
[231] 
 
Despite the fact that performance indicators are considered a promising answer to 
the demands for improved quality within the health care system, still the evidence 
of these indicators’ value in improving health outcomes of the population has been 
questioned in the literature. [228, 229, 233] For example; evidence about the 
effectiveness of Coronary Artery Bypass Graft (CABG), cataract surgery and of hip 
and knee replacement are well recognized attributable to health care, only if 
performed on appropriate patients. However, the ideal rates at which these 
procedures should be performed within the general population remains 
A 
B 
This text box is where the unabridged thesis included the following third party 
copyrighted material: 
Mainz, J., Defining and classifying clinical indicators for quality improvement. 
International Journal for Quality in Health Care, 2003. 15(6): p. 523-530. 
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unclear.[233] Similarly, an investigation of the use of waiting time data as a 
performance indicator in health care might offer easily measurable numbers, but 
this does not necessarily reflect the reality for the patients, the GPs, the treatment 
and/or the strategy behind these numbers.[234] 
Therefore, careful development, interpretation and evaluation of quality indicators 
in order to study the relationship between the effectiveness as well as the efficient 
use of health services are necessary. Such evaluation is essentially based on the 
analysis of reliable and valid research data regarding the structure, process, and 
outcome of health care activities.[219]  
Numerous research studies into a range of medical conditions (including congestive 
heart failure, stroke, and pneumonia) have shown significant linkages between 
processes of care and outcomes, particularly when the patient is the unit of 
analysis.[235] It is often necessary to evaluate the structure and process of care 
together, in order to interpret their outcome.[219] In other words, data concerning 
structure and process are fundamental if the researcher hopes to answer the 
question of whether the outcome of a particular disease was mainly influenced by 
the treatment itself, and/or as a result of the organisational framework (structure), 
or by the way it was delivered (process).[219, 236] For example; the patient’s 
ultimate outcome for a coronary angioplasty could depend on where the procedure 
took place (organizational structure), or on whether it performed on the correct 
patient and on whether it was properly carried out (process).[236]   
Fundholding is a crucial aspect to understanding the performance of any 
organization in seeking to create continuous improvement. Although research has 
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shown that differences in fundholding can explain only around 5% of the observed 
variation in referral, [201, 237] it is still logical to consider the effect of any 
commissioning process when evaluating health care quality. One of the essential 
aspects of these types of analysis involves identifying the best way to redirect 
resources toward those processes and structures of care that have been proved to 
have the most beneficial effect on patient outcomes.[235] 
Value in health care is considered a common objective that should bring together 
the activities of all stakeholders.  In this regard, Porter (2010) defines the concept of 
value in health care as “the patient health outcomes achieved per dollar spent”. He 
adds:  
“Value should always be defined around the customer, and in a well-functioning 
health care system, the creation of value for patients should determine the 
rewards for all other actors in the system. Since value depends on results, not 
inputs, value in health care is measured by the outcomes achieved, not the 
volume of services delivered, and shifting focus from volume to value is a central 
challenge.” [238] 
It has also been shown that improvement in disease-related outcome is often 
associated with reduced costs; for instance, early detection of some medical 
conditions can lead to less complex care, and perhaps less invasive treatment with 
fewer complications, resulting in reduced need for subsequent follow up.[239] 
However, this hypothesis cannot necessarily be applied to the treatment of all 
diseases. Arguably, screening programmes that are directed towards a broad range 
of the patient population can result in decreased value.[239]  
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Summary box 8 
Health indicators seek to measure organisation, structure, process or outcome of 
care in order to support quality assurance, allowing benchmarking between 
providers and analysis of time trends to monitor improvement.  An increasing range 
of generic and disease-specific indicators are available and are used by central 
government, the department of health, commissioners and providers to measure 
NHS performance.  Many indicators rely on analysis of routinely collected 
healthcare data, since prospective collection of bespoke audit datasets at the point 
of care delivery is logistically challenging, costly and often incomplete.  The next 
section describes routine data in healthcare settings. 
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1.8 The use of routine health care activity data to drive clinical care and outcomes 
Information continues to play an increasingly more central role in helping clinical 
staff to deliver safe and effective care to their patients. Many collected patient 
activity databases have been routinely developed throughout the world for the 
purposes of negotiation of hospital funding, allocation of resources, and strategy 
formulation within healthcare systems (Table 1.7) [240, 241].  Although most were 
never explicitly intended to be used for research purposes, recently they have been 
recognised as a unique data source for descriptive and comparative studies, and the 
number of specialist publications using these kinds of data sources is steadily 
increasing. [242] 
When prospective randomised control trials cannot be conducted because of 
impracticalities, expense or for any other reasons, the use of large administrative 
databases can provide observational methods that offer the opportunity for the 
assessment of health care practice.[243] This can also establish a resource with 
sound external validity, which is sometimes hard to achieve in randomised 
studies.[243] Likewise, it allows measurements to be defined independent of 
specialist units participating in the prospective collection of clinical databases such 
as those used for local and national audits. Hence routine health care activity might 
permit improved analysis of real world outcomes.[242] Furthermore, many studies 
have shown the potential value of feedback and performance assessment with 
regard to health care providers. [214, 244]For these reasons, it is vital that we make 
the best use of the data sources available in our health systems.  
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Table 1.7 Summary of the various sources of routine data along with their strength and 
weakness. Adapted from Oxford hand book of Public health, by Pencheon et al 
(2001).[245] 
Important sources of routine data for evaluation 
Vital statistics 
Cancer registration 
Communicable disease notification  
Hospital activity records  
Primary care records 
Prescribing records 
Insurance claims  
Emergency service records  
Litigation procedures  
 
Strength of routine data   
Large size  
Available quickly  
Multiple uses of data can be efficient 
100% ascertainment including subjects that have died 
Prospectively recorded information on past events 
reduces bias 
System-wide coverage reduces bias  
 
Weaknesses of routine data   
May not include items of interest 
Mostly process information 
Inflexible  
Access may be difficult to negotiate or expensive  
Analysis can be difficult because of size  
Quality may be variable or unknown  
 
 
1.8.1 Hospital Episodes Statistics (HES) Data  
1.8.1.1 The origin of HES data: 
In England, the most inclusive and widespread source of information is the hospital 
activity data held in patient administration systems (PAS).[246-248] Information 
written by clinical staff in the notes, letters and/or discharge summaries are next 
extracted to the PAS by clinical coding staff who are responsible for the translation 
of diagnostic or procedural terms, as written by a clinician in the patient record, 
This text box is where the unabridged thesis included 
the following third party copyrighted material: 
Pencheon, D., et al., Evaluating heath care using 
routine data, in Oxford Handbook of Public Health 
2001, Oxford University Press. 
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into an alphanumeric code, using the International Statistical Classification of 
Diseases and Related Health Problems ICD-10, and the Office of Population, 
Censuses and Surveys Classification of Interventions and Procedures OPCS-4.[248] 
Subsequently, extracts from PAS are transferred to the Secondary Uses Service 
(SUS) which is the protected central data store that receives and processes 
patients’ health related data for the whole of the NHS. After that, and at pre-
arranged times during the year, SUS sends extracts to (HES) dataset (Figure 1.7). 
[248] 
HES is the England’s storehouse for record level hospital data relating to all 
episodes of inpatient and day case care, and was originally started in 1987 following 
a report on the collection and usage of hospital information published by Dame 
Edith Körner (1921-2000).[246, 248] These data are available for each financial year 
from 1989-1990 onwards. Since its foundation, its data collection methods have 
changed substantially, mainly as a result to changes in NHS organisation.[246] For 
example, HES was first gathered (sub-nationally) by the regional health authorities, 
but in 1996 this process was moved to the NHS-Wide Clearing Service (NWCS). 
Since 2006, this has been taken over by the SUS,  under the control of the Health 
and Social Care Information Centre and the National Programme for IT.[246, 248] 
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Figure 1.8 Information flows for routinely collected data from its starting point (patient 
notes) to its final destination (HES)[248] 
 
1.8.1.2 Structure of HES data: 
For each financial year (from 1st April to 31st March) there are millions of records 
(episodes of care) within the HES data storehouse. This information represents all 
NHS-funded admitted patient care, and private care within NHS hospitals in England 
[247]. An episode or Finished Consultant Episode (FCE) is the period of time a 
patient spends under the care and responsibility of one consultant team. This is 
different from the patient's entire stay in hospital (Inpatient spell) which may 
consist of one or more FCEs. However, when the responsibility of a patient is 
transferred from one consultant to another within an inpatient spell, this is called a 
Transfer of care process.[248]  
HESID is the identifier that is unique to each patient and his/her HES.[249] This ID is 
essential for linking together records (episodes) for a single patient [247-249].  Each 
HES record (episode of care) can include more than 50 variables of information, 
collected directly by hospital providers or derived by the HES team. The nature of 
This text box is where the unabridged thesis included the following third party 
copyrighted material: 
rcplondon, Hospital Activity Data A Guide for Clinicians, the RCP Information 
Laboratory (iLab) 2007, Royal College of Physicians. 
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information collected in HES for each patient and in each episode of care is 
illustrated in (Figure 1.8). These data contain information about (A) Patients’ 
demographics, (B) Hospital level administrative details, (C) Care providers and (D) 
Mode of admission as well as coded diagnosis and procedures.  Details of all these 
variables will be presented in the main method section (Chapter 2) and the 
supporting appendices (Chapter 7). Here it is important to note that the usual 
approach for analysing HES data as described in the literature encompasses 
extracting only episodes or admissions according to the coded “primary diagnosis” 
(DIAG01), and then undertaking analyses on these extracted episodes alone and 
using the secondary diagnosis to study the patients’ related co-morbidity. [250-252] 
There are several limitation to this approach which will be discussed in (Chapter 3). 
 
 
 
 
 
81 
 
 
 
 
 
 
 
 
 
Figure 1.9 Illustrates the appearance of a typical extract of HES data. This data contains 
information about (A) Patients’ demographics, (B) Hospital level administrative details, (C) 
Care providers and (D) Mode of admission as well as Coded diagnosis and procedures. 
 
1.8.1.3 Limitations to the quality of HES data. 
There is an anecdotal concern about whether these large datasets, which are 
intended for use in health service planning and financial management, can also be 
used to reflect clinical performance [253], or for auditing purposes [254], or to 
support the appraisal and revalidation of consultant physicians  [255]. 
Additionally, it is believed by some that, such huge volumes of patient activity are 
generated continuously, and examination of every episode of care is not possible 
[248]. Furthermore, HES lacks information related to cancer staging as well as direct 
(A) The unique 
patients’ identifier, 
age, sex, ethnic 
group and 
deprivation status  
(B) The administrative 
details: e.g. dates of 
admission, discharge, 
start and end of the 
episode as well as in 
hospital deaths 
(C) Details about 
where the patients 
were managed e.g 
main specialty, 
consultant code, GP 
practice, Hospital and 
PCT codes 
(D) Clinical details, 
particularly admission and 
discharge methods, 
Diagnosis and procedures 
coded with ICD_10 and 
OPCS_4 codes. These codes 
are arranged as primary ( 
DIAG01 & OPERTN 01)  and 
up to 13 secondary 
diagnoses  and procedures 
coded positions  
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information on the patients’ quality of life or experience [247, 256]. Outpatient HES 
are still less complete and reliable; and fewer secondary diagnosis, co-morbidities 
and complications are recorded in the UK than are recorded in North America [241, 
247].  
 The Royal College of Physicians (RCP) Information Laboratory (iLab) notes that 
clinical coding rules and conventions are complex, and that accurate coding 
depends on clear medical documentation of diagnoses and procedures, as well as 
on effective translation of this information into codes by the coding staff. [257]  
The RCT (iLab) team also states that it is the responsibility of all NHS staff to 
guarantee that the information used in assessment making is as truthful and 
accurate as possible, since high quality information is essential for patient care, 
both directly and indirectly. Subsequently, iLab has proposed various scientific 
methods and communication channels between clinicians and coding staff, with a 
view to improving the quality of the collected data (Figure 1.9).  [248, 258] 
In this regard, Williams and Mann comment that: 
 “Even if patient episodes are captured, the clinical data recorded may be 
inaccurate. A retrospective audit in two hospitals, comparing diagnosis codes 
assigned by local staff with those assigned by members of an external coding 
team who did not know the locally assigned codes, found exact agreement for the 
main diagnosis in 43% and 60% of cases, and approximate agreement in 55% and 
72% of cases, respectively, in the two hospitals” [241]  
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On the other hand, Paul Aylin et al contest this finding, arguing that  
“Problems with data quality are often not uniform but vary by coding field, clinical 
area, Trust or occasionally region and by year. The approximate agreements in 
diagnostic coding in one study were quoted as 55% and 72% in two hospitals for a 
random assortment of diagnoses, but the paper goes on to document agreements 
of 86% and 91% for specific diagnoses such as asthma.”[259]  
Moreover, Aylin adds that comparison of UK records of co-morbidities with those in 
the US is inappropriate, since placing the patient in a more significant diagnosis and 
management position might lead to the repayment of more health care costs, 
according to the US health care system [259]. 
Before making HES information available in the data warehouse, HES must be 
subject to various validation and cleaning stages.[246, 260] For example; a process 
called ‘autocleaning’ ensures that data fields are inter-related and understandable 
both in isolation and also with reference to other variables. A subsequent process 
known as ‘validation’ involves the testing of data against a set of rules to identify 
any problems that remain after the autocleaning process.[260, 261]  
HES Processing Cycle and “autocleaning” are considered essential steps in data 
validation and cleaning to ensure and maintain good data quality. There is evidence 
that the coding accuracy of HES data has improved significantly over time. [262] 
Galland et al. (2000) found that HES coding for varicose vein surgery was 45% more 
accurate than local audit data in 1989, which had improved to 98% by 1995. [263] 
In addition, a systematic review of twelve studies from England and Wales, plus a 
further nine from Scotland, analysed the use of HES, PEDW (Patient Episodes 
Database of Wales) and ISD-NHSS (Information and Services Division of NHS 
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Scotland), concluding that the coding accuracy in England and Wales is as high as 
91% median coding accuracy for diagnostic codes, while in Scotland it is even 
higher, with 98% for procedure coding accuracy [264].     
More specifically, the National Cancer Intelligent Network (NCIN) recently 
published its findings that only a small percentage of patients with oesophageal 
(0.7%) and gastric (0.3%) cancers were recorded only in HES, without 
documentation in the cancer registry over the ten years of the verification period 
(1998-2007) for data quality.[265]  
 
Figure 1.10 Suggested ways to improve data quality. RCP 2007[248] 
 
 
 
 
 
 
This text box is where the unabridged thesis included the following third party 
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Summary box 9 
Many studies have illustrated the potential contribution that the national HES data 
might make to understand care delivery and outcomes.   But they also show how 
careful one must be to select  the right cases for study and to use clinical 
knowledge in constructing analyses.  It is the clinicians who understand the 
potential significance of the variables within the data, and can relate them to both 
local policies of care and to the terminology used in guideline documents.  Thus, if 
this project can derive a subset of all individual patient episodes of care from a 
national cohort of patients with OG cancer from the HES data, it should,  with  a 
meaningful approach and analysis, be possible to track those patients along their 
care pathway and link unsuspected variations in a particular aspect of care to 
outcome. 
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Chapter (2) Rationale, Hypothesis, Aims and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 Rational, Hypothesis and Aims 
 
87 
 
2.1 Rationale of the study 
Over the last few decades oesophago-gastric malignant tumours have remained a 
worldwide challenge with little sign of major improvements in survival rates. 
Symptoms that might be an indication of early-stage OG cancer are very common 
and non-specific.  Diagnosis therefore necessitates the investigation of symptoms 
though upper GI endoscopy (gastroscopy) in a relatively large group of patients, 
most of whom do not have malignant disease. OG cancer management involves 
complex decisions including the use of a relatively invasive endoscopic, surgical and 
oncological (non-surgical) approach. Cure is possible for a minority of cases through 
radical surgery and/or oncological treatment, but for many patients the disease is 
incurable at the time of diagnosis and the aim is to palliate symptoms. 
Although epidemiological and socio-economic factors are likely to account for 
geographical variation in the outcome of this disease, there is concern that 
variation in practice and inequality in access to cancer services may play a role. 
Direct access to gastroscopy from primary care was established in England during 
the 1980s [142] and fast-track access for those with more specific alarm (or “red 
flag”) symptoms was introduced into the NHS under the national cancer plan and 
the two week role system.[108] However, there has been little improvement in 
detection of curable cancer during this period.  
There has to date been no assessment of access to investigation (gastroscopy) in 
relation to to OG cancer related outcomes. Furthermore, it is still unknown whether 
worse patient outcomes are associated with low levels of utilisation of this gold 
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standard diagnostic investigation technique, or conversely whether high levels 
achieve tangible benefits. 
The NHS routinely collects a wide range of data about patients’ demographic, 
clinical and administrative information, as well as details of where they were 
treated.  Although this large source of information is regularly collected for analysis 
centrally, It has been argued that such analyses fail to explore the reliability and 
clinical relevance of the data and make ill-judged links to care quality.[241, 248] 
Hence, better techniques are needed to generate clinically-useful measures of care 
outcome capable of validation. 
2.2 Hypothesis: 
Outcomes for OG cancer may be associated with per capita rates of gastroscopy in 
the local general practice population. Specifically, cancer patients belonging to 
general practices with low rates of gastroscopy may have the poorest chance of a 
good outcome.  
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2.3 Aims and Objectives:  
1. Using Hospital Episodes Statistics (HES) data, to develop and validate 
methods for identifying patient populations with a coding sequence of 
diagnoses and procedures compatible with incident cases of OG cancer. To 
check the face-validity of data outputs by reference to external sources 
(local audit data and published national statistics) and thereby confirm their 
suitability as a tool for studying factors associated with OG cancer outcome. 
2. To analyse HES data, with linkage to external sources of population 
information at the general practice level, in order to explore variation of 
gastroscopy rates in the primary health care setting and then to test 
whether the gastroscopy rate in general practice populations in England is 
associated with patient outcomes for OG cancer. 
3. To identify whether practices with ‘low’ gastroscopy rates appear to be 
operating more selective referral practice, as reflected in a higher yield of 
serious pathology among subjects referred for investigation.  Methods will 
be developed to describe the diagnostic profile of all patients undergoing 
elective gastroscopy and to compare profiles across the spectrum of 
practices, both nationally (using HES data) and locally (using routinely 
collected endoscopy reporting data).  
These elements constitute the three inter-related work streams that form the basic 
structure of this thesis. The findings of each element will be presented in a separate 
chapter, with its own background, aims, results and discussion section.  The present 
chapter describes the various methodologies developed for data extraction, 
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internal and external linkage, case definition and specifications for the generation 
of patient-level variables, with reference to the relevant Appendices and Syntaxes 
(containing the listings used for code selection and syntax for data processing). 
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2.4 Methods: 
2.4.1 Source and storage of Hospital Episode Statistics data 
An extract of Hospital Episodes Statistics data for the years 2006-07 and 2007-08 
were supplied by Northgate Information Systems as [comma-separated values or 
character-separated values (CSV)] files, which were imported into the statistical 
software package, SPSS (Version 18 and 20). The data were stored on the University 
of Liverpool server as SPSS data files.  The electronic storage has restricted 
password-controlled access and is compliant with the data governance 
requirements for hosting and analysing HES data.  The processing and analysis of 
HES data was undertaken mainly in the statistical software package (SPSS), although 
some steps required importing/exporting between SPSS and a spreadsheet package 
(Microsoft Excel) unless otherwise stated.  
2.4.2 Extraction of valid episodes of care under adult medical and surgical 
specialties 
This section focuses on a number of stages of data cleaning and extraction required 
for reducing the main HES dataset, to contain only care episodes of interest for 
assessing the coded OG cancer patient journey.  
The original HES data contains episodes of care at acute NHS general hospitals and 
in other providers, such as paediatric hospitals or specialist maternity units. Initial 
data clean-up and filtering was undertaken for each individual data year followed 
by subsequent merging of the two data years. The procedures applied for the 2007-
08 dataset are described in detail. 
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Episodes of care admitted under the main medical and surgical specialties were 
first extracted from the original HES dataset.  This excludes specialities that are not 
relevant to the present study (such as gynaecology).  This procedure relies on the 
(Mainspef) variable in HES, a variable that codes the specialty of the admitting 
consultant team.  The list of codes  included and the syntax used for selecting these 
care episodes is given in (appendix 1, syntax 1).  
Further data clean-up was undertaken using the ENDAGE variable (patient age) in 
order to remove paediatric admissions (under the age of 16 years) and to remove 
episodes where there were missing or invalid ages (blanks or erroneous multi-digit 
values). The dataset was then limited to the 151 acute hospital Trusts in England 
(Syntax 2) using the relevant acute provider trust codes (PROCODE variable; see 
Appendix 2 for list of codes). Additional episodes were excluded from the dataset 
using the ADMIMETH variable in order to exclude maternity-related episodes 
(31=Admitted ante-partum; 32=Admitted post-partum; 82=the birth of a baby in 
this Health Care Provider; 83=Baby born outside the Health Care Provider except 
when born at home as intended; 84 and 99=Unknown).  
2.4.3  Identification of OG cancer cases and extraction of their comprehensive 
care histories: 
A number of procedures for processing the data were designed, tested and 
implemented within SPSS in order to identify patients who had a coded diagnosis of 
oesophageal or gastric cancer at any diagnostic position and at any time within the 
available dataset. Once individual cancer patients were identified, all episodes of 
inpatient care for that patient were identified, extracted and ordered 
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chronologically in order to compile a complete record of all hospital care for each 
case. 
The first stage of this process involves generating a list of all relevant diagnostic 
codes for OG cancer from the available International Classification of Diseases 
codes (ICD-10 version).  The codes selected are given in (Appendix 3). SPSS Syntax 
(Syntax 3) was written to flag the occurrence of any of these codes, not only at the 
primary position (DIAG1), but also at any of the 13 other available diagnostic 
positions for each care episode (DIAG2 to DIAG14). This generated a new binary 
variable (OGCANCER, 1=Episode contains an OG cancer code). Episodes with this 
variable (OGCANCER=1) were extracted, sorted by unique patient identifier (HESID) 
and by admission date in ascending order.  Using the “identify duplicate cases” 
function in SPSS, the chronologically first episode of care containing a cancer code 
for each patient was flagged with a new variable (PRIMARYFIRST=1).  These 
episodes were selected using the “selected cases” function and saved as a separate 
file.  This file (“OGC cases”) contains the first episode of care for each patient with 
an OG cancer code.  Manual checks on a random sample of patients were 
completed to ensure that the syntax was identifying the correct codes in each 
diagnostic position. 
Using the unique identifier for each cancer case, we then extracted all their care 
episodes from the main HES dataset. This involves identifying and extracting 
episodes where cancer was NOT a coded diagnosis for each cancer related HESID, 
by returning to the original dataset containing all care episodes under medical and 
surgical specialties (“Admitted Patient Care HES EPISODES dataset”). A new variable 
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(IDENTIFIER) was generated from the “OG cancer cases” file and the “merge” 
function in SPSS was used to flag all care episodes for the cancer patients; even 
episodes not coded with C15, C16 codes.  These episodes were extracted and saved 
as a “MASTER FILE”, one for 2006-07 and another for 2007-08 data year.   
Most cases of OG cancer are diagnosed by gastroscopy. It is expected that some 
cancer patients’ gastroscopy-related episodes might be coded with other diagnosis 
codes (such as “oesophageal stricture” or “gastric ulcer”) without any cancer codes 
appearing in that episode.  If a cancer code appears at the subsequent care episode 
when, for instance, the patient is readmitted for treatment of the cancer, then we 
know that the original endoscopy procedure was the point at which the cancer was 
diagnosed and the patient’s “journey” began. This highlights the need to identify 
sub-groups of cases for analysis according to whether the HES dataset contains a 
related care information (preferably starting with a diagnostic procedure) or has 
missing elements suggesting missing information (e.g. coding problems) or a 
previously diagnosed “prevalent” case whose care had begun in an earlier year. 
For these reasons, additional variables to act as a filter were flagged to show 
whether or not each patient had gastroscopy procedure highly related to the 
management of OG cancer within their episodes history. Such a filter was 
developed using published procedure codes and definitions.[266, 267] A syntax 
which includes these codes was then written up to mark these procedures 
(Appendix 4, syntax 4). Again this study was keen to show internal linkages, not 
only with procedures coded at primary position (OPERTN 1), but also at any other 
positions (OPERTN 2 to OPERTN 14). Once the above syntaxes were processed, 
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(SPSS function: FILE > NEW > SYNTAX) a new field variable, called the Gastroscopy 
filter, was produced. This method was applied for both 0607 and 0708 OG cancer 
master dataset.  
 
It also became essential to merge the 2006-07 and 2007-08 master data files for OG 
cancer patients. By do doing, we were able to trackback those patients who 
appeared in 2007-08 with no gastroscopy filter, to check whether the upper GI 
endoscopy code emerged in any episode relating to that particular patient within 
the 2006-07 data. To merge these two years’ worth of OG cancer patients’ history, 
it is important to make sure that all dataset variables are in the same order with the 
same variable names and format, and to have the same identifying HESID for each 
patient in both years before the merge. Additionally, prior to the merge, a new field 
was added to each master file called YEAR, to make it easier to identify which year 
the admission originated from. Afterwards, 2006-07 and 2007-08 master datasets 
were merged together to make a single dataset, again by using SPSS function (DATA 
> MERGE FILES > ADD CASES).  
The newly merged file (2006-08 merged OG cancer patients’ history file) contains all 
the episodes of care that are coded with oesophageal or gastric cancer (ICD-10 
codes: C-15s or C-16s), in addition to other episodes which these patients had 
before and after the appearance of these codes between 1st April 2006 and 31st 
March 2008. As a result, it was possible to flag the key milestones, such as the first 
OG cancer and the first gastroscopy procedure coding dates in the patient’s 
journey.  
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HES data does not include a date of diagnosis, and the first episode of care, coded 
with a definitive cancer code, is not a reliable starting point for the patient’s 
journey.[268] Manual review of the coding sequence for individual cancer cases 
revealed that some of the original primary diagnoses recorded at the time of the 
first (index) gastroscopy were non-specific symptom codes (eg, dysphagia) or non-
malignant diagnostic labels that would be compatible with cancer (eg, oesophageal 
stricture or gastric ulcer). The first appearance of a cancer code for such cases was 
typically within a few days or weeks of the index diagnostic gastroscopy, when the 
patient attended for another hospital episode (eg, therapeutic gastroscopy or 
surgery). By selecting cases whose first endoscopy episode occurred within 3 
months of the first cancer-coding episode (either as a day-case or during  hospital 
admission), we extracted a cohort of patients with a sequence of care episodes and 
procedures compatible with a new diagnosis of OG cancer (Syntax 5). 
2.4.4 Linkages of HES data to the statutory register of deaths data from the 
Office of National Statistics (ONS) 
Death in hospital is a recorded variable in HES but the dataset does not capture 
deaths occurring post-discharge from hospital. The present project was able to 
benefit from having access to further linkage of HES data to the statutory register of 
deaths held by the Office of National Statistics (ONS), and by using the same SPSS 
function mentioned above, to link the death date for each patient as another 
variable within the merged two-year file. Consequently, the DEATH DATE 0608 
variable was created, comprising the death dates returned from death files 2006-
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07/2007-08 ONS based on HESID. This new variable was used to give the number of 
cancer deaths and to enable crude mortality and survival analysis. 
 
2.4.5  Patient factors: demographic, comorbidity and socioeconomic variables 
Patients’ age and gender are coded variables in HES. Patients’ ethnicity groups were 
not available in the original 2007-08 data and hence this has not been included in 
this study. The recorded age of cancer cases was grouped into five year age bands 
(<55, 55–64, 65–74, 75–84 and ≥85 years) (Syntax 6).  
All diagnostic fields were screened for co-morbidities using ICD-10 codes from the 
Charlson index of co-morbidity [269, 270], in which OG cancer codes were omitted 
from the list (Appendix 5 and 6, Syntax 7 and 8). Every patient was assigned to the 
highest co-morbidity score within his/her coded care history within the dataset. A 
categorical co-morbidity variable was then allocated to each patient (none, 1 or ≥2 
co-morbidities) as previously described using (Syntax 9).[271] 
Within HES data, each patient episode contains a deprivation variable for the 
socioeconomic status of the lower super output area of residence at the time of 
admission (IMD04RK). Lower super output areas from the whole of the country 
(each including about 400 houses) were grouped into quintiles from the most 
deprived to the least deprived, based on their ranking in the Indices of Multiple 
Deprivation for England 2007.[272] Quintile 1 denotes patients living in the most 
socioeconomically disadvantaged areas of the country while Quintile 5 indicates the 
most affluent group (Syntax 10). 
 This ranking was originally made by combining the seven IMD domain scores using 
the following weights: [Income (22.5%); Employment (22.5%); Health Deprivation 
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and Disability (13.5%); Education, Skills and Training (13.5%); Barriers to Housing 
and Services (9.3%); Crime (9.3%); Living Environment (9.3%)].[273]  
 
2.4.6 Patient outcome variables 
2.4.6.1 Emergency admission during diagnostic pathway 
Every hospital inpatient spell or daycase procedure mode of admission is either 
elective or emergency and is a recoded variable in inpatients HES records (Syntax 
11). In this study, method for determining emergency presentations (diagnosis) of 
cancer cases are identified according to the episode containing the index (first) 
diagnostic procedure (gastroscopy) as either elective admission (i.e. daycase 
gastroscopy) or non-elective admission (i.e. gastroscopy performed during an 
unplanned ‘emergency’ hospitalization).  
The present study aimed to use the most relevant clinical care event (i.e. the first 
gastroscopy procedure) to identify the point of diagnosis of OG cancer within 
inpatient HES data. More recently, Eliss-Brook et al used both inpatient and/or 
outpatient HES activity data to attempt to establish an elective or emergency route 
of cancer diagnosis for a range of cancer types.[274] Although Eliss-brook used the 
same selection of admission method codes for elective (codes 11, 12 and 13) and 
emergency (codes 21, 22, 23, 24 and 28) admissions as the present study, their 
methodology selected any inpatient or outpatient event in closest proximity to the 
date of diagnosis as determined by linkage to cancer registration records extracted 
from the National Cancer Data Repository.[274-276] However, this approach did 
not identify whether these events included a specific diagnostic procedure for the 
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cancer in question – thereby examining all-cause events rather that a defined 
clinical milestone in the patient journey. 
The present study identifies an unplanned emergency diagnosis of cancer as 
representing the following categories of patient: (1) those admitted to hospital 
having never seen their GP and were diagnosed with cancer; (2) Patients who were 
very ill, or who had abnormal results, who had contacted their GP or the out of 
hours service, and were then admitted to hospital; and (3) patients who might be 
seen by their GP and were referred routinely or via a two-week wait, but who 
deteriorated before their scheduled appointment and were admitted to hospital 
and then diagnosed with cancer. 
This defines the mode of diagnosis as either elective or emergency. Once the mode 
of ‘’diagnosis’’ has been identified, it is re-linked according to HESID to be visible as 
the mode of diagnosis for every admission within the dataset, through use of the 
SPSS function DATA > MERGE FILES > ADD VARIABLES. It is important to note that 
any outcome measure used throughout this study (otherwise stated) has a value of 
1 if the admission was emergency (unplanned), and 0 if not. 
2.4.6.2 Surgery 
Surgical intervention for oesophago-gastric cancer was defined on the basis of 
coding a major surgical resection compatible with curative intent, using a list of 
previously reported OPCS-4 codes (Appendix 7 [277], Syntax 12). Additional steps 
were undertaken to identify these surgical codes in specialist surgical centres 
(hospitals other than the 152 acute trusts). For example, major resections happen 
at the Cardiothoracic Centre-Liverpool NHS Trust (RBQ) includes cases which were 
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originally diagnosed at the  Royal Liverpool and Broadgreen University Hospitals 
NHS Trust (RQ6). The identified surgical episodes through this procedure were then 
added to final analysis. Every cancer patient was classified as either having had a 
record of a major surgical resection or not. Where a patient might have a record of 
more than one OPCS surgical code allocated as a major resection for their 
treatment, these cases were only once in the analyses as they received a curative 
resection. 
2.4.6.3 Mortality 
The index diagnostic gastroscopy date was taken as the starting point or 
“provisional diagnosis date’’ for survival analysis, and mortality rates were 
calculated at various post gastroscopy time points (e.g. 30 days, 6 months and one 
year mortality) using death dates linked from the Office of National Statistics. The 
SPSS function used to record the number of days in between these two landmarks 
was [TRANSFORM > DATE AND TIME WIZARD  > CALCULATE WITH DATES AND 
TIMES > CALCULATE THE NO. OF TIME UNITS.] (Syntax 13). It is important to note 
that patients with no death date were censored to the 31/03/2009, which was the 
last death (follow up) date coded among the ONS death data.  
2.4.7 Gastroscopy procedures coded as in-patient or day-case procedure under 
adult medical and surgical specialties  
Using the previously described two-year download of the HES dataset containing 
more than 24 million care episodes (2006/7 and 2007/8), all hospital episodes 
containing a procedure code for diagnostic gastroscopy for adult patients (≥16 
years) were extracted using published procedure codes and definitions [266, 267] 
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(Appendix 4, Syntax 4). The process of ensuring that no duplicate procedure is 
included within the extracted data was achieved by using SPSS function (DATA > 
Identify duplicate cases > Define matching cases by > HESID, Admission date, 
DIAG01, DIAG02, PROCEDURE1, PROCEDURE2, GPCODE, EPIEND “Episode end 
date” and Consultant code “ CONSCD”).   
In England, all residents receiving NHS healthcare are registered with a general 
practice that comprises one or more family doctors providing primary care services 
to a defined practice population. Each general practice has an identifier code within 
HES. All gastroscopy procedures were recorded for persons registered at each 
general practice, via aggregate function within SPSS. 
Published data are available for the total number of adult patients (≥16 years) 
registered at each general practice, their gender and age profile for the relevant 
years.[278-280] The average counts of elective gastroscopies performed per 
practice per year were calculated. This value was divided by the relevant practice 
adult population to give an annualised crude rate of gastroscopy. To ensure that 
differences in the number of events (e.g. gastroscopy rate) observed in two or more 
populations (GP practices) were not due to differences in the age and sex profile, 
data for the practice population demographic profile [278], was measured 
alongside the Indirect age and sex standardization (or adjustment) of rates [281].  
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Indirect standardisation method summary: 
I. Calculate the number of OGD procedure related to every practice by 5 year 
age bands (15-19), (20-24),.......(80-84) and (>=85); and for males and 
females of the same age bands (15-19)m, (20-24)m,.......(80-84)m, (>=85), 
(15-19)f, (20-24)f,.......(80-84)f, and (>=85)f. These are the ‘’observed 
events’’. 
II. Calculate the reference event (total number of OGD procedures for the 
included practices) and reference population (total number of adult 
population registered in all practices in the study). 
III. reference crude rate (OGD rate for England) = reference Event/reference 
Population*100,000 
IV. Calculate the local (every practice) expected events= reference 
rate/practice population 
V. The standardization ratio= the observed events / expected events. 
VI. The indirect age-sex standardized OGD rate= standardized ratio*reference 
Crude rate/100. 
 
2.4.8 General practice Index of Multiple Deprivation (IMD) 
We assigned each general practice to a deprivation category (using deprivation 
quintiles of 1 = most deprived to 5 = least deprived). This was based on the national 
ranking of a practice-level average deprivation score based on the Index of Multiple 
Deprivation (IMD). The practice score represents a weighted average of the IMD 
scores for each Lower Super Output Area (LSOA) in which every given practice has 
patient registrations.[282] 
2.4.9 Statistical analysis:  
Analysis of variance and χ2 were used to compare differences in continuous and 
categorical variables. Univariate logistic regression was used to identify factors 
associated with emergency route of diagnosis, surgical resection rate and all-cause 
mortality at 1 year. Factors with a significance level of ≤0.1 on univariate analysis 
were included in the final multivariate regression model.   
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Chapter 3  Characteristics of the OG cancer patient population 
extracted from the Hospital Episode Statistics dataset, validation 
against independent national and local data and identification of 
patient-level predictor factors associated with cancer outcome 
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3.1 Introduction and objectives 
 
Routinely collected information on patient care has become an increasing feature 
of the National Health Service [264].  Much of the analysis of routine data has been 
‘top-down’ and clinical engagement in the generation, validation and use of 
analyses derived from these datasets has been limited.[248, 255, 257, 264, 283]  
There is considerable mistrust of data quality and a perceived lack of credibility for 
indicators derived from these routine statistics. [248] 
The benefits of extending an audit beyond a local hospital or cancer network have 
increasingly been acknowledged [112, 113, 248, 254]. Although clinically designed 
and owned audit datasets are excellent ways for reviewing and monitoring current 
practice against a predefined standard, nevertheless this type of activity can be very 
expensive and time-consuming and is often associated with major concerns relating 
to its totality, case ascertainment and the lack of enthusiastic staff, and sometimes 
to inadequate financial and practical resources [112, 113, 248, 284, 285]. It is also 
noted that medical audits are frequently limited to common conditions or 
procedures.[248] Moreover, audit data collection is processed outside the route 
revealed in HES, and hence it lacks the routine internal quality checks (as might be 
provided by data quality meetings or clinical coding audits) that are essential steps 
in the cases of SUS and HES.[248, 255]   
One example of such limitations was published by the Scottish Audit of Gastric and 
Oesophageal cancer 1997- 2000. Their report notes that:  
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“Approximately 60 % of the data were collected by the Data Mangers towards the 
end of the Audit because busy clinicians were unable to take the time to track 
down medical records and complete the forms. Therefore the Data Mangers faced 
lengthy searches for medical records, largely due to the fact that the locations of 
the medical records were inaccurately recorded but also because medical records 
had been destroyed following the patient’s death in some instances. This has an 
impact on the completeness of the data collected on some patients, which 
resulted in some cases having to be removed from the database before the final 
analysis as the cancer could not be confirmed ” [284]. 
On the other hand, there are legitimate and generic concerns regarding the 
completeness, precision and depth of routine administrative coding [264, 286, 287]. 
This chapter postulates that such issues with accuracy of diagnosis and procedure 
coding [286-288] are inevitable as the result of many factors. First, some diagnoses 
or procedures may be more difficult to code, for instance where the condition is 
rare and has a low prevalence or is difficult to diagnose. Secondly, there are 
occasions where the final diagnosis has not been finalised at the time of discharge, 
in which case coding of discharge data tends to be more prone to inaccuracy [250, 
264, 289, 290].  
In addition, the typical approach for analysing HES data as described in the 
literature involves extracting only episodes or admissions according to the coded 
“primary diagnosis”, and then undertaking analyses on these extracted episodes 
alone, using the secondary diagnosis to study the associated co-morbidity [250-252, 
291].  There are several limitations to this approach.  Primarily, the coding of the 
main diagnosis may vary from one episode to the next, depending on the reason for 
admission.  A range of conditions might appear as “primary” diagnosis at different 
times, particularly for a patient suffering from cancer.   
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The cancer code might appear as a secondary or lower order diagnosis, or may be 
missing entirely, from some care episodes.  By applying clinical logic, knowledge of 
care pathways and creating linkages between consecutive episodes for individual 
patients, it could be possible to make better use of HES data.   
In the case of OG cancer, the first care episode for a patient with an oesophageal 
stricture due to oesophageal cancer might be a daycase diagnostic procedure 
(Gastroscopy).  This episode of care will be recorded in HES but the coded primary 
diagnosis may be “oesophageal stricture” and there may be no cancer code in any 
diagnostic position.   
The results of biopsies taken during the daycase test may later prove that this 
stricture was cancerous.  This would not be recorded in the original daycase 
episode in HES data, however.  The patient may then have an outpatient visit and 
additional outpatient tests (e.g. CT scanning) but these are not recorded in the 
inpatient HES dataset.  The next care episode appearing in HES data might be 
another daycase procedure, this time for palliative stenting of the tumour.  This 
second inpatient episode is coded in HES with cancer as a primary diagnosis and 
with endoscopic stenting as a procedure.  Two weeks later, the patient is admitted 
as an emergency to hospital with pneumonia, remains in hospital ten days receiving 
palliative care and dies.  The coded primary diagnosis for this third and final care 
episode is “pneumonia” but a secondary diagnosis is recorded as oesophageal 
cancer.   
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A simplistic analysis of HES data using only episodes coded with a primary diagnosis 
of cancer would extract only the second episode of care from the dataset.  
However, once a case of cancer has been located in the dataset it should be 
possible to perform linkages in order to analyse all episodes of care for that patient, 
thereby identifying all relevant hospital interventions both before and after the first 
appearance of a cancer code in this patient’s history.  
 
3.2 Aims: 
1. To identify cases of OG cancer with HES data and to extract all coded NHS 
care episodes for each patient, building up a chronological record of all 
inpatient episodes for each patient. This involves distinguishing patients 
with complete data pathways from those with incomplete pathways 
(prevalent cases from previous data year, or cases with missing care 
episodes). 
2. To verify the accuracy of the flagged mode of admission (‘emergency’ versus 
‘elective’) for the index care episode as derived from the above longitudinal 
internal linkage method in HES data.  This involves comparing the flags 
derived from HES for a large sample of local cases (Aintree University 
Hospital, Liverpool, UK) with the ‘true’ (gold standard) mode of admission as 
determined from audit of the case records.  Each local case extracted from 
HES will be linked to a verified local case on the basis of age, gender, GP 
practice and relevant episode dates.  
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3. To describe the demographic and basic clinical characteristics of cancer 
cases extracted for England (2006-2008), as identified through this 
methodology and compared with external sources of national data (e.g. 
prospective national audit data, and NCIN) – thereby establishing the face-
validity of data outputs. 
4. To study the association between patient characteristics such as age, sex, 
co-morbidity and deprivation and outcome of OG Cancer, thereby defining 
the case-mix factors required for adjusting outcomes for confounding in 
subsequent studies. 
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3.3 Method: 
The main method used to extract patients population is described in (Chapter 2). In 
summary, the number of stages of data cleaning was first required to reduce the 
main HES dataset, so that the data includes only care episodes of interest for 
assessing OG cancer patient journey. All patients with one or more episodes 
containing a diagnostic code for oesophageal or gastric cancer were first identified 
by looking at the cancer code, not only at primary position but also at every other 
diagnostic position within the data. Using the unique patient’s identifier for each 
cancer case, we then extracted all their care episodes from the main HES dataset 
and ordered them chronologically. 
Unlike the cancer registry data in which the date of diagnosis represents the date of 
the histopathology report (where available), HES data does not contain a specific 
date of diagnosis, and the first episode of care coded with a definitive cancer code 
is not a reliable starting point for the patient’s journey.[268, 292, 293] The first 
appearance of a cancer code for such cases was typically within a few days or weeks 
of the index diagnostic gastroscopy when the patient attended for another hospital 
episode (e.g. therapeutic gastroscopy or surgery).  
Government policy gives a target of 2 weeks between the date of referral and the 
date of diagnosis for urgent referrals from general practitioners and a limit of 62 
day wait from urgent GP referral to first treatment for all cancers [108] OG cancer 
prospective (National) audit of cases collected within the same time window of this 
study shows that only 52% of urgent referrals were diagnosed within the target 
wait of two weeks. However, around 96.2% of these patients who were referred 
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through urgent GP referral pathway and 86.2% of patients referred through non-
urgent pathway were diagnosed within 12 weeks. [113] 
Hence, by selecting cases whose first upper GI endoscopy episode occurred within 3 
months of the first cancer-coding episode (either as a day-case or during a hospital 
admission), we extracted a cohort of patients with a sequence of care episodes, and 
diagnostic procedures compatible with a new diagnosis of OG cancer (Figure 3.1.).  
The successful development and validation of this complex linkage method was a 
key research milestone in the course of the project, since it was first necessary to 
overcome the limitations of HES data to extract a sample of OG cancer cases with 
strong face validity (i.e. total numbers, demographic profile and measured 
outcomes consistent with those expected for a national cohort of new cases). 
Binary logistic regression was used to test whether there are associations between 
various patient-level factors, namely age; gender; co-morbidity and deprivation as a 
predictor of emergency admission at the time of diagnosis; chance of major surgical 
resection; and mortality at one year.   
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Figure 3.1 Summary of the algorithm of included patients and their mode of diagnosis. For 
example, patients A and B who had gastroscopy codes and OG cancer codes within 3 
months period where included, whereas patinets C and D were not included. These 
excluded cases are likely to be prevalent cases (who were admitted within the current year 
of study). There might also be a small number of genuine 'incident' cases who were 
excluded because the episode containing the key primary diagnostic test (index 
gastroscopy) is 'missing' from their pathway – a coding issue or they went through an 
atypical diagnostic pathway, perhaps barium radiology or CT scan rather than gastroscopy - 
this would be uncommon. We considered patient A as diagnosed electively although 
his/her cancer code first appears following emergency admission. 
 
Patients A as an example of the selected mode of admission at “diagnosis” 
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3.3.1 Validation of linkage methods and data outputs: 
3.3.1.1 Local validation:  
Local validation was important to test the robustness of the OG cancer data 
extracted from HES, particularly for determining emergency admission at the time 
of diagnosis in which a sample of 143 locally-diagnosed cases of OG cancer was 
matched with the corresponding data from HES by linking to patients’ age (+/- 12 
months), gender, general practice code and diagnostic gastroscopy date. This 
analysis is based on collaboration with the digestive disease unit at Aintree 
University Hospital [Shawihdi, Stern, et al. 2011]. [294] Locally diagnosed cases 
were identified from hospital histopathology database, excluding tertiary referrals. 
2-year audit periods were defined matching the period of available national data, 
2006-08. Local emergency cases were defined as those who had diagnostic 
endoscopy that was triggered by unplanned attendance/admission to the accident 
and emergency department (emergency room). This includes patients who were 
admitted and underwent gastroscopy during an acute hospitalisation and also 
those who had an outpatient gastroscopy arranged after an unplanned (emergency) 
presentation to hospital. 
3.3.1.2 National validation:  
In order to test the reliability of our database inclusions, coding algorithms and 
linkage methods, we assessed the face-validity of the national cancer patient 
population extracted from HES data by comparing their characteristics and 
outcomes with independent reports from the national OG cancer audit [112, 113, 
177], cancer research UK [4, 6] and the NCIN[295].  These sources represent the 
most accurate national data available.  
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3.4 Results  
3.4.1 The extracted episodes of care coded with OG cancer patients and the 
selection of primary study population. 
Of approximately 12 million medical and surgical hospital episodes coded by the 
national routine data annually, fewer than 8% were excluded owing to invalid data 
entries (e.g. default/nonsense dates or missing key data fields (Table 3.1). This 
could indirectly indicate that the process of data “autocleaning” and “validation 
cycles” created by HES has achieved up to 92.8% accuracy. 
 Within the study period there were 130,466 episodes had at least one OG cancer 
related codes (C15, C16). Of these, 33,115 patients were identified – 86.5% using 
the first diagnostic position alone and 13.5% with the additional analysis of 
diagnosis positions 2 to 14. As a result of internal linkages within HES though the 
patients’ HESID, 42,397 (32.5%) more episode-related patient information records 
were obtained which had not been coded for OG cancer (Table 3.2, Figure 3.2).   
Table 3.1 Shows the effects of these main data cleaning stages 
Clean-up of original HES dataset episodes  2006/07 2007/08 
Dataset containing medical and surgical episodes 11,580,198   12,181,932 
minus blank ages 5699 10296  
minus invalid ages 28267  30141 
minus under 16's 404875  422100 
minus excluded trusts 380273  560307 
minus excluded admission methods 3393 3155  
Remaining number of episodes  10,757,691 (92.8%) 11,155,933 (91.5%)  
 
This study provides a well-matched number of episodes coded for OG cancer, as 
well as the number of individual patients coded at the primary, secondary, or any 
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other diagnosis position across the two years (Table 3.2). This would suggest that 
there is no major discrepancy in the coding process between these two data years, 
and also that the correct application of techniques was used to extract this 
information.    
Table 3.2 Shows the breakdown of numbers from all medical and surgical episodes to the 
number of individual OG cancer patients (At every diagnosis position). 
 2006/07 2007/08 2006/08 
Total medical and surgical episodes 10,757,691 11,155,933 NA 
Episodes with OG cancer codes 65,027 65,439 130,466 
Coded at primary position 52,193(80.3%) 50,783(77.6%) 102,975(78.9%) 
Coded at secondary position 7,544(11.6%) 8,234(12.6%) 15,778(12.1%) 
Coded at any other position (DIAG_3 to 
DIAG_14) 
5,290 (8.1%) 6,422 (9.8%) 11,713 (8.9%) 
Individual patients with OG cancer 18,693 19,261 33,115 
Coded at primary position 15,829(84.7%) 16,075(83.5%) 28,652(86.5%) 
Coded at secondary position 1,752(9.4%) 1,790(9.3%) 2,662(8.0%) 
Coded at any other position (DIAG_3 to 
DIAG_14) 
1,112(5.8%) 1,396(7.2%) 1,801(5.4%) 
Episodes related to OG cancer patients but 
without OG cancer related codes   
20,234 22,163 42,397 
 
It proved possible to make better use of HES data by identifying all relevant hospital 
episodes before the first appearance of a cancer code in the patients’ history. 
According to the method used (Figure 3.2), the number of patients with coded 
gastroscopy procedures was 24,659, of which 23521 (95.3%) had their procedure 
within three months before the initial cancer coding episode of care. Within this 
patients’ cohort  we found that 17% (around 1 in 5 cases) were initially coded ( at 
the time of index gastroscopy) with non OG cancer codes. Although some cases  
coded at a lower order position will be prevalent (established) cases, the rules for 
the chronological sequence of episodes would exclude them since prevalent cases 
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would lack the required coding pathway (i.e. with first diagnostic gastroscopy 
recorded within three months of cancer coding). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 OG cancer patients identification process. 
Episodes related to OG cancer patients but without OG 
cancer related codes   (n=42,397) derived from original 
HES dataset 2006/08 
Patients coded with OG cancer and OGD procedure OPCS-4 
codes (n=24659) 
Patients coded with OGD procedures codes ≤ 3 months before 
first OG cancer codes (n=23521) 
Coded with site/type specific OG cancer code (n=8206, 34.88%)                                                                 
Coded with unspecified OG cancer code (n=11314, 48.1%)                                                         
Coded with other minor or major pathology; for example, 
oesophagitis, peptic ulcer, dyspepsia, dysphagia (n= 4001, 17.0%) 
Patients had no OGD coded procedure within data 
study period (n=8456) 
Patients coded with OGD procedures codes > 3 months 
before first OG cancer codes (n=1138) 
Patients coded with OG cancer C15s, C16s ICD-10 codes 
(n=33115) 
  Coded at primary position [n=28,652(86.5%)] 
  Coded at secondary position [n=2,662(8.0%)] 
  Coded at any other position (DIAG_3 to DIAG_14) [n=1,801(5.4%) 
Episodes coded with OG cancer C15s, C16s ICD-10 codes 
(n=130,466) 
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3.4.2 Number of deaths for patients coded with oesophageal and gastric cancers 
HES (2006-8)  
Owing to the external linkages of patients’ ONS death dates, (Tables 3.3, Figures 
3.3, 3.4) show the distribution of the identified number of deaths for any patient 
coded in HES with oesophageal and gastric cancers, by age groups and gender with 
the comparison with other published data.   
Table 3.3 Shows the number of deaths for patients coded with oesophageal and gastric 
cancers, by age groups and gender, HES 2006-08 
  Oesophageal  Gastric   
 Male Female Persons Male Female Persons 
 HES (2006-08)1  3787 1966 5753 2926 1628 4554 
ONS (2005-07)2 3960 2069 6029 2723 1630 4353 
Cancer research UK (2008)3 4085 2046 6131 2635 1591 4226 
1 
average of two years for England, 
2 
average of three years for England [15], 
3 
Death coded in 2008 data year for 
England. [296, 297]  
 
 
 
Figure 3.3 Trends of deaths by gender and age groups for Oesophageal cancer. [297] 
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research UK. Stomach cancer mortality statistics. 24 June 2010 [cited 2013 06/09/2013]; Available from: 
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This text box is where the unabridged thesis included the following third party copyrighted 
material:  
Cancer research UK. Oesophageal cancer mortality statistics 29 April 2010 [cited 2013 
06/09/2013]; Available from: http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/oesophagus/mortality/. 
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Figure 3.4 Trends of deaths by gender and age groups for Gastric cancer.[296] 
 
Furthermore, the number of deaths related to oesophageal and gastric cancers, by 
age and gender groups have shown similar trends to the UK records published by 
Cancer Research UK.[296, 297] This suggests a successful external linkages with the 
ONS death registry data.   
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3.4.3 Demographic characteristics of cancer cases with a complete care pathway  
The counts and demographic characteristics of these cancer cases (n=23521) with a 
comprehensive clinical care pathway across the two years are summarized in (Table 
3.4). 
Table 3.4 Demographic characteristics of OG cancer patients with a valid pathway of care 
  Oesophageal  Gastric  OG cancer  
Patients n,% 15388   65.4% 8133   34.6% 23521   100% 
Age [Mean (SD), median] 71 (12) 72 73 (11) 75 72 (12) 73 
Age groups       
  < 55                                     1394 9.1% 566 7.0% 1960 8.3% 
  55 to 64                                   3169 20.6% 1059 13.0% 4228 18.0% 
  65 to 74                                     4371 28.4% 2249 27.7% 6620 28.1% 
  75 to 84                                     4671 30.4% 3043 37.4% 7714 32.8% 
  ≥ 85                                    1783 11.6% 1216 15.0% 2999 12.8% 
Gender       
 Male 10169 66.1% 5323 65.4% 15492 65.9% 
 Female 5219 33.9% 2810 34.6% 8029 34.1% 
Co-morbidity        
No co-morbidity 11761 76.4% 5517 67.8% 17278 73.5% 
1 co-morbidity  2542 16.5% 1607 19.8% 4149 17.6% 
≥ 2 co-morbidity  1085 7.1% 1009 12.4% 2094 8.9%  
Deprivation quintile       
Missing  170 1.1% 74 .9% 244 1.0 
 1 (Most deprived)                                 3071 20.0% 1919 23.6% 4990 21.2 
 2 3130 20.3% 1735 21.3% 4865 20.7 
 3 3173 20.6% 1635 20.1% 4808 20.4 
 4 3085 20.0% 1543 19.0% 4628 19.7 
 5 (Least deprived)                                2759 17.9% 1227 15.1% 3986 16.9 
 
 
 
 
119 
 
3.4.4 Route of diagnosis and outcome of OG Cancer cases in England and the 
association between patient level factors and outcomes. 
Overall, a quarter of cases were diagnosed following emergency hospitalization 
(Figure 3.5). It can also be seen from the data that a higher percentage of gastric 
cancers were diagnosed following unplanned emergency admissions.  
 
 
Figure 3.5 The number, percentage and 95% confidence interval of patients diagnosed during 
emergency admission, patients who had potentially curative surgical resection and patients 
who died within one year of diagnosis; results are shown for (A) Oesophageal, gastric and (B) 
Oesophageo-gastric cancer patients’ categories.  
3712 (24.1%) 
2434                      
(15.8%) 
8872 (57.7%) 
6667 (28.3%) 
1402                
(17.2%) 
5050 (62.1%) 
2955 (36.3%) 
3836 (16.3%) 
13922 (59.2%) 
 
 
A 
B 
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Further examination of the differences in these outcomes according to age, gender, 
co-morbidity and those in different deprivation quintiles are explored in (Tables 
3.5, 3.6 and Figure 3.6, 3.7, 3.8).  
This analysis reveals that the proportions of patients with these outcomes are 
relatively similar for males and females within each age band. However, females 
particularly in the older age groups experienced poorer results (Table 3.5). Poorer 
survival has also been highlighted for those patients diagnosed through the 
emergency presentation route, for patients who had no major surgical resection 
and for patients aged 85 and over (Figure 3.6). 
Even though most (73.5%) OG cancer patients appeared to have no coded 
comorbidity either during their index gastroscopy or within their first cancer-coded 
admission, the remaining (26.5%) patients with comorbidity tended (as expected) 
to have a worse outcome (Figure 3.7). 
This data further discloses that with respect to age groups, similar patient trends 
are distributed across the deprivation quintile (Figure 3.8). However, a higher 
percentage of the most deprived group of patients was diagnosed during 
emergencies (Table 3.6).  
The highest variation in the deprivation quintile across these outcomes was also 
among the emergency rote of diagnoses, which showed more than fivefold 
difference (Figure 3.9). This magnitude of variation might suggest that there could 
be some degree of inequality in the way these patients are managed, rather than 
simply differences in the burden of disease. Perhaps this might be due to less 
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effective use of elective diagnostic services (e.g., gastroscopy) despite its 
widespread availability.  
Table 3.5 The number, percentage of OG cancer patients diagnosed during emergency 
admission; patients who had potentially curative surgical resection and patients who died 
within one year of diagnosis. These crude outcomes are shown according to their age 
groups and gender distribution. 
Males N  Emergency  Surgery  Mortality 1 year 
All ages 15,492 4,192 27.0% 2,676 17.2% 9,018 58.2% 
  < 55                                     1375 309 22.47% 349 25.38% 655 47.63% 
  55 to 64                                   3114 603 19.36% 720 23.12% 1509 48.45% 
  65 to 74                                     4728 1093 23.12% 1027 21.72% 2525 53.40% 
  75 to 84                                     4822 1542 31.98% 547 11.34% 3227 66.92% 
  ≥ 85                                    1453 645 44.39% 33 2.27% 1102 75.84% 
 
Females N  Emergency  Surgery  
 
Mortality 1 year 
 All ages 8,029 2,475 30.8% 1,160 14.4% 4,904 61.0% 
  < 55                                     585 145 24.79% 161 27.52% 264 45.12% 
  55 to 64                                   1114 201 18.04% 304 27.29% 541 48.56% 
  65 to 74                                     1892 415 21.93% 391 20.67% 999 52.80% 
  75 to 84                                     2892 967 33.44% 279 9.65% 1880 65.00% 
  ≥ 85                                    1546 747 48.32% 25 1.62% 1220 78.91% 
 
Persons N  Emergency Surgery  
 
Mortality 1 year 
 All ages 23,521 6,667 28.30% 3,836 16.30% 13,922 59.20% 
  < 55                                     1960 454 23.16% 510 26.02% 919 46.88% 
  55 to 64                                   4228 804 19.02% 1024 24.22% 2050 48.48% 
  65 to 74                                     6620 1508 22.78% 1418 21.42% 3524 53.23% 
  75 to 84                                     7714 2509 32.53% 826 10.71% 5107 66.20% 
  ≥ 85                                    2999 1392 46.42% 58 1.93% 2322 77.42% 
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Figure 3.6 Highlights the poorer survival for those patients (A) diagnosed through the 
emergency presentation route, those patients (B) who had no major surgical resection and 
for both (A) and (B) patients’ aged 85 and over. 
A 
B  
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Figure 3.7 Shows the percentages, 95% confidence interval and trends of OG cancer 
patients’ outcomes in relation to patients’ co-morbidity groups. 
 
 
 
124 
 
 
 
 
 
Figure 3.8 The distribution of patients with coded diagnosis compatible with incident cases 
of OG cancer according to their age groups and by their socioeconomic status.  
 
 
Table 3.6 OG cancer patients’ outcomes in relation to quintiles of patients’ level 
deprivation, as measured by the English Indices of Deprivation 2007 
 Deprivation quintile Emergency Surgery  Mortality 1 year 
Missing  64 1.0% 25 0.7% 95 0.7% 
1 (Most deprived)                                 1625 24.4% 755 19.7% 3055 21.9% 
2 1412 21.2% 801 20.9% 2864 20.6% 
3 1348 20.2% 778 20.3% 2876 20.7% 
4 1211 18.2% 804 21.0% 2704 19.4% 
5 (Least deprived)                                1007 15.1% 673 17.5% 2328 16.7% 
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Figure 3.9 Shows the percentages, 95% confidence interval and trends of OG cancer patients 
diagnosed during emergency admission, patients who had potentially curative surgical 
resection and patients who died within one year of diagnosis in relation to quintiles of patients’ 
level deprivation as measured by the English Indices of Deprivation 2007. 
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Emergency patients, as expected were significantly older, with more co-morbidity. 
These cases also demonstrate a lower chance for potentially curative surgical 
treatment, higher early mortality and indeed a poorer survival rate at one year 
(Figure 3.10). 
 
 
 
 Diagnosed 
electively  
Diagnosed during 
emergency admission 
Patients n,% 16,854  71.65% 6,667 28.35% 
Age (Mean, SD) 70 11 75 12 
Gender      
  Male 11300 67.0% 4192 62.9% 
  Female 5554 33.0% 2475 37.1% 
 Co-morbidity groups         
  No co-morbidity 13726 81.4% 3552 53.3% 
  1 co-morbidity 2326 13.8% 1823 27.3% 
  ≥ 2 co-morbidity 802 4.8% 1292 19.4% 
Chance for major surgery 3294 19.5% 542 8.1% 
Early 30 days mortality 723 4.3% 1626 24.4% 
Survival at 1 year 8019 47.6% 1580 23.7% 
 
Figure 3.10 Route of diagnosis ( elective Vs. emergency) and outcomes for OG cancer 
patients 
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The Kaplan-Maier survival curves for these patients confirm an early and persistent 
separation between different routes (Figure 3.11, Log Rank p<0.001). Whilst the 
survival curves separate when the data is split into the different modes of 
admission, the differences remain significant, regardless of tumour site. Survival 
curves for oesophageal and gastric cancer are shown. (Figure 3.12)  
 
 
 
Figure 3.11 Kaplan-Maier survival curves for OG cancer patients according to their mode of 
diagnostic admission (emergency vs. elective) 
Oesophageo-gastric  cancer 
Emergency  
Elective  
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Figure 3.12 Kaplan-Maier survival curves for oesophageal and gastric cancer patients according 
to their mode of diagnostic admission (emergency vs. elective) 
Oesophageal cancer 
Gastric cancer 
Elective  
Elective  
Emergency  
Emergency  
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3.4.5 Validation of the OG cancer patient population extracted from HES 
The linkage methodology used in our 2-year data period identified 23,521 cancer 
cases. This equates to 11,761 new cases in England per year. This compares 
favourably (90.7%) to an annual figure of 12,957 reported by the NCIN for the 
whole of England [295] and (91.3%) with the ONS published annual figure of 12873. 
[15]  Such differences could be explained by the fact that for some patients the key 
primary diagnostic test (index gastroscopy) is 'missing' from their HES coded 
pathway. It is highly unlikely that such differences could bias the overall results 
because, first they are in small number (less that 9%) and secondly these excluded 
cases shared similar demographic characteristics to that of the included ones (i.e. 
no significant difference in age or gender profile).  No systematic bias in favour of 
the main hypothesis would be expected from studying a representative sample of 
over 90% of national cases. By contrast, case ascertainment in the National 
Oesophagogastric Cancer Audit was under 70%.[113]  
Patients’ sex distribution, median age, and the percentage of patients under the 
age of 55 in this cohort were consistent with the same figures reported for cases in 
the National Oesophago-gastric Cancer Audit [112, 113, 177, 298]. Numerous 
studies in various populations have also shown an association between 
socioeconomic deprivation status and risk of OG cancer [65] in keeping with our 
results.  
Similarly, this study defined the mode of admission by identifying the first clinically 
relevant episode of care in the patient pathway. Consequently, the percentage of 
OG cancer patients who were first admitted through the emergency route is 28.3% 
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(24.4% of oesophageal and 36.1% of gastric). Such proportions are very comparable 
with the information published by the NCIN, which reports that around a quarter 
(26%) of OG cancer patients (21% of oesophageal and 32% of gastric cancers) were 
diagnosed during emergency admissions within the same time period [275, 299].  
With respect to the other outcome variables, the resultant national rate of major 
surgical resection is 16.5% for OG cancers overall (15.5% reported by NCIN) [277], 
and the one-year survival rate following index gastroscopy is 40.7% (41.14% 
reported by the NCIN). [295] The close agreement of our data outputs with 
independent analyses of national cancer data, suggesting valid methodology.  
The linkage methodology has further been verified by the use of a local audit 
dataset, indicating that within the matched patient population between our local 
hospital and HES, the accuracy of method of admission, coded surgical resection 
date as well as death date were consistent in 141 (98.6%), 137 (93.8%) and 140 
(97.9%) cases respectively. 
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3.4.6 Patients factors associated with OG cancer outcome in England 
Binary Logistic Regression confirms that patients’ age, co-morbidity and deprivation 
are independent predictors of cancer diagnoses through the emergency 
presentation route, with potential chance for major surgical resection and mortality 
at 12 months in our national cohort, with gender not being a significant factor 
(Table 3.7, Figures 3.13, 3.14, and 3.15). 
Table 3.7 Patients factors associated with OG cancer outcome in England (n=23,521).  adjusted 
odds ratios with 95% CI based on Uni-variate logistic regression (Reference group = 1) 
Variable Emergency Admission 
OR                CI              p 
value 
Major Surgical Resection    
OR                CI              p 
value 
Death within 12 months     
OR                CI              p 
value 
Age 
         
< 55 1 - - 1 - - 1 - - 
55 to 64                                                                  0.77 0.68-0.88 <0.001 0.90 0.80-1.02 0.127 1.06 0.95-1.18 0.242 
65 to 74 0.97 0.86-1.10 .722 0.77 0.69-0.87 <0.001 1.28 1.16-1.42 <0.001 
75 to 84 1.59 1.42-1.79 <0.001 0.34 0.30-0.38 <0.001 2.21 2.00-2.45 <0.001 
≥ 85 2.87 2.53-3.26 <0.001 0.05 0.04-0.07 <0.001 3.88 3.43-4.39 <0.001 
Gender          
Female 1 - - 1 - - 1 - - 
Male 0.83 0.78-0.88 <0.001 0.80 0.75-0.87 <0.001 0.88 0.84-0.93 <0.001 
Co-morbidity 
         
No co-morbidity 1 - - 1 - - 1 - - 
1 co-morbidity 3.02 2.81-3.25 <0.001 0.97 0.88-1.06 .514 1.23 1.15-1.32 <0.001 
≥ 2 co-morbidity 6.22 5.65-6.84 <0.001 0.21 0.17-0.26 <0.001 3.44 3.06-3.85 <0.001 
GP Practices 
Deprivation 
         
1
 
 Most deprived 1 - - 1 - - 1 - - 
2 0.84 0.77-0.92 <0.001 1.10 0.99-1.23 .069 0.90 0.83-0.98 0.017 
3 0.80 0.74-0.88 <0.001 1.08 0.97-1.20 .152 0.94 0.86-1.02 0.155 
4 0.73 0.67-0.80 <0.001 1.17 1.05-1.31 0.003 0.89 0.82-0.96 0.005 
5
 
 Least deprived 0.70 0.63-0.76 <0.001 1.13 1.01-1.27 0.024 0.88 0.81-0.96 0.007 
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Figure 3.13 Patients factors ( Age, Gender, Comorbidity and Deprivation) associated with emergency route of diagnosis for ( n=23,521) cases of OG cancer 
in England.  Odds ratios with 95% CI based on multivariate logistic regression (Reference group =    ). Gender was not a predictor for patient’s 
outcome; hence it is omitted from the regression equation.      
 
 
OR   (95%CI)     P value 
Age group 
Co-morbidity 
Deprivation 
0.81 (0.70-0.93) 0.003 
1.0 (0.88-1.13) 0.972 
1.65 (1.46-1.87) <0.001 
2.93 (2.72-3.16) <0.001 
6.66 (6.03-7.35) <0.001 
0.84 (0.76-0.92) <0.001 
0.77 (0.71-0.85) <0.001 
0.71 (0.64-0.78) <0.001 
0.67 (0.60-0.74) <0.001 
3.28 (2.86-3.76) <0.001 
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Figure 3.14 Patients factors ( Age, Gender, Comorbidity and Deprivation) associated with major surgical resection for ( n=23,521) cases of OG 
cancer in England.  Odds ratios with 95% CI based on multivariate logistic regression (Reference group =    ). Gender was not a predictor for 
patient’s outcome; hence it is omitted from the regression equation.      
 
 
OR   (95%CI)     P value 
Age group 
Co-morbidity 
Deprivation 
0.86 (0.76-0.98) 0.026 
0.73 (0.65-0.82) <0.001 
0.32 (0.28-0.36) <0.001 
1.08 (0.98-1.19) 0.085 
0.20 (0.16-0.25) <0.001 
1.13 (1.01-1.27) 0.024 
1.19 (1.06-1.33) 0.002 
1.29 (1.15-1.44) <0.001 
1.25 (1.11-1.41) <0.001 
0.05 (0.03-0.03) <0.001 
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Figure 3.15 Patients factors ( Age, Gender, Comorbidity and Deprivation) associated with death at 12 month for ( n=23,521) cases of OG cancer in 
England.  Odds ratios with 95% CI based on multivariate logistic regression (Reference group =    ). Gender was not a predictor for patient’s 
outcome; hence it is omitted from the regression equation.   
OR   (95%CI)     P value 
Age group 
Co-morbidity 
Deprivation 
1.10 (0.99-1.23) 0.065 
1.34 (1.21-1.49) <0.001 
2.31 (2.09-2.57) <0.001 
1.15 (1.07-1.23) <0.001 
3.61 (3.21-4.06) <0.001 
0.89 (0.82-0.96) 0.007 
0.88 (0.81-0.96) 0.006 
0.84 (0.77-0.91) <0.001 
0.83 (0.76-0.91) <0.001 
4.15 (3.66-4.71) <0.001 
135 
 
3.5 Discussion:  
This chapter illustrates at national level that the total case numbers, demographic 
characteristics and measured outcome variables for the ‘incident’ patient cohort 
extracted from HES data are consistent with external independent analyses of 
available data for OG cancer in England.  Furthermore, by linking cases at one 
hospital to an audit database containing information from the local clinical records, 
it was possible to show close agreement between outcome variables (emergency 
admission; surgery; mortality) assigned using our algorithms in HES data and the 
‘real’ outcome recorded in the local records.  These face-validity checks suggest 
that careful application of clinical logic to the HES dataset can generate novel 
methods for overcoming the limitations of HES data such as lack of diagnosis date 
and the varied manner in which cancer cases may be coded diagnostically during 
the early phase of their pathway. 
The methods development phase of the research tested the possibility of finding a 
more reliable starting point for the OG cancer patient journey within the sequence 
of coded episodes contained within HES data. As mentioned in Chapter 1, the main 
diagnostic investigation for this type of malignancy is gastroscopy with biopsy 
(OGD) followed by histological processing and reporting to confirm the diagnosis 
[100, 115, 300, 301]. HES data lacks the histopathology report or formal diagnostic 
date. This makes the use of the ‘first coding date’ for cancer (i.e. the admission or 
discharge date taken from the episode containing the first recording of a cancer 
code for the patient) an unreliable indicator for the start of the patient journey for 
some patients. Thus, our novel method for identifying the ‘first’ relevant episode of 
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care in the cancer patient pathway was to flag the first coded diagnostic 
gastroscopy.  Although this index gastroscopy episode frequently contained the first 
appearance of a relevant OG cancer diagnostic code for that case, we found that 
17% of OG cancer cases captured by our methodology had other diagnostic codes 
recorded at first gastroscopy (e.g. gastric ulcer or oesophageal stricture), with the 
cancer code appearing at a subsequent episode (e.g. a repeat admission for 
stenting or surgery).  This confirms the unreliable nature of relying only on first 
appearance of cancer code to identify the start of the pathway. 
Having successfully generated a valid cancer population, this study sought to 
explore the association between the measured cancer outcomes and the described 
patient-level variables such as age, sex, co-morbidity and deprivation status.  As 
expected, analysis of patient characteristics and outcomes according to mode of 
admission (emergency or elective) confirmed that patients diagnosed during 
emergency admission were significantly older (75 vs 70), had more co-morbidity 
and a lower chance for potentially curative surgical treatment (8.1% vs 19.5%), and 
showed higher early mortality and indeed poorer survival (23.7% vs 47.6%).  We 
were able to compare these national patterns observed in HES data with an audit 
study of local cancer outcomes, which showed that locally diagnosed emergency 
cases were again older than elective (76.0 v 70.4 yrs; p<0.003), were less likely to 
have curative treatment (13.6% v 33.3%; p<0.013) and their median survival (138 v 
237 days, p=0.07) was also shorter. [294, 302]  
We further performed multiple logistic regression analysis to test whether there are 
associations between various patient-level factors available in HES (patients’ age, 
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gender, co-morbidity and deprivation) and the three cancer outcomes measured in 
this study. This confirmed the anticipated trends that poorer cancer outcomes are 
associated with advancing age, increased co-morbidity and higher levels of patient 
deprivation.   
It was not possible to report accurate data for individual tumour sites (i.e. 
oesophageal, junctional, distal gastric).  In general, we considered it more useful to 
study the OG cancer sites collectively since oesophageal and gastric cancer share 
common signs, symptoms, primary modality of diagnostic testing (gastroscopy) and 
referral guidelines. A high proportion of cases are also coded in HES under the least-
specific codes (C159 and C169) and sometimes with a mixed codes for both cancers. 
This creates difficulties in the analysis of specific tumour sub-location, particularly 
for the gastro-oesophageal junction. Similar limitations have also been noted by 
many published studies used both HES and national cancer registry data [22, 112, 
303-305].  However, the primary objectives of the research did not require the 
ability to extract tumour-site specific information. 
Another possible limitation relates to the minority of patients managed privately, 
information for whom is not available in HES [277]. Hence, incident patients who 
had their diagnostic gastroscopy in the private sector would not be identified. 
Although our rates of emergency admission during the diagnostic pathway were 
very close to those reported by the NCIN, it is noted that the National Oesophago-
gastric Cancer Audit reported lower percentages of emergency diagnosis for both 
cancers than our data.  However, this might be due to the recognised low rate of 
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case ascertainment achieved in the audit, leading to concerns about 
inclusion/exclusion bias. The national figures nevertheless still show the same trend 
that emergency diagnosis is somewhat more prevalent for gastric cancer than for 
oesophageal cancer (accepting the limitations of site-specific analysis in our own 
data), and emergency patients tend to have a lesser chance for curative treatment 
(17% v 39%) [113, 302] which is again similar to our own results.  
Deprivation is an important potential determinant of healthcare outcomes. The 
English IMD scores are derived from 38 indicators grouped into seven empirically 
weighted domains used to rank each LSOA from the least to the most deprived. 
Grouping of LSOAs into quintiles is the standard approach taken when generating 
ordinal categorical variables for socioeconomic status based on IMD. [306] The 
terminology adopted to describe the deprivation quintiles (“most deprived” to 
“least deprived”) is also in widespread use in the HES-related literature. [240, 268] 
Although the percentages of these outcomes by deprivation quintile have not been 
standardized for differences in the age structure within each quintile,  our data still 
shows that higher percentage of the most deprived group of patients were 
diagnosed during emergencies, had fewer surgeries and a relatively higher 
mortality at one year compared with the least deprived groups. Equivalent findings 
have been reported by the NCIN for both cancers using multiple datasets, including 
HES. [274, 276, 277]  
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The highest inequality by deprivation quintile within these outcomes was among 
the emergency diagnoses. Additional analyses are thus required to explain the 
causes underlying this observation. The recent Routes to Diagnosis, 2006-2008 
(NCIN) suggested that this difference is threefold for oesophageal cancer and 
tenfold for the gastric cancer population. [276]     
The main challenge in this study related to the general issue concerning the 
completeness, precision and depth of routine administrative coding. However, our 
methodological approach has striven to overcome such limitations by identifying, 
linking and chronological ordering of all individual patients care episodes to limit 
the acknowledged potential impact of coding error. [248, 255, 257, 264, 283].  
We were unable to study the frequencies and percentages of each specific tumour 
pathological type as a result of absence of important clinical details in HES data (i.e. 
pathology reports) and the use of less specific cancer codes. This information would 
be of descriptive interest given the changing epidemiology of oesophageal tumour 
types [2, 16, 22, 307, 308] but is not a requisite for studying factors associated with 
overall OG cancer outcomes. 
Other limitations are related to the lack of tumour staging in the main HES data. 
Although emergency admission during the diagnostic pathway may be unavoidable 
for a minority of clinical presentations of OG cancer (e.g. acute GI bleeding), it is 
important to note that this outcome is being taken as a proxy measure for 
diagnostic delay as well as an indication of advanced disease. Similarly, the rate of 
major surgical resection is reflective of earlier diagnosis, since only individuals with 
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early stage OG cancer will be candidates for potentially curative major resection. 
Hence, this project assumes that emergency admission at diagnosis, as well as the 
chance for obtaining surgical resection, are surrogate markers of patients’ stage at 
the time of diagnosis. 
Concluding statement: 
The results presented for this ‘methodological development’ phase of work do 
support the idea that HES data can provide a powerful tool for health services and 
epidemiologic research if analysed carefully using clinical logic.  By applying 
knowledge of the disease process and care pathways and insight into the 
limitations of the dataset (e.g. the variety of ways that cases might be coded over 
time), a bespoke method was generated and tested. The national-level analysis has 
generated ‘real-world’ descriptive statistics for OG cancer care in England that 
exhibit close agreement with independent published sources for national case 
number, demographics and key outcomes.  The cohort exhibits the expected 
associations between cancer outcome and patient-level sociodemographic (age; 
sex; deprivation) and co-morbidity variables. The resulting master dataset of cancer 
cases for 2006-2008 provides the platform for exploring factors associated with OG 
cancer outcomes in England.   
The next chapter describes the results of additional work to generate methods for 
analysing rates of elective gastroscopy at the level of individual general practices 
and describes this variation.  By linking the master dataset for cancer cases and the 
GP practice-level data for gastroscopy rates, it is then possible to build a series of 
univariate, stratified and multiple variable binary logistic regression analyses (with 
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extensive sensitivity analyses) to test the main study question in a national-scale 
ecological study –  ‘Is there an association between rates of gastroscopy in general 
practice populations and OG cancer outcome?’ 
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Chapter 4 Variation in elective gastroscopy rates in English general 
practices and outcomes for oesophago-gastric cancer: retrospective 
analysis of Hospital Episode Statistics 
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4.1 Introduction 
Gastroscopy is the gold standard investigation for identifying serious causes of 
dyspepsia. This test is relatively expensive, uncomfortable and not without small 
risk. In England, to a great extent, most of the referral for upper GI endoscopy is 
made through primary care. Direct access to gastroscopy from primary care was 
established during the 1980s,[136] and fast-track access for those with alarm 
symptoms was introduced into the NHS more than 10 years ago under the National 
Cancer Plan. [108, 309] However, there has been little improvement in the 
detection of curable cancer over this period. Overall, approximately three-quarters 
of cases of OG cancer are diagnosed at a late and inoperable stage in the UK. [33, 
177] 
Given the unresolved questions regarding the value of gastroscopy both in 
managing dyspepsia and in detecting curable cancer, variation in the rates of 
gastroscopy across primary care is inevitable. The recent NHS Atlas of Variation also 
demonstrates that such degrees of variation observed for both cancer diagnosis 
and gastroscopy were greater than can be explained by variations in the incidence 
and prevalence of disease. [185, 186]  
Analysis of gastroscopy activity data for Primary Care Trusts (PCT) shows more than 
a twofold range across England.[185] However, this study believes that aggregated 
data for groups of practices may mask wider variation between individual general 
practice centres. Assessment of access to this gold standard investigation according 
to patient outcomes, rather than according to the availability or utilisation of this 
diagnostic service, is lacking. Hence, showing cancer outcomes at the two ends of 
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the variation spectrum at GP practice level might provide some promising answers 
that could yet support the role of this procedure in managing patients with 
suspected OG cancer. 
4.2 Aim 
This chapter aims to test the hypothesis that outcomes for OG cancer patients may 
be associated with local rates of gastroscopy in the general practice population. We 
postulated that general practices with relatively low per capita rates of gastroscopy 
may be less likely to identify curable cancers, whereas those with higher levels of 
gastroscopy may increase the chance of earlier diagnosis and curative treatment.  
 
4.3 Objectives 
 To identify general practices in England with validated incident OG cancer 
cases as described in chapter 3 
 To explore the variation of gastroscopy rates at the general practice level 
after adjustment for the practice registered population demographics. 
 To test whether gastroscopy rates in general practice populations in England 
are associated with the outcome for OG cancer patients. These outcome 
variables include emergency admission during the diagnostic pathway, the 
chance for major surgical resection and mortality at twelve months. Any 
association between local rates of gastroscopy and outcome should be 
independent of possible confounders such as age and deprivation.  
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4.4 Method  
4.4.1 The eligibility criteria for general practices included in the study  
Per capita gastroscopy volume was determined by extracting diagnostic 
gastroscopy procedures from our previously described two year download of HES 
data (chapter 2). Procedures were then aggregated at GP practice level. Details of 
the codes and standardization methods for gastroscopy rate used are also 
described in (chapter 2). 
GP practices in England with a known population list size were (n=8,338). [278] 
Matching of the unique GP practice code with that recorded in our two year 
download of HES data showed that the number of practices with at least one OGD 
procedure coded in HES was (n=8,250) in which (n=8,232) of them had at least one 
elective gastroscopy. This group of practices was subsequently linked to practices 
with OG cancer coded diagnosis, revealing that (n= 7,217) of them had at least one 
prevalent coded OG cancer case, of which (n= 6,650) practices were related to 
cancer patients with valid care pathways (Incidence cases are described in chapter 
3). With regards to the practice deprivation IMD scores [279], around 137 practices 
were lacking essential information, leaving just (n= 6,513) eligible practices for the 
final analysis (Figure 4.1). These practices were ranked nationally according to their 
age- and sex-adjusted annual gastroscopy rate and then divided into tertiles (low, 
medium and high tertiles).  
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In England GP practice size varies from single handed general practitioner to multi-
partner practices and may change from one year to another.[310] It has also been 
reported that over the last decades more GPs are arranged to work in larger 
practices by the fact that the number of practices decreased by around 9% from 
1997 to 2007.  For these reasons, the selected practices in this study were further 
checked for any major alterations in their total adult list size within the 
corresponding data years (2006/7 to 2007/8). This step was performed using data 
supplied by the Health and Social Care Information Centre for the two data years 
which showed close agreement in year-to-year populations for the study practices 
over this period.  
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Figure 4.1 The eligibility criteria for general practices included in the study 
4.4.2 OG cancer outcome 
All general practices in England with incident cases of OG cancer as defined in 
chapter 3 were combined with their total elective diagnostic gastroscopy activity. 
Outcome measures for cancer cases were: emergency admission during diagnostic 
pathway; major surgical resection; and mortality at 1 year. The origin, definition 
and process of extraction and validation of these outcomes were described in 
chapters 2 and 3. The origin and methods of extraction of both patients and 
practice level factors used in this part of study are also described in the section on 
method (chapter 2). Although the inequality in patients outcome according to the 
8338 GP practices in England with 
population list size, 2008  
6513 eligible practices for the final 
analysis  
 8232 GP practices with ≥ 1 elective 
OGD procedure  
 7217 GP practices with ≥ 1 OG cancer 
coded case 
 6,650 GP practices with ≥ 1 OG cancer 
case with pathway of care compatible 
with incident case 
 
 
 8250 GP practices with ≥ 1 coded OGD 
procedure  
 1719 GP practices with ≥ 1 elective 
OGD procedure were excluded.  
 1015 GP practices with no OG 
cancer coded patients 
 567 GP practices with no OG 
cancer patients with a valid 
pathway 
 137 GP practices excluded 
because of unknown IMD score 
 
In summary: the eligibility criteria for general practices included in the study involve all 
general practices in England that satisfy (1) data available for mid-year practice 
population list size and demographics and average deprivation score of registered 
patients; (2) one or more incident cases of OG cancer identified for the practice from the 
HES dataset. 
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patients’ factors are reported in chapter 3, in the present chapter it is necessary 
also to use these patients’ casemix with other possible practice level covariates in 
the regression model, to test whether gastroscopy rates at the practice level tertile 
(exposure of interest) could also act as an independent predictor of patient 
outcomes (Figure 4.2.).  
4.4.3 Statistical analysis: 
Unless stated, analysis of variance (ANOVA) and χ2 tests have been used to 
compare differences in continuous and categorical variables between the three 
groups of practices. Univariate logistic regression was used to identify factors 
associated with patient outcomes. Factors with a significance level of ≤0.1 on 
univariate analysis were included in the final multivariate regression model. 
 
4.4.4 Sensitivity analysis: 
Several additional multivariate analyses using an alternative ‘exposure’ variable to 
express the gastroscopy rate of the patients’ general practice were undertaken. 
First, this was done by substituting the elective gastroscopy rate tertiles for 
quintiles and reassigning each practice to one of five groups, according to their rank 
order of age-sex-adjusted elective gastroscopy per capita. Second, we reassigned 
each practice to a quintile based on the gastroscopy rate for people over the age of 
55 years. This age cut-off reflects the rate of gastroscopy performed in the ‘higher 
risk’ population for cancer as identified in recent guidelines.  Third, we substituted 
the practice level categorical variable (tertile or quintile group) for a continuous 
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scale variable reflecting the actual rate of gastroscopy at the practice (expressed as 
a rate per 100 to simplify interpretation of ORs). 
 
The NHS Atlas reported the variation in the rate of gastroscopy procedures at the 
level of primary care trusts (PCT) across all the 152 PCTs in England and then 
applied an arbitrary exclusion of five (about 3%) PCTs from each end of the referral 
spectrum.[x]  In the present study, no arbitrary exclusion of the highest or lowest 
3% of referring practices was applied, since this was judged unnecessary given the 
grouping of practices into tertiles or quintiles rather than studying individual 
practices.  However, had we excluded 3% of practices from each end of the 6,513 
practices included in this study, there would have been no change to the calculated 
national average rate of gastroscopy nor any change to the magnitude of variation 
shown across the tertile or quintile groupings. 
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Figure 4.2 Illustrates the regression model to test whether gastroscopy rate at the practice 
level (exposure of interest) could also act as an independent predictor of patient outcomes 
after adjusting for the possible covariates. 
 
 
 
 
 
 
 
• Age group (<55, 55-64, 65-74, 75-84, 85+) 
• Sex (male, female) 
• Co-morbidity (None, 1, 2+) 
• Patients level Deprivation (Quintile) 
• Practice level Deprivation (Quintile) 
• Emergency admission at diagnosis 
• Major surgical resection  
• Mortality at one year  
Outcomes   
Predictors: Exposure of interest 
General practice gastroscopy rate 
(Tertile), (Quintile) and (Continuous variable) 
Predictors  
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4.5 Results 
4.5.1 General practices included in the study and their rates of elective 
gastroscopy 
During the study period, there were 6,513 general practices eligible for this 
analysis. These practices served a total combined adult population of 39,773,433, in 
which 332,868 elective gastroscopies were recorded per year. Overall, this gives a 
crude national per capita activity rate of 8.4 elective gastroscopy procedures per 
1000 adults per year in England (Figure 4.3) The practices were ranked nationally 
according to their age and sex-adjusted annual elective gastroscopy rate and then 
divided into tertiles (low, medium and high tertiles) as shown in (Figure 4.4). 
Although most of the results have been presented in relation to these tertile, since 
this seems a particularly informative approach, the key findings were also justified 
using other method of exposure in the sensitivity analysis section. 
 
 
Figure 4.3 Histogram showing the normal distribution of the GP practices according to their 
age-sex standardized gastroscopy rate per 1000 practice population.  
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Figure 4.4 GP practices ranked nationally according to their age- and sex-adjusted annual 
gastroscopy rate and then divided into tertiles (low, medium and high tertiles)   
Tertiling of practices by their adjusted elective gastroscopy activity reveals that 
their mean rate for the high tertile group of practices (12.9 per 1000) was more 
than 2.5 times (250%) that of practices in the low tertile group (4.4 per 1000) (Table 
4.1). The age specific rate for the ≥55 years (Age cut off for gastroscopy referral) of 
elective gastroscopy procedures performed were also 2.76 times more in high 
tertile practices. Moreover, it is clear from the table that higher proportions of 
gastroscopies performed during emergency episodes were coded along with 
general practices with low rates of elective procedures (Table 4.1).  It is important 
to note that over the study period for capturing total elective gastroscopy activity 
data, 88.2% of the procedures were unique (ie, ‘first-time’ for individual patients 
within the 2-year time window). The corresponding figures for each general 
practice tertile were within 1% of each other (low tertile: 89%; middle tertile: 89%; 
high tertile 88%). 
6, 513 English general practices 
153 
 
Table 4.1 The 6,513 General Practices related Gastroscopy procedures number, mode 
(Elective vs. Emergency) and rates. Results presented overall (total) and grouped into the 
practice tertiles according to age-sex standardized rate of elective gastroscopy. (HES data: 
2006/7-2007/8)  
 Total Low tertile 
practices 
 
p 
Middle tertile 
practices 
High tertile 
practices 
Number of practices  6513 2171 2171 2171 
Registered adult patients 39,773,433  13,634,374 13,861,641 12,277,418 
Total annual Gastroscopy (n) 411,175 83,792 141,240 186,143 
  Elective procedures (n, %) 332,868 (81) 61,137 (73) 114,819 (81) 156,912 (84.3) 
  Emergency procedures (n, %) 78,307 (19) 22,655 (27) 26,421 (19) 29,231 (15.7) 
     
Average elective gastroscopy rate per 1000 practice population, (SD)     
  Crude (Un-adjusted) rate  8.4 (4.2) 4.5 (2) 8.2 (1.4) 12.9 (3.5) 
  Standardized (Adjusted) rate 8.5 (4.1) 4.4 (1.8) 8.1 (0.8) 12.9 (3.1) 
  Age specific (≥ 55) rate 16.5 (7.8) 8.9 (4.1) 16.2 (2.5) 24.6 (5.8) 
 
The demographic characteristics of these practices are described in (Table 4.2). The 
populations served by the tertile groups of practices showed no significant 
differences with respect to age or gender profile. However, there was a significant 
difference in the distribution of practices with respect to the “average” practice-
level deprivation variable (quintile) – the low tertile group contained the lowest 
proportion of “most deprived” practices whereas the high tertile group contained 
the highest proportion. Generally, practices within the most socially disadvantaged 
group illustrated higher rates of gastroscopy. The most affluent group of practices, 
however, showed the opposite trend. (Figure 4.5.)  
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Table 4.2 Demographic characteristics of 6,513 General Practices in England grouped into 
tertiles according to their age-sex standardized rate of diagnostic elective gastroscopy.  
Characteristic                        Total  Low tertile 
practices  
(n=2,171) 
Middle tertile 
practices 
(n=2,171) 
High tertile 
practices 
(n=2,171) 
Adult age groups n,%    
 
  < 55                                     26,336,483 (66.2) 8,954,744 (65.67) 9,188,880 (66.28) 8,192,859 (66.73) 
  55 to 64                                   5,715,513 (14.3) 1,992,359 (14.61) 1,983,889 (14.31) 1,739,265 (14.16) 
  65 to 74                                     4,033,883 (10.1) 1,398,613 (10.25) 1,400,338 (10.10) 1,234,932 (10.05) 
  75 to 84                                     2,649,347 (6.6) 917,894 (6.73) 924,825 (6.67) 806,628 (6.57) 
  ≥ 85                                    1,038,207 (2.6) 370,764 (2.71) 363,709 (2.62) 303,734 (2.47) 
Gender                                               
 
  Male                                               19,679,660 (49.5) 6,765,876 (49.62) 6,844,554 (49.37) 6,069,230 (49.43) 
  Female                                             20,093,773 (50.5) 6,868,498 (50.37) 7,017,087 (50.62) 6,208,188 (50.56) 
Practice deprivation 
quintile                     
   
 
  Q1 (most deprived)                                 1,122 (17.2) 243 (11.19) 298 (13.72) 581 (26.76) 
  Q2 1,261 (19.3) 295 (13.58) 410 (18.88) 556 (25.61) 
  Q3 1,336 (20.5) 438 (20.17) 438 (20.17) 460 (21.18) 
  Q4 1,377 (21.1) 531 (24.45) 502 (23.12) 344 (15.84) 
  Q5 (least deprived)                                1,417 (21.7) 664 (30.58) 523 (24.09) 230 (10.59) 
 
 
 
 
 
<0.001  
Ns   
Ns   
p value  
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Figure 4.5 The average practices gastroscopy rate with 95% CI distributed according to their  
level of deprivation. 
 
In addition, practices within the same average deprivation quintile exhibited wide 
variation in rates of gastroscopy. For example, of these 6,513 included practices, 
there were 1,222 practices serving the poorest local populations (deprivation 
quintile 1). For these “deprived” practices, mean adjusted gastroscopy rate was 4.1 
per 1,000 for the low tertile group of practices and 13.9 per 1,000 for the high 
tertile group. Similarly, there were 1,415 practices serving the least deprived 
populations (quintile 5). For these least deprived practices, the average rate was 4.8 
per 1,000 for the low tertile group and 11.4 per 1,000 for the high tertile group of 
practices (Figure 4.6). 
10.3 
7.0 
7.6 
8.4 
9.4 
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Figure 4.6 shows the age- sex adjusted rate with 95% CI of elective gastroscopy according 
to the practice level deprivation and across the practice tertile groups. 
 
The strength of such association has further been investigated using linear 
regression analysis, showing that only 7.9% of variation in age-sex adjusted practice 
rates is associated with practice-level deprivation (adjusted R-square: 0.079), 
suggesting that most variation in gastroscopy rates is not accounted for by the 
average deprivation score of the practice population.  
 
 
Low tertile 
Middle tertile 
High tertile 
4.1 
4.8 
4.2 4.1 4.3 
8.3 
8.0 8.1 
8.1 8.2 
13.9 
11.4 
12.1 
12.7 12.9 
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4.5.2 Characteristics of individuals who had elective Gastroscopy procedure 
across the tertile groups of general practices 
 
587,256 individuals were coded with an elective gastroscopy procedure linked to 
the 6,513 practices in the study during the 2-year period. The demographic 
characteristics across the tertile groups of practices for these patients are 
summarised in (Table 4.3).  
There was a small but significant difference in the mean age, with the High tertile 
group appearing to have younger patients who had this procedure. Again, the 
distribution of the patients’ socioeconomic profile among this tertile was similar to 
that described in relation to the practices’ average deprivation, in which the high 
tertile group of practices had the highest proportion of “most deprived” patients, 
and the low tertile group had the highest proportion of “least deprived” patients 
undergoing gastroscopy. 
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Table 4.3 The number and demographic characteristics of individuals who had elective 
gastroscopy at the patient’s first elective gastroscopy related hospital episode (across the 
GP practice terile groups) 
 Total Low tertile 
practices 
 
p 
Middle tertile 
practices 
High tertile 
practices 
p value 
Patients 587,256 108,679 203,771 274,806 - 
Age, mean (SD) years                                59.2 (16.5) 60.2 (16.6) 59.5 (16.5) 58.4 (16.4)   <0.001 
Age groups       
  < 55                                     215514 (36.7) 37035 (34.1) 72772 (35.7) 105707 (38.5)  
  55 to 64                                   127237 (21.7) 23321 (21.5) 44014 (21.6) 59902 (21.8)  
  65 to 74                                     126421 (21.5) 23949 (22.0) 44455 (21.8) 58017 (21.1)  
  75 to 84                                     95628 (16.3) 19440 (17.9) 34238 (16.8) 41950 (15.3)  
  ≥ 85                                    22456 (3.8) 4934 (4.5) 8292 (4.1) 9230 (3.4)  
Gender        
  Male 263261 (44.8) 49696 (45.7) 91257 (44.8) 122308 (44.5) Ns 
--- 
 
  Female 323949 (55.2) 58973 (54.3) 112498 (55.2) 152478 (55.5)  
patients deprivation        
Q1 (Most deprived) 126220 (21.6) 12185 (11.3) 32741 (16.1) 81294 (29.7)  
Q2 118623 (20.3) 16885 (15.6) 40028 (19.7) 61710 (22.5)  
Q3 119242 (20.4) 21809 (20.2) 43216 (21.3) 54217 (19.8)  
Q4 115317 (19.7) 25698 (23.7) 44208 (21.8) 45411 (16.6)  
Q5 (Least deprived) 105772 (18.1) 31653 (29.2) 42818 (21.1) 31301 (11.4)  
      
 
 
 
 
 
 
 
 
 
 
 
 
<0.001  
 
 
 
<0.001  
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4.5.3 Per capita rate of gastroscopy and OG cancer outcome 
The characteristics of the OG cancer patients by tertile of general practice 
gastroscopy rate are summarised in (Table 4.4).  At the time of index gastroscopy, 
the average age of cancer patients belonging to practices in the low tertile group 
was approximately one year older than those belonging to high tertile practices. 
There was no difference with respect to gender or frequency of co-morbidities 
across the three groups of practices. The distribution of patient-level deprivation 
score for the cancer patients across the three practice tertile groups show that the 
greatest proportion of most deprived cancer patients were in the high tertile group 
whereas the greater proportion of least deprived cases belonged to the low tertile 
group of general practices (Table 4.4).   
Comparison of crude (unadjusted) outcomes across the tertile showed highly 
significant differences for all three outcome measures (emergency admission during 
diagnostic pathway, major surgical resection and mortality within 1-year of index 
gastroscopy) as shown in (Figure 4.7). Hence, when aggregated nationally, those 
patients belonging to the low tertile practices (lowest gastroscopy rates) had 
poorest cancer outcomes.  This is despite the fact that overall this group of general 
practices tended to be serving less deprived practice populations (Table 4.2) and 
had a lower proportion of “most deprived” cancer patients (Table 4.4). 
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Table 4.4 Characteristics of 22,488 OG cancer patients by tertile of general practice 
gastroscopy volume (analysis of HES data for England, 2006-2008) 
Patient characteristics Low tertile 
practices  
 
Middle tertile 
practices 
 
High tertile 
practices 
 
P value 
Number of cases 6,196 7,913 8,379 - 
Age, mean (sd)                                      72.2 (11.9) 71.6 (11.7) 71.3 (11.6) 0.004 
Age groups*                                             
  < 55                                     508 (8.2) 628 (7.9) 714 (8.5)  
  55 to 64                                   1049 (16.9) 1445 (18.3) 1538 (18.4) Ns  
  65 to 74                                     1672 (27.0) 2255 (28.5) 2415 (28.8)  
  75 to 84                                     2058 (33.2) 2578 (32.6) 2750 (32.8)  
  ≥ 85                                    909 (14.7) 1007 (12.7) 962 (11.5)  
Gender     
 Male 4045 (65.3) 5239 (66.2) 5517 (65.8) Ns 
 Female 2151 (34.7) 2674 (33.8) 2862 (34.2) Ns   
Co-morbidity groups                                     
 1 (No co-morbidity)                                4486 (72.4) 5920 (74.8) 6149 (73.4) Ns  
 2 (1 co-morbidity)                                 1112 (17.9) 1344 (17.0) 1508 (18.0) Ns  
 3 (2 or more co-morbidity)                         598 (9.7) 649 (8.2) 722 (8.6) Ns  
Patient deprivation quintile                   
 1 (Most deprived)                                 822 (13.4) 1361 (17.3) 2567 (30.8)  
 2 1094 (17.8) 1646 (20.9) 1915 (23.0) <0.001 
 3 1275 (20.7) 1700 (21.6) 1636 (19.6)  
 4 1470 (23.9) 1671 (21.2) 1344 (16.1)  
 5 (Least deprived)                                1494 (24.3) 1492 (19.0) 873 (10.5)  
 
161 
 
 
P=0.004 
 
p<0.001 
 A 
B 
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Figure 4.7 Comparison of crude outcomes for OG cancer across the general practice tertile 
groups (low, middle or high gastroscopy rate per capita). (A) Emergency admission during the 
diagnostic pathway; (B) Major surgical resection; (C) Mortality at 1 year from index gastroscopy. 
Stratified analysis of crude outcomes according to patient-level deprivation (Figure 
4.8, 4.9 and 4.10) revealed that the imbalance in patient outcome across the three 
groups of practices was most marked among the most deprived in society (quintile 
1).  Hence, for the most deprived cases of OG cancer in England, the rate of surgery 
was just 12.5% for those belonging to low tertile practices, 13.2% for those 
belonging to medium tertile practices and 17.5% for those registered with a high 
tertile practice (p<0.001; Pearson Chi-square; Figure 4.8). Similar trends were 
apparent for the other outcomes (Figure 4.9 and Figure 4.10).  
p<0.001 
 C 
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OG cancer patients 
 deprivation group 
Low tertile  
 
Middle tertile 
 
High tertile 
 
P value 
1 (Most deprived)                                 355/822 (43.2 %) 412/1361 (30.3 %) 753/2567 (29.3 %) <0.001 
2 412/1094 (37.6 %) 456/1646 (27.7 %) 474/1915 (24.7 %) <0.001 
3 444/1275 (34.8 %) 459/1700 (27.0 %) 371/1636 (22.7 %) <0.001 
4 467/1470 (31.7 %) 413/1671 (24.7 %) 289/1344 (21.5 %) <0.001 
5 (Least deprived)                                415/1494 (27.7 %) 341/1492 (22.8 %) 202/873 (23.1 %) 0.003 
 
Figure 4.8 Crude (unadjusted) rate of emergency admission as a route of diagnosis of OG 
cancer patients according to general practice tertile for gastroscopy rate (low, middle or 
high): Stratified for deprivation quintile of the patient based on their individual LSOA code. 
Quintile 1 refers to patients living in the most socioeconomically deprived areas of England. 
 
 
 
 
 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p=0.003 
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OG cancer patients 
 deprivation group 
Low tertile  
 
Middle tertile 
 
High tertile 
 
P value 
1 (Most deprived)                                 103/822 (12.5 %) 180/1361 (13.2 %) 450/2567 (17.5 %) 0.001 
2 153/1094 (13.9 %) 281/1646 (17.1 %) 344/1915 (17.9 %) 0.016 
3 200/1275 (15.7 %) 261/1700 (15.3 %) 293/1636 (17.9 %) n/s 
4 233/1470 (15.8 %) 321/1671 (19.2 %) 234/1344 (17.4 %) 0.047 
5 (Least deprived)                                264/1494 (17.7 %) 251/1492 (16.8 %) 139/873 (15.9 %) n/s 
 
Figure 4.9 Crude (unadjusted) rate of major surgical resection for OG cancer patients 
according to general practice tertile for gastroscopy rate (low, middle or high): Stratified for 
deprivation quintile of the patient based on their individual LSOA code. Quintile 1 refers to 
patients living in the most socioeconomically deprived areas of England.  
 
 
 
p<0.001 
p=0.017 
p=0.047 
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OG cancer patients  
deprivation group 
Low tertile  
 
Middle tertile 
 
High tertile 
 
P value 
1 (Most deprived)                                 525/822 (63.8 %) 830/1361 (60.9 %) 1546/2567 (60.2 %) n/s 
2 685/1094 (62.6 %) 965/1646 (58.6 %) 1093/1915 (57.1 %) 0.012 
3 787/1275 (61.7 %) 1044/1700 (61.4 %) 921/1636 (56.3 %) 0.002 
4 888/1470 (60.4 %) 959/1671 (57.4 %) 768/1344 (57.1 %) n/s 
5 (Least deprived)                                891/1494 (59.6 %) 849/1492 (56.9 %) 510/873 (58.4 %) n/s 
 
Figure 4.10 Crude (unadjusted) mortality at 12 months for OG cancer patients according to 
general practice tertile for gastroscopy rate (low, middle or high): Stratified for deprivation 
quintile of the patient based on their individual LSOA code. Quintile 1 refers to patients 
living in the most socioeconomically deprived areas of England. 
 
 
 
p=0.012 
p=0.002 
 
 
 
166 
 
Finally, we performed multiple logistic regression analysis to identify factors 
associated with each of the three cancer outcomes after adjustment for potentially 
confounding co-variates.  This confirmed independent associations between poorer 
cancer outcomes and advancing age, increased co-morbidity and patient 
deprivation quintile (Tables 4.5, 4.6 and 4.7).  As expected, poorer patient 
deprivation status was associated with worse outcomes. The general practice 
(average) deprivation quintile was an independent predictor only for emergency 
admission. 
Consistent with our hypothesis, we found that the exposure of interest (general 
practice gastroscopy rate tertile) was a significant and independent predictor for all 
three cancer outcome variables. Hence, after adjustment for age, co-morbidity and 
deprivation, there were highly significant associations between cancer outcomes 
and the general practice rate of gastroscopy. Compared to patients belonging to 
practices in the highest tertile, those in the lowest gastroscopy rate tertile were 
1.73 times as likely to be admitted as an emergency during the diagnostic pathway 
(Table 4.5), 0.87 times as likely to undergo major surgical resection (Table 4.6) and 
1.14 times as likely to be dead within 12 months of gastroscopy (Table 4.7). 
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Table 4.5 Factors associated with emergency admission during diagnostic pathway in 
patients with OG cancer in England (n=22,488).  Unadjusted and adjusted odds ratios with 
95% CI based on univariate and multivariate logistic regression (Reference group = 1) 
Variable n,% Unadjusted (univariate) 
OR                CI              p value 
Adjusted (multivariate)                                  
OR                CI              p value 
Age group        
  < 55 421/1850 (22.75) 1 - - 1 - - 
  55 to 64 752/4032 (18.65) 0.77 0.68-0.89 <0.001 0.82 0.71-0.95 0.01 
  65 to 74 1434/6342 (22.61) 0.99 0.87-1.12 0.895 1.03 0.90-1.18 0.62 
  75 to 84 2375/7386 (32.15) 1.60 1.42-1.81 <0.001 1.69 1.49-1.92 <0.001 
  ≥ 85 1322/2878 (45.93) 2.88 2.53-3.28 <0.001 3.30 2.87-3.80 <0.001 
Gender        
  Female 2352/7687 (30.59) 1 - - 1 - - 
  Male 3952/14801 (26.7) 0.82 0.77-0.87 <0.001 0.93 0.87-0.99 0.033 
Co-morbidity groups        
  No co-morbidity 3361/16555 (20.3) 1 - - 1 - - 
  1 co-morbidity 1728/3964 (43.59) 3.03 2.81-3.26 <0.001 2.95 2.74-3.19 <0.001 
  ≥ 2 co-morbidities 1215/1969 (61.7) 6.32 5.73-6.98 <0.001 6.85 6.19-7.58 <0.001 
Practice deprivation        
 1
 
 Most deprived 1020/3215 (31.72) 1 - - 1 - - 
 2 1283/4415 (29.06) 0.88 0.79-0.97 0.012 0.84 0.76-0.94 0.004 
 3 1389/4923 (28.21) 0.84 0.76-0.93 0.001 0.84 0.74-0.94 0.004 
 4 1334/5001 (26.67) 0.78 0.71-0.86 <0.001 0.79 0.70-0.90 <0.001 
 5
 
 Least deprived 1278/4934 (25.9) 0.75 0.68-0.83 <0.001 0.75 0.66-0.86 <0.001 
Patient deprivation 
[a]
  
       
  1
 
 Most deprived 1520/4750 (32) 1 - - 1 - - 
  2 1342/4655 (28.82) 0.86 0.78-0.94 0.001 0.86 0.78-0.96 0.006 
  3 1274/4611 (27.62) 0.81 0.74-0.88 <0.001 0.80 0.71-0.89 <0.001 
  4 1169/4485 (26.06) 0.74 0.68-0.82 <0.001 0.74 0.66-0.84 <0.001 
  5
 
 Least deprived 958/3859 (24.82) 0.70 0.63-0.77 <0.001 0.68 0.59-0.78 <0.001 
Practice gastroscopy 
rate tertile 
 
       
  High 2105/8379 (25.12) 1 - - 1 - - 
  Middle 2092/7913 (26.43) 1.07 0.99-1.14 0.055 1.19 1.10-1.29 <0.001 
  Low 2107/6196 (34) 1.53 1.42-1.65 <0.001 1.73 1.60-1.88 <0.001 
[a]
 Excluding 128 (0.6%) with missing deprivation score  
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Table 4.6 Factors associated with chance for major surgical resection in patients with OG 
cancer in England (n=22,488).  Unadjusted and adjusted odds ratios with 95% CI based on 
univariate and multivariate logistic regression (Reference group = 1) 
Variable n,% Unadjusted (univariate) 
OR                CI              p value 
Adjusted (multivariate)                               
OR                CI              p value 
Age group        
< 55 491/1850 (26.54) 1 - - 1 - - 
55 to 64 994/4032 (24.65) 0.90 0.79-1.02 0.122 0.86 0.75-0.97 0.023 
65 to 74 1371/6342 (21.61) 0.76 0.67-0.86 <0.001 0.72 0.64-0.81 <0.001 
75 to 84 806/7386 (10.91) 0.33 0.29-0.38 <0.001 0.31 0.28-0.36 <0.001 
≥ 85 57/2878 (1.98) 0.05 0.04-0.07 <0.001 0.05 0.03-0.06 <0.001 
Gender        
Female 1129/7687 (14.68) 1 - - 1 - - 
Male 2590/14801 (17.49) 1.23 1.14-1.32 <0.001 n/s n/s n/s 
Co-morbidity groups        
No co-morbidity 2944/16555 (17.78) 1 - - 1 - - 
1 co-morbidity 689/3964 (17.38) 0.97 0.88-1.06 0.552 1.09 0.99-1.20 0.070 
≥ 2 co-morbidity 86/1969 (4.36) 0.21 0.16-0.26 <0.001 0.20 0.16-0.25 <0.001 
Practice deprivation 
 
       
1
 
 Most deprived 567/3215 (17.63) 1 - - 1 - - 
2 725/4415 (16.42) n/s n/s n/s n/s n/s n/s 
3 795/4923 (16.14) n/s n/s n/s n/s n/s n/s 
4 814/5001 (16.27) n/s n/s n/s n/s n/s n/s 
5
 
 Least deprived 818/4934 (16.57) n/s n/s n/s n/s n/s n/s 
Patient deprivation        
1
 
 Most deprived 733/4750 (15.43) 1 - - 1 - - 
2 778/4655 (16.71) n/s n/s n/s 1.15 1.02-1.29 0.015 
3 754/4611 (16.35) n/s n/s n/s 1.20 1.07-1.35 0.001 
4 788/4485 (17.56) n/s n/s n/s 1.32 1.17-1.48 <0.001 
5
 
 Least deprived 654/3859 (16.94) n/s n/s n/s 1.28 1.13-1.44 <0.001 
Practice gastroscopy 
rate tertile 
 
       
High 1465/8379 (17.48) 1 - - 1 - - 
Middle 1297/7913 (16.39) 0.92 0.85-1.01 0.063 0.90 0.82-0.98 0.019 
Low 957/6196 (15.44) 0.86 0.78-0.94 0.001 0.87 0.79-0.95 0.004 
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Table 4.7 Factors associated with 12 month mortality in patients with OG cancer in England 
(n=22,488).  Unadjusted and adjusted odds ratios with 95% CI based on univariate and 
multivariate logistic regression (Reference group = 1) 
Variable n, % Unadjusted (univariate) 
OR                CI              p value 
Adjusted (multivariate)                                  
OR                CI              p value 
Age group        
  < 55 874/1850 (47.24) 1 - - 1 - - 
  55 to 64 1964/4032 (48.71) 1.06 0.95-1.18 0.296 1.10 0.99-1.24 0.075 
  65 to 74 3385/6342 (53.37) 1.27 1.15-1.41 <0.001 1.33 1.20-1.48 <0.001 
  75 to 84 4867/7386 (65.89) 2.15 1.94-2.39 <0.001 2.26 2.03-2.51 <0.001 
  ≥ 85 2232/2878 (77.55) 3.85 3.40-4.37 <0.001 4.13 3.63-4.70 <0.001 
Gender        
  Female 4695/7687 (61.07) 1 - - 1 - - 
  Male 8627/14801 (58.28) 0.89 0.84-0.94 <0.001 n/s n/s n/s 
Co-morbidity groups        
  No co-morbidity 9295/16555 (56.14) 1 - - 1 - - 
  1 co-morbidity 2421/3964 (61.07) 1.22 1.14-1.31 <0.001 1.14 1.06-1.22 <0.001 
  ≥ 2 co-morbidity 1606/1969 (81.56) 3.45 3.07-3.88 <0.001 3.61 3.20-4.07 <0.001 
Practice deprivation 
 
       
  1
 
 Most deprived 1890/3215 (58.78) 1 - - 1 - - 
  2 2652/4415 (60.06) n/s n/s n/s n/s n/s n/s 
  3 2909/4923 (59.08) n/s n/s n/s n/s n/s n/s 
  4 2959/5001 (59.16) n/s n/s n/s n/s n/s n/s 
  5
 
 Least deprived 2912/4934 (59.01) n/s n/s n/s n/s n/s n/s 
Patient deprivation         
  1
 
 Most deprived 2901/4750 (61.07) 1 - - 1 - - 
  2 2743/4655 (58.92) 0.91 0.84-0.99 0.034 0.88 0.81-0.96 0.006 
  3 2752/4611 (59.68) 0.94 0.86-1.02 0.169 0.87 0.80-0.95 0.002 
  4 2615/4485 (58.3) 0.89 0.82-0.96 0.007 0.82 0.75-0.89 <0.001 
  5
 
 Least deprived 2250/3859 (58.3) 0.89 0.81-0.97 0.009 0.81 0.74-0.89 <0.001 
Practice gastroscopy 
rate tertile 
 
       
  High  4861/8379 (58.01) 1 - - 1 - - 
  Middle  4667/7913 (58.97) 1.04 0.97-1.10 0.212 1.06 0.99-1.13 0.056 
  Low  3794/6196 (61.23) 1.14 1.06-1.22 <0.001 1.14 1.06-1.22 <0.001 
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4.5.4 Sensitivity analyses  
To further confirm the association between the practice gastroscopy rate and 
cancer outcome, additional multivariate analyses using different “exposure” 
variables were used to express the gastroscopy rate of the patient’s general 
practice. In all cases, these analyses confirmed the independent association 
between gastroscopy rate at the general practice and all three cancer outcomes 
after adjustment for confounders (Figures 4.11-4.14). 
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Figure 4.11 Sensitivity analyses showing the association between general practice elective 
gastroscopy rates and emergency route of diagnosis for 22,488 cases of OG cancer. Logistic 
regression (multi-variate) analysis using (A) Quintile of adjusted elective gastroscopy rate, and 
(B) Quintile of age-specific rate (>55 years) where Quintile 1 refers to the Highest. 
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Figure 4.12 Sensitivity analyses showing the association between general practice elective 
gastroscopy rates and major surgical resection for 22,488 cases of OG cancer. Logistic 
regression (multi-variate) analysis using (A) Quintile of adjusted elective gastroscopy rate, 
and (B) Quintile of age-specific rate (>55 years) where Quintile 1 refers to the Highest. 
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Figure 4.13 Sensitivity analyses showing the association between general practice elective 
gastroscopy rates and mortality at 12 month for 22,488 cases of OG cancer. Logistic 
regression (multi-variate) analysis using (A) Quintile of adjusted elective gastroscopy rate, 
and (B) Quintile of age-specific rate (>55 years) where Quintile 1 refers to the Highest. 
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Figure 4.14 Sensitivity analyses confirming association between general practice elective 
gastroscopy rates and emergency route of diagnosis, major surgical resection and death at 
12 month for 22 488 cases of OG cancer. Logistic regression (multi-variate) analysis using 
continuous variable for (A) actual age-sex-adjusted elective gastroscopy rate of the 
patient’s general practice (expressed as rate per 100 population) and (B) continuous 
variable for actual age-specific rate for adults >55 years of age. The OR represents the 
change in odds per unit increase in gastroscopy rate (eg, an increase from 1 per 100 to 2 
per 100 practice population per year).  
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4.6 Discussion 
This chapter has confirmed the wide variability in per capita rates of elective 
gastroscopy at the level of general practice populations. This variation does not 
appear to be explained by simple demographics factors in keeping with the 
published literature. [185] With regard to the NICE clinical guideline age related cut-
off for gastroscopy referral, this study measures not only the crude and adjusted 
gastroscopy rate but also explored the age specific rate among patients aged 55 
years and above, which further emphasises the wider variation between tertiles.  
Although practices serving populations in more deprived areas were more likely to 
have higher rates of gastroscopy, there was no simple relationship between 
gastroscopy rates and socioeconomic status, and most variation appears 
unexplained by this factor. Further research is therefore required to understand the 
causes for practice-level variation in gastroscopy rates. 
To our knowledge, this is the first study examining the association between primary 
care gastroscopy rates and cancer outcome, albeit the need for research in this area 
has been highlighted.[164] Consistent with our main hypothesis, we found that 
cancer outcomes were significantly different for patients belonging to practices 
with low, medium or high gastroscopy rates. After adjusting for confounding 
variables, we found that patients diagnosed from a practice within the lowest 
tertile of gastroscopy rate were significantly less likely to undergo major surgery 
than those from a practice in the highest tertile.  
Inequality in outcome was most divergent for cancer patients from the lowest 
deprivation category. Similar trends of inequality in the rate of emergency 
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admission and all-cause mortality within a year of gastroscopy were apparent. 
These data provide strong evidence for an independent association between OG 
cancer outcomes and gastroscopy rates at the local practice level. It is interesting to 
note that across the tertiles of practices (low through medium to high), there is a 
very small but significant trend for lower mean age of cancer patients at the time of 
index gastroscopy this would be consistent with a trend towards earlier diagnosis in 
areas exposed to higher rates of gastroscopy. 
These findings do not imply that individual general practices with low or high rates 
of gastroscopy are exhibiting poor or good practice, nor that low rates are always 
associated with worse outcomes. It is not possible from routine data to judge 
whether the level of gastroscopy at an individual practice is ‘appropriately’ low or 
high. However, our study suggests that populations that are exposed to lower rates 
of investigation appear, on average, to experience worse cancer outcomes. It is of 
particularly concern that patients belonging to the most disadvantaged 
socioeconomic category have the greatest inequality in cancer outcomes with 
respect to practice gastroscopy rates.  
As expected, socioeconomic deprivation was found to be an independent predictor 
of poor cancer outcomes for OG tumours—this phenomenon has been described 
for a range of cancers.[77, 268, 311]  
In this part of the study, general practices belonging to the low tertile for 
gastroscopy rate are, on average, serving more affluent populations, and have the 
lowest proportion of cancer patients from the most disadvantaged areas. Hence, 
the inferior outcomes for this group of ‘low-referring’ practices, overall, cannot be 
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explained by a confounding influence of deprivation. Our stratified analyses for 
deprivation illustrate a potential reason for this paradox—socially disadvantaged 
patients who are registered with a low referring practice have particularly poor 
outcomes (the worst in the country). This suggests that a ‘low’ gastroscopy rate is a 
potential indicator that might be used to identify practices where doctors may wish 
to review their referral policies, particularly in more deprived areas, where practice 
gastroscopy rates tend to be higher. 
Strengths of this study include the utilization of patient population data that 
allowed us to test our hypothesis on a national scale with the benefit of large 
numbers. This part of the project captures gastroscopy procedures coded in HES 
across 2006-2008 data years. The extracted elective procedures were not filtered 
by diagnostic field, and therefore they include both patients who were 
subsequently diagnosed with cancer and those who were not subsequently coded 
with cancer. These procedures were summed for persons registered at each 
general practice as coded in the national data, and only practices with incident OG 
cancer cases within the same data years (as described in chapter 3) were included 
in the final analysis. Furthermore, we undertook extensive sensitivity analyses using 
a range of approaches to quantify the exposure of interest, and found the findings 
to be robust. 
Our national gastroscopy rate in general population is 8.4 per 1000 populations per 
annum, matching the previously reported BSG figure of 8.6 in 1992 and 10.0 per 
1000 in 2001.[146] The 2007 NICE commissioning guidance of upper GI endoscopy 
service reported that the average referral rate was 5.4 per 1000 per year based on 
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the prevalence of alarm symptoms through the rapid access services and 7.5 per 
1000 per year if patients were referred by the standard open access service.[149] 
This NICE guidance also reports that the average (directly standardized) rate of this 
procedure was 9.5 per 1000 per year according to the analysis of data that was 
collected by the Information Centre as part of the hospital episode statistics 2004-
2007 returns.[149]  
The benchmarked indirect standardization method was used in our study to 
measure the practices’ adjusted gastroscopy rates which showed almost no 
difference with the observed crude rates at either national or tertile level. This 
suggests that there are no major discrepancies in the age and sex profiles between 
these practices. Generally, this small effect of standardization for age, sex and social 
class on the variation in the referral rate for general practices has been well 
reported in the previous literature. [201] Wilkin and Smith, for example, concluded 
that there are similar proportions of patients at each age, gender and social class 
group that had referral; however, high referrers were referring more patients in 
each category.[312]  
This study presents the national elective gastroscopy activity data for more than 
2000 GP practices in each tertile within a 2 year time window, and therefore any 
apparent variation is highly unlikely to be affected by the fact that random variation 
in the number of referrals could be due to chance. Such issue was previously 
reported by various studies as a result of their small number of included referral 
and the short period of data collection. [201, 313] 
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Certainly, this analysis like any other ecological or observational study accepts that 
it can be at risk of ‘ecological fallacy’ and cannot adjust for all possible confounders. 
[314] Thus this study makes no claim that our findings of such association between 
per-capita gastroscopy rate and OG cancer outcome necessarily proves causality. 
[314] 
While it is essential to acknowledge that some data discrepancies are inevitable, it 
is unlikely that these have systematically biased the results in favour of the 
hypothesis. This chapter has reported the great care taken to explore potential bias 
in our approach to data aggregation through the undertaking of extensive 
sensitivity analyses. Each case of OG cancer was assigned a range of alternative 
variables to express the gastroscopy rate at the patient’s local practice.[314, 315] 
Hence, instead of expressing the rate as tertile groups alone, we examined 
quintiles, continuous variables (i.e. the absolute rate for each individual practice) 
and age-specific rates for patients over 55 years old.[314, 315]  This meant re-
assigning practices and their relative ranking across a range of scenarios, to produce 
alternative patient-level exposure variables. We studied not one but three 
measures of cancer outcome in patient-level binary logistic regression 
analyses.[314, 315]  Although we cannot exclude ecological fallacy, the remarkable 
consistency of our results gives weight to our findings. [314, 315] 
Although there was a significant difference in the distribution of practices with 
respect to the practice-level deprivation variable, at the same time, all tertile 
groups contained practices from every deprivation quintile. Additionally, general 
practices serving populations with the same average deprivation score exhibited a 
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wide spectrum of gastroscopy rates, after adjusting for age and sex profile. The 
magnitude of such association was further explored by linear regression analysis, 
which is shown to be at less than 8%. Hence deprivation status provides little effect 
on the variation observed.   
This analysis did not adjust for possible variation between hospitals in cancer 
treatment outcome, since this was not a likely confounder given our study design 
and the selected outcome measures. The emergency admission during diagnostic 
pathway, for instance, is a surrogate marker for diagnostic delay or failure of 
elective referral. This outcome will not be influenced by the quality of the local 
hospital treatment after diagnosis. Similarly, the rate of major surgical resection is 
unquestionably reflective of earlier diagnosis, since only patients with an early 
stage disease will be candidates for potentially curative resection. Neither of these 
outcome variables is relevant to subsequent post-diagnostic management at the 
local hospital. 
Whilst the one year mortality after index gastroscopy will be dictated largely by 
cancer stage at the time of diagnosis and it is certainly plausible that institutional-
level variations in staging investigations, treatment quality and surgical volume may 
impact on survival rates [127], nevertheless the majority of patients with OG cancer 
tend to be diagnosed at a late and incurable stage. Our overall cancer mortality 
statistic is therefore unlikely to be influenced significantly by this phenomenon.  
In a climate of cost restraint in the UK national health system, there is an inevitable 
and reasonable focus on identifying and constraining ‘excessive’ use of secondary 
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care investigations. [315] Local initiatives aimed at reducing gastroscopy activity 
may well avoid unnecessary investigations for younger patients with benign disease 
without compromising clinical outcome. [315] However, analysis of the findings 
from this study suggest that there is a pressing need to focus on both ends of the 
referral volume spectrum. [315]  
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Chapter 5 Variation in elective gastroscopy rates in English general 
practice populations:  Is there evidence to suggest different 
thresholds for referral between practices? 
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5.1 Introduction 
In the UK, general practice is the key mode for delivering primary health care to the 
resident population. Each practice contains one or more family doctors who usually 
work with a practice manager, nurses and other associated health professionals 
such as health visitors, all of whom are responsible for the care of patients 
registered on their list. 
The Royal College of General Practitioners (RCGP) define primary care as:  
‘…the first level contact with people taking action to improve health in a 
community. In a system with a gatekeeper, all initial (non-emergency) 
consultations with doctors, nurses or other health staff’.  
 
With almost 300 million general practice consultations per year, general practice is 
for most people the first and most commonly used way of accessing the NHS.[310, 
316]  
Generally, variations in referral rates from primary care level generalists to more 
specialised secondary care services have been a long-standing clinical and economic 
concern.[185, 186, 205, 206] As noted in Chapter 1, dyspepsia is a very common 
reason for people to visit their GP, accounting for 3-4% of all consultations [317].  
Serious underlying disease is rare and the typical GP (serving approximately 2,000 
patients) may see only one to two new case of upper gastrointestinal cancer per 
year. [10] UK general practitioners fulfil an important gatekeeper role in selecting 
dyspeptic patients for upper GI endoscopy, and they are encouraged to adhere to 
NICE guidelines [147, 148, 213].  A key focus of these guidelines is the empirical 
(symptom-based) treatment of dyspepsia including non-invasive strategies (H. 
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pylori ‘test-and-treat’) and early gastroscopy is advocated mainly for those with 
suspected cancer on the basis of ‘alarm’ or ‘red flag’ features. However, the poor 
sensitivity and specificity of alarm features for diagnosis of upper GI cancers is 
acknowledged. [87, 88, 94] 
Hence, GPs face a challenging task. On the one hand, a ‘gate-keeper’ role is 
mandated by NICE guidelines, and it is a role that seeks to restrict ‘over-
investigation’ of benign symptoms. On the other, the identification of cancer cases 
by ‘alarm symptoms’ alone remains unreliable, so that the majority of cases are 
diagnosed at a late and incurable stage. Other symptoms might predict O-G cancer, 
but with absolute risks of about 1 %.[91] This makes for a dilemma in distinguishing 
patients with dyspepsia manageable at GP level from the minority who need 
referral to specialist care or diagnostic gastroscopy.  
A fast-track system for investigation of patients with alarm features (under the ‘two 
week rule’) was implemented under the National Cancer Plan. [108]  Although 
promoted as an attempt to improve the number of early-stage cancers detected, 
numerous studies have shown that the adoption of this pathway has produced little 
improvement in the detection of curable cancer. [164, 173, 176]   This is consistent 
with the concern that the ‘alarm’ features identified as triggers to fast-track referral 
are often features of more advanced disease.  
Moreover, for various tumour types there is evidence that patients identified by 
GPs as having ‘suspected cancer’ may fall outside the strict national referral criteria 
and yet do indeed have an underlying malignancy [147, 148, 213-215]. Baughan et 
184 
 
al (2011) suggest that there may be additional factors that lead to clinical suspicion 
of cancer but that do not satisfy simplistic referral rules.[216, 318] 
Expert opinion from primary care has expressed concern that: 
“… GPs are being forced to ‘manipulate' the two-week cancer pathway by 
inflexible NICE referral criteria that make no allowances for their ‘sixth sense' ” 
[319] 
There are further suggestions that: 
“There is good evidence that there is a terrific variation in the way GPs use the 
two-week pathway. What we see is that some practices use it a lot, but relatively 
few of these patients have cancer. Other practices use it very little, but most of 
the patients referred have cancer”….“What matters is not really how many 
patients you refer, but how many of those patients are diagnosed with cancer. We 
would like to see a high detection rate through the two-week wait pathway.” 
[319] 
 
 
Figure 5.1 OG cancer patients’ pathway of care, routes of diagnosis and possible level of 
delayed diagnosis.  
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Variation in thresholds for gastroscopy referral is an entirely expected phenomenon 
given the controversy that exists regarding the correct placement of this 
investigation in the management of upper gastrointestinal symptoms.[320] 
In chapter 4, evidence was presented to show an association between variations in 
rates of elective gastroscopy at the level of general practice populations, and 
outcomes for oesophago-gastric cancer.[315]  Specifically, we have found that low 
rates are associated with risk of poorer outcome. We have shown also that 
deprivation explains only a small proportion (less that 8 %) of the observed 
variation in gastroscopy rates. Further studies are presented in the present chapter 
to test the idea that wide variation in rates of gastroscopy between practices is 
reflective (at least to some extent) of genuine differences in clinical ‘threshold’ for 
referral.  We postulated that practices with relatively low rates of gastrosopy may 
be operating more selective referral policies, thereby reserving gastroscopy for 
older patients and/or those with more severe symptoms (e.g. alarm symptoms).  If 
so, it should be possible to find evidence for a difference in the age distribution and 
‘diagnostic yield’ (proportion of patients with serious pathology) among patients 
referred for gastroscopy from ‘low referring’ practices.   
The work described in this chapter also seeks to confirm the phenomenon of ‘small 
area’ variation in gastroscopy rates between general practices that are situated in 
close geographical proximity.  The factors that determine rates of gastroscopy for 
general practices across the country are likely to be complex, and variation in 
clinical practice is clearly but one of several factors.  It was not possible to control 
for differences in local symptom prevalence, consultation behaviour or variable 
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access to local secondary care diagnostics in our national study.  However,  the 
demonstration of wide variation in referral rates within a small geographical area 
would lend support to the notion that practice rates are ‘unexplained’ by such 
confounders and that a key determinant of variation must be differences in referral 
practice. 
Finally, we wished to examine the possible association at practice level between 
overall rates of referral under the two week rule for all cancer types and the rate of 
gastroscopy. The assumption underlying such association was to test whether 
practices with low gastroscopy rates are also low in their use of the two week wait 
system in general – an association that could support the idea of generalised 
differences in referral behaviour. 
5.2 Aims and objectives 
This chapter aims to provide evidence to support the idea that there are different 
thresholds for referral between general practices in England. Such a hypothesis 
could (at least in part) explain the very wide variation we have observed in per 
capita gastroscopy rates in general practice populations 
Using both national and local audit data, the studies described in this final part of 
the thesis aim to show: 
1) That the demographic and clinical pattern of patients undergoing elective 
gastroscopy from low, middle and high referring practices is compatible with 
differences in referral threshold.  Hence, practices with low gastroscopy 
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rates would be expected to refer older patients (on average) and have a 
higher yield of serious pathology. 
2) That wide variation in per capita gastroscopy rates can be demonstrated 
within small geographical areas and even adjacent practices, where it is 
reasonable to assume relatively consistent symptom burden and cultural-
behavioural factors relating to consultation.  
Aims (1) and (2) will be tested first in national (HES) data. Then, an 
independent local study will seek to confirm these observations using 
locally-derived data from one hospital centre and focussing on practices 
referring exclusively to this centre. This study eliminates any potential 
confounding influence of variation in secondary care provision or access to 
gastroscopy. 
3) Whether there is an association between practice level elective gastroscopy 
rate and the per capita rate of total referrals under the ‘two week wait’ 
(TWW) for cancers in general. The prediction here is for there to be a 
positive correlation between these measures, reflecting a common ‘referral 
threshold’ factor.  Hence, low users of fast-track cancer services in general 
might be expected to have relatively low rates of gastroscopy. 
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5.3 Method  
5.3.1 Gastroscopy procedure diagnostic profile  
5.3.1.1 National diagnostic profile 
A key requirement was development of a methodology for categorising the coded 
diagnoses recorded for all elective gastroscopy procedures.  A very wide selection 
of ICD-10 diagnostic codes are available for encoding gastroscopy episodes and a 
classification system was needed to allocate patients into logical baskets of 
conditions. 
Using the previously described elective gastroscopy procedure dataset (containing 
all procedures coded in HES for the GP practices in the study, 2006-2008 (chapter 
4), a method was designed to allocate diagnosis codes at the primary position of 
the patients’ first gastroscopy and cluster these diagnoses into six groups as 
follows: 
1. Upper GI cancer (C15-C16 codes)  
2. Major acid peptic disease. 
3. Normal or minor pathologies. 
4. Other GI neoplasm. 
5. Upper GI symptoms codes only. 
6. Miscellaneous. 
Subsequently, the same grouping of codes was undertaken across all other 
diagnostic positions.  An algorithm was then developed to apply a hierarchy system 
to allocate each gastroscopy to the most ‘serious’ category recoded.  This reflects 
the fact that several codes (including the use of symptom codes at position 1) may 
be recorded to describe the endoscopy findings.  This involved a ranking (Group 1 
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being the highest and Group 6 the lowest rank). For example; if any coding position 
(DIAG 1-14) contained an ICD-10 code for OG cancer (Group 1), then this patient 
was labelled with an upper GI cancer diagnosis.  This avoided mislabelling a cancer 
case if a symptom code (e.g. Dysphagia) or complication of cancer (e.g. oesophageal 
stricture, unspecified) was recorded in position 1 above the cancer diagnosis.  
Similarly, if a patient had a code from Group 2 (Major acid-peptic lesions) at any 
position, then this patient was categorized as a Group 2 unless there was an OG 
cancer code recorded (Group 1). This process was repeated until group 6 
(Miscellaneous) where patients have no code related to any other higher ranked 
group from position 1 to 14.  
5.3.1.2 Local diagnostic profile (analysis of routine local endoscopy datasets) 
Elective gastroscopy procedures performed locally at Aintree University Hospital 
(Liverpool, UK) in the period between April 2009 and March 2012 were identified 
using the endoscopy reporting tool (Unisoft).  Each endoscopy report was linked to 
the individual patient’s GP practice. Practices with a known population list size and 
demographics were selected.  An inclusion criterion was that each practice in the 
study was confirmed as referring predominantly to our centre, based on examining 
the profile of coded gastroscopies recorded in our HES dataset.  Hence, all 63 
practices in the study were verified as having at least 90% of all their elective 
gastroscopy procedures coded at our Trust (PROCODE: REM) during 2006-2008.  As 
described previously (Chapter 2), the age-sex adjusted elective gastroscopy rates 
were calculated but using the locally recorded gastroscopy counts taken from the 
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hospital reporting tool.  Practices were ranked and divided into local tertiles (21 
practices each). 
The local hospital reporting tool contains a greater clinical depth of information 
than was available from national HES data.  Hence, in the local study the 
gastroscopy reports in Unisoft were analysed to obtain information about 
endoscopic indication (Figures 5.2) in addition to the categorising of endoscopy 
findings (Figure 5.3). These characteristics were studied first by route of referral 
(two week wait vs. other elective routes) and then across the local tertile of 
practices’ gastroscopy rate. Sub-analysis was also carried out for those fast tracking 
patients who were deemed to be at higher risk of cancer. At Aintree University 
Hospital, this service is known as RAUGICS (Rapid Access Upper GI Cancer Service). 
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Figure 5.2 System used in the local study for categorising referral indication (symptom profile) 
based on information recorded in the endoscopy reporting system (UNISOFT).  
 
Figure 5.3 System used in the local study for categorising diagnosis profile of gastroscopy 
procedures as recorded in the UNISOFT reporting tool.  
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5.3.2 Small area variation in gastroscopy rate across general practices  
5.3.2.1 National HES data: Intra-PCT variation in practice rates of gastroscopy 
Firstly, we aimed to describe the range of variation in general practice gastroscopy 
rates within individual primary care trusts (PCTs) in England.  During the study 
period, the general practices in the study (n=6513) were grouped administratively 
and geographically into PCTs responsible for commissioning services from their 
local hospitals. For each individual PCT (n=152), we determined the absolute range 
of adjusted gastroscopy rate for the study practices (lowest to highest rate) and 
calculated the magnitude of variation across the local PCT range.  Practices within a 
single PCT will share common local referral pathways and guidelines and will have 
access to the same local hospital secondary care services. 
5.3.2.2 Local database study:  Geographical mapping of local general practices 
To further establish evidence for small area variation in practice gastroscopy rates, 
we adopted a geographical mapping technique to seek examples of practices with 
wide differences in gastroscopy rate but in very close geographical proximity. Using 
general practice postcode data provided by the Health and Social Care Information 
Centre (HSCIC) [321], followed by manual verification, we generated a spreadsheet 
of postcode data for each general practice included in the local study (n=63). The 
practices were then mapped using public domain mapping software (Google Fusion 
Tables) [322] and were colour coded for gastroscopy rate per capita, according to 
their tertiles distribution (low, middle and high groups). The resulting map provides 
a visual illustration of geographical location of practices.  
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5.3.3 Associations between practice level gastroscopy rate and the rate of two 
week wait referrals for any form of cancer 
 
5.3.3.1 National data 
 External data from the National Cancer Intelligence Network (NCIN) were obtained 
for the study practices.  The dataset contains age-adjusted rates of two week wait 
(TWW) referrals for any suspected cancer (i.e. all types). [323] The correlation 
between overall rates of TWW referrals and rates of adjusted gastroscopy rates 
(derived from HES) were examined.  Analyses were further stratified for practices 
deprivation status (by quintiles) to explore the potential influence of socioeconomic 
deprivation. 
5.3.3.2 Local data 
Similarly, correlations between practice population rates of gastroscopy and of 
TWW referrals in general were examined using the local datasets.  The local 
gastroscopy dataset allowed elective gastroscopies to be categorised as fast-track 
(TWW) or not. This information is not encoded in the national (HES) datasets but 
was available in the endoscopy reporting system.  For the local practices, this 
allowed the study of ‘fast-track’ referrals alone and the calculation of the 
percentage of all gastroscopy procedures performed via the TWW system (i.e. the 
number of upper GI endoscopies performed via TWW route divided by the total 
number of elective gastroscopies).  
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5.4 Results 
5.4.1 National diagnostic profile and comparison across practice tertiles 
Nationally, the diagnostic profile of individual patients at their first elective 
gastroscopy related hospital episodes during the data period is demonstrated in 
(Figure 5.4). Upper gastrointestinal malignancy accounts for only 2.1% of all 
patients undergoing investigation. Other major acid-peptic lesions (e.g. peptic 
ulcers) account for a further 11.6% of people undergoing the procedure. The 
remaining 86.2% of gastroscopies are coded mainly with minor pathologies or with 
symptom codes only. 
 
 
 
 
 
 
Patients had elective gastroscopy for all reasons 
Patients, n  587,256 
Age (Mean, SD) 59.2 (16.5) 
Patients diagnosis profile  
  Upper GI cancer 12569 (2.1) 
  Major acid-peptic lesions 68229 (11.6) 
  Normal or minor 
pathologies only 
299706 (51.0) 
  Ot er neoplasms 14920 (2.5) 
  Symptom codes only 142955 (24.3) 
  Miscellaneous codes 48877 (8.3) 
 
Figure 5.4 Total number of individual patients undergoing elective upper GI endoscopy in 
England (2006-2008) and the diagnostic profile based on categorisation of coded diagnoses  
 
Symptom codes 
OG cancer 
Major acid peptic 
lesions 
Normal of minor 
pathologies only 
Miscellaneous  
Other neoplasms  
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Comparison of diagnostic profiles among patients referred for gastroscopy 
procedures across the practice gastroscopy rate tertiles (Figure 5.5) reveals a higher 
proportion of serious pathology in the low tertile group (cancers and major acid-
peptic lesions; p<0.001, Chi Square test). To be precise, in relation to the total 
number of patients who had gastroscopy in each tertile, high referring practices 
appear to have more patients coded with normal or minor gastroscopy findings, 
while within the low tertile practice population, there were more patients allocated 
to more serious pathologies. Furthermore, the mean age of patients referred for 
gastroscopy was highest for low tertile practices (Table in lower panel of Figure 
5.5).  This pattern of slightly older age and higher yield of serious pathology among 
‘low referring’ practices is consistent with a more selective or restrictive approach 
to gastroscopy.  
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Patients had elective 
gastroscopy for all reasons 
Low tertile 
practices 
 
p 
Middle tertile 
practices 
High tertile 
practices 
p value 
Patients, n  108,679 203,771 274,806 - 
Age (Mean, SD) 60.2 (16.6) 59.5 (16.5) 58.4 (16.4) <0.001 
Patients diagnosis profile    
  Upper GI cancer (C15,C16) 3025 (2.8) 4612 (2.3) 4932 (1.8)  
  Major acid-peptic lesions 13570 (12.5) 23565 (11.6) 31094 (11.3)  
  Normal or minor pathologies 
only 
51516 (47.4) 101609 (49.9) 146581 (53.3) <0.001 
  Other neoplasms 3224 (3.0) 5283 (2.6) 6413 (2.3)  
  Symptom codes only 26768 (24.6) 51440 (25.2) 64747 (23.6)  
  Miscellaneous codes 10576 (9.7) 17262 (8.5) 21039 (7.7)  
 
Figure 5.5 Number of individuals undergoing upper GI endoscopy across the GP practice tertile 
groups and their spectrum of coded diagnoses 
 
 
 
 
 
 
 15.3% 
13.1% 
13.9% 
<0.001 
OG cancers and major acid-peptic lesions Normal/Minor or other pathology   
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5.4.2 Local (Aintree University Hospital) Gastroscopy activity: 
Information relating to 13,082 elective gastroscopy cases was collected locally. Of 
these, 4,003 (30.6%) procedures were through the fast-track (TWW) referral 
pathway, known locally as RAUGICS (Rapid Access Upper GI Cancer Service) (Table 
5.1). As expected, on average the patients referred via RAUGICS were older than for 
other elective routes reflecting the age cut-off of 55 years for those without alarm 
symptoms. It is also clear from this table that the fast-track system was used mainly 
to investigate patients who predominantly (76.5%) referred with alarm symptoms. 
As expected, a higher “yield” for cancer diagnosis was observed among patients 
referred though the two week wait system.  
Table 5.1 Demographics, referral indication (symptom profile) and diagnostic profile for 13,082 
local individuals who underwent elective (non-emergency) gastroscopy.  Data are presented 
overall (total elective) and categorised according to “fast-track” (RAUGICS) or other routes. 
  Total 
elective 
RAUGICS Other 
elective 
p value 
Number of patients 13082 4003 (30.6) 9079 (69.4)  
Age, Mean ( SD) 56 (17) 60 (16) 55 (17) <0.001 
Over 55 n,% 7272 (55.6) 2630 (65.7) 4642(51.1) <0.001 
Under 55 n,% 5810 (44.4) 1373 (34.3) 4437 (48.9)  
Gender         
Female n,% 7364 (56.3) 2332 (58.3) 5032 (55.4) 0.003 
Male n,% 5718 (43.7) 1671 (41.7) 4047 (44.6)  
Symptoms profile         
ALARM symptoms n,% 6266 (47.9) 3062 (76.5) 3204 (35.3) <0.001 
Non- Alarm symptoms, including 
Isolated dyspepsia  n,%  
6816 (52.1) 941 (23.5) 5875 (64.7)  
Diagnosis profile      
OG cancer n,% 182 (1.4) 95 (2.4) 87 (1.0) <0.001 
Serious Benign n,% 3907 (29.9) 1182 (29.5) 2725 (30.0) n/s 
Normal or Mild n,% 8993 (68.7) 2726(68.1) 6267 (69.0) n/s 
198 
 
Analysis of patient profiles according to the local practice gastroscopy tertiles 
shows wide variation in rates of elective gastroscopy between practice populations 
served by the same local hospital (>2 fold difference in mean rate between low and 
high groups, as shown in (Table 5.2).  Consistent with the national picture based on 
coded diagnoses extracted from HES data, our analysis of diagnoses recorded in the 
local gastroscopy reporting system demonstrates that practices with low rates of 
gastroscopy tend to have a higher “diagnostic yield” of serious pathology and 
slightly older patients referred for investigation. In additional, the local profile 
shows that low tertile practices had a higher proportion of patients investigated 
with alarm or red-flag symptoms than the other practice groups.  This provides 
further evidence for an association between low rates of gastroscopy in the 
practice population and a higher threshold for referral. The above trends were 
maintained among patients who had their diagnostic procedures specifically 
through the Rapid Access Upper GI Cancer Service (Table 5.3) and for those who 
had their gastroscopies through any other elective routes (Table 5.4). 
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Table 5.2 The total number of local individuals undergoing elective (non-emergency) 
Gastroscopy  across the local GP practice tertile groups and their spectrum of indications 
(symptoms) and diagnosis profiles.  
  Total Low Middle High p value 
Number of practices, n 63 21 21 21 n/s 
Age-sex adjusted gastroscopy 
rate,  Mean ( SD) 
11.5 (4.1) 7.3 (1.2) 11.0 (0.98) 16.3 (2.7) <0.0001 
Number of patients 13082 2115 3969 6998 <0.001 
Age, Mean ( SD) 56 (17) 59 (16) 57 (17) 55 (17) <0.001 
Over 55 n,% 7272 (55.6) 1307 ( 61.8) 2283 ( 57.5) 3682 (52.6) <0.001 
Under 55 n,% 5810 (44.4) 808 (38.2) 1686 (42.5) 3316 (47.4)  
Gender           
Female n,% 7364 (56.3) 1181 (55.8) 2195 (55.3) 3988 (57.0) n/s 
Male n,% 5718 (43.7) 934 (44.2) 1774 (44.7) 3010 (43.0)  
Symptoms profile           
Alarm symptoms n,% 6266 (47.9) 1064 (50.3) 1936 (48.8) 3266 (46.7) 0.006 
Non-Alarm n,%  6816 (52.1) 1051 (49.7) 2033 (51.2) 3732 (53.3)  
Diagnosis profile       
OG cancer n,% 182 (1.4) 46 (2.2) 64 (1.6) 72 (1.0) <0.001 
Serious Benign n,% 3907 (29.9) 662 (31.3) 1221 (30.8) 2024 (28.9) 0.037 
Normal or Mild n,% 8993 (68.7) 1407 (66.5) 2684 (67.6) 4902 (70.0) 0.002 
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Table 5.3 The number of local individuals had their elective Gastroscopy through RAUGICS 
system across the local GP practice tertile groups and their spectrum of indications (symptoms) 
and diagnosis profiles. 
 Total Low Middle High p value 
Number of patients 4003 549 1048 2406  
Age, Mean ( SD) 60(16) 64(15) 61(16) 59(16) <0.001 
Over 55 n,% 2630 ( 65.7) 415 (75.6) 714 (68.1) 1501 (62.4) <0.001 
Under 55 n,% 1373 (34.3) 134 (24.4) 334 (31.9) 905 (37.6)  
Gender           
Female n,% 2332 (58.3) 313 (57.0) 584 (55.7) 1435 (59.6)  n/s 
Male n,% 1671 (41.7) 236 (43.0) 464 (44.3) 971 (40.4)  
Symptoms profile          
Alarm symptoms n,% 3062 (76.5) 413 (75.2) 816 (77.9) 1833 (76.2) n/s 
Non-Alarm n,%  941 (23.5) 136 (24.8) 232 (22.1) 573 (23.8)  
Diagnosis profile           
OG cancer n,% 95 (2.4) 26 (4.7) 29 (2.8) 40 (1.7) <0.001 
Serious Benign n,% 1182 (29.5) 163 (29.7) 326 (31.1) 693 (28.8) n/s 
Normal or Mild n,% 2726 (68.1) 360 (65.6) 693 (66.1) 1673 (69.5) 0.056 
  
Table 5.4 The number of local individuals who had their gastroscopy through non-RAUGICS 
elective pathways and their spectrum of indications (symptoms) and diagnosis profiles across 
the local GP practice tertile groups. 
 Total Low Middle High p value 
Number of patients 9079 1566 2921 4592  
Age, Mean ( SD) 57 (17) 57 (17) 56 (17) 53 (17) <0.001 
Over 55 n,% 892 (57.0) 892 (57.0) 1569 (53.7) 2181 (47.5) <0.001 
Under 55 n,% 674 (43.0) 674 (43.0) 1352 (46.3) 2411 (52.5)  
Gender           
Female n,% 5032 (55.4) 868 (55.4) 1611 (55.2) 2553 (55.6)  n/s 
Male n,% 4047 (44.6) 698 (44.6) 1310 (44.8) 2039 (44.4)  
Symptoms profile          
Alarm symptoms n,% 3204 (35.3) 651 (41.6) 1120 (38.3) 1433 (31.2) <0.001 
Non-Alarm n,%  5875 (64.7) 915 (58.4) 1801 (61.7) 3159 (68.8)  
Diagnosis profile          
OG cancer n,% 87 (1.0) 20 (1.3) 35 (1.2) 32 (0.7) 0.03 
Serious Benign n,% 2725 (30.0) 499 (31.9) 895 (30.6) 1331 (29.0) n/s 
Normal or Mild n,% 6267 (69.0) 1047 (66.9) 1991 (68.2) 3229 (70.3) 0.01 
  
 
 
201 
 
5.4.3 Small area variation in gastroscopy rate across general practices  
5.4.3.1 National Intra-PCT variation 
Of the 152 PCTs in England, variation across the range of gastroscopy rates among 
practices in each PCT was less than fivefold in 10 PCTs (6.6%), 5–10-fold in 49 PCTs 
(32.2%), and more than 10-fold in the remaining 94 PCTs (61.4%). This 
demonstrates that practices in relatively close proximity to one another, and served 
by the same local group of hospitals, show a wide spectrum of per capita 
gastroscopy rates. This would support the role of general practitioner referral 
policies as a key determinant of gastroscopy rate, rather than simply the local 
burden of disease. 
5.4.3.2 Local geographical mapping of general practices 
Geographical mapping of practices in our local area according to gastroscopy rate 
has shown low, middle and high gastroscopy referring practices within small 
distances of each other (e.g. 2 miles). This confirms very wide inter-practice 
variation in gastroscopy rate among practices served by the same local endoscopy 
services (Figure 5.6). 
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Figure 5.6 Presents mapping of local practices according to their distribution of gastroscopy 
rate. Google Fusion Table [322] 
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5.4.4 The association between practice per capita rates of elective gastroscopy 
and the rate of two week wait referrals for any form of cancer 
For practices in the national study, comparison across the elective gastroscopy rate 
tertiles show small but significant variation in rates of fast-track (TWW) referrals for 
suspected cancer.  The mean rate of TWW referral for any form of cancer was 
lowest for the low gastroscopy rate tertile and highest for the group of practices in 
the high tertile (Figure 5.7). 
 
 
Figure 5.7 Mean rates of two week wait referrals for any form of cancer across the national 
tertiles of general practice gastroscopy rates (low, middle or high) 
 
Nationally, the practice gastroscopy rates and the general rate of TWW referrals 
show modest but consistently positive correlations overall and across the 
deprivation quintiles (Figure 5.8).  This suggests at practice level there are shared 
factors that determine the two rates of referral that are not related to age profile of 
the population (as the rates are age-adjusted), nor specific to deprived or affluent 
areas. 
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Locally, the strength of the association between the two rates was stronger.  
Clearly, the local study excludes or reduces the influence of local symptom or 
disease prevalence, consultation behaviour or variable access to local secondary 
care diagnostics. Figure 5.9 shows stronger correlation with higher R squared 
values. The simple message appears to be that practices that are ‘low’ for 
gastroscopy also tend to be ‘low’ for TWW referrals in general. This could be 
consistent with varying 'thresholds' for referral operating among groups of doctors 
in practices.  There are unlikely to be differing burdens of symptoms or cancer 
incidence across a relatively small geographical area and the mapping exercise 
confirmed that high and low tertile practices can be located within 1-2 miles.  
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 Pearson r 95% CI R2  Squared P value 
All practices 0.112 0.087-0.136 0.012 <0.001 
Q1 0.289 0.233-0.342 0.083 <0.001 
Q2 0.231 0.177-0.283 0.053 <0.001 
Q3 0.083 0.029-0.136 0.007 0.0026 
Q4 0.119 0.066-0.171 0.014 <0.001 
Q5 0.211 0.16-0.26 0.045 <0.001 
Figure 5.8 Shows the association between the primary care rate of gastroscopy and the rate of 
two week wait referral for all cancer in general and across practice deprivation quintile. 
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 Pearson r 95% CI R2  Squared P value 
A 0.604 0.405-0.748 0.365 <0.001 
B 0.398 0.164-0.589 0.158 0.001 
 
Figure 5.9 Shows the local level association between the primary care rate of gastroscopy and 
(A) the rate of two week wait referral for all cancer in general, and with (B) The percentage of 
gastroscopy performed though TWW system. 
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5.5 Discussion  
This study demonstrates that practices with low rates of gastroscopy tend to have 
higher “diagnostic yield” of serious pathology. Although a higher yield may be 
regarded as more consistent with closer adherence to referral guidelines, it may 
also reflect a more restrictive “gatekeeper” approach or even indicate an increased 
risk of delayed referral i.e. at a later stage in the disease process. The trends in both 
the national and local results strongly support this finding, particularly with the 
presence of a higher mean age at endoscopy among low referring practices. This 
data could also suggest that high referring practices are more likely to refer patients 
with low risk “but not no risk” symptoms. 
This chapter further explores the extent of these variations within each Primary 
Care Trust, indicating that in over 90% of PCTs in England there is evidence for over 
two-fold variation in gastroscopy rates across the local practices and a fifth of the 
PCTs exhibited more than 5-fold local variation.  This, along with the mapping 
results of local practices according to their tertile, demonstrates that practices in 
very close proximity to one another and serviced by the same endoscopy unit still 
often show different referrer rates. This would support the contention that the role 
of general practitioner referral policies is a significant determinant of gastroscopy 
rate, rather than just factors such as the local burden of disease or access to local 
hospital services or data issues (e.g. variable hospital coding). 
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There is a weak but consistently positive correlation at the practice level between 
gastroscopy rates and referral rates for suspected cancer in general under the two 
week wait route. This association is stronger (higher R squared values) at the local 
level than nationally, perhaps reflecting the exclusion or reduction of confounding 
influences of local symptom or disease prevalence, consultation behaviour or 
variable access to local secondary care diagnostics; factors which would be hard to 
control for at the national level.  It is reasonable to suggest that variation in referral 
behaviour explains the observed association between age-adjusted referral rates 
for the two week wait system in general (all cancers) and rates of gastroscopy. 
Meechan et al, also shows that referral rates per capita for TWW are directly 
correlated to the proportion of cancers treated actively that were 2WW referrals 
(“detection rate”) – i.e. high referral rates into the fast-track system are associated 
with a great proportion of cancer cases being treated actively.[324]  Furthermore, 
they show that referral rates per capita for TWW are inversely related to the 
proportion of 2WW referrals which result in a cancer diagnosis (“conversion rate”) 
– i.e. high referral rates into the fast-track system are associated with a lower yield 
of pathology.[324]  Although a low conversion rate might imply inefficient use of 
the 2WW referral system, the higher the detection rate (active treatment) could 
reflect  better patients outcomes with fewer patients diagnosed via other 
routes.[122] While the referral rate could give us a general view on the behaviour 
of the referral practice which is the aim of this part of the study, the relation 
between detection rate and conversion rate appears to be more informative in 
term of the appropriateness of clinical practice.[324]  However, our data show that 
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whilst high levels of gastroscopy referral are associated with a low yield of serious 
pathology (i.e. a “low conversion rate” for gastroscopy in general), such high 
referral rates are also linked to better OG outcomes such as surgical resection (i.e. a 
“high” detection rate). 
 
We acknowledge the role of individual patients’ care-seeking behaviour as a factor 
in determining consultation, and hence, gastroscopy referral. However, it is unlikely 
that such individual factors could operate within one general practice population, 
and yet not operate within neighbouring populations, and still produce the 
magnitude of variation we have observed.  
However, it must be acknowledged that there is potential for variation in rates of 
investigation as a result of differences in disease burden and/or health care seeking 
behaviour and that these population factors may be influenced by deprivation 
status. [325, 326]  
“ Evidence has been reported of variation by deprivation status in the use of 
primary care services and in hospital admission patterns. The fourth national 
study of morbidity statistics from general practice found that patients from 
deprived areas were more likely to consult a general practitioner with a complaint 
subsequently diagnosed as cancer ” [77] 
However, evidence was presented in chapter 4 to show that deprivation explains 
less than 8% of the observed variation in age- and sex-adjusted gastroscopy rates 
across England. There is no simple association between the multiple underlying 
causes of dyspepsia and socio-economic status.  The local studies presented in this 
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chapter replicate the trends observed in national data.  Our centre serves a 
relatively homogenous, predominantly urban population in which major cultural 
differences in consultation behaviour or disease burden are unlikely factors in 
explaining small area variation in gastroscopy rates.  
 
Local findings are in support of our argument that low gastroscopy referring 
practices are likely to include a greater proportion of practitioners with a more 
restrictive “gatekeeper” approach.  This is supported by local results (Tables 5.2, 
5.3, and 5.4) which demonstrate that these group of practices are reserving 
gastroscopy for older patients (significantly higher percentage of those over 55 
years); to those with more severe symptoms (significantly higher percentages of 
individuals presented with alarm symptoms). The proportion of patients with 
serious disease also increased in the same pattern, with low tertile practices having 
the highest proportion of serious disease (i.e. OG cancers). 
Recent evidence results from the analysis of data from the 2010 National Cancer 
Patient Experience Survey in England suggests that ‘primary care’ delay is an 
important factor in OG cancer, in which between 25% of oesophageal and 36% of 
gastric cancer cases had three or more consultations with their GP before 
referral.[326] The first National Audit of Cancer Diagnosis in Primary Care also 
shows that only 50% were referred through urgent (fast-track) pathways.[182] 
Another qualitative study using data from this national audit, involving the analysis 
of free text, comments on possible causes for avoidable delays in diagnosis. It notes 
that, according to the perceptions of participating GPs, the commonest reasons for 
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delay for oesophageal and gastric cancer patients were GP assessments (16%, 14% 
respectively), referral delays (32%, 23% respectively) and investigation delays (27%, 
34% respectively).[327] 
Previous experience from Scotland also showed that around 25% of patients 
diagnosed with upper GI cancer were not referred for a month or more following 
their first GP presentation.[318] The same group also showed that oesophago-
gastric cancer was among the cancer types with the lowest ‘pick up’ rate of 
referrals with an eventual diagnosis of cancer (11.2%) and that around 2% of those 
whose referral did not meet the urgent suspected cancer criteria did in fact have a 
diagnosis of cancer. [318] 
A recent study by Hansen et al (2011) also highlights the possible association 
between delayed cancer diagnosis and GP practice characteristics. [167] however, 
variables such as GP gender, age, CME activity, and practice list size are identified as 
explaining only a tiny part of the variation.[167]   
Thus, it remains an open question whether some of the variation in gastroscopy 
rate, as well as cancer outcome, can be explained by other factors relating to the 
interaction between patients and GP practice characteristics. Our study shows that 
lower threshold for referring with lower risk symptoms were among the high 
referring practices. This could also suggest that GP doctors’ professional and 
individual interpretations of NICE guidance in dyspepsia management may 
influence both their communication about patients’ symptoms, and also the timing 
of their referrals for gastroscopy. It is important to note that this does not imply 
that there is either a lack of knowledge or poor medical performance, but it could 
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mainly reflect diagnostic features, their sensitivity of the appraisal of cancer 
symptoms and their attitudes towards risk.  
It is well recognised that clinical history is a poor guide to the underlying diagnosis 
of dyspepsia. [328] Hence, a better way of detecting symptomatic patients as they 
present to their general practitioner is required [91, 329], in addition to a more 
advanced system for validating referral guidelines intended to reduce the number 
of inappropriate referrals within the system. Of further concern is the fact that data 
from other interventional studies remains limited. Although such data might 
support or refute our findings, policies that actively encourage restriction of 
gastroscopy procedures to investigate dyspepsia may have unintended adverse  
impacts on long term survival from OG cancer.  
The national diagnostic profile analysis shows that upper gastrointestinal 
malignancy accounted for only 2.1% of all patients undergoing gastroscopy 
investigation. This represents OG cancer cases coded for those who had all 
gastroscopy procedures performed through various elective routes, including the 
two week wait system. It is one of the HES related limitations that it cannot be 
possible to distinguish between patients who started their journey through various 
elective routes. 
It is worth mentioning that the local audit finding for gastroscopy diagnosis profile 
not only acts in support of the study hypothesis but also shows the potential of 
using HES data despite the known issues of its coding – our algorithms used to 
interrogate HES data produced very similar findings in national data as those found 
in local data that relied on original gastroscopy reports.  Hence, the local audit work 
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adds further validation steps to the methods used for selection of the most likely 
codes for the described national diagnostic categories.  
It is difficult to define what would be the “ideal” rate of gastroscopy at the level of 
GP practices, nor is it possible to identify whether ‘low’ or ‘high’ rates are 
inappropriate at an individual practice.  Arguably, low rates of negative 
investigation and a high diagnostic yield are desirable but not if the positive 
diagnosis occurs at a late, incurable stage.  In the case of OG cancer, if earlier 
diagnosis is to be achieved then more evidence is needed to support primary care 
and less restrictive guidelines would be required to allow adoption of lower 
threshold for referring individuals with lower risk symptoms (‘low risk, but not no 
risk’).  The overall message of guidelines for dyspepsia supports a “watch and wait 
approach” and managerial and financial focus is on  high rates and perceived “over-
referral”.  Nevertheless, the data techniques developed and tested in this work 
show potential for exploring small area variation and focussing not only on ‘high’ 
referrers. It is possible to identify practice populations with particularly low rates of 
investigation compared to adjacent practices.  Local cancer initiatives could explore 
the reasons why a minority of local practice  populations have unexpectedly low 
referral rates compared with local norms.    
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Chapter 6: General discussion and future directions 
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6.1 Overall summary of the thesis 
This thesis has sought to explore national inequalities in outcome for oesophago-
gastric cancer in England, and whether such disparity is associated with the 
variation in gastroscopy rates in General Practice populations. This section is 
intended to summarize the main purpose of each chapter as well as pointing out 
the key achievements and contributions of the research, with reference to the 
three main aims and objectives listed in (Chapter 2).    
In brief, the first chapter (Chapter 1) provides a general clinical overview of OG 
cancer and describes service provision and organization of care in England. It 
highlights the challenging ‘gate-keeper’ role played by general practitioners in 
distinguishing the large majority of dyspeptic patients who have functional or 
benign underlying causes (who can be managed effectively within the primary care 
setting without invasive investigation) from those with sinister disease who need 
referral for specialist diagnostic investigation. The process of making this distinction 
is complicated by unresolved controversy regarding the optimum role of 
gastroscopy in managing dyspepsia and the imperfect evidence-base for existing 
referral guidelines. The chapter then summarizes the literature regarding variations 
in health care and the ways that health care systems make use of clinical indicators 
to study inequality or unwarranted variation. The chapter further aims to familiarize 
the reader with the nature of routinely collected health care information, with 
particular attention on Hospital Episode Statistics (HES) – considering both its 
potential weaknesses (relating to data quality and the relatively limited clinical 
content) and it’s growing application in developing measures aimed at driving 
improved care and outcomes.  
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Chapter 2 presented the rationale for the study, with a direct exploration of the gap 
in knowledge as identified from the literature review. This review had helped 
establish the original hypothesis and aims of the study. Additionally, this central 
part of the thesis along with the supporting appendices (Chapter 7) details our 
innovative method of developing a more clinically directed approach in using HES 
data to identify OG cancer patients population with pathways of care compatible 
with new incident cases. The successful validation of this complex linkage method 
as presented in (Chapter 3) was a key research milestone in the course of the 
project.  
Chapter 3 provides the first results, assessing the reliability of our database 
inclusions, coding algorithms and linkage methodology, and testing the face validity 
using both national and local (Audit) data output. In addition, the same chapter 
describes the association between cancer outcomes and some patient level 
variables, such as age, sex, co-morbidity and deprivation status. 
Chapter 4 confirms the wide variability in per capita rates of gastroscopy at the 
level of general practice populations, which cannot be explained by patients’ 
demographics. It also reports the novel finding that variation in rates of gastroscopy 
at the level of general practice populations is associated with outcome of 
oesophageal and gastric cancers.[315] More specifically, GP gastroscopy rates act 
as a predictor of cancer outcome, after adjusting for various confounders. [315] 
The final study of the thesis, described in (Chapter 5), confirms that practices with 
relatively low rates of gastrosopy (low tertile) are shown to be operating more 
selective referral practices with a stronger gatekeeper approach, thereby reserving 
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gastroscopy for older patients or for those with more severe symptoms (e.g. alarm 
symptoms) associated with serious disease. On the other hand, practitioners at high 
tertile practices tend to have a lower threshold for gastroscopy referral, most of 
which produce a normal gastroscopy finding. This is suggestive of the fact that high 
gastroscopy practices are presumably investigating more non-NICE symptom 
patients. 
The factors responsible for difference in gastroscopy rate between general 
practices populations are likely to be complex, including differences in local 
symptom prevalence and ‘care seeking behaviour’ and possible differences in GP 
access to hospital-based gastroscopy services.[114]  However, the finding of wide 
variation within relatively small geographical areas suggests a role for unexplained 
variation.[314] 
In other words, the magnitude of this variation is still difficult to be explained by 
these local factors alone. This claim is supported by, first, local mapping which 
shows that such variation is apparent between practices within a very close 
geographical distance to each other, serviced by the same hospital or Endoscopy 
Unit. Secondly, our national linkage to the NCIN two week wait referral rate for all 
cancer data shows that low tertile practices are not only low for referring for 
gastroscopy but are also low in using the two week wait referral system (and yet 
according to the national cancer plan, this pathway should be unrestricted for most 
suspected cancer patients).  
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Although it is difficult to measure individual patients’ consultation behaviour, which 
it is expected might influence results, our analysis of using only practices within the 
most socially disadvantaged group whose population, according to the published 
literature, tend to have higher consultation rate showed a relatively stronger 
association.  
Although the approach of the practices within the low tertile group can be seen as 
more consistent with the current guidelines policies at one end, it has also been 
suggested that these guidelines could discourage some GPs from using what has 
been described as their “sixth sense” in deciding which patients need to be 
referred.[319]  
The two week wait pick-up rates reported in various studies suggest that this 
pathway is still diagnosing a low proportion of patients with OG cancer. [302, 330] 
Our local endoscopy audit shows that 2.4 % of patients going via RAUGICS were 
diagnosed with OG cancer, with a local tertile diagnostic yielding a range from 4.7 % 
in high referring practices to 1.7% among low tertile practices. Whilst such fast 
tracking does increase the overall yield of diagnosis of cancer in all tertiles (Low, 
Middle and High), the yield remains relatively small, given the considerable 
workload required. 
Having shown that low tertile group of practices tend to produce the worst cancer 
outcomes, particularly in the most deprived areas in the country, we strongly 
recommend that the current guidelines are re-evaluated, providing clearer criteria 
for identifying the best candidates to have gastroscopy at the right time. It is hoped 
that the findings of this study will at least encourage further debate in this area. 
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6.2 Methodological challenges, strengths, weaknesses and limitations  
The reporting of the epidemiological research in this thesis follows STROBE 
guidelines (Strengthening the reporting of observational studies in epidemiology) to 
provide the essential information on methodology and findings. [331]  
 
The strengths of our study include the novel application of clinically-developed 
algorithms to analyse the chronological sequence of coded care episodes for each 
patient, our verification of the techniques by direct comparison to a local patient-
level audit, and the validation of the patient population and outcome variables 
against independent external sources of national data for OG cancer. Hence, this 
was not simply a top-down analysis of HES data, but rather took several validation 
steps to confirm the methodology, minimise the risk of data errors and to check the 
clinical face-validity of the outputs. 
Extensive use of sensitivity analyses was undertaken with respect to the ‘exposure’ 
variable of interest (rate of gastroscopy in the general practice population), starting 
with aggregation into tertiles of age- and sex-adjusted rate but re-testing the 
associations using quintiles and absolute (continuous) rates including the 
gastroscopy rate for people over the age of 55 years.  
A benefit of using this logistic regression method is that it permits adjustment both 
by categorical variables and by continuous variables.[332] Hence, we have further 
confirmed the study findings, even after substituting the practice level categorical 
variable (aggregations of practices into tertile or quintile groups) for a continuous 
scale variable, reflecting the actual rate of gastroscopy at each individual practice.  
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Weaknesses and limitations of the research relate to the generic concern regarding 
the completeness, precision and depth of routine administrative coding. We 
applied transparent inclusion/exclusion criteria and validation steps to limit the 
impact of coding error, and tested our hypothesis against three outcome variables.  
A separate analysis of different sub-groups of OG cancers based on anatomical 
location or histology was not possible within routine coding, but this was not 
relevant to the primary study question. Although a small number of patients are 
diagnosed or referred from the private sector, the data for this minority of patients 
are not easily available. [277]  
Lack of the clinical information provided by GPs as well as staging of the disease 
within HES are considered as another limitations, which have prevented this study 
from measuring the benefit of gastroscopy rate in identifying early stage disease at 
the national level. This study was also limited by not having information on patient 
behaviour, exercise, diet, smoking and drinking habit. [268, 333] These factors are 
thought to be partly or largely beyond the GPs’ control, and they might also 
influence poorer cancer outcomes.[333]  
In addition, GP practice level information is limited particularly at the national level, 
and the associations between QOF scores and various outcomes such as emergency 
admissions and mortality were described as small and inconsistent.[292] The 
influence of deprivation status on the outcomes was considerably stronger.[334] 
 The focus of this thesis is on the potential for primary care delay in the diagnosis of 
OG cancers, and specifically on the key decision to refer for elective gastroscopy 
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with the provision of current guidelines. The outcome variables were selected in 
this research to reflect the diagnostic pathway, rather than subsequent hospital-
based care or treatment outcome. As illustrated by our intra PCT variation, local 
gastroscopy audit data and geographical mapping, we find that practices within the 
same geographical area are distributed across different tertiles and yet are served 
by the same hospitals.  In other words, an individual hospital will serve practices 
across a spectrum of referral rates. Hence, we do not believe that institutional 
variation is relevant to our primary analysis.   
Both “first ever” gastroscopies and “re-referrals” would be captured within total 
elective activity counts aggregated at general practice level.  These are both 
relevant to exploring GP thresholds for referral and re-referral when dealing with 
dyspeptic patients.  It is true that a proportion of repeat procedures will be follow-
up ‘scopes initiated by hospitals (e.g. gastric ulcer healing) and a very small 
contribution from elective screening programmes (e.g. re-calls by hospitals for 
Barrett’s “surveillance”) but the vast majority of elective gastroscopy activity is for 
symptomatic dyspeptic patients. Within the study period, the majority (88.2%) of 
the procedures were coded for the “first-time” for the included patients within the 
2-year time window. Most importantly, comparable figures were observed between 
practice tertiles.  It would be hard to consider that some putative hospital-based 
factor related to differing local policies for repeat scopes or Barrett’s surveillance 
could lead to a systematic bias in this study – the variation of interest is reasonably 
between general practices exhibiting wide variation in rates of investigation. 
Furthermore, only a tiny minority of total oesophageal adenocarcinoma cases are 
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diagnosed within Barrett’s surveillance programmes [335] and unlikely to be of 
relevance to our study of OG cancer and GP-level variation.  When analysing 
diagnostic profiles of investigated patients across the three groups of practices, we 
show a very clear gradient both in average age and rate of “major pathologies” 
from low, through middle to high tertile practices.  This is consistent with the 
grouping of practices being a valid surrogate marker for differing thresholds of 
referral for gastroscopy. 
Delay in seeking medical care after symptom onset is a potential factor in delayed 
cancer diagnosis.[33, 181] This relates partially to the biological nature and 
anatomical location of these tumours—a factor common to all patients, and hence 
not a confounding influence as such in this study.  
A range of socioeconomic characteristics has been associated with consultation 
behaviour in primary care which might reflect “patient delay” [336], but our 
analysis adjusts for age, gender and socioeconomic status. We acknowledge a role 
for patient behavioural factors in determining consultation, and hence gastroscopy 
referral. However, it is unlikely that such individual factors could operate 
systematically within one general practice population, and not within neighbouring 
populations, and yet still create the magnitude of variation we have observed 
within individual PCTs and in our locality. Therefore, further research is required to 
better understand the causes for practice-level variation in gastroscopy rates.  
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6.3 Clinical and research implications and future direction.  
The finding of this study could be used to inform both national guidance and local 
initiatives aimed at improving outcomes for OG cancer through earlier diagnosis.  
This study suggests that practices with low rates of gastroscopy should review their 
practice. It has been highlighted that the inequality in outcome with respect to 
gastroscopy rate was greater in magnitude when practices were grouped according 
to gastroscopy in >55 year olds. This implies that new guidelines should consider a 
lower threshold for referral in older subjects, rather than the current emphasis on 
alarm symptoms. Furthermore, there is scope for targeted local initiatives to ensure 
appropriate rates of gastroscopy in practices serving socioeconomically 
disadvantaged areas.  
There is a legitimate focus on identifying and constraining “unnecessary” use of 
expensive secondary care investigations specially in the present climate of cost 
containment in the UK healthcare system. However, this study has revealed that 
practices with the lowest rates of gastroscopy tend to achieve the worst outcomes 
for OG cancer, particularly in those living in the most deprived areas.  Local 
initiatives aimed at reducing gastroscopy activity may well avoid excessive 
investigations for younger patients with benign condition without affecting clinical 
outcome. However, this study suggests that there is a need to concentrate on both 
ends of the referral spectrum.[315] 
Our findings should stimulate research to establish the costs and benefits of 
programmes designed to encourage targeted increases in gastroscopy rates in 
selected local populations. If the situation is to improve, revision of current referral 
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guidelines requires urgent attention, along with strategies for managing patients 
with low risk symptoms and to support compliance.[315] 
More than 13.6 million people are served by low tertile practices. If this population 
experienced similar average gastroscopy rate as the middle tertile group (8.1 per 
1,000), we estimate that this would require 49,301 extra procedures. Assuming a 
daycase gastroscopy cost of £431 [337]  this would cost £21,325,250 nationally. If 
this increase in gastroscopy activity results in the same surgical resection rate as 
shown by the middle tertile group, this implies a 0.95% absolute rise (15.44% to 
16.39%) or an extra 59 surgical candidates from low tertile practices (0.95% of 
6,196 patients). This suggests a cost of over £360,000 per additional potential 
surgical cure.[315] 
Published median survival for un-resectable OG cancers are approximately 6-9 
months [338] whereas corresponding survival data reported after radical surgery 
are 27-38 months.[339, 340] Thus, it has been estimated that diagnosis at an 
operable stage may extend life by 18-32 months on average (around 2.5 years). This 
puts the crude cost-per-life-year saved for our hypothetical scenario at around 
£140,000. Alternatively, it is known that only about a fifth of surgical cases achieve 
5-year survival and potential long term cure [177] – this equates to just 12 lives 
saved of the 59 predicted extra surgical cases at a cost of £21.3 Million.[315] 
This crude calculation relies on simplistic assumptions, and a formal economic 
analysis would be required to model the full stream of potential costs and benefits 
arising from interventions to modify gastroscopy referral practice.[315] 
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Nevertheless, our estimate suggests that a simple strategy to encourage a 
generalized increase in gastroscopy across all populations served by the ‘low tertile’ 
practices appears costly compared to alternative healthcare investments. Scarce 
resources might be deployed more cost-effectively within gastroenterology by 
increasing rates of other tests such as colonoscopy. Economic models exploring the 
cost-effectiveness of a range of colonoscopy-based screening strategies for 
colorectal cancer have suggested a cost per life-year saved below a threshold of 
US$ 40,000 (£25,000). [315, 341] 
In practice, a range of alternative strategies might address current inequalities in 
OG cancer outcome but at lower opportunity costs. We favour more targeted 
locally-led intervention to enable general practitioners to identify whether their 
gastroscopy rates are low in relation to local norms (i.e. “local outliers”), 
particularly in socioeconomically disadvantaged areas, with a focus on increasing 
access to gastroscopy for older subjects at risk of cancer. Costs could be offset by 
simultaneous efforts to encourage reductions in gastroscopy among younger 
dyspeptic patients where non-invasive strategies are appropriate [147], targeting 
practices at the high end of the referral volume continuum. The local generation 
and sharing of practice-level comparative data on gastroscopy could allow GPs, 
commissioners and endoscopy units to work together to reduce inequalities. 
One of the reasons for delay in OG cancer diagnosis could be that patients have 
poor understanding or awareness of its main signs and symptoms.[342-344]  A 
previous study shows that around two thirds of cases were symptomatic for more 
than 3 months. [345] Local study in Liverpool included 37,500 individuals over 40 
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years of age who were registered with 12 general practices tests the efficacy of 
education by home letter, found that this intervention produce improvement in 
resection rate and curability, but the longer term survival was not affected.[346] 
Although improving the survival of OG cancer is likely to require more complex and 
intensive interventions, still a new public health campaigns for the awareness of 
symptoms and risk factors at the national level are important if the cancer is to be 
detected at an earlier and potentially curable stage.[347] Such argument could be 
supported by the recent media campaigns in England which planned to increase 
awareness of symptoms of colon cancer, have improved public alertness of its 
common symptoms. This was accompanied with a concurrent increase of about 
50% in patients attending their GP with symptoms of change in bowel habit and/or 
rectal bleeding, along with comparable increases in urgent referrals and 
colonoscopy.[348] Finding of our research could therefore be used to better direct 
similar intervention specially among the most disadvantaged members of the 
society whom particularly belong to low referring practices.  
The magnitude of variation we have shown in rates of gastroscopy is consistent 
with wide differences in clinical practice across primary care and possible 
inequalities in access to investigation. Although national NICE guidelines were 
originally expected to reduce such variation, for some cancer types, tools such as 
the Risk Assessment Tool (RATs) [349] and “Qcancer” [329, 350] (both of which 
might act to improve case selection) could be the way forward in helping GPs to 
better judge the individual patient’s likelihood of cancer and to select those who 
have symptoms of potential cancer, but who do not qualify under the NICE 
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guidance for specialist referral and/or further investigation.  These tools are based 
on the epidemiology of cancer symptoms in primary care by giving risk estimates 
for patients presenting with for example, single symptom of cancer, pairs of 
symptoms and repeat attendances.[351] 
For example, the National Cancer Action Team publication,[349] which evaluates 
the utilization of RATs for suspected cancer in general practice, showed that 
patients with higher risk scores were more likely to be investigated. The qualitative 
part of the same study illustrates that RATs raised the GPs’ willingness to 
investigate for cancer and it also helped provide reassurance when investigation 
was not needed, especially in patients with atypical presentations.[349] 
Even though these tools appear logical and might offer the potential for the 
improved use of the available resources, more research will still be required to 
overcome the challenge of how best to incorporate these risk tools into routine 
clinical practice.[351] 
It is also expected that these risk modules might not be applicable in the cases of 
suspected OG cancers without a corresponding reduction in the unit cost of 
providing endoscopy, so that individuals with low risk (but not no risk) dyspepsia 
symptoms can be offered prompt endoscopy.   
However, a better understanding how cancer outcome relates to previous 
encounters with primary care is essential. Therefore, further research efforts 
encompassing both HES and more detailed primary care records will be crucial to 
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help examine how existing information and databases can be better used to 
improve cancer outcomes. 
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6.4 Conclusion and recommendations 
In the context of health service research, the results of this study support the idea 
that HES data can be especially powerful when carefully interpreted with clinical 
background knowledge, and that it has an unexplored potential for producing 
answers to clinical research questions. The national-level analysis provides ‘real-
world’ descriptive statistics for OG cancer care in England, which has been 
adequately validated against recently published clinical audits and other statistics 
to eliminate the worry of selection bias.  
There remain inequalities in outcome for oesophago-gastric cancer in England and 
this is associated with gastroscopy rates in general practice populations. There is 
potential for primary care delay in the diagnosis of OG cancers, and specifically the 
key decision to refer low risk (but not no risk) patients for elective gastroscopy with 
the provision of current guideline and route of diagnosis.  
Guidelines are proposed to reduce variation in practice. However, the association 
between variation in investigation rates and cancer outcome shown by this study 
has identified a strong reason to reflect on whether current guidelines are “fit-for-
purpose” or “implemented effectively”. Therefore, this study recommends that 
practices with low rates of gastroscopy should review their current policies, 
particularly those serving the most deprived members of the society.  
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Appendix 7.1 Specialties included in the analysis  
CODE NAME STATUS 
300 GENERAL MEDICINE MEDICAL 
301 GASTROENTEROLOGY MEDICAL 
302 ENDOCRINOLOGY MEDICAL 
303 CLINICAL HAEMATOLOGY MEDICAL 
305 CLINICAL PHARMACOLOGY MEDICAL 
313 CLINICAL IMMUNOLOGY and ALLERGY MEDICAL 
314 REHABILITATION MEDICAL 
315 PALLIATIVE MEDICINE MEDICAL 
320 CARDIOLOGY MEDICAL 
330 DERMATOLOGY MEDICAL 
340 RESPIRATORY MEDICINE (also known as thoracic medicine) MEDICAL 
350 INFECTIOUS DISEASES MEDICAL 
352 TROPICAL MEDICINE MEDICAL 
360 GENITOURINARY MEDICINE MEDICAL 
361 NEPHROLOGY MEDICAL 
370 MEDICAL ONCOLOGY MEDICAL 
400 NEUROLOGY MEDICAL 
410 RHEUMATOLOGY MEDICAL 
430 GERIATRIC MEDICINE MEDICAL 
823 HAEMATOLOGY MEDICAL 
100 GENERAL SURGERY SURGICAL 
101 UROLOGY SURGICAL 
110 TRAUMA & ORTHOPAEDICS SURGICAL 
120 ENT SURGICAL 
130 OPHTHALMOLOGY SURGICAL 
140 ORAL SURGERY SURGICAL 
145 ORAL & MAXILLO FACIAL SURGERY SURGICAL 
150 NEUROSURGERY SURGICAL 
160 PLASTIC SURGERY SURGICAL 
170 CARDIOTHORACIC SURGERY SURGICAL 
180 ACCIDENT & EMERGENCY SURGICAL 
190 ANAESTHETICS SURGICAL 
192 CRITICAL CARE MEDICINE SURGICAL 
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Appendix 7.2 Trust included in the analysis 
Between the 2 dataset years Hammersmith (RQN) and St Mary’s (RJ5) hospitals had 
merged to become Imperial (RYJ).  RQN codes and RJ5 codes were amended to (RYJ). It is 
also important to note that two surgical centres The Cardiothoracic Centre (RBQ) and The 
Royal Marsden (RPY) were added to identify OGC cases who had surgical resection. 
 
PROCODE DESCRIPTION 
5QT ISLE OF WIGHT PCT 
RA2 ROYAL SURREY COUNTY HOSPITAL NHS TRUST 
RA3 WESTON AREA HEALTH NHS TRUST 
RA4 YEOVIL DISTRICT HOSPITAL NHS FOUNDATION TRUST 
RA7 UNIVERSITY HOSPITALS OF BRISTOL NHS FOUNDATION TRUST 
RA9 SOUTH DEVON HEALTHCARE NHS FOUNDATION TRUST 
RAE BRADFORD TEACHING HOSPITALS NHS FOUNDATION TRUST 
RAJ SOUTHEND UNIVERSITY HOSPITAL NHS FOUNDATION TRUST 
RAL ROYAL FREE HAMPSTEAD NHS TRUST 
RAP NORTH MIDDLESEX UNIVERSITY HOSPITAL NHS TRUST 
RAS THE HILLINGDON HOSPITAL NHS TRUST 
RAX KINGSTON HOSPITAL NHS TRUST 
RBA TAUNTON AND SOMERSET NHS FOUNDATION TRUST 
RBD DORSET COUNTY HOSPITAL NHS FOUNDATION TRUST 
RBK WALSALL HOSPITALS NHS TRUST 
RBL WIRRAL UNIVERSITY TEACHING HOSPITAL NHS FOUNDATION TRUST 
RBN ST HELENS AND KNOWSLEY HOSPITALS NHS TRUST 
RBT MID CHESHIRE HOSPITALS NHS FOUNDATION TRUST 
RBZ NORTHERN DEVON HEALTHCARE NHS TRUST 
RC1 BEDFORD HOSPITAL NHS TRUST 
RC3 EALING HOSPITAL NHS TRUST 
RC9 LUTON AND DUNSTABLE HOSPITAL NHS FOUNDATION TRUST 
RCB YORK HOSPITALS NHS FOUNDATION TRUST 
RCC SCARBOROUGH AND NORTH EAST YORKSHIRE HEALTH CARE NHS TRUST 
RCD HARROGATE AND DISTRICT NHS FOUNDATION TRUST 
RCF AIREDALE NHS TRUST 
RCX THE QUEEN ELIZABETH HOSPITAL KING'S LYNN NHS TRUST 
RD1 ROYAL UNITED HOSPITAL BATH NHS TRUST 
RD3 POOLE HOSPITAL NHS FOUNDATION TRUST 
RD7 HEATHERWOOD AND WEXHAM PARK HOSPITALS NHS FOUNDATION TRUST 
RD8 MILTON KEYNES HOSPITAL NHS FOUNDATION TRUST 
RDD BASILDON AND THURROCK UNIVERSITY HOSPITALS NHS FOUNDATION TRUST 
RDE COLCHESTER HOSPITAL UNIVERSITY NHS FOUNDATION TRUST 
RDU FRIMLEY PARK HOSPITAL NHS FOUNDATION TRUST 
RDZ THE ROYAL BOURNEMOUTH AND CHRISTCHURCH HOSPITALS NHS FOUNDATION TRUST 
RE9 SOUTH TYNESIDE NHS FOUNDATION TRUST 
REF ROYAL CORNWALL HOSPITALS NHS TRUST 
REM AINTREE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST 
RF4 BARKING, HAVERING AND REDBRIDGE HOSPITALS NHS TRUST 
RFF BARNSLEY HOSPITAL NHS FOUNDATION TRUST 
RFR THE ROTHERHAM NHS FOUNDATION TRUST 
RFS CHESTERFIELD ROYAL HOSPITAL NHS FOUNDATION TRUST 
RFW WEST MIDDLESEX UNIVERSITY HOSPITAL NHS TRUST 
RG2 QUEEN ELIZABETH HOSPITAL NHS TRUST 
RG3 BROMLEY HOSPITALS NHS TRUST 
RGC WHIPPS CROSS UNIVERSITY HOSPITAL NHS TRUST 
RGN PETERBOROUGH AND STAMFORD HOSPITALS NHS FOUNDATION TRUST 
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RGP JAMES PAGET UNIVERSITY HOSPITALS NHS FOUNDATION TRUST 
RGQ IPSWICH HOSPITAL NHS TRUST 
RGR WEST SUFFOLK HOSPITALS NHS TRUST 
RGT CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST 
RGZ QUEEN MARY'S SIDCUP NHS TRUST 
RH8 ROYAL DEVON AND EXETER NHS FOUNDATION TRUST 
RHM SOUTHAMPTON UNIVERSITY HOSPITALS NHS TRUST 
RHQ SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST 
RHU PORTSMOUTH HOSPITALS NHS TRUST 
RHW ROYAL BERKSHIRE NHS FOUNDATION TRUST 
RJ1 GUY'S AND ST THOMAS' NHS FOUNDATION TRUST 
RJ2 THE LEWISHAM HOSPITAL NHS TRUST 
RJ5 ST MARYS NHS TRUST 
RJ6 MAYDAY HEALTHCARE NHS TRUST 
RJ7 ST GEORGE'S HEALTHCARE NHS TRUST 
RJC SOUTH WARWICKSHIRE GENERAL HOSPITALS NHS TRUST 
RJD MID STAFFORDSHIRE NHS FOUNDATION TRUST 
RJE UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE NHS TRUST 
RJF BURTON HOSPITALS NHS TRUST 
RJL NORTHERN LINCOLNSHIRE AND GOOLE HOSPITALS NHS FOUNDATION TRUST 
RJN EAST CHESHIRE NHS TRUST 
RJR COUNTESS OF CHESTER HOSPITAL NHS FOUNDATION TRUST 
RJZ KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST 
RK5 SHERWOOD FOREST HOSPITALS NHS FOUNDATION TRUST 
RK9 PLYMOUTH HOSPITALS NHS TRUST 
RKB UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST 
RKE THE WHITTINGTON HOSPITAL NHS TRUST 
RL4 THE ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST 
RLN CITY HOSPITALS SUNDERLAND NHS FOUNDATION TRUST 
RLQ HEREFORD HOSPITALS NHS TRUST 
RLT GEORGE ELIOT HOSPITAL NHS TRUST 
RM1 NORFOLK AND NORWICH UNIVERSITY HOSPITALS NHS FOUNDATION TRUST 
RM2 UNIVERSITY HOSPITAL OF SOUTH MANCHESTER NHS FOUNDATION TRUST 
RM3 SALFORD ROYAL NHS FOUNDATION TRUST 
RM4 TRAFFORD HEALTHCARE NHS TRUST 
RMC BOLTON HOSPITALS NHS TRUST 
RMP TAMESIDE HOSPITAL NHS FOUNDATION TRUST 
RN1 WINCHESTER AND EASTLEIGH HEALTHCARE NHS TRUST 
RN3 SWINDON AND MARLBOROUGH NHS TRUST 
RN5 BASINGSTOKE AND NORTH HAMPSHIRE NHS FOUNDATION TRUST 
RN7 DARTFORD AND GRAVESHAM NHS TRUST 
RNA DUDLEY GROUP OF HOSPITALS NHS TRUST 
RNH NEWHAM UNIVERSITY HOSPITAL NHS TRUST 
RNJ BARTS AND THE LONDON NHS TRUST 
RNL NORTH CUMBRIA UNIVERSITY HOSPITALS NHS TRUST 
RNQ KETTERING GENERAL HOSPITAL NHS TRUST 
RNS NORTHAMPTON GENERAL HOSPITAL NHS TRUST 
RNZ SALISBURY NHS FOUNDATION TRUST 
RP5 DONCASTER AND BASSETLAW HOSPITALS NHS FOUNDATION TRUST 
RPA MEDWAY NHS FOUNDATION TRUST 
RPL WORTHING AND SOUTHLANDS HOSPITALS NHS TRUST 
RPR ROYAL WEST SUSSEX NHS TRUST 
RQ6 ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST 
RQ8 MID ESSEX HOSPITAL SERVICES NHS TRUST 
RQM CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST 
RQN HAMMERSMITH NHS TRUST 
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RQQ HINCHINGBROOKE HEALTH CARE NHS TRUST 
RQW THE PRINCESS ALEXANDRA HOSPITAL NHS TRUST 
RQX HOMERTON UNIVERSITY HOSPITAL NHS FOUNDATION TRUST 
RR1 HEART OF ENGLAND NHS FOUNDATION TRUST 
RR7 GATESHEAD HEALTH NHS FOUNDATION TRUST 
RR8 LEEDS TEACHING HOSPITALS NHS TRUST 
RRF WRIGHTINGTON, WIGAN AND LEIGH NHS TRUST 
RRK UNIVERSITY HOSPITAL BIRMINGHAM NHS FOUNDATION TRUST 
RRV UNIVERSITY COLLEGE LONDON HOSPITALS NHS FOUNDATION TRUST 
RTD THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST 
RTE GLOUCESTERSHIRE HOSPITALS NHS FOUNDATION TRUST 
RTF NORTHUMBRIA HEALTHCARE NHS FOUNDATION TRUST 
RTG DERBY HOSPITALS NHS FOUNDATION TRUST 
RTH OXFORD RADCLIFFE HOSPITALS NHS TRUST 
RTK ASHFORD AND ST PETER'S HOSPITALS NHS TRUST 
RTP SURREY AND SUSSEX HEALTHCARE NHS TRUST 
RTR SOUTH TEES HOSPITALS NHS TRUST 
RTX UNIVERSITY HOSPITALS OF MORECAMBE BAY NHS TRUST 
RV8 NORTH WEST LONDON HOSPITALS NHS TRUST 
RVJ NORTH BRISTOL NHS TRUST 
RVL BARNET AND CHASE FARM HOSPITALS NHS TRUST 
RVR EPSOM AND ST HELIER UNIVERSITY HOSPITALS NHS TRUST 
RVV EAST KENT HOSPITALS UNIVERSITY NHS TRUST 
RVW NORTH TEES AND HARTLEPOOL NHS FOUNDATION TRUST 
RVY SOUTHPORT AND ORMSKIRK HOSPITAL NHS TRUST 
RW3 CENTRAL MANCHESTER AND MANCHESTER CHILDREN'S UNIVERSITY HOSPITALS NHS TRUST 
RW6 PENNINE ACUTE HOSPITALS NHS TRUST 
RWA HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST 
RWD UNITED LINCOLNSHIRE HOSPITALS NHS TRUST 
RWE UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST 
RWF MAIDSTONE AND TUNBRIDGE WELLS NHS TRUST 
RWG WEST HERTFORDSHIRE HOSPITALS NHS TRUST 
RWH EAST AND NORTH HERTFORDSHIRE NHS TRUST 
RWJ STOCKPORT NHS FOUNDATION TRUST 
RWP WORCESTERSHIRE ACUTE HOSPITALS NHS TRUST 
RWW NORTH CHESHIRE HOSPITALS NHS TRUST 
RWY CALDERDALE AND HUDDERSFIELD NHS FOUNDATION TRUST 
RX1 NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST 
RXC EAST SUSSEX HOSPITALS NHS TRUST 
RXF MID YORKSHIRE HOSPITALS NHS TRUST 
RXH BRIGHTON AND SUSSEX UNIVERSITY HOSPITALS NHS TRUST 
RXK SANDWELL AND WEST BIRMINGHAM HOSPITALS NHS TRUST 
RXL BLACKPOOL, FYLDE AND WYRE HOSPITALS NHS FOUNDATION TRUST 
RXN LANCASHIRE TEACHING HOSPITALS NHS FOUNDATION TRUST 
RXP COUNTY DURHAM AND DARLINGTON NHS FOUNDATION TRUST 
RXQ BUCKINGHAMSHIRE HOSPITALS NHS TRUST 
RXR EAST LANCASHIRE HOSPITALS NHS TRUST 
RXW SHREWSBURY AND TELFORD HOSPITAL NHS TRUST 
RYJ IMPERIAL COLLEGE HEALTHCARE NHS TRUST 
RBQ The Cardiothoracic Centre - Liverpool NHS Trust 
RPY The Royal Marsden NHS FD Trust 
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Appendix 7.3 Describe the OG cancer ICD-10 codes used in this study 
ICD10 Code description 
C150 Malignant neoplasm of cervical part of oesophagus  
C151 Malignant neoplasm of thoracic part of oesophagus  
C152 Malignant neo of abdominal part of oesophagus  
C153 Malignant neoplasm of UPPER third of oesophagus 
C154 Malignant neoplasm of MID third of oesophagus 
C155 Malignant neoplasm of lower third of oesophagus  
C158 Malignant neoplasm overlapping lesion of oesophagus  
C159 Malignant neoplasm of oesophagus unspecified  
C160 Malignant neoplasm of cardia of stomach  
C161 Malignant neoplasm of fundus of stomach  
C162 Malignant neoplasm of body of stomach  
C163 Malignant neoplasm of pyloric antrum  
C164 Malignant neoplasm of pylorus 
C165 Malignant neoplasm of lesser curvature of stomach  
C166 Malignant neoplasm of greater curvature of stomach   
C168 Malignant neoplasm overlapping lesion of stomach  
C169 Malignant neoplasm of stomach  unspecified  
 
Appendix 7.4 The diagnostic gastroscopy procedure OPCS-4 codes used in this study 
OPCS-4 Code Code description  
G16  Diagnostic fibreoptic endoscopic examination of oesophagus                                                             
G161 Diagnostic fibreoptic endoscopic examination of oesophagus and biopsy of lesion of 
oesophagus                          
G168 Other specified diagnostic fibreoptic endoscopic examination of oesophagus                                             
G169 Unspecified diagnostic fibreoptic endoscopic examination of oesophagus                                                 
G45  Diagnostic fibreoptic endoscopic examination of upper gastrointestinal tract                                           
G451 Fibreoptic endoscopic examination of upper gastrointestinal tract and biopsy of lesion of 
upper gastrointestinal tract 
G454 Fibreoptic endoscopic examination of upper gastrointestinal tract and staining of gastric 
mucosa                       
G458 Other specified diagnostic fibreoptic endoscopic examination of upper gastrointestinal 
tract                           
G459 Unspecified diagnostic fibreoptic endoscopic examination of upper gastrointestinal tract                               
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Appendix 7.5 Charlson Index of Comorbidity weights and codes.[269] 
Condition  Weights ICD10 codes 
Acute myocardial 
infarction 
1 I21, I22, I252 
Congestive heart 
failure 
1 I50 
Peripheral 
vascular disease 
1 I71, I790, I739, R02, Z958, Z959 
Cerebral vascular 
accident 
1 I60, I61, I62, I63, I65, I66, G450, G451, G452, G458, G459, G46, I64, 
G454, I670, I671, I672, I674, I675, I676, I677, I678, I679, I681, I682, 
I688, I69 
Dementia 1 F00, F01, F02, F051 
Pulmonary 
disease 
1 J40, J41, J42, J44, J43, J45, J46, J47, J67, J44, J60, J61, J62, J63, J66, 
J64, J65  
Connective tissue 
disorder 
1 M32, M34, M332, M053, M058, M059, M060, M063, M069, M050, 
M052, M051, M353 
Peptic ulcer 1 K25, K26, K27, K28 
Liver disease 1 K702, K703, K73, K717, K740, K742, K746, K743, K744, K745 
Diabetes 1 E109, E119, E139, E149, E101, E111, E131, E141, E105, E115, E135, 
E145 
Diabetes 
complications 
2 E102, E112, E132, E142 E103, E113, E133, E143 E104, E114, E134, 
E144 
Paraplegia 2 G81 G041, G820, G821, G822 
Renal disease  2 N03, N052, N053, N054, N055, N056, N072, N073, N074, N01, N18, 
N19, N25 
Cancer  2 C0, C1, C2, C3, C40, C41, C43, C45, C46, C47, C48, C49, C5, C6, C70, 
C71, C72, C73, C74, C75, C76, C81, C82, C83, C84, C85, C883, C887, 
C889, C900, C901, C91, C92, C93, C940, C941, C942, C943, C9451, 
C947, C95, C96 
Metastatic cancer 3 C77, C78, C79, C80 
Severe liver 
disease 
3 K729, K766, K767, K721 
HIV  6 B20, B21, B22, B23, B24 
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Appendix 7.6 the adapted version of ICD10 comorbidity codes those were originally 
developed by Sundararajan et al.[269, 270]  
 Code descriptions 
I210 Acute transmural myocardial infarction of 
anterior wall I211 Acute t ansmural myocardial infarction of inferior 
wall I212 Acute transmural myocardial infarction of other 
sites I213 Acute transmural myocardial infarction of 
unspecified site I214 Acute subendocardial myocardial infarction 
I219 Acute myocardial infarction  unspecified 
I220 Subsequent myocardial infarction of anterior wall 
I221 Subsequent myocardial infarction of inferior wall 
I228 Subsequent myocardial infarction of other sites 
I229 Subsequent myocardial infarction of unspecified 
site I252 Old myocardial infarction 
I500 Congestive heart failure 
I501 Left ventricular failure 
I509 Heart failure  unspecified 
I710 Dissection of aorta [any part] 
I711 Thoracic aortic aneurysm  ruptured 
I712 Thoracic aortic aneurysm  without mention of 
rupture I713 Abdominal aortic aneurysm  ruptured 
I714 Abdominal aortic aneurysm  without mention of 
rupture I715 Thoracoabdominal aortic aneurysm  ruptured 
I716 Thoracoabdominal aortic aneurysm  without 
mention of ruptur I718 Aortic aneurysm of unspecified site  ruptured 
I719 Aortic aneurysm of unspec site  without mention 
of rupture I790 Aneurysm of aorta in diseases classified 
elsewhere I739 Peripheral vascular disease  unspecified 
R02
X 
Gangrene  not elsewhere classified 
Z95
8 
Presence of other cardiac and vascular implants 
and grafts Z95
9 
Presence of cardiac and vascular implant and 
graft unspec I601 Subarachnoid haemorrhage from middle cerebral 
artery I602 Subarachnoid haemorrhage from anterior 
communicating artery I603 Subarachnoid haemorrhage from posterior 
communicating arter I604 Subarachnoid haemorrhage from basilar artery 
I605 Subarachnoid haemorrhage from vertebral artery 
I606 Subarachnoid haemorrhage from other 
intracranial arteries I607 Subarachnoid haemorrhage from intracranial 
artery  unspec I608 Other subarachnoid haemorrhage 
I609 Subarachnoid haemorrhage  unspecified 
I610 Intracerebral haemorrhage in hemisphere  
subcortical I611 Intracerebral haemorrhage in hemisphere  
cortical I612 Intracerebral haemorrhage in hemisphere  
unspecified I613 Intracerebral haemorrhage in brain stem 
I614 Intracerebral haemorrhage in cerebellum 
I615 Intracerebral haemorrhage  intraventricular 
I616 Intracerebral haemorrhage  multiple localized 
I618 Other intracerebral haemorrhage 
I619 Intracerebral haemorrhage  unspecified 
I620 Subdural haemorrhage (acute)(nontraumatic) 
I621 Nontraumatic extradural haemorrhage 
I629 Intracranial haemorrhage (nontraumatic)  
unspecified I630 Cerebral infarct due to thrombosis of precerebral 
arteries I631 Cerebral infarction due to embolism of 
precerebral arteries I632 Cereb infarct due unsp occlusion or stenos 
precerebrl arts I633 Cerebral infarction due to thrombosis of cerebral 
arteries I634 Cerebral infarction due to embolism of cerebral 
arteries I635 Cerebrl infarct due unspec occlusion or stenos 
cerebrl arts 
I636 Cereb infarct due cerebral venous thrombosis  
nonpyogenic I638 Other cerebral infarction 
I639 Cerebral infarction  unspecified 
I650 Occlusion and stenosis of vertebral artery 
I651 Occlusion and stenosis of basilar artery 
I652 Occlusion and stenosis of carotid artery 
I653 Occlusion and stenosis of multip and bilat 
precerebrl arts I658 Occlusion and stenosis of other precerebral 
artery I659 Occlusion and stenosis of unspecified precerebral 
artery I660 Occlusion and stenosis of middle cerebral artery 
I661 Occlusion and stenosis of anterior cerebral artery 
I662 Occlusion and stenosis of posterior cerebral 
artery I663 Occlusion and stenosis of cerebellar arteries 
I664 Occlusion and stenosis of multiple and bilat 
cerebrl arts I668 Occlusion and stenosis of other cerebral artery 
I669 Occlusion and stenosis of unspecified cerebral 
artery G45
0 
Vertebro-basilar artery syndrome 
G45
1 
Carotid artery syndrome (hemispheric) 
G45
2 
Multiple and bilateral precerebral artery 
syndromes G45
8 
Other transient cerebral ischaemic attacks and 
related synd G45
9 
Transient cerebral ischaemic attack  unspecified 
G46
0 
Middle cerebral artery syndrome 
G46
1 
Anterior cerebral artery syndrome 
G46
2 
Posterior cerebral artery syndrome 
G46
3 
Brain stem stroke syndrome 
G46
4 
Cerebellar stroke syndrome 
G46
5 
Pure motor lacunar syndrome 
G46
6 
Pure sensory lacunar syndrome 
G46
7 
Other lacunar syndromes 
G46
8 
Oth vascular syndromes of brain in 
cerebrovascular dis G45
4 
Transient global amnesia 
I64
X 
Stroke  not specified as haemorrhage or 
infarction I670 Dissection of cerebral arteries  nonruptured 
I671 Cerebral aneurysm  nonruptured 
I672 Cerebral atherosclerosis 
I674 Hypertensive encephalopathy 
I675 Moyamoya disease 
I676 Nonpyogenic thrombosis of intracranial venous 
system I677 Cerebral arteritis  not elsewhere classified 
I678 Other specified cerebrovascular diseases 
I679 Cerebrovascular disease  unspecified 
I681 Cerebral arteritis in infect & parasit dis classif 
elsewh I682 Cerebral arteritis in other diseases classified 
elsewhere I688 Other cerebrovascular disorders in diseases EC 
I690 Sequelae of subarachnoid haemorrhage 
I691 Sequelae of intracerebral haemorrhage 
I692 Sequelae of other nontraumatic intracranial 
haemorrhage I693 Sequelae of cerebral infarction 
I694 Sequelae of stroke  not spec as haemorrhage or 
infarction I698 Sequelae of other and unspecified 
cerebrovascular diseases F00
0 
Dementia in Alzheimer s disease with early onset 
F00
1 
Dementia in Alzheimer s disease with late onset 
F00
2 
Dementia in Alzheimer s disease  atypical or 
mixed type F00
9 
Dementia in Alzheimer s disease  unspecified 
F01
0 
Vascular dementia of acute onset 
F01
1 
Multi-infarct dementia 
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F01
2 
Subcortical vascular dementia 
F01
3 
Mixed cortical and subcortical vascular dementia 
F01
8 
Other vascular dementia 
F01
9 
Vascular dementia  unspecified 
F02
0 
Dementia in Pick s disease 
F02
1 
Dementia in Creutzfeldt-Jakob disease 
F02
2 
Dementia in Huntington s disease 
F02
3 
Dementia in Parkinson s disease 
F02
4 
Dementia in human immunodef virus [HIV] 
disease F02
8 
Dementia in other specified diseases classified 
elsewhere F05
1 
Delirium superimposed on dementia 
J40
X 
Bronchitis  not specified as acute or chronic 
J41
0 
Simple chronic bronchitis 
J41
1 
Mucopurulent chronic bronchitis 
J41
8 
Mixed simple and mucopurulent chronic 
bronchitis J42
X 
Unspecified chronic bronchitis 
J43
0 
MacLeod s syndrome 
J43
1 
Panlobular emphysema 
J43
2 
Centrilobular emphysema 
J43
8 
Other emphysema 
J43
9 
Emphysema  unspecified 
J44
0 
Chronic obstruct pulmonary dis with acute lower 
resp infec J44
1 
Chron obstruct pulmonary dis wth acute 
exacerbation  unspec J44
8 
Other specified chronic obstructive pulmonary 
disease J44
9 
Chronic obstructive pulmonary disease  
unspecified J45
0 
Predominantly allergic asthma 
J45
1 
Nonallergic asthma 
J45
8 
Mixed asthma 
J45
9 
Asthma  unspecified 
J46
X 
Status asthmaticus 
J47
X 
Bronchiectasis 
J60
X 
Coalworker s pneumoconiosis 
J61
X 
Pneumoconiosis due to asbestos and other 
mineral fibres J62
0 
Pneumoconiosis due to talc dust 
J62
8 
Pneumoconiosis due to other dust containing 
silica J63
0 
Aluminosis (of lung) 
J63
1 
Bauxite fibrosis (of lung) 
J63
2 
Berylliosis 
J63
3 
Graphite fibrosis (of lung) 
J63
4 
Siderosis 
J63
5 
Stannosis 
J63
8 
Pneumoconiosis due to other specified inorganic 
dusts J64
X 
Unspecified pneumoconiosis 
J65
X 
Pneumoconiosis associated with tuberculosis 
J66
0 
Byssinosis 
J66
1 
Flax-dresser s disease 
J66
2 
Cannabinosis 
J66
8 
Airway disease due to other specific organic 
dusts M3
20 
Drug-induced systemic lupus erythematosus 
M3
21 
Systemic lupus erythematosus with organ or sys 
involv M3
28 
Other forms of systemic lupus erythematosus 
M3
29 
Systemic lupus erythematosus  unspecified 
M3
40 
Progressive systemic sclerosis 
M3
41 
CR(E)ST syndrome 
M3
42 
Systemic sclerosis induced by drugs and 
chemicals M3
48 
Other forms of systemic sclerosis 
M3
49 
Systemic sclerosis  unspecified 
M3
32 
Polymyositis 
M0
53 
Rheumatoid arthritis with involvement of oth 
organs and sys M0
58 
Other seropositive rheumatoid arthritis 
M0
59 
Seropositive rheumatoid arthritis  unspecified 
M0
60 
Seronegative rheumatoid arthritis 
M0
63 
Rheumatoid nodule 
M0
69 
Rheumatoid arthritis  unspecified 
M0
50 
Felty s syndrome 
M0
52 
Rheumatoid vasculitis 
M0
51 
Rheumatoid lung disease 
M3
53 
Polymyalgia rheumatica 
K25
0 
Gastric ulcer  acute with haemorrhage 
K25
1 
Gastric ulcer  acute with perforation 
K25
2 
Gastric ulcer  acute with both haemorrhage and 
perforation K25
3 
Gastric ulcer  acute without haemorrhage or 
perforation K25
4 
Gastric ulcer  chronic or unspecified with 
haemorrhage K25
5 
Gastric ulcer  chronic or unspecified with 
perforation K25
6 
Chronic or unspecified with both haemorrhage 
and perforatio K25
7 
Gastric ulcer  chronic without haemorrhage or 
perforation K25
9 
Unspec as acute or chronic w out haemorrhage 
or perforation K26
0 
Duodenal ulcer  acute with haemorrhage 
K26
1 
Duodenal ulcer  acute with perforation 
K26
2 
Duodenal ulcer  acute with both haemorrhage 
and perforation K26
3 
Duodenal ulcer  acute without haemorrhage or 
perforation K26
4 
Duodenal ulcer  chronic or unspecified with 
haemorrhage K26
5 
Duodenal ulcer  chronic or unspecified with 
perforation K26
6 
Chronic or unspecified with both haemorrhage 
and perforatio K26
7 
Duodenal ulcer  chronic without haemorrhage or 
perforation K26
9 
Unspec as acute or chronic w out haemorrhage 
or perforation K27
0 
Peptic ulcer  acute with haemorrhage 
K27
1 
Peptic ulcer  acute with perforation 
K27
2 
Peptic ulcer  acute with both haemorrhage and 
perforation K27
3 
Peptic ulcer  acute without haemorrhage or 
perforation K27
4 
Peptic ulcer  chronic or unspecified with 
haemorrhage K27
5 
Peptic ulcer  chronic or unspecified with 
perforation K27
6 
Chronic or unspecified with both haemorrhage 
and perforatio K27
7 
Peptic ulcer  chronic without haemorrhage or 
perforation K27
9 
Unspec as acute or chronic w out haemorrhage 
or perforation K28
0 
Gastrojejunal ulcer  acute with haemorrhage 
K28
1 
Gastrojejunal ulcer  acute with perforation 
K28
2 
Acute with both haemorrhage and perforation 
K28
3 
Acute without haemorrhage or perforation 
K28
4 
Gastrojejunal ulcer  chronic or unspecified with 
haemorrhag K28
5 
Gastrojejunal ulcer  chronic or unspecified with 
perforatio K28
6 
Chronic or unspecified with both haemorrhage 
and perforatio K28
7 
Chronic without haemorrhage or perforation 
K28
9 
Unspec as acute or chronic w out haemorrhage 
or perforation K70
2 
Alcoholic fibrosis and sclerosis of liver 
K70
3 
Alcoholic cirrhosis of liver 
K73
1 
Chronic lobular hepatitis  not elsewhere classified 
K73
2 
Chronic active hepatitis  not elsewhere classified 
K73
8 
Other chronic hepatitis  not elsewhere classified 
K73
9 
Chronic hepatitis  unspecified 
K71
7 
Toxic liver disease with fibrosis and cirrhosis of 
liver K74
0 
Hepatic fibrosis 
K74
2 
Hepatic fibrosis with hepatic sclerosis 
K74
6 
Other and unspecified cirrhosis of liver 
K74
3 
Primary biliary cirrhosis 
K74
4 
Secondary biliary cirrhosis 
K74
5 
Biliary cirrhosis  unspecified 
E10
9 
Insulin-dependent diabetes mellitus without 
complications E11
9 
Non-insulin-depend diabetes mellitus without 
complication E13
9 
Other specified diabetes mellitus without 
complications 
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E14
9 
Unspecified diabetes mellitus without 
complications E10
1 
Insulin-dependent diabetes mellitus with 
ketoacidosis E11
1 
Non-insulin-dependent diabetes mellitus with 
ketoacidosis E13
1 
Other specified diabetes mellitus with 
ketoacidosis E14
1 
Unspecified diabetes mellitus with ketoacidosis 
E10
5 
Insulin-dependent diabetes mellitus with periph 
circ comps E11
5 
Non-insulin-depend diabetes mellitus with periph 
circ comp E13
5 
Other specified diabetes mellitus with periph circ 
comps E14
5 
Unspecified diabetes mellitus with periph 
circulatory comps E10
2 
Insulin-dependent diabetes mellitus with renal 
complication E11
2 
Non-insulin-dependent diabetes mellitus with 
renal comps E13
2 
Other specified diabetes mellitus with renal 
complications E14
2 
Unspecified diabetes mellitus with renal 
complications E10
3 
Insulin-dependent diabetes mellitus with 
ophthalmic comps E11
3 
Non-insulin-dependent diabetes mellitus with 
ophthalm comps E13
3 
Other specified diabetes mellitus with 
ophthalmic comps E14
3 
Unspecified diabetes mellitus with ophthalmic 
complications E10
4 
Insulin-dependent diabetes mellitus with 
neurological comps E11
4 
Non-insulin-dependent diabetes mellitus with 
neuro comps E13
4 
Other specified diabetes mellitus with 
neurological comps E14
4 
Unspecified diabetes mellitus with neurological 
comps G81
0 
Flaccid hemiplegia 
G81
1 
Spastic hemiplegia 
G81
9 
Hemiplegia  unspecified 
G04
1 
Tropical spastic paraplegia 
G82
0 
Flaccid paraplegia 
G82
1 
Spastic paraplegia 
G82
2 
Paraplegia  unspecified 
N03
1 
Focal and segmental glomerular lesions 
N03
2 
Diffuse membranous glomerulonephritis 
N03
3 
Diffuse mesangial proliferative 
glomerulonephritis N03
4 
Diffuse endocapillary proliferative 
glomerulonephritis N03
5 
Diffuse mesangiocapillary glomerulonephritis 
N03
6 
Chronic nephritic syndrome  dense deposit 
disease N03
7 
Diffuse concentric glomerulonephritis 
N03
8 
Chronic nephritic syndrome  other 
N03
9 
Chronic nephritic syndrome  unspecified 
N05
2 
Diffuse membranous glomerulonephritis 
N05
3 
Diffuse mesangial proliferative 
glomerulonephritis N05
4 
Diffuse endocapillary proliferative 
glomerulonephritis N05
5 
Diffuse mesangiocapillary glomerulonephritis 
N05
6 
Unspecified nephritic syndrome  dense deposit 
disease N07
2 
Diffuse membranous glomerulonephritis 
N07
3 
Diffuse mesangial proliferative 
glomerulonephritis N07
4 
Diffuse endocapillary proliferative 
glomerulonephritis N01
0 
Minor glomerular abnormality 
N01
1 
Focal and segmental glomerular lesions 
N01
2 
Diffuse membranous glomerulonephritis 
N01
3 
Diffuse mesangial proliferative 
glomerulonephritis N01
4 
Diffuse endocapillary proliferative 
glomerulonephritis N01
5 
Diffuse mesangiocapillary glomerulonephritis 
N01
6 
Dense deposit disease 
N01
7 
Diffuse concentric glomerulonephritis 
N01
8 
Rapidly progressive nephritic syndrome  other 
N01
9 
Rapidly progressive nephritic syndrome  
unspecified N18
0 
End-stage renal disease 
N18
8 
Other chronic renal failure 
N18
9 
Chronic renal failure  unspecified 
N19
X 
Unspecified renal failure 
N25
0 
Renal osteodystrophy 
N25
1 
Nephrogenic diabetes insipidus 
N25
8 
Other disorders resulting from impaired renal 
tubular funct N25
9 
Disorder result from impaired renal tubular 
function unspec C00
0 
Malignant neoplasm of external upper lip 
C00
1 
Malignant neoplasm of external lower lip 
C00
2 
Malignant neoplasm of external lip  unspecified 
C00
3 
Malignant neoplasm of upper lip  inner aspect 
C00
4 
Malignant neoplasm of lower lip  inner aspect 
C00
5 
Malignant neoplasm of lip  unspecified  inner 
aspect C00
6 
Malignant neoplasm of commissure of lip 
C00
8 
Malignant neoplasm of overlapping lesion of lip 
C00
9 
Malignant neoplasm of lip  unspecified 
C01
X 
Malignant neoplasm of base of tongue 
C02
0 
Malignant neoplasm of dorsal surface tongue 
C02
1 
Malignant neoplasm of border of tongue 
C02
2 
Malignant neoplasm of ventral surface of tongue 
C02
3 
Malignant neo of anterior two-thirds of tongue  
part uns C02
4 
Malignant neoplasm of lingual tonsil 
C02
8 
Malignant neoplasm of overlapping lesion of 
tongue C02
9 
Malignant neoplasm of tongue  unspecified 
C03
0 
Malignant neoplasm of upper gum 
C03
1 
Malignant neoplasm of lower gum 
C03
9 
Malignant neoplasm of gum unspecified 
C04
0 
Malignant neoplasm of floor of anterior floor of 
mouth C04
1 
Malignant neoplasm of lateral floor of mouth 
C04
8 
Malignant neoplasm  overlapping lesion of floor 
of mouth C04
9 
Malignant neoplasm of floor of mouth  floor of 
mouth  unspe C05
0 
Malignant neoplasm of hard palate 
C05
1 
Malignant neoplasm of soft palate 
C05
2 
Malignant neoplasm of uvula 
C05
8 
Malignant neoplasm  overlapping lesion of palate 
C05
9 
Malignant neoplasm of palate  unspecified 
C06
0 
Malignant neoplasm cheek mucosa 
C06
1 
Malignant neoplasm of vestibule of mouth 
C06
2 
Malignant neoplasm of retromolar area 
C06
8 
Malignant neoplasm  overlap les of oth & unsp 
part of mouth C06
9 
Malignant neoplasm of part of mouth  
unspecified C07
X 
Malignant neoplasm of parotid gland 
C08
0 
Malignant neoplasm of submandibular gland 
C08
1 
Malignant neoplasm of sublingual gland 
C08
8 
Malignant neoplasm  overlapping lesion of major 
saliv gland C08
9 
Malignant neoplasm of major salivary gland  
unspecified C09
0 
Malignant neoplasm tonsillar fossa 
C09
1 
Malig neo of tonsillar pillar (anterior)(posterior) 
C09
8 
Malignant neoplasm of overlapping lesion of 
tonsil C09
9 
Malignant neoplasm of tonsil unspecified 
C10
0 
Malignant neoplasm of vallecula 
C10
1 
Malignant neoplasm of anterior surface of 
epiglottis C10
2 
Malignant neoplasm of lateral wall of oropharynx 
C10
3 
Malignant neoplasm of posterior wall of 
oropharynx C10
4 
Malignant neoplasm of branchial cleft 
C10
8 
Malignant neoplasm overlapping lesion of 
oropharynx C10
9 
Malignant neoplasm of oropharynx unspecified 
C11
0 
Malignant neoplasm of superior wall of 
nasopharynx C11
1 
Malignant neoplasm of posterior wall of 
nasopharynx C11
2 
Malignant neoplasm of lateral wall of 
nasopharynx C11
3 
Malignant neoplasm of anterior wall of 
nasopharynx C11
8 
Malignant neoplasm overlapping lesion of 
nasopharynx C11
9 
Malignant neoplasm of nasopharynx unspecified 
C12
X 
Malignant neoplasm of pyriform sinus 
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C13
0 
Malignant neoplasm of hypopharynx  postcricoid 
region C13
1 
Malig neoplasm aryepiglottic fold  
hypopharyngeal aspect C13
2 
Malignant neoplasm posterior wall of 
hypopharynx C13
8 
Malignant neoplasm overlapping lesion of 
hypopharynx C13
9 
Malignant neoplasm of hypopharynx unspecified 
C14
0 
Malignant neoplasm of pharynx  unsp 
C14
2 
Malignant neoplasm of Waldeyer s ring 
C14
8 
Malig neo  overlapping lesion of lip  oral cavity & 
pharynx C17
0 
Malignant neoplasm of small intestine  
duodenum C17
1 
Malignant neoplasm of small intestine  jejunum 
C17
2 
Malignant neoplasm of small intestine  ileum 
C17
3 
Malignant neoplasm of small intestine  Meckel s 
diverticulu C17
8 
Malignant neoplasm overlapping lesion of small 
intestine C17
9 
Malignant neoplasm of small intestine  
unspecified C18
0 
Malignant neoplasm of caecum 
C18
1 
Malignant neoplasm of appendix 
C18
2 
Malignant neoplasm of ascending colon 
C18
3 
Malignant neoplasm of hepatic flexure 
C18
4 
Malignant neoplasm of transverse colon 
C18
5 
Malignant neoplasm of splenic flexure 
C18
6 
Malignant neoplasm of descending colon 
C18
7 
Malignant neoplasm of sigmoid colon 
C18
8 
Malignant neoplasm overlapping lesion of colon 
C18
9 
Malignant neoplasm of colon  unspecified 
C19
X 
Malignant neoplasm of rectosigmoid junction 
C20
X 
Malignant neoplasm of rectum 
C21
0 
Malignant neoplasm of anus  unspecified 
C21
1 
Malignant neoplasm of anal canal 
C21
2 
Malignant neoplasm of cloacogenic zone 
C21
8 
Malig neo  overlapping lesion of rectum  anus 
and anal cana C22
0 
Malignant neoplasm  liver cell carcinoma 
C22
1 
Malignant neoplasm  intrahep bile duct 
carcinoma C22
2 
Malignant neoplasm  hepatoblastoma 
C22
3 
Malignant neoplasm  angiosarcoma of liver 
C22
4 
Malignant neoplasm  other sarcomas of liver 
C22
7 
Malignant neoplasm  oth spec carcinomas of liver 
C22
9 
Malignant neoplasm  liver  unspecified 
C23
X 
Malignant neoplasm of gallbladder 
C24
0 
Malignant neoplasm of extrahepatic bile duct 
C24
1 
Malignant neoplasm of Ampulla of Vater 
C24
8 
Malignant neoplasm overlapping lesion of biliary 
tract C24
9 
Malignant neoplasm of biliary tract  unspecified 
C25
0 
Malignant neoplasm of head of pancreas 
C25
1 
Malignant neoplasm of body of pancreas 
C25
2 
Malignant neoplasm of tail of pancreas 
C25
3 
Malignant neoplasm of pancreatic duct 
C25
4 
Malignant neoplasm of endocrine pancreas 
C25
7 
Malignant neoplasm of other parts of pancreas 
C25
8 
Malignant neoplasm  overlapping lesion of 
pancreas C25
9 
Malignant neoplasm of pancreas  unspecified 
C26
0 
Malignant neoplasm of intestinal tract  part unsp 
C26
1 
Malignant neoplasm of spleen 
C26
8 
Malignant neoplasm  overlapping lesion of 
digestive system C26
9 
Malignant neoplasm of ill-def sites within 
digestive system C30
0 
Malignant neoplasm of nasal cavity 
C30
1 
Malignant neoplasm of middle ear 
C31
0 
Malignant neoplasm of maxillary sinus 
C31
1 
Malignant neoplasm of ethmoidal sinus 
C31
2 
Malignant neoplasm of frontal sinus 
C31
3 
Malignant neoplasm of sphenoidal sinus 
C31
8 
Malignant neoplasm  overlapping lesion 
accessory sinuses C31
9 
Malignant neoplasm of accessory sinus  unsp 
C32
0 
Malignant neoplasm of glottis 
C32
1 
Malignant neoplasm of supraglottis 
C32
2 
Malignant neoplasm of subglottis 
C32
3 
Malignant neoplasm of laryngeal cartilage 
C32
8 
Malignant neoplasm  overlapping lesion of larynx 
C32
9 
Malignant neoplasm of larynx  unspecified 
C33
X 
Malignant neoplasm of trachea 
C34
0 
Malignant neoplasm of main bronchus 
C34
1 
Malignant neoplasm of upper lobe  bronchus or 
lung C34
2 
Malignant neoplasm of middle lobe  bronchus or 
lung C34
3 
Malignant neoplasm of lower lobe  bronchus or 
lung C34
8 
Malignant neoplasm of overlap les of bronchus & 
lung C34
9 
Malignant neoplasm of bronchus or lung  unspec 
C37
X 
Malignant neoplasm of thymus 
C38
0 
Malignant neoplasm of heart  mediastinum & 
pleura  heart C38
1 
Malignant neoplasm of anterior mediastinum 
C38
2 
Malignant neoplasm of posterior mediastinum 
C38
3 
Malig neo heart  mediastinum & pleura 
mediastinum part unsp C38
4 
Malignant neoplasm of pleura 
C38
8 
Malig neo  overlapping lesion of heart  
mediastinum & pleur C39
0 
Malignant neoplasm of upper respiratory tract  
part unsp C39
8 
Malignant neoplasm  overlap lesion of resp & 
intrathor orgs C39
9 
Malignant neoplasm of ill-def sites within the 
resp sys C40
0 
Malignant neoplasm of scapula and long bones of 
upper limb C40
1 
Malignant neoplasm of short bones of upper limb 
C40
2 
Malignant neoplasm of long bones of lower limb 
C40
3 
Malignant neoplasm of short bones of lower limb 
C40
8 
Malignant neoplasm  overlap les bone and artic 
cart of limb C40
9 
Malignant neoplasm of bone and artic cart of 
limb  unsp C41
0 
Malignant neoplasm of bones of skull and face 
C41
1 
Malignant neoplasm of mandible 
C41
2 
Malignant neoplasm of vertebral column 
C41
3 
Malignant neoplasm of ribs  sternum and clavicle 
C41
4 
Malignant neoplasm of sacrum and coccyx 
C41
8 
Malignant neoplasm  overlap lesion bon and 
articular cart C41
9 
Malignant neoplasm of bone and articular 
cartilage  unsp C43
0 
Malignant melanoma of lip 
C43
1 
Malignant melanoma of eyelid  including canthus 
C43
2 
Malignant melanoma of ear and ext auricular 
canal C43
3 
Malignant melanoma of other and unspecified 
parts of face C43
4 
Malignant melanoma of scalp and neck 
C43
5 
Malignant melanoma of trunk 
C43
6 
Malignant melanoma of upper limb  including 
shoulder C43
7 
Malignant melanoma of lower limb  including hip 
C43
8 
Malignant melanoma of skin 
C43
9 
Malignant melanoma of skin  unsp 
C45
0 
Mesothelioma of pleura 
C45
1 
Mesothelioma of peritoneum 
C45
2 
Mesothelioma of pericardium 
C45
7 
Mesothelioma of other sites 
C45
9 
Mesothelioma  unspecified 
C46
0 
Kaposi s sarcoma of skin 
C46
1 
Kaposi s sarcoma of soft tissue 
C46
2 
Kaposi s sarcoma of palate 
C46
3 
Kaposi s sarcoma of lymph nodes 
C46
7 
Kaposi s sarcoma of other sites 
C46
8 
Kaposi s sarcoma of multiple organs 
C46
9 
Kaposi s sarcoma  unspecified 
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C47
0 
Malignant neoplasm of peripheral nerve of head  
face & neck C47
1 
Malignant neoplasm of peripheral nerve upp limb 
incl should C47
2 
Malignant neoplasm of peripheral nerve of low 
limb  incl hi C47
3 
Malignant neoplasm of peripheral nerve of 
thorax C47
4 
Malignant neoplasm of peripheral nerve of 
abdomen C47
5 
Malignant neoplasm of peripheral nerve of pelvis 
C47
6 
Malignant neoplasm of peripheral nerve of trunk  
unspec C47
8 
Malignant neoplasm overlap lesion periph nerve 
& auton ns C47
9 
Malignant neoplasm periph nerve & autonomic 
ns  unspec C48
0 
Malignant neoplasm of retroperitoneum 
C48
1 
Malignant neoplasm of spec parts of peritoneum 
C48
2 
Malignant neoplasm of peritoneum  unsp 
C48
8 
Malignant neoplasm of overlap lesion retroperit 
& peritoneu C49
0 
Malignant neoplasm of conn and soft tiss head  
face & neck C49
1 
Malignant neoplasm of conn and soft tiss upp 
limb inc shoul C49
2 
Malignant neoplasm of conn and soft tiss lower 
limb inc hip C49
3 
Malignant neoplasm of conn and soft tiss of 
thorax C49
4 
Malignant neoplasm of conn and soft tiss of 
abdomen C49
5 
Malignant neoplasm of conn and soft tiss of 
pelvis C49
6 
Malignant neoplasm of conn and soft tiss of trunk  
unsp C49
8 
Malignant neoplasm  overlap lesion connective & 
soft tiss C49
9 
Malignant neoplasm of connective and soft tissue  
unsp C50
0 
Malignant neoplasm of nipple and areola 
C50
1 
Malignant neoplasm of central portion of breast 
C50
2 
Malignant neoplasm of upper-inner quadrant of 
breast C50
3 
Malignant neoplasm of lower-inner quadrant of 
breast C50
4 
Malignant neoplasm of upper-outer quadrant of 
breast C50
5 
Malignant neoplasm of lower-outer quadrant of 
breast C50
6 
Malignant neoplasm of axillary tail of breast 
C50
8 
Malignant neoplasm  overlapping lesion of breast 
C50
9 
Malignant neoplasm of breast  unspecified 
C51
0 
Malignant neoplasm of labium majus 
C51
1 
Malignant neoplasm of labium minus 
C51
2 
Malignant neoplasm of clitoris 
C51
8 
Malignant neoplasm of overlapping lesion of 
vulva C51
9 
Malignant neoplasm of vulva  unspecified 
C52
X 
Malignant neoplasm of vagina 
C53
0 
Malignant neoplasm of endocervix 
C53
1 
Malignant neoplasm of exocervix 
C53
8 
Malignant neoplasm  overlapping lesion of cervix 
uteri C53
9 
Malignant neoplasm of cervix uteri  unsp 
C54
0 
Malignant neoplasm of isthmus uteri 
C54
1 
Malignant neoplasm of endometrium 
C54
2 
Malignant neoplasm of myometrium 
C54
3 
Malignant neoplasm of fundus uteri 
C54
8 
Malignant neoplasm overlapping lesion of corpus 
uteri C54
9 
Malignant neoplasm of corpus uteri  unsp 
C55
X 
Malignant neoplasm of uterus  part unspecified 
C56
X 
Malignant neoplasm of ovary 
C57
0 
Malignant neoplasm of fallopian tube 
C57
1 
Malignant neoplasm of broad ligament 
C57
2 
Malignant neoplasm of round ligament 
C57
3 
Malignant neoplasm of parametrium 
C57
4 
Malignant neoplasm of uterine adnexa  unsp 
C57
7 
Malignant neoplasm of other specified female 
genital organs C57
8 
Malignant neoplasm  overlapping lesion female 
genital organ C57
9 
Malignant neoplasm of female genital organ  
unspecified C58
X 
Malignant neoplasm of placenta 
C60
0 
Malignant neoplasm of prepuce 
C60
1 
Malignant neoplasm of glans penis 
C60
2 
Malignant neoplasm of body of penis 
C60
8 
Malignant neoplasm  overlapping lesion of penis 
C60
9 
Malignant neoplasm of penis  unspecified 
C61
X 
Malignant neoplasm of prostate 
C62
0 
Malignant neoplasm of undescended testis 
C62
1 
Malignant neoplasm of descended testis 
C62
9 
Malignant neoplasm of testis  unspecified 
C63
0 
Malignant neoplasm of epididymis 
C63
1 
Malignant neoplasm of spermatic cord 
C63
2 
Malignant neoplasm of scrotum 
C63
7 
Malignant neoplasm of other specified male 
genital orgs C63
8 
Malignant neoplasm  overlapping lesion male 
genital orgs C63
9 
Malignant neoplasm of male genital organ  
unspecified C64
X 
Malignant neoplasm of kidney  except renal 
pelvis C65
X 
Malignant neoplasm of renal pelvis 
C66
X 
Malignant neoplasm of ureter 
C67
0 
Malignant neoplasm of trigone of bladder 
C67
1 
Malignant neoplasm of dome of bladder 
C67
2 
Malignant neoplasm of lateral wall of bladder 
C67
3 
Malignant neoplasm of anterior wall of bladder 
C67
4 
Malignant neoplasm of posterior wall of bladder 
C67
5 
Malignant neoplasm of bladder neck 
C67
6 
Malignant neoplasm of ureteric orifice 
C67
7 
Malignant neoplasm of urachus 
C67
8 
Malignant neoplasm  overlapping lesion of 
bladder C67
9 
Malignant neoplasm of bladder  unspecified 
C68
0 
Malignant neoplasm of urethra 
C68
1 
Malignant neoplasm of paraurethral gland 
C68
8 
Malignant neoplasm of overlapping lesion urinary 
organs C68
9 
Malignant neoplasm of urinary organ  unspecified 
C69
0 
Malignant neoplasm of conjunctiva 
C69
1 
Malignant neoplasm of cornea 
C69
2 
Malignant neoplasm of retina 
C69
3 
Malignant neoplasm of choroid 
C69
4 
Malignant neoplasm of ciliary body 
C69
5 
Malignant neoplasm of lacrimal gland and duct 
C69
6 
Malignant neoplasm of orbit 
C69
8 
Malignant neoplasm  overlapping lesion eye and 
adnexa C69
9 
Malignant neoplasm of eye  unspecified 
C70
0 
Malignant neoplasm of  cerebral meninges 
C70
1 
Malignant neoplasm of spinal meninges 
C70
9 
Malignant neoplasm of meninges  unspecified 
C71
0 
Malignant neoplasm of cerebrum  except lobes & 
ventricles C71
1 
Malignant neoplasm of cerebrum  frontal lobe 
C71
2 
Malignant neoplasm of cerebrum  temporal lobe 
C71
3 
Malignant neoplasm of cerebrum  parietal lobe 
C71
4 
Malignant neoplasm of cerebrum  occipital lobe 
C71
5 
Malignant neoplasm of cerebrum  cerebral 
ventricle C71
6 
Malignant neoplasm of cerebrum  cerebellum 
C71
7 
Malignant neoplasm of cerebrum  brain stem 
C71
8 
Malignant neoplasm of cerebrum  overlapping 
lesion of brain C71
9 
Malignant neoplasm of cerebrum  brain  
unspecified C72
0 
Malignant neoplasm of spinal cord 
C72
1 
Malignant neoplasm of cauda equina 
C72
2 
Malignant neoplasm of Olfactory nerve 
C72
3 
Malignant neoplasm of Optic nerve 
C72
4 
Malignant neoplasm of Acoustic nerve 
C72
5 
Malignant neoplasm of other and unspecified 
cranial nerves C72
8 
Malignant neoplasm  overlapping lesion 
brain&other part CNS C72
9 
Malignant neoplasm of Central Nervous System  
unspecified 
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C73
X 
Malignant neoplasm of thyroid gland 
C74
0 
Malignant neoplasm of cortex of adrenal gland 
C74
1 
Malignant neoplasm of medulla of adrenal gland 
C74
9 
Malignant neoplasm of adrenal gland  unsp 
C75
0 
Malignant neoplasm of parathyroid gland 
C75
1 
Malignant neoplasm of pituitary gland 
C75
2 
Malignant neoplasm of craniopharyngeal duct 
C75
3 
Malignant neoplasm of pineal gland 
C75
4 
Malignant neoplasm of carotid body 
C75
5 
Malignant neoplasm of aortic body and other 
paraganglia C75
8 
Malignant neoplasm  pluriglandular involvment  
unspecified C75
9 
Malignant neoplasm of endocrine gland  
unspecified C76
0 
Malignant neoplasm of head  face & neck 
C76
1 
Malignant neoplasm of thorax 
C76
2 
Malignant neoplasm of abdomen 
C76
3 
Malignant neoplasm of pelvis 
C76
4 
Malignant neoplasm of upper limb 
C76
5 
Malignant neoplasm of lower limb 
C76
7 
Malignant neoplasm of other ill-defined sites 
C76
8 
Malignant neoplasm  overlap lesion oth & ill-
defined sites C81
0 
Hodgkin s disease  lymphocytic predominance 
C81
1 
Hodgkin s disease  nodular sclerosis 
C81
2 
Hodgkin s disease  mixed cellularity 
C81
3 
Hodgkin s disease  lymphocytic depletion 
C81
7 
Hodgkin s disease  other Hodgkin s disease 
C81
9 
Hodgkin s disease  Hodgkin s disease  unspecified 
C82
0 
Follicular non-Hodgkin s small cleaved cell 
lymphoma C82
1 
Follicular non-Hodg mixed sml cleavd & lge cell 
lymphoma C82
2 
Follicular non-Hodgkin s large cell lymphoma 
C82
7 
Follicular non-Hodgkin s other types of 
lymphoma C82
9 
Follicular non-Hodgkin s unspecified lymphoma 
C83
0 
Diffuse non-Hodgkin s small cell 
(diffuse)lymphoma C83
1 
Diffuse non-Hodgkin s small cleaved cell (diffuse) 
lymphoma C83
2 
Diffuse non-Hodgkin mixed sml & lge cell 
(diffuse) lymphoma C83
3 
Diffuse non-Hodgkin s large cell (diffuse) 
lymphoma C83
4 
Diffuse non-Hodgkin s immunoblastic (diffuse) 
lymphoma C83
5 
Diffuse non-Hodgkin s lymphoblastic (diffuse) 
lymphoma C83
6 
Diffuse non-Hodgkin s lymphoma 
undifferentiated (diffuse) C83
7 
Diffuse non-Hodgkin s lymphoma  Burkitt s 
tumour C83
8 
Other types of diffuse non-Hodgkin s lymphoma 
C83
9 
Diffuse non-Hodgkin s lymphoma  unspecified 
C84
0 
Peripheral and cutaneous T-cell lymphomas  
mycosis fungoide C84
1 
Peripheral and cutaneous T-cell lymphomas  
Sezary s disease C84
2 
Peripheral and cutaneous T-cell lymphomas  T-
zone lymphoma C84
3 
Periph & cutan T-cell lymphomas  
lymphoepithelioid lymphoma C84
4 
Periph & cutan T-cell lymphomas  peripheral T-
cell lymphoma C84
5 
Periph & cutan T-cell lymphomas  oth & unsp T-
cell lymphoma C85
0 
Oth & unspec types of non-Hodgkin s lymphoma  
lymphosarcoma C85
1 
Oth & unsp types non-Hodgkin s B-cell lymphoma  
unsp C85
7 
Oth specified types of non-Hodgkin s lymphoma 
C85
9 
Non-Hodgkin s lymphoma  unspecified type 
C88
3 
Malignant immunoproliferative small intestinal 
disease C88
7 
Other malignant immunoproliferative diseases 
C88
9 
Malignant immunoproliferative disease  
unspecified C90
0 
Multiple myeloma 
C90
1 
Plasma cell leukaemia 
C91
0 
Acute lymphoblastic leukaemia 
C91
1 
Chronic lymphocytic leukaemia 
C91
2 
Subacute lymphocytic leukaemia 
C91
3 
Prolymphocytic leukaemia 
C91
4 
Hairy-cell leukaemia 
C91
5 
Adult T-cell leukaemia 
C91
7 
Other lymphoid leukaemia 
C91
9 
Lymphoid leukaemia  unspecified 
C92
0 
Acute myeloid leukaemia 
C92
1 
Chronic myeloid leukaemia 
C92
2 
Subacute myeloid leukaemia 
C92
3 
Myeloid sarcoma 
C92
4 
Acute promyelocytic leukaemia 
C92
5 
Acute myelomonocytic leukaemia 
C92
7 
Other myeloid leukaemia 
C92
9 
Myeloid leukaemia  unspecified 
C93
0 
Acute monocytic leukaemia 
C93
1 
Chronic monocytic leukaemia 
C93
2 
Subacute monocytic leukaemia 
C93
7 
Other monocytic leukaemia 
C93
9 
Monocytic leukaemia  unspecified 
C94
0 
Acute erythraemia & erythroleukaemia 
C94
1 
Chronic erythraemia 
C94
2 
Acute megakaryoblastic leukaemia 
C94
3 
Mast cell leukaemia 
C94
5 
Acute myelofibrosis 
C94
7 
Other specified leukaemias 
C95
0 
Acute leukaemia of unsp cell type 
C95
1 
Chronic leukaemia unsp cell type 
C95
2 
Subacute leukaemia unsp cell type 
C95
7 
Other leukaemia unspecified cell type 
C95
9 
Leukaemia  unspecified 
C96
0 
Letterer-Siwe disease 
C96
1 
Malignant histiocytosis 
C96
2 
Malignant mast cell tumour 
C96
3 
True histiocyt lymphoma 
C96
7 
Oth spec malig neop lymphoid h poietic & related 
tissue C96
9 
Malig neop lymphoid haematopoietic and related 
tissue unspe C77
0 
Sec & uns malig neoplasm of lymph nodes of 
head  face & nec C77
1 
Sec & uns malignant neoplasm of intrathoracic 
lymph nodes C77
2 
Sec & uns malignant neoplasm of intra-
abdominal lymph nodes C77
3 
Sec & uns malig neoplasm of axillary & upp limb 
lymph nodes C77
4 
Sec & uns malig neoplasm of inguinal & low limb 
lymph nodes C77
5 
Sec & uns malignant neoplasm of intrapelvic 
lymph nodes C77
8 
Sec & uns malig neoplasm of lymph nodes of 
multiple regions C77
9 
Sec & uns malignant neoplasm of lymph node  
unspecified C78
0 
Secondary malignant neoplasm of lung 
C78
1 
Secondary malignant neoplasm of mediastinum 
C78
2 
Secondary malignant neoplasm of pleura 
C78
3 
Secondary malignant neoplasm of oth & unsp 
respiratory orgs C78
4 
Secondary malignant neoplasm of small intestine 
C78
5 
Secondary malignant neoplasm of large intest & 
rectum C78
6 
Secondary malignant neoplasm of 
retroperitoneum & peritoneu C78
7 
Secondary malignant neoplasm of liver 
C78
8 
Secondary malignant neoplasm of other & unsp 
digestive orgs C79
0 
Secondary malignant neoplasm of kidney & renal 
pelvis C79
1 
Secondary malignant neoplasm of oth & uns 
urinary organs C79
2 
Secondary malignant neoplasm of skin 
C79
3 
Secondary malignant neoplasm of brain & 
cerebral meninges C79
4 
Secondary malignant neoplasm of oth & unsp 
parts nervous sy C79
5 
Secondary malignant neoplasm of bone and bone 
marrow C79
6 
Secondary malignant neoplasm of ovary 
C79
7 
Secondary malignant neoplasm of adrenal gland 
C79
8 
Secondary malignant neoplasm of other specified 
sites 
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C80
X 
Malignant neoplasm without specification of site 
K72
9 
Hepatic failure  unspecified 
K76
6 
Portal hypertension 
K76
7 
Hepatorenal syndrome 
K72
1 
Chronic hepatic failure 
B20
0 
HIV disease resulting in mycobacterial infection 
B20
1 
HIV disease resulting in other bacterial infections 
B20
2 
HIV disease resulting in cytomegaloviral disease 
B20
3 
HIV disease resulting in other viral infections 
B20
4 
HIV disease resulting in candidiasis 
B20
5 
HIV disease resulting in other mycoses 
B20
6 
HIV disease resulting in Pneumocystis carinii 
pneumonia B20
7 
HIV disease resulting in multiple infections 
B20
8 
HIV dis resulting in oth infectious and parasitic dis 
B20
9 
HIV disease resulting in unspec infectious or 
parasitic dis B21
0 
HIV disease resulting in Kaposi s sarcoma 
B21
1 
HIV disease resulting in Burkitt s lymphoma 
B21
2 
HIV dis resulting oth types of non-Hodgkin s 
lymphoma B21
3 
HIV dis result oth mal neo lymphoid 
haematopoietic rel tis B21
7 
HIV disease resulting in multiple malignant 
neoplasms B21
8 
HIV disease resulting in other malignant 
neoplasms B21
9 
HIV disease resulting in unspecified malignant 
neoplasm B22
0 
HIV disease resulting in encephalopathy 
B22
1 
HIV disease resulting in lymphoid interstitial 
pneumonitis B22
2 
HIV disease resulting in wasting syndrome 
B22
7 
HIV dis resulting in multiple diseases classif 
elsewhere B23
0 
Acute HIV infection syndrome 
B23
1 
HIV dis result (persistent) generalized 
lymphadenopathy B23
2 
HIV dis result haematologic / immunologic 
abnorm NEC B23
8 
HIV disease resulting in other specified conditions 
B24
X 
Unspecified human immunodefiency virus [HIV] 
disease 
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Appendix 7.7 describe the OG cancer related surgical procedure OPCS-4 codes used in this 
study 
OPCS-4 codes Code description    
G011 Oesophagogastrectomy and anastomosis of oesophagus to stomach  
G012 Oesophagogastrectomy and anastomosis of oesophagus to transposed jejunum 
G013 Oesophagogastrectomy and anastomosis of oesophagus to jejunum NEC 
G018 Other specified excision of oesophagus and stomach     
G019 Unspecified excision of oesophagus and stomach     
G021 Total oesophagectomy and anastomosis of pharynx to stomach   
G022 Total oesophagectomy and interposition of microvascularly attached jejunum 
G023 Total oesophagectomy and interposition of jejunum NEC     
G024 Total oesophagectomy and interposition of microvascularly attached colon 
G025 Total oesophagectomy and interposition of colon NEC     
G028 Other specified total excision of oesophagus     
G029 Unspecified total excision of oesophagus       
G031 Partial oesophagectomy and end to end anastomosis of oesophagus   
G032 Partial oesophagectomy and interposition of microvascularly attached jejunum 
G035 Partial oesophagectomy and interposition of microvascularly attached colon 
G036 Partial oesophagectomy and interposition of colon NEC     
G038 Other specified partial excision of oesophagus     
G039 Unspecified partial excision of oesophagus       
G271 Total gastrectomy and excision of surrounding tissue    
G272 Total gastrectomy and anastomosis of oesophagus to duodenum   
G273 Total gastrectomy and interposition of jejunum     
G274 Total gastrectomy and anastomosis of oesophagus to transposed jejunum 
G275 Total gastrectomy and anastomosis of oesophagus to jejunum NEC   
G278 Other specified total excision of stomach       
G281 Partial gastrectomy and anastomosis of stomach to duodenum   
G282 Partial gastrectomy and anastomosis of stomach to transposed jejunum   
G283 Partial gastrectomy and anastomosis of stomach to jejunum NEC   
G288 Other specified partial excision of stomach       
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Appendix 7.8 Coded diagnostic profile at 
the first diagnostic gastroscopy 
procedure 
 OG cancer C15, C16 ICD-10 codes 
C150 Malignant neoplasm of cervical part of oesophagus 
C151 Malignant neoplasm of thoracic part of oesophagus 
C152 Malignant neo of abdominal part of oesophagus 
C153 Malignant neoplasm of upper third of oesophagus 
C154 Malignant neoplasm of middle third of oesophagus 
C155 Malignant neoplasm of lower third of oesophagus 
C158 Malignant neoplasm overlapping lesion of 
oesophagus C159 Malignant neoplasm of oesophagus unspecified 
C160 Malignant neoplasm of cardia of stomach 
C161 Malignant neoplasm of fundus of stomach 
C162 Malignant neoplasm of body of stomach 
C163 Malignant neoplasm of pyloric antrum 
C164 Malignant neoplasm of pylorus 
C165 Malignant neoplasm of lesser curvature of stomach, 
unsp C166 Malignant neoplasm of greater curvature of stomach, 
unsp C168 Malignant neoplasm overlapping lesion of stomach 
C169 Malignant neoplasm of stomach, unspecified 
 Major acid-peptic lesions 
K221 Ulcer of oesophagus 
K222 Oesophageal obstruction 
K250 Gastric ulcer, acute with haemorrhage 
K251 Gastric ulcer, acute with perforation 
K252 Gastric ulcer, acute with both haemorrhage and 
perforation K253 Gastric ulcer, acute without haemorrhage or 
perforation K254 Gastric ulcer, chronic or unspecified with 
haemorrhage K255 Gastric ulcer, chronic or unspecified with perforation 
K257 Gastric ulcer, chronic without haemorrhage or 
perforation K260 Duodenal ulcer, acute with haemorrhage 
K261 Duodenal ulcer, acute with perforation 
K262 Duodenal ulcer, acute with both haemorrhage and 
perforation K263 Duodenal ulcer, acute without haemorrhage or 
perforation K264 Duodenal ulcer, chronic or unspecified with 
haemorrhage K265 Duodenal ulcer, chronic or unspecified with 
perforation K267 Duodenal ulcer, chronic without haemorrhage or 
perforation K270 Peptic ulcer, acute with haemorrhage 
K271 Peptic ulcer, acute with perforation 
K272 Peptic ulcer, acute with both haemorrhage and 
perforation K273 Peptic ulcer, acute without haemorrhage or 
perforation K274 Peptic ulcer, chronic or unspecified with haemorrhage 
K275 Peptic ulcer, chronic or unspecified with perforation 
K277 Peptic ulcer, chronic without haemorrhage or 
perforation K280 Gastrojejunal ulcer, acute with haemorrhage 
K284 Gastrojejunal ulcer, chronic or unspecified with 
haemorrhage K312 Hourglass stricture and stenosis of stomach 
K315 Obstruction of duodenum 
Q393 Congenital stenosis and stricture of oesophagus 
 Normal or minor pathologies  
K20X Oesophagitis 
K210 Gastro-oesophageal reflux disease with oesophagitis 
K219 Gastro-oesophageal reflux disease without 
oesophagitis K229 Disease of oesophagus, unspecified 
K230 Tuberculous oesophagitis 
K291 Other acute gastritis 
K292 Alcoholic gastritis 
K293 Chronic superficial gastritis 
K294 Chronic atrophic gastritis 
K295 Chronic gastritis, unspecified 
K296 Other gastritis 
K297 Gastritis, unspecified 
K298 Duodenitis 
K299 Gastroduodenitis, unspecified 
K319 Disease of stomach and duodenum, unspecified 
K449 Diaphragmatic hernia without obstruction or 
gangrene K458 Other spec abdom hernia without obstruction or 
gangrene K469 Unspecified abdominal hernia without obstruction or 
gangrene Q394 Oesophageal web 
Q401 Congenital hiatus hernia 
 Other neoplasms 
C170 Malignant neoplasm of small intestine, duodenum 
C171 Malignant neoplasm of small intestine, jejunum 
C172 Malignant neoplasm of small intestine, ileum 
C178 Malignant neoplasm overlapping lesion of small 
intestine C179 Malignant neoplasm of small intestine, unspecified 
C180 Malignant neoplasm of caecum 
C181 Malignant neoplasm of appendix 
C182 Malignant neoplasm of ascending colon 
C183 Malignant neoplasm of hepatic flexure 
C184 Malignant neoplasm of transverse colon 
C186 Malignant neoplasm of descending colon 
C188 Malignant neoplasm overlapping lesion of colon 
C189 Malignant neoplasm of colon, unspecified 
C19X Malignant neoplasm of rectosigmoid junction 
C20X Malignant neoplasm of rectum 
C210 Malignant neoplasm of anus, unspecified 
C211 Malignant neoplasm of anal canal 
C220 Malignant neoplasm, liver cell carcinoma 
C221 Malignant neoplasm, intrahep bile duct carcinoma 
C222 Malignant neoplasm, hepatoblastoma 
C227 Malignant neoplasm, oth spec carcinomas of liver 
C229 Malignant neoplasm, liver, unspecified 
C23X Malignant neoplasm of gallbladder 
C240 Malignant neoplasm of extrahepatic bile duct 
C241 Malignant neoplasm of Ampulla of Vater 
C248 Malignant neoplasm overlapping lesion of biliary tract 
C249 Malignant neoplasm of biliary tract, unspecified 
C250 Malignant neoplasm of head of pancreas 
C251 Malignant neoplasm of body of pancreas 
C252 Malignant neoplasm of tail of pancreas 
C253 Malignant neoplasm of pancreatic duct 
C257 Malignant neoplasm of other parts of pancreas 
C258 Malignant neoplasm, overlapping lesion of pancreas 
C259 Malignant neoplasm of pancreas, unspecified 
C260 Malignant neoplasm of intestinal tract, part unsp 
C268 Malignant neoplasm, overlapping lesion of digestive 
system C269 Malignant neoplasm of ill-def sites within digestive 
system C481 Malignant neoplasm of spec parts of peritoneum 
C784 Secondary malignant neoplasm of small intestine 
C785 Secondary malignant neoplasm of large intest & 
rectum C787 Secondary malignant neoplasm of liver 
C788 Secondary malignant neoplasm of other & unsp 
digestive orgs C883 Malignant immunoproliferative small intestinal 
disease D010 Carcinoma in situ colon 
D011 Carcinoma in situ rectosigmoid junction 
D012 Carcinoma in situ rectum  
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D013 Carcinoma in situ anus and anal canal 
D014 Carcinoma in situ other and unspecified parts of 
intestine D015 Carcinoma in situ liver, gallbladder and bile ducts 
D017 Carcinoma in situ other specified digestive organs 
D120 Benign neoplasm of caecum 
D121 Benign neoplasm of appendix 
D122 Benign neoplasm of ascending colon 
D123 Benign neoplasm of transverse colon 
D125 Benign neoplasm of sigmoid colon 
D126 Benign neoplasm of colon, unspecified 
D128 Benign neoplasm of rectum 
D129 Benign neoplasm of anus and anal canal 
D133 Benign neoplasm of other and unsp parts of small 
intestine D134 Benign neoplasm of liver 
D135 Benign neoplasm of extrahepatic bile ducts 
D136 Benign neoplasm of pancreas 
D137 Benign neoplasm of endocrine pancreas 
D139 Benign neoplasm of ill-defined site within the 
digestive sys D152 Benign neoplasm of mediastinum 
D175 Benign lipomatous neoplasm of intra-abdominal 
organs D214 Benign neoplasm of conn & soft tiss of abdomen 
D372 Neoplasm uncert / unkn behav small intestine 
D374 Neoplasm uncert / unkn behav colon 
D375 Neoplasm uncert / unkn behav rectum 
B217 HIV disease resulting in multiple malignant neoplasms 
B218 HIV disease resulting in other malignant neoplasms 
C01X Malignant neoplasm of base of tongue 
C020 Malignant neoplasm of dorsal surface tongue 
C021 Malignant neoplasm of border of tongue 
C022 Malignant neoplasm of ventral surface of tongue 
C024 Malignant neoplasm of lingual tonsil 
C028 Malignant neoplasm of overlapping lesion of tongue 
C029 Malignant neoplasm of tongue, unspecified 
C031 Malignant neoplasm of lower gum 
C040 Malignant neoplasm of floor of anterior floor of 
mouth C048 Malignant neoplasm, overlapping lesion of floor of 
mouth C049 Malignant neoplasm of floor of mouth, floor of 
mouth, unspec C050 Malignant neoplasm of hard palate 
C051 Malignant neoplasm of soft palate 
C052 Malignant neoplasm of uvula 
C058 Malignant neoplasm, overlapping lesion of palate 
C059 Malignant neoplasm of palate, unspecified 
C060 Malignant neoplasm cheek mucosa 
C062 Malignant neoplasm of retromolar area 
C068 Malignant neoplasm, overlap les of oth & unsp part of 
mouth C069 Malignant neoplasm of part of mouth, unspecified 
C07X Malignant neoplasm of parotid gland 
C080 Malignant neoplasm of submandibular gland 
C089 Malignant neoplasm of major salivary gland, 
unspecified C090 Malignant neoplasm tonsillar fossa 
C091 Malig neo of tonsillar pillar (anterior)(posterior) 
C098 Malignant neoplasm of overlapping lesion of tonsil 
C099 Malignant neoplasm of tonsil unspecified 
C100 Malignant neoplasm of vallecula 
C101 Malignant neoplasm of anterior surface of epiglottis 
C102 Malignant neoplasm of lateral wall of oropharynx 
C103 Malignant neoplasm of posterior wall of oropharynx 
C109 Malignant neoplasm of oropharynx unspecified 
C111 Malignant neoplasm of posterior wall of nasopharynx 
C112 Malignant neoplasm of lateral wall of nasopharynx 
C113 Malignant neoplasm of anterior wall of nasopharynx 
C119 Malignant neoplasm of nasopharynx unspecified 
C12X Malignant neoplasm of pyriform sinus 
C130 Malignant neoplasm of hypopharynx, postcricoid 
region C131 Malig neoplasm aryepiglottic fold, hypopharyngeal 
aspect C132 Malignant neoplasm posterior wall of hypopharynx 
C139 Malignant neoplasm of hypopharynx unspecified 
C140 Malignant neoplasm of pharynx, unsp 
C148 Malig neo, overlapping lesion of lip, oral cavity & 
pharynx C185 Malignant neoplasm of splenic flexure 
C187 Malignant neoplasm of sigmoid colon 
C218 Malig neo, overlapping lesion of rectum, anus and 
anal canal C300 Malignant neoplasm of nasal cavity 
C310 Malignant neoplasm of maxillary sinus 
C311 Malignant neoplasm of ethmoidal sinus 
C312 Malignant neoplasm of frontal sinus 
C320 Malignant neoplasm of glottis 
C321 Malignant neoplasm of supraglottis 
C322 Malignant neoplasm of subglottis 
C323 Malignant neoplasm of laryngeal cartilage 
C328 Malignant neoplasm, overlapping lesion of larynx 
C329 Malignant neoplasm of larynx, unspecified 
C33X Malignant neoplasm of trachea 
C340 Malignant neoplasm of main bronchus 
C341 Malignant neoplasm of upper lobe, bronchus or lung 
C342 Malignant neoplasm of middle lobe, bronchus or lung 
C343 Malignant neoplasm of lower lobe, bronchus or lung 
C348 Malignant neoplasm of overlap les of bronchus & lung 
C349 Malignant neoplasm of bronchus or lung, unspec 
C37X Malignant neoplasm of thymus 
C380 Malignant neoplasm of heart, mediastinum & pleura, 
heart C381 Malignant neoplasm of anterior mediastinum 
C383 Malig neo heart, mediastinum & 
pleura,mediastinum,part unsp C384 Malignant neoplas  of pleura 
C390 Malignant neoplasm of upper respiratory tract, part 
unsp C402 Malignant neoplasm of long bones of lower limb 
C410 Malignant neoplasm of bones of skull and face 
C411 Malignant neoplasm of mandible 
C412 Malignant neoplasm of vertebral column 
C433 Malignant melanoma of other and unspecified parts 
of face C434 Malignant melanoma of scalp and neck 
C435 Malignant melanoma of trunk 
C436 Malignant melanoma of upper limb, including 
shoulder C437 Malignant melanoma of lower limb, including hip 
C439 Malignant melanoma of skin, unsp 
C440 Other malignant neoplasms of skin of lip 
C441 Other malignant neoplasms of skin of eyelid, incl 
canthus C443 Oth malignant neoplasm of skin of oth & unsp parts of 
face C444 Other malignant neoplasms of skin of scalp and neck 
C445 Other malignant neoplasms of skin of trunk 
C447 Other malignant neoplasms of skin of lower limb, incl 
hip C449 Other malignant neoplasms of skin, unspecified 
C450 Mesothelioma of pleura 
C451 Mesothelioma of peritoneum 
C457 Mesothelioma of other sites 
C459 Mesothelioma, unspecified 
C467 Kaposi's sarcoma of other sites 
C469 Kaposi's sarcoma, unspecified 
C474 Malignant neoplasm of peripheral nerve of abdomen 
C480 Malignant neoplasm of retroperitoneum 
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C482 Malignant neoplasm of peritoneum, unsp 
C490 Malignant neoplasm of conn and soft tiss head, face & 
neck C492 Malignant neoplasm of conn and soft tiss,lower 
limb,inc hip C493 Malignant neoplasm of conn and soft tiss of thorax 
C494 Malignant neoplasm of conn and soft tiss of abdomen 
C495 Malignant neoplasm of conn and soft tiss of pelvis 
C498 Malignant neoplasm, overlap lesion connective & soft 
tiss C499 Malignant neoplasm of connective and soft tissue, 
unsp C500 Malignant neoplasm of nipple and areola 
C502 Malignant neoplasm of upper-inner quadrant of 
breast C504 Malignant neoplasm of upper-outer quadrant of 
breast C505 Malignant neoplasm of lower-outer quadrant of 
breast C506 Malignant neoplasm of axillary tail of breast 
C508 Malignant neoplasm, overlapping lesion of breast 
C509 Malignant neoplasm of breast, unspecified 
C519 Malignant neoplasm of vulva, unspecified 
C52X Malignant neoplasm of vagina 
C539 Malignant neoplasm of cervix uteri, unsp 
C541 Malignant neoplasm of endometrium 
C549 Malignant neoplasm of corpus uteri, unsp 
C55X Malignant neoplasm of uterus, part unspecified 
C56X Malignant neoplasm of ovary 
C579 Malignant neoplasm of female genital organ, 
unspecified C609 Malignant neoplasm of penis, unspecified 
C61X Malignant neoplasm of prostate 
C620 Malignant neoplasm of undescended testis 
C621 Malignant neoplasm of descended testis 
C629 Malignant neoplasm of testis, unspecified 
C64X Malignant neoplasm of kidney, except renal pelvis 
C65X Malignant neoplasm of renal pelvis 
C66X Malignant neoplasm of ureter 
C671 Malignant neoplasm of dome of bladder 
C672 Malignant neoplasm of lateral wall of bladder 
C674 Malignant neoplasm of posterior wall of bladder 
C676 Malignant neoplasm of ureteric orifice 
C679 Malignant neoplasm of bladder, unspecified 
C688 Malignant neoplasm of overlapping lesion urinary 
organs C689 Malignant neoplasm of urinary organ, unspecified 
C701 Malignant neoplasm of spinal meninges 
C709 Malignant neoplasm of meninges, unspecified 
C710 Malignant neoplasm of cerebrum, except lobes & 
ventricles C711 Malignant neoplasm of cerebrum, frontal lobe 
C712 Malignant neoplasm of cerebrum, temporal lobe 
C713 Malignant neoplasm of cerebrum, parietal lobe 
C716 Malignant neoplasm of cerebrum, cerebellum 
C718 Malignant neoplasm of cerebrum, overlapping lesion 
of brain C719 Malignant neoplasm of cerebrum, brain, unspecified 
C720 Malignant neoplasm of spinal cord 
C73X Malignant neoplasm of thyroid gland 
C749 Malignant neoplasm of adrenal gland, unsp 
C759 Malignant neoplasm of endocrine gland, unspecified 
C760 Malignant neoplasm of head, face & neck 
C763 Malignant neoplasm of pelvis 
C767 Malignant neoplasm of other ill-defined sites 
C770 Sec & uns malig neoplasm of lymph nodes of head, 
face & neck C773 Sec & uns malig neoplasm of axillary & upp limb 
lymph nodes C774 Sec & uns malig neoplasm of inguinal & low limb 
lymph nodes C775 Sec & uns malignant neoplasm of intrapelvic lymph 
nodes C778 Sec & uns malig neoplasm of lymph nodes of multiple 
regions C779 Sec & uns malignant neoplasm of lymph node, 
unspecified 
C780 Secondary malignant neoplasm of lung 
C781 Secondary malignant neoplasm of mediastinum 
C782 Secondary malignant neoplasm of pleura 
C783 Secondary malignant neoplasm of oth & unsp 
respiratory orgs C786 Secondary malignant neoplasm of retroperitoneum & 
peritoneum C791 Secondary malignant neoplasm of oth & uns urinary 
organs C792 Secondary malignant neoplasm of skin 
C793 Secondary malignant neoplasm of brain & cerebral 
meninges C795 Secondary malignant neoplasm of bone and bone 
marrow C796 Secondary malignant neoplasm of ovary 
C797 Secondary malignant neoplasm of adrenal gland 
C798 Secondary malignant neoplasm of other specified 
sites C80X Malignant neoplasm without specification of site 
C810 Hodgkin's disease, lymphocytic predominance 
C811 Hodgkin's disease, nodular sclerosis 
C812 Hodgkin's disease, mixed cellularity 
C817 Hodgkin's disease, other Hodgkin's disease 
C819 Hodgkin's disease, Hodgkin's disease, unspecified 
C822 Follicular non-Hodgkin's large cell lymphoma 
C827 Follicular non-Hodgkin's other types of lymphoma 
C829 Follicular non-Hodgkin's unspecified lymphoma 
C830 Diffuse non-Hodgkin's small cell (diffuse)lymphoma 
C833 Diffuse non-Hodgkin's large cell (diffuse) lymphoma 
C835 Diffuse non-Hodgkin's lymphoblastic (diffuse) 
lymphoma C837 Diffuse non-Hodgkin's lymphoma, Burkitt's tumour 
C838 Other types of diffuse non-Hodgkin's lymphoma 
C839 Diffuse non-Hodgkin's lymphoma, unspecified 
C840 Peripheral and cutaneous T-cell lymphomas, mycosis 
fungoides C841 Peripheral and cutaneous T-cell lymphomas, Sezary's 
disease C844 Periph & cutan T-cell lymphomas, peripheral T-cell 
lymphoma C845 Periph & cutan T-cell lymphomas, oth & unsp T-cell 
lymphomas C850 Oth & unspec types of non-Hodgkin's lymphoma, 
lymphosarcoma C851 Oth & unsp types non-Hodgkin's B-cell lymphoma, 
unsp C857 Oth specified types of non-Hodgkin's lymphoma 
C859 Non-Hodgkin's lymphoma, unspecified type 
C880 Waldenstrom's macroglobulinaemia 
C900 Multiple myeloma 
C901 Plasma cell leukaemia 
C902 Malignant plasma cell neoplasm, extramedullary 
plasmacytoma C910 Acute lymphoblastic leukaemia 
C911 Chronic lymphocytic leukaemia 
C913 Prolymphocytic leukaemia 
C914 Hairy-cell leukaemia 
C915 Adult T-cell leukaemia 
C919 Lymphoid leukaemia, unspecified 
C920 Acute myeloid leukaemia 
C921 Chronic myeloid leukaemia 
C924 Acute promyelocytic leukaemia 
C925 Acute myelomonocytic leukaemia 
C927 Other myeloid leukaemia 
C929 Myeloid leukaemia, unspecified 
C950 Acute leukaemia of unsp cell type 
C951 Chronic leukaemia unsp cell type 
C961 Malignant histiocytosis 
C969 Malig neop lymphoid haematopoietic and related 
tissue unspec C97X Malignant neoplasms of independent (primary) 
multiple sites D000 Carcinoma in situ of lip, oral cavity and pharynx 
D020 Carcinoma in situ larynx 
D021 Carcinoma in situ trachea 
D022 Carcinoma in situ bronchus and lung 
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D049 Carcinoma in situ of skin unspecified 
D051 Intraductal carcinoma in situ 
D059 Carcinoma in situ of breast, unspecified 
D090 Carcinoma in situ of bladder 
D093 Carcinoma in situ of thyroid and other endocrine 
glands D101 Benign neoplasm of tongue 
D102 Benign neoplasm of floor of mouth 
D103 Benign neoplasm of other and unsp parts of mouth 
D104 Benign neoplasm of tonsil 
D105 Benign neoplasm of other parts of oropharynx 
D106 Benign neoplasm of nasopharynx 
D107 Benign neoplasm of hypopharynx 
D109 Benign neoplasm of pharynx, unspecified 
D110 Benign neoplasm of parotid gland 
D119 Benign neoplasm of major salivary gland, unspecified 
D124 Benign neoplasm of descending colon 
D127 Benign neoplasm of rectosigmoid junction 
D140 Benign neoplasm of mid ear, nasal cav & accessory 
sinus D141 Benign neoplasm of larynx 
D143 Benign neoplasm of bronchus and lung 
D157 Benign neoplasm of other specified intrathoracic 
organs D162 Benign neoplasm of long bones of lower limb 
D170 Benign lipomatous neop skin/subcut tis head face & 
neck D171 Benign lipomatous neoplasm skin and subcut tissue of 
trunk D173 Benign lipomatous neop skin/subcut tis other/unspec 
sites D179 Benign lipomatous neoplasm, unspecified 
D180 Haemangioma, any site 
D181 Lymphangioma, any site 
D190 Benign neoplasm of mesothelial tissue of pleura 
D191 Benign neoplasm of mesothelial tissue of peritoneum 
D210 Benign neoplasm of conn & soft tiss of head, face and 
neck D219 Benign neoplasm of conn & soft tiss, unspecified 
D269 Other benign neoplasms of uterus, unspecified 
D27X Benign neoplasm of ovary 
D300 Benign neoplasm of kidney 
D303 Benign neoplasm of bladder 
D320 Benign neoplasm of cerebral meninges 
D321 Benign neoplasm of spinal meninges 
D329 Benign neoplasm of meninges, unspecified 
D330 Benign neoplasm of brain, supratentorial 
D332 Benign neoplasm of brain, unspecified 
D333 Benign neoplasm of cranial nerves 
D34X Benign neoplasm of thyroid gland 
D350 Benign neoplasm of adrenal gland 
D351 Benign neoplasm of parathyroid gland 
D352 Benign neoplasm of pituitary gland 
D354 Benign neoplasm of pineal gland 
D360 Benign neoplasm of lymph nodes 
D361 Benign neoplasm of periph nerves & autonomic 
nervous system D369 Benign neoplasm of unspecified site 
D370 Neoplasm uncert / unkn behav lip, oral cavity and 
pharynx D380 Neoplasm uncert / unkn behav larynx 
D381 Neoplasm uncert / unkn behav trachea, bronchus and 
lung D382 Neoplasm uncert / unkn behav pleura 
D383 Neoplasm uncert / unkn behav mediastinum 
D391 Neoplasm uncert / unkn behav ovary 
D410 Neoplasm uncert / unkn behav kidney 
D412 Neoplasm uncert / unkn behav ureter 
D414 Neoplasm uncert / unkn behav bladder 
D429 Neoplasm uncert / unkn behav meninges, unspecified 
D430 Neoplasm uncert / unkn behav brain, supratentorial 
D431 Neoplasm uncert / unkn behav brain, infratentorial 
D432 Neoplasm uncert / unkn behav brain, unspecified 
D440 Neoplasm uncert / unkn behav thyroid gland 
D441 Neoplasm uncert / unkn behav adrenal gland 
D443 Neoplasm uncert / unkn behav pituitary gland 
D444 Neoplasm uncert / unkn behav craniopharyngeal duct 
D447 Neoplasm uncert / unkn behav aortic body & oth 
paraganglia D448 Neoplasm uncert / unkn behav pluriglandular 
involvement D449 Neoplasm uncert / unkn behav endocrine gland, 
unspecified D480 Neoplasm uncert or unknown behaviour of bone & 
artic cart D481 Neoplasm uncert or unknown behaviour of conn & 
oth soft tis D489 Neoplasm of uncertain or unknown behaviour, 
unspecified G210 Malignant neuroleptic syndrome 
H602 Malignant otitis externa 
Q850 Neurofibromatosis (nonmalignant) 
 Symptom codes 
D500 Iron deficiency anaemia secondary to blood loss 
(chronic) D508 Other iron deficiency anaemias 
D509 Iron deficiency anaemia, unspecified 
D510 Vitamin B12 defic anaemia due to intrinsic factor 
deficiency D513 Other dietary vitamin B12 deficiency anaemia 
D518 Other vitamin B12 deficiency anaemias 
D519 Vitamin B12 deficiency anaemia, unspecified 
D520 Dietary folate deficiency anaemia 
D521 Drug-induced folate deficiency anaemia 
D528 Other folate deficiency anaemias 
D529 Folate deficiency anaemia, unspecified 
D531 Other megaloblastic anaemias, not elsewhere 
classified D538 Other specified nutritional anaemias 
D539 Nutritional anaemia, unspecified 
D648 Other specified anaemias 
D649 Anaemia, unspecified 
E164 Abnormal secretion of gastrin Hypergastrinaemia 
Zollinger-Ellison syndrome K30X Dyspepsia 
K920 Haematemesis 
K921 Melaena 
R071 Chest pain on breathing 
R073 Other chest pain 
R074 Chest pain, unspecified 
R101 Pain localized to upper abdomen 
R104 Other and unspecified abdominal pain 
R11X Nausea and vomiting 
R12X Heartburn 
R13X Dysphagia 
R190 Intra-abdominal and pelvic swelling, mass and lump 
R229 Localized swelling, mass and lump, unspecified 
R529 Pain, unspecified 
R630 Anorexia 
R634 Abnormal weight loss 
R933 Abn finds diagnostic imaging of oth parts of digestive 
tract R935 Abn finds diag imaging oth abdo region inc 
retroperitoneum R938 Abn finds on diag imaging of other spec body 
structures Z800 Family history of malignant neoplasm Family history 
of malignant neoplasm of digestive organs Z808 Fa ily history of malignant neoplasm Family history 
of malignant neoplasm of other organs or sys  Miscellaneous codes 
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Appendix 7.9 STROBE Statement 
STROBE Statement—checklist of items that should be included in reports of observational studies 
 Item 
No Recommendation 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the 
title or the abstract 
(b) Provide in the abstract an informative and balanced summary 
of what was done and what was found 
Yes (see title and abstract page 5) 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the 
investigation being reported 
Yes (see INTRODUCTION summary boxes in chapter 1- and 
RATIONALE in chapter 2 page 87) 
Objectives 3 State specific objectives, including any prespecified hypotheses 
Yes (see chapter 2 pages 88 and 89) 
Methods 
Study design 4 Present key elements of study design early in the paper 
Yes (see main METHOD  chapters 2 and 3 along with supporting 
appendices chapter 7) 
Setting 5 Describe the setting, locations, and relevant dates, including 
periods of recruitment, exposure, follow-up, and data collection 
Yes (see main METHOD section in chapters 2 and 3 ) 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and 
methods of selection of participants. Describe methods of follow-
up 
Case-control study—Give the eligibility criteria, and the sources 
and methods of case ascertainment and control selection. Give 
the rationale for the choice of cases and controls 
Cross-sectional study—Give the eligibility criteria, and the sources 
and methods of selection of participants 
Yes (see METHODS pages 111-115, 147, 188 and 191) 
(b) Cohort study—For matched studies, give matching criteria and 
number of exposed and unexposed 
Case-control study—For matched studies, give matching criteria 
and the number of controls per case 
Variables 7 Clearly define all outcomes, exposures, predictors, potential 
confounders, and effect modifiers. Give diagnostic criteria, if 
applicable 
Yes (see pages  97-100 and 150 ) 
Data sources/ 
measurement 
8  For each variable of interest, give sources of data and details of 
methods of assessment (measurement). Describe comparability 
of assessment methods if there is more than one group 
Yes (See METHOD sections in chapter 2,3,4,5 ) 
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Bias 9 Describe any efforts to address potential sources of bias 
Yes (See method sections in chapters 3, 4, and 5. Mainly 
Sensitivity analysis section in chapter 4) 
Study size 10 Explain how the study size was arrived at 
N/A All cases in a national cohort 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. 
If applicable, describe which groupings were chosen and why 
Yes ( Method sections in Chapter 4 and 5 ) 
Statistical methods 12 (a) Describe all statistical methods, including those used to 
control for confounding 
(b) Describe any methods used to examine subgroups and 
interactions 
(c) Explain how missing data were addressed 
(d) Cohort study—If applicable, explain how loss to follow-up was 
addressed 
Case-control study—If applicable, explain how matching of cases 
and controls was addressed 
Cross-sectional study—If applicable, describe analytical methods 
taking account of sampling strategy 
(e) Describe any sensitivity analyses 
Yes (See Analytical Approach sections in pages 102, 148, 149, 
188-190, and 193 ) notably under ‘Sensitivity Analyses 
 
Results 
Participants 13 (a) Report numbers of individuals at each stage of study—eg numbers 
potentially eligible, examined for eligibility, confirmed eligible, included in 
the study, completing follow-up, and analysed 
(b) Give reasons for non-participation at each stage 
(c) Consider use of a flow diagram 
Yes (summarised in early stages of each RESULTS section of chapters 3, 4 and 
5) 
Descriptive 
data 
14 (a) Give characteristics of study participants (eg demographic, clinical, social) 
and information on exposures and potential confounders 
(b) Indicate number of participants with missing data for each variable of 
interest 
(c) Cohort study—Summarise follow-up time (eg, average and total amount) 
Yes (summarised in early stages of each RESULTS section of chapters 3, 4 and 
5) 
Outcome data 15 Cohort study—Report numbers of outcome events or summary measures 
over time 
Case-control study—Report numbers in each exposure category, or summary 
measures of exposure 
Cross-sectional study—Report numbers of outcome events or summary 
measures 
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Yes (summarised in Tables 4.1-4.7, 5.1-5.4, and figures 5.4-5.5) 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (eg, 95% confidence interval). Make clear 
which confounders were adjusted for and why they were included 
(b) Report category boundaries when continuous variables were categorized 
(c) If relevant, consider translating estimates of relative risk into absolute risk 
for a meaningful time period 
Yes (See Tables and figures for crude and adjusted estimates in chapter 4) 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and 
sensitivity analyses 
Yes (See sensitivity analysis result section in chapter  4) 
Discussion 
Key results 18 Summarise key results with reference to study objectives 
Yes – See early stages of each discussion sections of chapters 3, 4 and 5 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias 
or imprecision. Discuss both direction and magnitude of any potential bias 
Yes,  See discussion section of chapters 3, 4, 5, and 6 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and other 
relevant evidence 
Yes, See general discussion section in chapter 6 
Generalisability 21 Discuss the generalisability (external validity) of the study results 
Yes, local audit validation sections in chapter 3 and 5  
 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study 
and, if applicable, for the original study on which the present article is based 
YES – see the acknowledgment  
  
 
 
 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological 
background and published examples of transparent reporting. The STROBE checklist is best used in 
conjunction with this article (freely available on the Web sites of PLoS Medicine at 
http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and 
Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at 
www.strobe-statement.org. 
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Syntax 7.1 Assign speciality type  
This syntax was used to assign a Specialty Type of 1 for a surgical specialty and 2 for a 
medical specialty, based on the Specialty code (Mainspef) of the episode.    
For 2006-07 data year there were 11,580,198 episodes. (Medical = 6.336.909 (54.7%), 
Surgical = 5,243,289 (45.3%) and for 2007-08 there were= 12,181,932 episodes. (Medical = 
6,581,016 (54.0%), Surgical = 5,600,916 (46.0%) 
COMPUTE SPECIALTYTYPE = 0. 
EXECUTE. 
IF (MAINSPEF = 300| 
MAINSPEF = 301| 
MAINSPEF = 302| 
MAINSPEF = 303| 
MAINSPEF = 305| 
MAINSPEF = 313| 
MAINSPEF = 314| 
MAINSPEF = 315| 
MAINSPEF = 320| 
MAINSPEF = 330| 
MAINSPEF = 340| 
MAINSPEF = 350| 
MAINSPEF = 352| 
MAINSPEF = 360| 
MAINSPEF = 361| 
MAINSPEF = 370| 
MAINSPEF = 400| 
MAINSPEF = 410| 
MAINSPEF = 430| 
MAINSPEF = 823)SPECIALTYTYPE = 2. 
EXECUTE. 
 
IF (MAINSPEF = 100| 
MAINSPEF = 101| 
MAINSPEF = 110| 
MAINSPEF = 120| 
MAINSPEF = 130| 
MAINSPEF = 140| 
MAINSPEF = 145| 
MAINSPEF = 150| 
MAINSPEF = 160| 
MAINSPEF = 170| 
MAINSPEF = 180| 
MAINSPEF = 190| 
MAINSPEF = 192)SPECIALTYTYPE = 1. 
EXECUTE. 
 
Syntax 7.2 Trust selection  
COMPUTE TRUSTINC = 0. 
EXECUTE. 
 
IF (PROCODE = '5QT'| 
PROCODE = 'RA2'| 
PROCODE = 'RA3'| 
PROCODE = 'RA4'| 
PROCODE = 'RA7'| 
PROCODE = 'RA9'| 
PROCODE = 'RAE'| 
PROCODE = 'RAJ'| 
PROCODE = 'RAL'| 
PROCODE = 'RAP'| 
PROCODE = 'RAS'| 
PROCODE = 'RAX'| 
PROCODE = 'RBA'| 
PROCODE = 'RBD'| 
PROCODE = 'RBK'| 
PROCODE = 'RBL'| 
PROCODE = 'RBN'| 
PROCODE = 'RBT'| 
PROCODE = 'RBZ'| 
PROCODE = 'RC1'| 
PROCODE = 'RC3'| 
PROCODE = 'RC9'| 
PROCODE = 'RCB'| 
PROCODE = 'RCC'| 
PROCODE = 'RCD'| 
PROCODE = 'RCF'| 
PROCODE = 'RCX'| 
PROCODE = 'RD1'| 
PROCODE = 'RD3'| 
PROCODE = 'RD7'| 
PROCODE = 'RD8'| 
PROCODE = 'RDD'| 
PROCODE = 'RDE'| 
PROCODE = 'RDU'| 
PROCODE = 'RDZ'| 
PROCODE = 'RE9'| 
PROCODE = 'REF'| 
PROCODE = 'REM'| 
PROCODE = 'RF4'| 
PROCODE = 'RFF'| 
PROCODE = 'RFR'| 
PROCODE = 'RFS'| 
PROCODE = 'RFW'| 
PROCODE = 'RG2'| 
PROCODE = 'RG3'| 
PROCODE = 'RGC'| 
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PROCODE = 'RGN'| 
PROCODE = 'RGP'| 
PROCODE = 'RGQ'| 
PROCODE = 'RGR'| 
PROCODE = 'RGT'| 
PROCODE = 'RGZ'| 
PROCODE = 'RH8'| 
PROCODE = 'RHM'| 
PROCODE = 'RHQ'| 
PROCODE = 'RHU'| 
PROCODE = 'RHW'| 
PROCODE = 'RJ1'| 
PROCODE = 'RJ2'| 
PROCODE = 'RJ5'| 
PROCODE = 'RJ6'| 
PROCODE = 'RJ7'| 
PROCODE = 'RJC'| 
PROCODE = 'RJD'| 
PROCODE = 'RJE'| 
PROCODE = 'RJF'| 
PROCODE = 'RJL'| 
PROCODE = 'RJN'| 
PROCODE = 'RJR'| 
PROCODE = 'RJZ'| 
PROCODE = 'RK5'| 
PROCODE = 'RK9'| 
PROCODE = 'RKB'| 
PROCODE = 'RKE'| 
PROCODE = 'RL4'| 
PROCODE = 'RLN'| 
PROCODE = 'RLQ'| 
PROCODE = 'RLT'| 
PROCODE = 'RM1'| 
PROCODE = 'RM2'| 
PROCODE = 'RM3'| 
PROCODE = 'RM4'| 
PROCODE = 'RMC'| 
PROCODE = 'RMP'| 
PROCODE = 'RN1'| 
PROCODE = 'RN3'| 
PROCODE = 'RN5'| 
PROCODE = 'RN7'| 
PROCODE = 'RNA'| 
PROCODE = 'RNH'| 
PROCODE = 'RNJ'| 
PROCODE = 'RNL'| 
PROCODE = 'RNQ'| 
PROCODE = 'RNS'| 
PROCODE = 'RNZ'| 
PROCODE = 'RP5'| 
PROCODE = 'RPA'| 
PROCODE = 'RPL'| 
PROCODE = 'RPR'| 
PROCODE = 'RQ6'| 
PROCODE = 'RQ8'| 
PROCODE = 'RQM'| 
PROCODE = 'RQN'| 
PROCODE = 'RQQ'| 
PROCODE = 'RQW'| 
PROCODE = 'RQX'| 
PROCODE = 'RR1'| 
PROCODE = 'RR7'| 
PROCODE = 'RR8'| 
PROCODE = 'RRF'| 
PROCODE = 'RRK'| 
PROCODE = 'RRV'| 
PROCODE = 'RTD'| 
PROCODE = 'RTE'| 
PROCODE = 'RTF'| 
PROCODE = 'RTG'| 
PROCODE = 'RTH'| 
PROCODE = 'RTK'| 
PROCODE = 'RTP'| 
PROCODE = 'RTR'| 
PROCODE = 'RTX'| 
PROCODE = 'RV8'| 
PROCODE = 'RVJ'| 
PROCODE = 'RVL'| 
PROCODE = 'RVR'| 
PROCODE = 'RVV'| 
PROCODE = 'RVW' 
|PROCODE = 'RVY'| 
PROCODE = 'RW3'| 
PROCODE = 'RW6'| 
PROCODE = 'RWA'| 
PROCODE = 'RWD'| 
PROCODE = 'RWE'| 
PROCODE = 'RWF'| 
PROCODE = 'RWG'| 
PROCODE = 'RWH'| 
PROCODE = 'RWJ'| 
PROCODE = 'RWP'| 
PROCODE = 'RWW'| 
PROCODE = 'RWY'| 
PROCODE = 'RX1'| 
PROCODE = 'RXC'| 
PROCODE = 'RXF'| 
PROCODE = 'RXH'| 
PROCODE = 'RXK'| 
PROCODE = 'RXL'| 
PROCODE = 'RXN'| 
PROCODE = 'RXP'| 
PROCODE = 'RXQ'| 
PROCODE = 'RXR'| 
PROCODE = 'RXW'| 
PROCODE = 'RYJ')TRUSTINC = 1. 
EXECUTE. 
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Syntax 7.3 OG cancer syntax  
COMPUTE CANCER1 = 0. 
EXECUTE. 
IF (DIAG01 = "C169"| 
DIAG01 = "C160"| 
DIAG01 = "C161"| 
DIAG01 = "C162"| 
DIAG01 = "C163"| 
DIAG01 = "C164"| 
DIAG01 = "C165"| 
DIAG01 = "C166"| 
DIAG01 = "C168"| 
DIAG01 = "C159"| 
DIAG01 = "C158"| 
DIAG01 = "C150"| 
DIAG01 = "C151"| 
DIAG01 = "C152"| 
DIAG01 = "C153"| 
DIAG01 = "C154"| 
DIAG01 = "C155")CANCER1 = 1. 
EXECUTE. 
The same syntax was applied to identify these codes in other diagnostic position (DIAG02 to DIAG 
14)                                                                                                                                                                                                      
Then these 14 new variables ( CANCER1 + CANCER2+…..+CANCER14) were added and a new variable 
called OGCANCER was created which then updated by the following syntax to develop a binary 
variable that show whether the patients (episodes) had been coded with any of these codes or not. 
COMPUTE HaveOGCANCER = 0. 
EXECUTE. 
IF (OGCANCER > 0)HaveOGCANCER = 1. 
EXECUTE. 
 
Syntax 7.4 Diagnostic gastroscopy syntax 
COMPUTE GASTROSCOPYpro1 = 0. 
EXECUTE. 
if(OPERTN1 = 'G451'| 
OPERTN1 = 'G459'| 
OPERTN1 = 'G45'| 
OPERTN1 = 'G169'| 
OPERTN1 = 'G458'| 
OPERTN1 = 'G161'| 
OPERTN1 = 'G16'| 
OPERTN1 = 'G168'| 
OPERTN1 = 'G454')GASTROSCOPYpro1 = 1. 
EXECUTE . 
The same syntax was applied to identify these codes in other diagnostic position (OPERTN02 to 
OPERTN14)                                                                                                                                                                                                      
Then these 14 new variables (GASTROSCOPYpro1 + GASTROSCOPYpro2+…..+ GASTROSCOPYpro14) 
were added and a new variable called diagnostic gastroscopy was created which then updated by 
the following syntax to develop a binary variable that show whether the patients (episodes) had 
been coded with any of these codes or not. 
COMPUTE HaveGASTROSCOPY = 0. 
EXECUTE. 
IF (diagnostic gastroscopy > 0)HaveGASTROSCOPY = 1. 
EXECUTE. 
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Identification of the first Gastroscopy procedure date (FGD) 
This process commenced by selecting all patients in 2006/08 merged OGC patients’ 
episodes dataset who have had a diagnostic gastroscopy in PROCEDURE 1 position and 
Create a field called diagnostic gastroscopy DATE and update to equal the PRODATE 1 (i.e. 
procedure date at position 1); the resulted file need to be saved as separate dataset,(Doing 
the same action for PROCEDURE positions 2 to 14, each time creating a separate dataset, 
and then creating a field called diagnostic gastroscopy DATE which should equal its 
PRODATE) then by merging all 14 datasets together (all dataset variables should be in the 
same order with the same variable names and format before the merge) by that the 
diagnostic gastroscopy DATE variable will have the date of every diagnostic procedure code 
in every episode of care in one column.  After that, using the “identify duplicate cases” 
function in SPSS, the chronologically first episode of care containing the first episode for 
each patient was flagged with a new variable (PRIMARYFIRST=1).  Then the last episode 
was also flagged with another new variable (PRIMARYLAST=1).  These two new variables 
represent the first and the last diagnostic gastroscopy that each patient have had in his or 
her management journey along with their date.  
 
Syntax 7.5 Identification of the first OG cancer coding date (FOGCD) 
The processes commences by first, ‘Sorting’ the data by the patients’ HESID and date of 
admissions in ascending order. Then using the “identify duplicate cases” function in SPSS, 
the chronologically first episode of care containing the first admission date for each patient 
will be flagged with a new variable (PRIMARYFIRST=1). Using the Select function to copy 
the PRIMARYFIRST=1 into a new dataset. From the resulted data, copy “episode end date” 
variable along with the patients’ HESID into another new dataset and rename the “episode 
end date” to be “OGC 1ST episode end date”, then save the resulted file as “0608 OGC 
patients’ first episode end date”. Following that, this new variable can be added to the 
main OG cancer dataset using SPSS function: DATA > MERGE FILE > ADD VARIABLE.  
By calculation the number of days between the first OG cancer coding date (FOGCD) and 
the first Gastroscopy procedure date (FGD) and by using the following syntax we extracted 
a cohort of patients with a sequence of care episodes and diagnostic procedures 
compatible with a new diagnosis of OG cancer. 
COMPUTE STUDYGROUP = 0. 
EXECUTE. 
IF (number of days between the (FOGCD) and the (FGD) ≥0 & number of days between the (FOGCD) 
and the (FGD)  ≤90) STUDYGROUPS = 1. 
EXECUTE. 
OG cancer incidence cases selection syntax 
COMPUTE STUDYGROUPS = 0. 
EXECUTE. 
IF (FirstOGcancerCodingDate_MINUS_FirstGastroscopyDate = 0) STUDYGROUPS = 1. 
EXECUTE. 
IF (FirstOGcancerCodingDate_MINUS_FirstGastroscopyDate  >0 & 
FirstOGcancerCodingDate_MINUS_FirstGastroscopyDate <=90) STUDYGROUPS = 2. 
EXECUTE. 
IF (FirstOGcancerCodingDate_MINUS_FirstGastroscopyDate >90) STUDYGROUPS = 3. 
EXECUTE. 
IF (FirstOGcancerCodingDate_MINUS_FirstGastroscopyDate <0) STUDYGROUPS = 4. 
EXECUTE. 
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Syntax 7.6 Patients’ age group syntax  
COMPUTE AGEGROUP = 0. 
EXECUTE. 
IF (ENDAGE < 55) AGEGROUP = 1. 
EXECUTE. 
IF (ENDAGE > 54 & ENDAGE < 65) AGEGROUP = 2. 
EXECUTE. 
IF (ENDAGE > 64 & ENDAGE <75) AGEGROUP = 3. 
EXECUTE. 
IF (ENDAGE >74 & ENDAGE <85) AGEGROUP = 4. 
EXECUTE. 
IF (ENDAGE >84) AGEGROUP = 5. 
EXECUTE. 
 
Syntax 7.7 Comorbidity syntax (charson’s scores ) 
COMPUTE COMORBID1 = 0. 
EXECUTE. 
IF (DIAG01 = 'E101'|DIAG01 = 'E105'|DIAG01 = 'E109'|DIAG01 = 'E111'|DIAG01 = 'E115'|DIAG01 = 
'E119'|DIAG01 = 'E131'|DIAG01 = 'E135'|DIAG01 = 'E139'|DIAG01 = 'E141'|DIAG01 = 'E145'|DIAG01 
= 'E149'|DIAG01 = 'F000'|DIAG01 = 'F001'|DIAG01 = 'F002'|DIAG01 = 'F009'|DIAG01 = 
'F010'|DIAG01 = 'F011'|DIAG01 = 'F012'|DIAG01 = 'F013'|DIAG01 = 'F018'|DIAG01 = 'F019'|DIAG01 
= 'F020'|DIAG01 = 'F021'|DIAG01 = 'F022'|DIAG01 = 'F023'|DIAG01 = 'F024'|DIAG01 = 
'F028'|DIAG01 = 'F051'|DIAG01 = 'G450'|DIAG01 = 'G451'|DIAG01 = 'G452'|DIAG01 = 
'G454'|DIAG01 = 'G458'|DIAG01 = 'G459'|DIAG01 = 'G460'|DIAG01 = 'G461'|DIAG01 = 
'G462'|DIAG01 = 'G463'|DIAG01 = 'G464'|DIAG01 = 'G465'|DIAG01 = 'G466'|DIAG01 = 
'G467'|DIAG01 = 'G468'|DIAG01 = 'I210'|DIAG01 = 'I211'|DIAG01 = 'I212'|DIAG01 = 'I213'|DIAG01 = 
'I214'|DIAG01 = 'I219'|DIAG01 = 'I220'|DIAG01 = 'I221'|DIAG01 = 'I228'|DIAG01 = 'I229'|DIAG01 = 
'I252'|DIAG01 = 'I500'|DIAG01 = 'I501'|DIAG01 = 'I509'|DIAG01 = 'I601'|DIAG01 = 'I602'|DIAG01 = 
'I603'|DIAG01 = 'I604'|DIAG01 = 'I605'|DIAG01 = 'I606'|DIAG01 = 'I607'|DIAG01 = 'I608'|DIAG01 = 
'I609'|DIAG01 = 'I610'|DIAG01 = 'I611'|DIAG01 = 'I612'|DIAG01 = 'I613'|DIAG01 = 'I614'|DIAG01 = 
'I615'|DIAG01 = 'I616'|DIAG01 = 'I618'|DIAG01 = 'I619'|DIAG01 = 'I620'|DIAG01 = 'I621'|DIAG01 = 
'I629'|DIAG01 = 'I630'|DIAG01 = 'I631'|DIAG01 = 'I632'|DIAG01 = 'I633'|DIAG01 = 'I634'|DIAG01 = 
'I635'|DIAG01 = 'I636'|DIAG01 = 'I638'|DIAG01 = 'I639'|DIAG01 = 'I64X'|DIAG01 = 'I650'|DIAG01 = 
'I651'|DIAG01 = 'I652'|DIAG01 = 'I653'|DIAG01 = 'I658'|DIAG01 = 'I659'|DIAG01 = 'I660'|DIAG01 = 
'I661'|DIAG01 = 'I662'|DIAG01 = 'I663'|DIAG01 = 'I664'|DIAG01 = 'I668'|DIAG01 = 'I669'|DIAG01 = 
'I670'|DIAG01 = 'I671'|DIAG01 = 'I672'|DIAG01 = 'I674'|DIAG01 = 'I675'|DIAG01 = 'I676'|DIAG01 = 
'I677'|DIAG01 = 'I678'|DIAG01 = 'I679'|DIAG01 = 'I681'|DIAG01 = 'I682'|DIAG01 = 'I688'|DIAG01 = 
'I690'|DIAG01 = 'I691'|DIAG01 = 'I692'|DIAG01 = 'I693'|DIAG01 = 'I694'|DIAG01 = 'I698'|DIAG01 = 
'I710'|DIAG01 = 'I711'|DIAG01 = 'I712'|DIAG01 = 'I713'|DIAG01 = 'I714'|DIAG01 = 'I715'|DIAG01 = 
'I716'|DIAG01 = 'I718'|DIAG01 = 'I719'|DIAG01 = 'I739'|DIAG01 = 'I790'|DIAG01 = 'J450'|DIAG01 = 
'J451'|DIAG01 = 'J458'|DIAG01 = 'J459'|DIAG01 = 'J46X'|DIAG01 = 'J47X'|DIAG01 = 'J60X'|DIAG01 = 
'J61X'|DIAG01 = 'J620'|DIAG01 = 'J628'|DIAG01 = 'J630'|DIAG01 = 'J631'|DIAG01 = 'J632'|DIAG01 = 
'J633'|DIAG01 = 'J634'|DIAG01 = 'J635'|DIAG01 = 'J638'|DIAG01 = 'J64X'|DIAG01 = 'J65X'|DIAG01 = 
'J660'|DIAG01 = 'J661'|DIAG01 = 'J662'|DIAG01 = 'J668'|DIAG01 = 'K250'|DIAG01 = 'K251'|DIAG01 = 
'K252'|DIAG01 = 'K253'|DIAG01 = 'K254'|DIAG01 = 'K255'|DIAG01 = 'K256'|DIAG01 = 'K257'|DIAG01 
= 'K259'|DIAG01 = 'K260'|DIAG01 = 'K261'|DIAG01 = 'K262'|DIAG01 = 'K263'|DIAG01 = 
'K264'|DIAG01 = 'K265'|DIAG01 = 'K266'|DIAG01 = 'K267'|DIAG01 = 'K269'|DIAG01 = 'K270'|DIAG01 
= 'K271'|DIAG01 = 'K272'|DIAG01 = 'K273'|DIAG01 = 'K274'|DIAG01 = 'K275'|DIAG01 = 
'K276'|DIAG01 = 'K277'|DIAG01 = 'K279'|DIAG01 = 'K280'|DIAG01 = 'K281'|DIAG01 = 'K282'|DIAG01 
= 'K283'|DIAG01 = 'K284'|DIAG01 = 'K285'|DIAG01 = 'K286'|DIAG01 = 'K287'|DIAG01 = 
'K289'|DIAG01 = 'K702'|DIAG01 = 'K703'|DIAG01 = 'K717'|DIAG01 = 'K731'|DIAG01 = 'K732'|DIAG01 
= 'K738'|DIAG01 = 'K739'|DIAG01 = 'K740'|DIAG01 = 'K742'|DIAG01 = 'K743'|DIAG01 = 
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'K744'|DIAG01 = 'K745'|DIAG01 = 'K746'|DIAG01 = 'M050'|DIAG01 = 'M051'|DIAG01 = 
'M052'|DIAG01 = 'M053'|DIAG01 = 'M058'|DIAG01 = 'M059'|DIAG01 = 'M060'|DIAG01 = 
'M063'|DIAG01 = 'M069'|DIAG01 = 'M320'|DIAG01 = 'M321'|DIAG01 = 'M328'|DIAG01 = 
'M329'|DIAG01 = 'M332'|DIAG01 = 'M340'|DIAG01 = 'M341'|DIAG01 = 'M342'|DIAG01 = 
'M348'|DIAG01 = 'M349'|DIAG01 = 'M353'|DIAG01 = 'R02X'|DIAG01 = 'Z958'|DIAG01 = 
'Z959')COMORBID1 = 1. 
EXECUTE. 
IF (DIAG01 = 'C000'|DIAG01 = 'C001'|DIAG01 = 'C002'|DIAG01 = 'C003'|DIAG01 = 'C004'|DIAG01 = 
'C005'|DIAG01 = 'C006'|DIAG01 = 'C008'|DIAG01 = 'C009'|DIAG01 = 'C01X'|DIAG01 = 
'C020'|DIAG01 = 'C021'|DIAG01 = 'C022'|DIAG01 = 'C023'|DIAG01 = 'C024'|DIAG01 = 
'C028'|DIAG01 = 'C029'|DIAG01 = 'C030'|DIAG01 = 'C031'|DIAG01 = 'C039'|DIAG01 = 
'C040'|DIAG01 = 'C041'|DIAG01 = 'C048'|DIAG01 = 'C049'|DIAG01 = 'C050'|DIAG01 = 
'C051'|DIAG01 = 'C052'|DIAG01 = 'C058'|DIAG01 = 'C059'|DIAG01 = 'C060'|DIAG01 = 
'C061'|DIAG01 = 'C062'|DIAG01 = 'C068'|DIAG01 = 'C069'|DIAG01 = 'C07X'|DIAG01 = 
'C080'|DIAG01 = 'C081'|DIAG01 = 'C088'|DIAG01 = 'C089'|DIAG01 = 'C090'|DIAG01 = 
'C091'|DIAG01 = 'C098'|DIAG01 = 'C099'|DIAG01 = 'C100'|DIAG01 = 'C101'|DIAG01 = 
'C102'|DIAG01 = 'C103'|DIAG01 = 'C104'|DIAG01 = 'C108'|DIAG01 = 'C109'|DIAG01 = 
'C110'|DIAG01 = 'C111'|DIAG01 = 'C112'|DIAG01 = 'C113'|DIAG01 = 'C118'|DIAG01 = 
'C119'|DIAG01 = 'C12X'|DIAG01 = 'C130'|DIAG01 = 'C131'|DIAG01 = 'C132'|DIAG01 = 
'C138'|DIAG01 = 'C139'|DIAG01 = 'C140'|DIAG01 = 'C142'|DIAG01 = 'C148'| 
DIAG01 = 'C170'|DIAG01 = 'C171'|DIAG01 = 'C172'|DIAG01 = 'C173'|DIAG01 = 'C178'|DIAG01 = 
'C179'|DIAG01 = 'C180'|DIAG01 = 'C181'|DIAG01 = 'C182'|DIAG01 = 'C183'|DIAG01 = 
'C184'|DIAG01 = 'C185'|DIAG01 = 'C186'|DIAG01 = 'C187'|DIAG01 = 'C188'|DIAG01 = 
'C189'|DIAG01 = 'C19X'|DIAG01 = 'C20X'|DIAG01 = 'C210'|DIAG01 = 'C211'|DIAG01 = 
'C212'|DIAG01 = 'C218'|DIAG01 = 'C220'|DIAG01 = 'C221'|DIAG01 = 'C222'|DIAG01 = 
'C223'|DIAG01 = 'C224'|DIAG01 = 'C227'|DIAG01 = 'C229'|DIAG01 = 'C23X'|DIAG01 = 
'C240'|DIAG01 = 'C241'|DIAG01 = 'C248'|DIAG01 = 'C249'|DIAG01 = 'C250'|DIAG01 = 
'C251'|DIAG01 = 'C252'|DIAG01 = 'C253'|DIAG01 = 'C254'|DIAG01 = 'C257'|DIAG01 = 
'C258'|DIAG01 = 'C259'|DIAG01 = 'C260'|DIAG01 = 'C261'|DIAG01 = 'C268'|DIAG01 = 
'C269'|DIAG01 = 'C300'|DIAG01 = 'C301'|DIAG01 = 'C310'|DIAG01 = 'C311'|DIAG01 = 
'C312'|DIAG01 = 'C313'|DIAG01 = 'C318'|DIAG01 = 'C319'|DIAG01 = 'C320'|DIAG01 = 
'C321'|DIAG01 = 'C322'|DIAG01 = 'C323'|DIAG01 = 'C328'|DIAG01 = 'C329'|DIAG01 = 
'C33X'|DIAG01 = 'C340'|DIAG01 = 'C341'|DIAG01 = 'C342'|DIAG01 = 'C343'|DIAG01 = 
'C348'|DIAG01 = 'C349'|DIAG01 = 'C37X'|DIAG01 = 'C380'|DIAG01 = 'C381'|DIAG01 = 
'C382'|DIAG01 = 'C383'|DIAG01 = 'C384'|DIAG01 = 'C388'|DIAG01 = 'C390'|DIAG01 = 
'C398'|DIAG01 = 'C399'|DIAG01 = 'C400'|DIAG01 = 'C401'|DIAG01 = 'C402'|DIAG01 = 
'C403'|DIAG01 = 'C408'|DIAG01 = 'C409'|DIAG01 = 'C410'|DIAG01 = 'C411'|DIAG01 = 
'C412'|DIAG01 = 'C413'|DIAG01 = 'C414'|DIAG01 = 'C418'|DIAG01 = 'C419'|DIAG01 = 
'C430'|DIAG01 = 'C431'|DIAG01 = 'C432'|DIAG01 = 'C433'|DIAG01 = 'C434'|DIAG01 = 
'C435'|DIAG01 = 'C436'|DIAG01 = 'C437'|DIAG01 = 'C438'|DIAG01 = 'C439'|DIAG01 = 
'C450'|DIAG01 = 'C451'|DIAG01 = 'C452'|DIAG01 = 'C457'|DIAG01 = 'C459'|DIAG01 = 
'C460'|DIAG01 = 'C461'|DIAG01 = 'C462'|DIAG01 = 'C463'|DIAG01 = 'C467'|DIAG01 = 
'C468'|DIAG01 = 'C469'|DIAG01 = 'C470'|DIAG01 = 'C471'|DIAG01 = 'C472'|DIAG01 = 
'C473'|DIAG01 = 'C474'|DIAG01 = 'C475'|DIAG01 = 'C476'|DIAG01 = 'C478'|DIAG01 = 
'C479'|DIAG01 = 'C480'|DIAG01 = 'C481'|DIAG01 = 'C482'|DIAG01 = 'C488'|DIAG01 = 
'C490'|DIAG01 = 'C491'|DIAG01 = 'C492'|DIAG01 = 'C493'|DIAG01 = 'C494'|DIAG01 = 
'C495'|DIAG01 = 'C496'|DIAG01 = 'C498'|DIAG01 = 'C499'|DIAG01 = 'C500'|DIAG01 = 
'C501'|DIAG01 = 'C502'|DIAG01 = 'C503'|DIAG01 = 'C504'|DIAG01 = 'C505'|DIAG01 = 
'C506'|DIAG01 = 'C508'|DIAG01 = 'C509'|DIAG01 = 'C510'|DIAG01 = 'C511'|DIAG01 = 
'C512'|DIAG01 = 'C518'|DIAG01 = 'C519'|DIAG01 = 'C52X'|DIAG01 = 'C530'|DIAG01 = 
'C531'|DIAG01 = 'C538'|DIAG01 = 'C539'|DIAG01 = 'C540'|DIAG01 = 'C541'|DIAG01 = 
'C542'|DIAG01 = 'C543'|DIAG01 = 'C548'|DIAG01 = 'C549'|DIAG01 = 'C55X'|DIAG01 = 
'C56X'|DIAG01 = 'C570'|DIAG01 = 'C571'|DIAG01 = 'C572'|DIAG01 = 'C573'|DIAG01 = 
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'C574'|DIAG01 = 'C577'|DIAG01 = 'C578'|DIAG01 = 'C579'|DIAG01 = 'C58X'|DIAG01 = 
'C600'|DIAG01 = 'C601'|DIAG01 = 'C602'|DIAG01 = 'C608'|DIAG01 = 'C609'|DIAG01 = 
'C61X'|DIAG01 = 'C620'|DIAG01 = 'C621'|DIAG01 = 'C629'|DIAG01 = 'C630'|DIAG01 = 
'C631'|DIAG01 = 'C632'|DIAG01 = 'C637'|DIAG01 = 'C638'|DIAG01 = 'C639'|DIAG01 = 
'C64X'|DIAG01 = 'C65X'|DIAG01 = 'C66X'|DIAG01 = 'C670'|DIAG01 = 'C671'|DIAG01 = 
'C672'|DIAG01 = 'C673'|DIAG01 = 'C674'|DIAG01 = 'C675'|DIAG01 = 'C676'|DIAG01 = 
'C677'|DIAG01 = 'C678'|DIAG01 = 'C679'|DIAG01 = 'C680'|DIAG01 = 'C681'|DIAG01 = 
'C688'|DIAG01 = 'C689'|DIAG01 = 'C690'|DIAG01 = 'C691'|DIAG01 = 'C692'|DIAG01 = 
'C693'|DIAG01 = 'C694'|DIAG01 = 'C695'|DIAG01 = 'C696'|DIAG01 = 'C698'|DIAG01 = 
'C699'|DIAG01 = 'C700'|DIAG01 = 'C701'|DIAG01 = 'C709'|DIAG01 = 'C710'|DIAG01 = 
'C711'|DIAG01 = 'C712'|DIAG01 = 'C713'|DIAG01 = 'C714'|DIAG01 = 'C715'|DIAG01 = 
'C716'|DIAG01 = 'C717'|DIAG01 = 'C718'|DIAG01 = 'C719'|DIAG01 = 'C720'|DIAG01 = 
'C721'|DIAG01 = 'C722'|DIAG01 = 'C723'|DIAG01 = 'C724'|DIAG01 = 'C725'|DIAG01 = 
'C728'|DIAG01 = 'C729'|DIAG01 = 'C73X'|DIAG01 = 'C740'|DIAG01 = 'C741'|DIAG01 = 
'C749'|DIAG01 = 'C750'|DIAG01 = 'C751'|DIAG01 = 'C752'|DIAG01 = 'C753'|DIAG01 = 
'C754'|DIAG01 = 'C755'|DIAG01 = 'C758'|DIAG01 = 'C759'|DIAG01 = 'C760'|DIAG01 = 
'C761'|DIAG01 = 'C762'|DIAG01 = 'C763'|DIAG01 = 'C764'|DIAG01 = 'C765'|DIAG01 = 
'C767'|DIAG01 = 'C768'|DIAG01 = 'C810'|DIAG01 = 'C811'|DIAG01 = 'C812'|DIAG01 = 
'C813'|DIAG01 = 'C817'|DIAG01 = 'C819'|DIAG01 = 'C820'|DIAG01 = 'C821'|DIAG01 = 
'C822'|DIAG01 = 'C827'|DIAG01 = 'C829'|DIAG01 = 'C830'|DIAG01 = 'C831'|DIAG01 = 
'C832'|DIAG01 = 'C833'|DIAG01 = 'C834'|DIAG01 = 'C835'|DIAG01 = 'C836'|DIAG01 = 
'C837'|DIAG01 = 'C838'|DIAG01 = 'C839'|DIAG01 = 'C840'|DIAG01 = 'C841'|DIAG01 = 
'C842'|DIAG01 = 'C843'|DIAG01 = 'C844'|DIAG01 = 'C845'|DIAG01 = 'C850'|DIAG01 = 
'C851'|DIAG01 = 'C857'|DIAG01 = 'C859'|DIAG01 = 'C883'|DIAG01 = 'C887'|DIAG01 = 
'C889'|DIAG01 = 'C900'|DIAG01 = 'C901'|DIAG01 = 'C910'|DIAG01 = 'C911'|DIAG01 = 
'C912'|DIAG01 = 'C913'|DIAG01 = 'C914'|DIAG01 = 'C915'|DIAG01 = 'C917'|DIAG01 = 
'C919'|DIAG01 = 'C920'|DIAG01 = 'C921'|DIAG01 = 'C922'|DIAG01 = 'C923'|DIAG01 = 
'C924'|DIAG01 = 'C925'|DIAG01 = 'C927'|DIAG01 = 'C929'|DIAG01 = 'C930'|DIAG01 = 
'C931'|DIAG01 = 'C932'|DIAG01 = 'C937'|DIAG01 = 'C939'|DIAG01 = 'C940'|DIAG01 = 
'C941'|DIAG01 = 'C942'|DIAG01 = 'C943'|DIAG01 = 'C945'|DIAG01 = 'C947'|DIAG01 = 
'C950'|DIAG01 = 'C951'|DIAG01 = 'C952'|DIAG01 = 'C957'|DIAG01 = 'C959'|DIAG01 = 
'C960'|DIAG01 = 'C961'|DIAG01 = 'C962'|DIAG01 = 'C963'|DIAG01 = 'C967'|DIAG01 = 
'C969'|DIAG01 = 'E102'|DIAG01 = 'E103'|DIAG01 = 'E104'|DIAG01 = 'E112'|DIAG01 = 'E113'|DIAG01 
= 'E114'|DIAG01 = 'E132'|DIAG01 = 'E133'|DIAG01 = 'E134'|DIAG01 = 'E142'|DIAG01 = 
'E143'|DIAG01 = 'E144'|DIAG01 = 'G041'|DIAG01 = 'G810'|DIAG01 = 'G811'|DIAG01 = 
'G819'|DIAG01 = 'G820'|DIAG01 = 'G821'|DIAG01 = 'G822'|DIAG01 = 'N010'|DIAG01 = 
'N011'|DIAG01 = 'N012'|DIAG01 = 'N013'|DIAG01 = 'N014'|DIAG01 = 'N015'|DIAG01 = 
'N016'|DIAG01 = 'N017'|DIAG01 = 'N018'|DIAG01 = 'N019'|DIAG01 = 'N031'|DIAG01 = 
'N032'|DIAG01 = 'N033'|DIAG01 = 'N034'|DIAG01 = 'N035'|DIAG01 = 'N036'|DIAG01 = 
'N037'|DIAG01 = 'N038'|DIAG01 = 'N039'|DIAG01 = 'N052'|DIAG01 = 'N053'|DIAG01 = 
'N054'|DIAG01 = 'N055'|DIAG01 = 'N056'|DIAG01 = 'N072'|DIAG01 = 'N073'|DIAG01 = 
'N074'|DIAG01 = 'N180'|DIAG01 = 'N188'|DIAG01 = 'N189'|DIAG01 = 'N19X'|DIAG01 = 
'N250'|DIAG01 = 'N251'|DIAG01 = 'N258'|DIAG01 = 'N259')COMORBID1 = 2. 
EXECUTE. 
IF (DIAG01 = 'C770'|DIAG01 = 'C771'|DIAG01 = 'C772'|DIAG01 = 'C773'|DIAG01 = 'C774'|DIAG01 = 
'C775'|DIAG01 = 'C778'|DIAG01 = 'C779'|DIAG01 = 'C780'|DIAG01 = 'C781'|DIAG01 = 
'C782'|DIAG01 = 'C783'|DIAG01 = 'C784'|DIAG01 = 'C785'|DIAG01 = 'C786'|DIAG01 = 
'C787'|DIAG01 = 'C788'|DIAG01 = 'C790'|DIAG01 = 'C791'|DIAG01 = 'C792'|DIAG01 = 
'C793'|DIAG01 = 'C794'|DIAG01 = 'C795'|DIAG01 = 'C796'|DIAG01 = 'C797'|DIAG01 = 
'C798'|DIAG01 = 'C80X'|DIAG01 = 'K721'|DIAG01 = 'K729'|DIAG01 = 'K766'|DIAG01 = 
'K767')COMORBID1 = 3. 
EXECUTE. 
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IF (DIAG01 = 'B200'|DIAG01 = 'B201'|DIAG01 = 'B202'|DIAG01 = 'B203'|DIAG01 = 'B204'|DIAG01 = 
'B205'|DIAG01 = 'B206'|DIAG01 = 'B207'|DIAG01 = 'B208'|DIAG01 = 'B209'|DIAG01 = 
'B210'|DIAG01 = 'B211'|DIAG01 = 'B212'|DIAG01 = 'B213'|DIAG01 = 'B217'|DIAG01 = 
'B218'|DIAG01 = 'B219'|DIAG01 = 'B220'|DIAG01 = 'B221'|DIAG01 = 'B222'|DIAG01 = 
'B227'|DIAG01 = 'B230'|DIAG01 = 'B231'|DIAG01 = 'B232'|DIAG01 = 'B238'|DIAG01 = 
'B24X')COMORBID1 = 6. 
EXECUTE. 
The same syntax was applied to identify these codes in other diagnostic position (DIAG02 
to DIAG 14)  
 
Syntax 7.8 Comorbidity syntax 
(present or not) 
 
COMPUTE 
NONCANCERCOMORB1 = 
0. 
EXECUTE. 
IF (DIAG01 = 'I210'| 
DIAG01 = 'I211'| 
DIAG01 = 'I212'| 
DIAG01 = 'I213'| 
DIAG01 = 'I214'| 
DIAG01 = 'I219'| 
DIAG01 = 'I220'| 
DIAG01 = 'I221'| 
DIAG01 = 'I228'| 
DIAG01 = 'I229'| 
DIAG01 = 'I252'| 
DIAG01 = 'I500'| 
DIAG01 = 'I710'| 
DIAG01 = 'I711'| 
DIAG01 = 'I712'| 
DIAG01 = 'I713'| 
DIAG01 = 'I714'| 
DIAG01 = 'I715'| 
DIAG01 = 'I716'| 
DIAG01 = 'I718'| 
DIAG01 = 'I719'| 
DIAG01 = 'I738'| 
DIAG01 = 'I739'| 
DIAG01 = 'I600'| 
DIAG01 = 'I601'| 
DIAG01 = 'I602'| 
DIAG01 = 'I603'| 
DIAG01 = 'I604'| 
DIAG01 = 'I605'| 
DIAG01 = 'I606'| 
DIAG01 = 'I607'| 
DIAG01 = 'I608'| 
DIAG01 = 'I609'| 
DIAG01 = 'I610'| 
DIAG01 = 'I611'| 
DIAG01 = 'I612'| 
DIAG01 = 'I613'| 
DIAG01 = 'I614'| 
DIAG01 = 'I615'| 
DIAG01 = 'I616'| 
DIAG01 = 'I618'| 
DIAG01 = 'I619'| 
DIAG01 = 'I620'| 
DIAG01 = 'I621'| 
DIAG01 = 'I629'| 
DIAG01 = 'I630'| 
DIAG01 = 'I631'| 
DIAG01 = 'I632'| 
DIAG01 = 'I633'| 
DIAG01 = 'I634'| 
DIAG01 = 'I635'| 
DIAG01 = 'I636'| 
DIAG01 = 'I638'| 
DIAG01 = 'I639'| 
DIAG01 = 'I64X'| 
DIAG01 = 'I650'| 
DIAG01 = 'I651'| 
DIAG01 = 'I652'| 
DIAG01 = 'I653'| 
DIAG01 = 'I658'| 
DIAG01 = 'I659'| 
DIAG01 = 'I660'| 
DIAG01 = 'I661'| 
DIAG01 = 'I662'| 
DIAG01 = 'I663'| 
DIAG01 = 'I664'| 
DIAG01 = 'I668'| 
DIAG01 = 'I669'| 
DIAG01 = 'I670'| 
DIAG01 = 'I671'| 
DIAG01 = 'I672'| 
DIAG01 = 'I673'| 
DIAG01 = 'I674'| 
DIAG01 = 'I675'| 
DIAG01 = 'I676'| 
DIAG01 = 'I677'| 
DIAG01 = 'I678'| 
DIAG01 = 'I679'| 
DIAG01 = 'I680'| 
DIAG01 = 'I681'| 
DIAG01 = 'I682'| 
DIAG01 = 'I688'| 
DIAG01 = 'I690'| 
DIAG01 = 'I691'| 
DIAG01 = 'I692'| 
DIAG01 = 'I693'| 
DIAG01 = 'I694'| 
DIAG01 = 'I698'| 
DIAG01 = 'F000'| 
DIAG01 = 'F001'| 
DIAG01 = 'F002'| 
DIAG01 = 'F009'| 
DIAG01 = 'F010'| 
DIAG01 = 'F011'| 
DIAG01 = 'F012'| 
DIAG01 = 'F013'| 
DIAG01 = 'F018'| 
DIAG01 = 'F019'| 
DIAG01 = 'F020'| 
DIAG01 = 'F021'| 
DIAG01 = 'F022'| 
DIAG01 = 'F023'| 
DIAG01 = 'F024'| 
DIAG01 = 'F028'| 
DIAG01 = 'F03X'| 
DIAG01 = 'F051'| 
DIAG01 = 'J40X'| 
DIAG01 = 'J410'| 
DIAG01 = 'J411'| 
DIAG01 = 'J418'| 
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DIAG01 = 'J42X'| 
DIAG01 = 'J430'| 
DIAG01 = 'J431'| 
DIAG01 = 'J432'| 
DIAG01 = 'J438'| 
DIAG01 = 'J439'| 
DIAG01 = 'J440'| 
DIAG01 = 'J441'| 
DIAG01 = 'J448'| 
DIAG01 = 'J449'| 
DIAG01 = 'J450'| 
DIAG01 = 'J451'| 
DIAG01 = 'J458'| 
DIAG01 = 'J459'| 
DIAG01 = 'J46X'| 
DIAG01 = 'J47X'| 
DIAG01 = 'J60X'| 
DIAG01 = 'J61X'| 
DIAG01 = 'J620'| 
DIAG01 = 'J628'| 
DIAG01 = 'J630'| 
DIAG01 = 'J631'| 
DIAG01 = 'J632'| 
DIAG01 = 'J633'| 
DIAG01 = 'J634'| 
DIAG01 = 'J635'| 
DIAG01 = 'J638'| 
DIAG01 = 'J64X'| 
DIAG01 = 'J65X'| 
DIAG01 = 'J660'| 
DIAG01 = 'J661'| 
DIAG01 = 'J662'| 
DIAG01 = 'J668'| 
DIAG01 = 'J670'| 
DIAG01 = 'J671'| 
DIAG01 = 'J672'| 
DIAG01 = 'J673'| 
DIAG01 = 'J674'| 
DIAG01 = 'J675'| 
DIAG01 = 'J676'| 
DIAG01 = 'J677'| 
DIAG01 = 'J678'| 
DIAG01 = 'J679'| 
DIAG01 = 'M050'| 
DIAG01 = 'M051'| 
DIAG01 = 'M052'| 
DIAG01 = 'M059'| 
DIAG01 = 'M060'| 
DIAG01 = 'M063'| 
DIAG01 = 'M069'| 
DIAG01 = 'M300'| 
DIAG01 = 'M301'| 
DIAG01 = 'M302'| 
DIAG01 = 'M303'| 
DIAG01 = 'M308'| 
DIAG01 = 'M310'| 
DIAG01 = 'M311'| 
DIAG01 = 'M312'| 
DIAG01 = 'M313'| 
DIAG01 = 'M314'| 
DIAG01 = 'M315'| 
DIAG01 = 'M316'| 
DIAG01 = 'M318'| 
DIAG01 = 'M319'| 
DIAG01 = 'M320'| 
DIAG01 = 'M321'| 
DIAG01 = 'M328'| 
DIAG01 = 'M329'| 
DIAG01 = 'M332'| 
DIAG01 = 'M339'| 
DIAG01 = 'M340'| 
DIAG01 = 'M341'| 
DIAG01 = 'M342'| 
DIAG01 = 'M348'| 
DIAG01 = 'M349'| 
DIAG01 = 'M350'| 
DIAG01 = 'M351'| 
DIAG01 = 'M352'| 
DIAG01 = 'M353'| 
DIAG01 = 'M354'| 
DIAG01 = 'M355'| 
DIAG01 = 'M356'| 
DIAG01 = 'M357'| 
DIAG01 = 'K250'| 
DIAG01 = 'K251'| 
DIAG01 = 'K252'| 
DIAG01 = 'K253'| 
DIAG01 = 'K254'| 
DIAG01 = 'K255'| 
DIAG01 = 'K256'| 
DIAG01 = 'K257'| 
DIAG01 = 'K259'| 
DIAG01 = 'K260'| 
DIAG01 = 'K261'| 
DIAG01 = 'K262'| 
DIAG01 = 'K263'| 
DIAG01 = 'K264'| 
DIAG01 = 'K265'| 
DIAG01 = 'K266'| 
DIAG01 = 'K267'| 
DIAG01 = 'K269'| 
DIAG01 = 'K270'| 
DIAG01 = 'K271'| 
DIAG01 = 'K272'| 
DIAG01 = 'K273'| 
DIAG01 = 'K274'| 
DIAG01 = 'K275'| 
DIAG01 = 'K276'| 
DIAG01 = 'K277'| 
DIAG01 = 'K279'| 
DIAG01 = 'K280'| 
DIAG01 = 'K281'| 
DIAG01 = 'K282'| 
DIAG01 = 'K283'| 
DIAG01 = 'K284'| 
DIAG01 = 'K285'| 
DIAG01 = 'K286'| 
DIAG01 = 'K287'| 
DIAG01 = 'K289'| 
DIAG01 = 'K701'| 
DIAG01 = 'K702'| 
DIAG01 = 'K703'| 
DIAG01 = 'K704'| 
DIAG01 = 'K709'| 
DIAG01 = 'K710'| 
DIAG01 = 'K711'| 
DIAG01 = 'K712'| 
DIAG01 = 'K713'| 
DIAG01 = 'K714'| 
DIAG01 = 'K715'| 
DIAG01 = 'K716'| 
DIAG01 = 'K717'| 
DIAG01 = 'K718'| 
DIAG01 = 'K719'| 
DIAG01 = 'K721'| 
DIAG01 = 'K729'| 
DIAG01 = 'K730'| 
DIAG01 = 'K731'| 
DIAG01 = 'K732'| 
DIAG01 = 'K738'| 
DIAG01 = 'K739'| 
DIAG01 = 'K740'| 
DIAG01 = 'K741'| 
DIAG01 = 'K742'| 
DIAG01 = 'K743'| 
DIAG01 = 'K744'| 
DIAG01 = 'K745'| 
DIAG01 = 'K746'| 
DIAG01 = 'K753'| 
DIAG01 = 'K754'| 
DIAG01 = 'K758'| 
DIAG01 = 'K764'| 
DIAG01 = 'K765'| 
DIAG01 = 'K766'| 
DIAG01 = 'K767'| 
DIAG01 = 'K768'| 
DIAG01 = 'E102'| 
DIAG01 = 'E103'| 
DIAG01 = 'E104'| 
DIAG01 = 'E105'| 
DIAG01 = 'E106'| 
DIAG01 = 'E107'| 
DIAG01 = 'E108'| 
DIAG01 = 'E109'| 
DIAG01 = 'E112'| 
DIAG01 = 'E113'| 
DIAG01 = 'E114'| 
DIAG01 = 'E115'| 
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DIAG01 = 'E116'| 
DIAG01 = 'E117'| 
DIAG01 = 'E118'| 
DIAG01 = 'E119'| 
DIAG01 = 'E132'| 
DIAG01 = 'E133'| 
DIAG01 = 'E134'| 
DIAG01 = 'E135'| 
DIAG01 = 'E136'| 
DIAG01 = 'E137'| 
DIAG01 = 'E138'| 
DIAG01 = 'E139'| 
DIAG01 = 'E142'| 
DIAG01 = 'E143'| 
DIAG01 = 'E144'| 
DIAG01 = 'E145'| 
DIAG01 = 'E146'| 
DIAG01 = 'E147'| 
DIAG01 = 'E148'| 
DIAG01 = 'E149'| 
DIAG01 = 'G810'| 
DIAG01 = 'G811'| 
DIAG01 = 'G819'| 
DIAG01 = 'G820'| 
DIAG01 = 'G821'| 
DIAG01 = 'G822'| 
DIAG01 = 'N001'| 
DIAG01 = 'N002'| 
DIAG01 = 'N003'| 
DIAG01 = 'N004'| 
DIAG01 = 'N005'| 
DIAG01 = 'N007'| 
DIAG01 = 'N010'| 
DIAG01 = 'N011'| 
DIAG01 = 'N012'| 
DIAG01 = 'N013'| 
DIAG01 = 'N014'| 
DIAG01 = 'N015'| 
DIAG01 = 'N016'| 
DIAG01 = 'N017'| 
DIAG01 = 'N018'| 
DIAG01 = 'N019'| 
DIAG01 = 'N020'| 
DIAG01 = 'N021'| 
DIAG01 = 'N022'| 
DIAG01 = 'N023'| 
DIAG01 = 'N024'| 
DIAG01 = 'N025'| 
DIAG01 = 'N026'| 
DIAG01 = 'N027'| 
DIAG01 = 'N030'| 
DIAG01 = 'N031'| 
DIAG01 = 'N032'| 
DIAG01 = 'N033'| 
DIAG01 = 'N034'| 
DIAG01 = 'N035'| 
DIAG01 = 'N036'| 
DIAG01 = 'N037'| 
DIAG01 = 'N038'| 
DIAG01 = 'N039'| 
DIAG01 = 'N040'| 
DIAG01 = 'N041'| 
DIAG01 = 'N042'| 
DIAG01 = 'N043'| 
DIAG01 = 'N044'| 
DIAG01 = 'N045'| 
DIAG01 = 'N046'| 
DIAG01 = 'N047'| 
DIAG01 = 'N048'| 
DIAG01 = 'N049'| 
DIAG01 = 'N050'| 
DIAG01 = 'N051'| 
DIAG01 = 'N052'| 
DIAG01 = 'N053'| 
DIAG01 = 'N054'| 
DIAG01 = 'N055'| 
DIAG01 = 'N056'| 
DIAG01 = 'N057'| 
DIAG01 = 'N071'| 
DIAG01 = 'N072'| 
DIAG01 = 'N073'| 
DIAG01 = 'N074'| 
DIAG01 = 'N075'| 
DIAG01 = 'N180'| 
DIAG01 = 'N188'| 
DIAG01 = 'N189'| 
DIAG01 = 'N19X'| 
DIAG01 = 'N250'| 
DIAG01 = 'Z992'| 
DIAG01 = 'B200'| 
DIAG01 = 'B201'| 
DIAG01 = 'B202'| 
DIAG01 = 'B203'| 
DIAG01 = 'B204'| 
DIAG01 = 'B205'| 
DIAG01 = 'B206'| 
DIAG01 = 'B207'| 
DIAG01 = 'B208'| 
DIAG01 = 'B209'| 
DIAG01 = 'B210'| 
DIAG01 = 'B211'| 
DIAG01 = 'B212'| 
DIAG01 = 'B213'| 
DIAG01 = 'B217'| 
DIAG01 = 'B218'| 
DIAG01 = 'B219'| 
DIAG01 = 'B220'| 
DIAG01 = 'B221'| 
DIAG01 = 'B222'| 
DIAG01 = 'B227'| 
DIAG01 = 'B230'| 
DIAG01 = 'B231'| 
DIAG01 = 'B232'| 
DIAG01 = 'B238'| 
DIAG01 = 
'B24X')NONCANCERCOMO
RB1 = 1. 
 
 
EXECUTE. 
The same syntax was applied to identify these codes in other diagnostic position (DIAG02 
to DIAG 14) Then these 14 new variables (NONCANCERCOMORB1 + 
NONCANCERCOMORB2+…..+ NONCANCERCOMORB14) were added and a new variable 
called AllComorbidity was created which then updated by the following syntax to develop 
a binary variable that show whether the patients (episodes) had been coded with any of 
these codes or not. 
COMPUTE HaveComorbidity = 0. 
EXECUTE. 
IF (AllComorbidity > 0)HaveComorbidity = 1. 
EXECUTE.  
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Syntax 7.9 Comorbidity grouping syntax 
COMPUTE comorbidityGROUPS = 0. 
EXECUTE. 
IF (AllComorbidity = 0) comorbidityGROUPS = 1. 
EXECUTE. 
IF (AllComorbidity =1) comorbidityGROUPS = 2. 
EXECUTE. 
IF (AllComorbidity >1) comorbidityGROUPS = 3. 
EXECUTE. 
Syntax 7.10 Deprivation grouping  
The IMD score/rank has a range of 0 – 32482 which is based on Income, Employment, 
Health and Disability, Barriers to Housing, Crime and Living Environment within a postcode. 
Simply we have split the IMD scoring system 0 – 32482 into 5 parts, and developed the 
following syntax to assign a quintile to each Admission/patient, so we can analyse the level 
of deprivation the patients/disease actually fits into in the country. 
COMPUTE NATDEPRIVQUINTILE = 0. 
EXECUTE. 
IF (DEPRIV < 6497)NATDEPRIVQUINTILE = 1. 
EXECUTE. 
IF (DEPRIV > 6496 & DEPRIV < 12993)NATDEPRIVQUINTILE = 2. 
EXECUTE. 
IF (DEPRIV > 12992 & DEPRIV < 19490)NATDEPRIVQUINTILE = 3. 
EXECUTE. 
IF (DEPRIV > 19489 & DEPRIV < 25986)NATDEPRIVQUINTILE = 4. 
EXECUTE. 
IF (DEPRIV > 25985 & DEPRIV < 32483)NATDEPRIVQUINTILE = 5. 
EXECUTE. 
Syntax 7.11 Admission methods syntax  
This syntax was used to update a new variable called ADMISSMETHTYPE that is defines how 
the patient was admitted to hospital for the spell. First of all, the syntax creates a variable 
called ADMISSMETHTYPE and sets to 0, it then updates this variable dependant on what 
code is present in ADMIMETH.  If ADMIMETH is equal to 11,12,13 then it is an ELECTIVE 
spell and ADMISSMETHTYPE is then updated to code 1.  If ADMIMETH is equal to 
21,22,23,24,28 then it is an EMERGENCY spell and ADMISSMETHTYPE is then updated to 
code 4. A new variable is now created called ADMMETHTYPE which will take the Admission 
type and the Patient Classification field which looks how the patient was managed into 
account.  The syntax commands if ADMIMETHTYPE is equal to 1 and CLASS PAT is equal to 1 
then update ADMMETHTYPE to 1, this means that this is an ELECTIVE ORDINARY admission.   
The syntax commands if ADMIMETHTYPE is equal to 81 then update ADMMETHTYPE to 1, 
this means that this is an ELECTIVE ORDINARY admission.   The syntax commands if 
ADMIMETHTYPE is equal to 1 and CLASS PAT is equal to 2 then update ADMMETHTYPE to 
2, this means that this is an ELECTIVE DAYCASE admission.   The syntax commands if 
ADMIMETHTYPE is equal to 1 and CLASS PAT is equal to 3 and 4 then update 
ADMMETHTYPE to 3, this means that this is an ELECTIVE REGULAR ATTENDER admission.   
The syntax commands if ADMIMETHTYPE is equal to 4 then update ADMMETHTYPE to 4, 
this means that this is an EMERGENCY admission. 
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COMPUTE ADMISSMETHTYPE = 0 . 
EXECUTE . 
IF (ADMIMETH = 11| 
ADMIMETH = 12| 
ADMIMETH = 13)ADMISSMETHTYPE = 1. 
EXECUTE . 
IF (ADMIMETH = 21| 
ADMIMETH = 22| 
ADMIMETH = 23| 
ADMIMETH = 24| 
ADMIMETH = 28)ADMISSMETHTYPE = 4. 
EXECUTE . 
COMPUTE ADMMETHTYPE = 0 . 
EXECUTE . 
IF (ADMISSMETHTYPE= 1 & 
CLASSPAT = 1) ADMMETHTYPE = 1 . 
EXECUTE . 
IF (ADMIMETH = 81) ADMMETHTYPE = 1 . 
EXECUTE . 
IF (ADMISSMETHTYPE= 1 & 
CLASSPAT = 2) ADMMETHTYPE = 2 . 
EXECUTE . 
IF (ADMISSMETHTYPE= 1 & 
CLASSPAT = 3) ADMMETHTYPE = 3 . 
EXECUTE . 
IF (ADMISSMETHTYPE= 1 & 
CLASSPAT = 4) ADMMETHTYPE = 3 . 
EXECUTE . 
IF (ADMISSMETHTYPE= 4) ADMMETHTYPE = 4 
. 
EXECUTE . 
 
Syntax 7.12 Major surgical resection syntax 
COMPUTE SurgeryPro1 = 0. 
EXECUTE. 
 
if(OPERTN1 = 'G011'| 
OPERTN1 = 'G281'| 
OPERTN1 = 'G282'| 
OPERTN1 = 'G283'| 
OPERTN1 = 'G288'| 
OPERTN1 = 'G029'| 
OPERTN1 = 'G012'| 
OPERTN1 = 'G013'| 
OPERTN1 = 'G018'| 
OPERTN1 = 'G019'| 
OPERTN1 = 'G021'| 
OPERTN1 = 'G022'| 
OPERTN1 = 'G023'| 
OPERTN1 = 'G024'| 
OPERTN1 = 'G025'| 
OPERTN1 = 'G028'| 
OPERTN1 = 'G271'| 
OPERTN1 = 'G272'| 
OPERTN1 = 'G273'| 
OPERTN1 = 'G274'| 
OPERTN1 = 'G275'| 
OPERTN1 = 'G278'| 
OPERTN1 = 'G031'| 
OPERTN1 = 'G032'| 
OPERTN1 = 'G035'| 
OPERTN1 = 'G036'| 
OPERTN1 = 'G038'| 
OPERTN1 = 'G039')SurgeryPro1 = 1. 
EXECUTE. 
 
The same syntax was applied to identify these codes in other diagnostic position 
(OPERTN02 to OPERTN14) Then these 14 new variables (SurgeryPro1 + SurgeryPro2+…..+ 
SurgeryPro14) were added and a new variable called OG cancer Major resection was 
created which then updated by the following syntax to develop a binary variable that show 
whether the patients (episodes) had been coded with any of these codes or not.  
COMPUTE HaveMajorResection = 0. 
EXECUTE. 
IF (OG cancer Major resection > 0) HaveMajorResection = 1.EXECUTE. 
Syntax 7.13 Thirty days and one year mortality syntax 
COMPUTE mortality At ONE year = 0. 
EXECUTE. 
IF (diagnosisToDeath < 366) mortality At ONE year = 1. 
EXECUTE. 
COMPUTE mortality within 30 days = 0. 
EXECUTE. 
IF (diagnosisToDeath < 31) mortality within 30 days = 1. 
EXECUTE. 
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Syntax 7.14 Age groups at first diagnostic gastroscopy syntax (for age 
standardization) 
COMPUTE EndAgeAtGastroscopy15_19 = 0. 
EXECUTE. 
IF (ENDAGE_first >=15 & ENDAGE_first <=19)EndAgeAtGastroscopy15_19 = 1. 
EXECUTE . 
COMPUTE EndAgeAtGastroscopy20_24 = 0. 
EXECUTE. 
IF (ENDAGE_first >=20 & ENDAGE_first <=24)EndAgeAtGastroscopy20_24 = 1. 
EXECUTE . 
COMPUTE EndAgeAtGastroscopy25_29 = 0. 
EXECUTE. 
IF (ENDAGE_first >=25 & ENDAGE_first <=29)EndAgeAtGastroscopy25_29 = 1. 
EXECUTE . 
COMPUTE EndAgeAtGastroscopy30_34 = 0. 
EXECUTE. 
IF (ENDAGE_first >=30 & ENDAGE_first <=34)EndAgeAtGastroscopy30_34 = 1. 
EXECUTE . 
COMPUTE EndAgeAtGastroscopy35_39 = 0. 
EXECUTE. 
IF (ENDAGE_first >=35 & ENDAGE_first <=39)EndAgeAtGastroscopy35_39 = 1. 
EXECUTE . 
COMPUTE EndAgeAtGastroscopy40_44 = 0. 
EXECUTE. 
IF (ENDAGE_first >=40 & ENDAGE_first <=44)EndAgeAtGastroscopy40_44 = 1. 
EXECUTE . 
COMPUTE EndAgeAtGastroscopy45_49 = 0. 
EXECUTE. 
IF (ENDAGE_first >=45 & ENDAGE_first <=49)EndAgeAtGastroscopy45_49 = 1. 
EXECUTE . 
COMPUTE EndAgeAtGastroscopy50_54 = 0. 
EXECUTE. 
IF (ENDAGE_first >=50 & ENDAGE_first <=54)EndAgeAtGastroscopy50_54 = 1. 
EXECUTE . 
COMPUTE EndAgeAtGastroscopy55_59 = 0. 
EXECUTE. 
IF (ENDAGE_first >=55 & ENDAGE_first <=59)EndAgeAtGastroscopy55_59 = 1. 
EXECUTE . 
COMPUTE EndAgeAtGastroscopy60_64 = 0. 
EXECUTE. 
IF (ENDAGE_first >=60 & ENDAGE_first <=64)EndAgeAtGastroscopy60_64 = 1. 
EXECUTE . 
COMPUTE EndAgeAtGastroscopy65_69 = 0. 
EXECUTE. 
IF (ENDAGE_first >=65 & ENDAGE_first <=69)EndAgeAtGastroscopy65_69 = 1. 
EXECUTE . 
COMPUTE EndAgeAtGastroscopy70_74 = 0. 
EXECUTE. 
IF (ENDAGE_first >=70 & ENDAGE_first <=74)EndAgeAtGastroscopy70_74 = 1. 
EXECUTE . 
COMPUTE EndAgeAtGastroscopy75_79 = 0. 
EXECUTE. 
IF (ENDAGE_first >=75 & ENDAGE_first <=79)EndAgeAtGastroscopy75_79 = 1. 
EXECUTE . 
COMPUTE EndAgeAtGastroscopy80_84 = 0. 
EXECUTE. 
IF (ENDAGE_first >=80 & ENDAGE_first <=84)EndAgeAtGastroscopy80_84 = 1. 
EXECUTE . 
COMPUTE EndAgeAtGastroscopyMorethan85 = 0. 
EXECUTE. 
IF (ENDAGE_first >84)EndAgeAtGastroscopyMorethan85 = 1. 
EXECUTE . 
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